CONTINUOUS L-DOPA SECRETION BY AAV GENE THERAPY TO IMPROVE THE TREATMENT OF PARKINSON’S DISEASE by Antunes, Andre Saraiva Leao Marcelo
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 








CONTINUOUS L-DOPA SECRETION BY AAV GENE THERAPY TO IMPROVE THE
TREATMENT OF PARKINSON’S DISEASE
Antunes, Andre Saraiva Leao Marcelo
Awarding institution:
King's College London
Download date: 06. Nov. 2017
	  	  	  	  	  
CONTINUOUS	  L-­‐DOPA	  SECRETION	  BY	  AAV	  
GENE	  THERAPY	  TO	  IMPROVE	  THE	  
TREATMENT	  OF	  PARKINSON’S	  DISEASE	  	  	  	  	  
André	  Saraiva	  Leão	  Marcelo	  Antunes	  	   A	  thesis	  submitted	  to	  King’s	  College	  London	  for	  the	  degree	  of	  Doctor	  of	  Philosophy	  	  	   Department	  of	  Infectious	  Diseases	  King’s	  College	  London	  School	  of	  Medicine	  	   -­‐April	  2016-­‐	  	   	  
	   2	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  “I	  have	  no	  doubt	  at	  all	  that	  science	  and	  peace	  will	  one	  day	  conquer	  ignorance	  and	  violence.	  The	   future	  belongs	   to	   those	  who	  serve	  mankind.	  The	  young	  scientists	  know	   many	   secrets,	   which	   we	   do	   not.	   Their	   morale	   must	   remain	   high.	  Laboratories	  must	  fill	  the	  world	  and	  you	  must,	  at	  the	  end	  of	  your	  lives,	  be	  able	  to	  say	  that	  you	  have	  done	  what	  you	  could”	  	  Louis	  Pasteur	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Abstract	  Parkinson’s	  disease	  (PD)	  is	  characterised	  by	  progressive	  degeneration	  of	  the	  dopaminergic	   neurons	   in	   the	   substantia	   nigra	   leading	   to	   severe	   motor	  complications.	   Standard	   oral	   treatment	   with	   L-­‐DOPA	   provides	   powerful	  symptomatic	   relief,	   but	   disabling	   side	   effects	   eventually	   develop	   due	   to	   the	  pulsatile	  stimulation	  of	  the	  dopamine	  receptors.	  In	  this	  thesis,	  two	  gene	  therapy	  strategies	   were	   evaluated	   as	   potential	   treatments	   to	   diminish	   the	   fluctuations	  inherent	  to	  oral	  medication.	  In	   the	   first	   project,	   I	   evaluated	   a	   proof-­‐of-­‐concept	   for	   AAV-­‐mediated	  continuous	   L-­‐DOPA	   synthesis	   in	   the	   periphery.	   I	   could	   show	   that,	   in	   healthy	  mice,	  hepatic	  L-­‐DOPA	  production	  and	  release	  can	  be	  achieved	  by	  the	  delivery	  of	  tyrosine	   hydroxylase	   (TH)	   and	   GTP-­‐cyclohydrolase-­‐1	   (GCH1),	   but	   to	   achieve	  plasma	   L-­‐DOPA	   levels	   that	   approximate	   those	   achieved	   with	   oral	   treatment	  additional	   organs	  may	  need	   to	  be	   targeted.	  Therefore	   a	   tricistronic	   vector	  was	  generated	   that	   encoded	   TH,	   GCH1	   and	   6-­‐pyrovoyltetrahydopterin	   synthase	  (PTPS)	  under	  the	  control	  of	  a	  ubiquitous	  promoter	  to	  achieve	  L-­‐DOPA	  synthesis	  in	  muscle	  and	  liver.	  Preclinical	  studies	  are	  currently	  ongoing	  to	  test	  the	  potential	  of	  this	  vector.	  The	  second	  project	  builds	  on	  strong	  preclinical	  data	  generated	  in	  a	  rat	  model	  of	  PD	  and	  assesses	  safety	  and	  efficacy	  of	  an	  AAV	  vector	  harbouring	  TH	  and	  GCH1	  delivered	  to	  the	  brain	  of	  MPTP-­‐lesioned	  non-­‐human	  primates	  (NHP).	  I	  show	  that	  intervention	   is	  safe	  and	   leads	  to	  symptomatic	   improvement	  without	  worsening	  pre-­‐established	   dyskinesia.	   However,	   it	  was	   discovered	   that	   vector	   production	  invariably	   leads	   to	   the	   formation	   of	   two	   vector	   species	   due	   to	   recombination	  between	   identical	  promoter	  sequences.	  Alternative	  vectors	  were	  designed	  with	  the	  goal	  to	  further	  improve	  transgene	  expression	  and	  clinical	  effect,	  and	  to	  avoid	  the	  generation	  of	  additional	  vector	  species.	  However,	   these	  did	  not	  prove	  to	  be	  superior	  in	  animal	  models	  of	  PD.	  The	  data	   indicate	   that	   (1)	  AAV-­‐mediated	  continuous	  L-­‐DOPA	  delivery	   in	   the	  periphery	  is	  feasible	  but	  requires	  further	  optimisation	  and	  assessment	  in	  animal	  models	   to	   fully	  demonstrate	  proof-­‐of-­‐concept,	   (2)	  AAV-­‐mediated	  continuous	  L-­‐DOPA	   delivery	   has	   clinical	   relevance	   but	  may	   require	   improved	   vector	   design	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and	  the	  achievement	  of	  stronger	  preclinical	  efficacy	  data	  to	  warrant	  progression	  to	  clinical	  trials.	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   Homovanillic	  acid	  IHC	   	   Immunohistochemistry	  ILAS	   	   Institute	  of	  laboratory	  animal	  sciences	  IMS	   	   Industrial	  methylated	  spirit	  IRES	   	   Internal	  ribosome	  entry	  site	  ITR	   	   Inverted	  terminal	  repeat	  LB	   	   Lysogeny	  broth	  LCA	   	   Leber's	  congenital	  amaurosis	  L-­‐DOPA	   L-­‐3,4-­‐dihydroxyphenylalanine	  LID	   	   L-­‐DOPA-­‐induced	  dyskinesia	  LPL	   	   Human	  lipoprotein	  lipase	  LRRK2	  	   Leucine-­‐rich	  repeat	  kinase	  2	  MAO	   	   Monoamine	  oxidase	  ML	   	   Mediolateral	  MLD	   	   Metachromatic	  leukodystrophy	  MOI	   	   Multiplicity	  of	  infection	  MPSIIIA	   Mucopolysaccharidosis	  type	  IIIA	  MPTP	   	   1-­‐methyl-­‐4-­‐phenyl-­‐1,2,3,6-­‐tetrahydropyridine	  MWCO	  	   Molecular	  weight	  cut	  off	  mRNA	  	   Messenger	  RNA	  NCBI	   	   National	  center	  for	  biotechnology	  information	  NEB	   	   New	  England	  Biolabs	  NHP	   	   Non-­‐human	  primate	  NGF	   	   Nerve	  growth	  factor	  NTN	   	   Neuturin	  NTP	   	   Nucleoside	  triphosphate	  OD	   	   Optical	  density	  ORF	   	   Open	  reading	  frame	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OSA	   	   1-­‐Octanesulfonic	  acid	  OTCD	   	   Ornithine	  transcarbamylase	  deficiency	  PAGE	  	   	   Poly-­‐acrylamide	  gel	  electrophoresis	  PAH	   	   Phenylalanine	  hydroxylase	  PBS	  	   	   Phosphate	  buffered	  saline	  PC	   	   Posterior	  commissure	  PCA	   	   Perchloric	  acid	  PCR	   	   Polymerase	  chain	  reaction	  PD	   	   Parkinson’s	  disease	  PDGFR	   Platelet-­‐derived	  growth	  factor	  receptor	  PEI	   	   Polyethylinimine	  PFA	  	   	   Paraformaldehyde	  PH	   	   Peak	  height	  PHR	   	   Peak	  height	  ratio	  PINK1	  	   PTEN-­‐induced	  putative	  kinase	  1	  PTEN	   	   Phosphatase	  and	  tensin	  homolog	  PTPS	   	   6-­‐Pyruvoyl-­‐tetrahydropterin	  synthase	  qPCR	   	   Quantitative	  real-­‐time	  PCR	  rAAV	   	   Recombinant	  AAV	  vectors	  RE	   	   Restriction	  endonuclease	  RNA	   	   Ribonucleic	  acid	  RPE65	  	   Retinal	  pigment	  epithelium-­‐specific	  protein	  RT	   	   RT	  reverse	  transcriptase	  SCID-­‐X1	   X-­‐linked	  severe	  combined	  immunodeficiency	  SDS	   	   Sodium	  dodecyl	  sulphate	  SEM	   	   Standard	  error	  of	  the	  mean	  SMA	   	   Spinal	  muscular	  atrophy	  SMN1	   	   Survival	  of	  motor	  neuron	  1	  SNc	   	   Substantia	  nigra	  pars	  compacta	  ssDNA	  	   Single-­‐stranded	  DNA	  STD	   	   Standard	  STN	   	   Subthalamic	  nucleus	  Str	   	   Striatum	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SURE	   	   Stop	  Unwanted	  Rearrangement	  Events	  SV40	   	   Simian	  virus	  40	  SYN	   	   Human	  synapsin	  promoter	  TAE	   	   Tris	  base,	  acetic	  acid	  and	  EDTA	  buffer	  TALENs	   Transcription	  activator-­‐like	  effector	  nucleases	  TEMED	  	   N,N,N’,N’-­‐tetramethylethylenediamine	  TH	   	   Tyrosine	  hydroxylase	  tTH	   	   Truncated	  TH	  UCLA	   	   University	  of	  California,	  Los	  Angeles	  UPDRS	   Unified	  Parkinson's	  Disease	  Rating	  Scale	  VA	  RNA	   Viral	  associated	  RNA	  VMAT2	   Vesicular	  monoamine	  transporter	  2	  VP	   	   Viral	  protein	  VTA	   	   Ventral	  tegmental	  area	  WHX	   	   Woodchuck	  hepatitis	  virus	  X	  protein	  WPRE	   	   Woodchuck	  Posttranscriptional	  Regulatory	  Element	  WT	   	   Wild	  type	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Chapter	  1 Introduction	  	  
1.1 Gene	  Therapy	  	  
1.1.1 History	  and	  Development	  The	   development	   of	   gene	   therapy	   began	   in	   the	   early	   1960s	   with	   the	  realisation	   that	   exogenous	   DNA	   could	   be	   introduced	   into	   mammalian	   cells	  (Rabotti	   1963;	   Borenfreund	   et	   al.	   1970).	   Years	   later,	   the	   discovery	   that	   the	  polyomavirus	   SV40	   integrated	   its	   DNA	   into	   the	   host	   cell	   genome	   during	   the	  process	   of	   neoplastic	   transformation	   led	   to	   the	   assumption	   that	   stable	   and	  functional	   gene	   transfer	   between	   two	   different	   systems	   must	   be	   possible	  (Sambrook	  et	  al.	  1968).	  Rather	  prematurely,	  in	  the	  early	  1970s,	  a	  first	  attempt	  of	  gene	   transfer	   to	   treat	   three	   young	   patients	   suffering	   from	   arginase	   deficiency	  was	  performed	  by	  injecting	  them	  with	  the	  wild-­‐type	  cottontail	  rabbit	  papilloma	  virus	  (CRPV)	   under	   the	   mistaken	   assumption	   that	   the	   wild-­‐type	   virus	   would	  encode	  the	  gene	  for	  arginase	  (Orth	  et	  al.	  1967;	  Terheggen	  et	  al.	  1975).	  Only	  years	  later,	   with	   the	   advent	   of	   recombinant	   DNA	   technology,	   the	   development	   of	  methods	  for	  gene	  delivery	  into	  eukaryotic	  cells	  and	  a	  better	  understanding	  of	  the	  genetic	  basis	  of	  many	  diseases	  did	  the	  field	  regain	  confidence	  in	  the	  potential	  of	  gene	  therapy	  to	  treat	  human	  diseases	  (Graham	  &	  van	  der	  Eb	  1973;	  Maniatis	  et	  al.	  1976;	  Wigler	  et	  al.	  1978;	  Mulligan	  et	  al.	  1979;	  Jackson	  et	  al.	  1992).	  However,	  in	  1980	  another	  rather	  premature	  study	  was	  conducted	  in	  humans,	  in	  which	  blood	  was	   reinfused	   in	   thalassemia	   patients	   after	   it	   was	   transfected	   in	   vitro	   with	  plasmids	   containing	   the	   human	   globin	   and	   a	   viral	   thymidine	   kinase	   gene.	   This	  study,	   severely	   criticised	   by	   the	   scientific	   community,	   had	   not	   received	  permission	  from	  the	  UCLA	  Institutional	  Review	  Board	  and	  led	  to	  the	  sanctioning	  of	  the	  principal	   investigator	  by	  the	  NIH	  (Sun	  1982).	  This	  episode	  prompted	  the	  discussion	   on	   the	   ethics	   and	   public	   policy	   aspects	   of	   gene	   therapy	   ultimately	  leading	  to	  the	  creation	  of	  a	  committee	  by	  the	  NIH	  to	  regulate	  the	  application	  of	  gene	   therapy	   in	   humans	   (Friedmann	   1992;	   Sheridan	   2011).	   The	   episode	   also	  preceded	   a	   10-­‐year	   gap	   in	   which	   no	   clinical	   trials	   of	   gene	   transfer	   were	  attempted.	   During	   this	   time	   researchers	   gained	   a	   better	   understating	   of	   the	  biology	  of	  different	  viruses	  and,	  more	   importantly,	   they	   learned	  how	  to	  modify	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viral	   genomes	   and	   efficiently	   produce	   recombinant	   vectors	   (Shimotohno	   and	  Temin	  1981;	  Doehmer	  et	  al.	  1982;	  Mann,	  Mulligan,	  and	  Baltimore	  1983;	  Miller,	  Law,	  and	  Verma	  1985;	  Markowitz,	  Goff,	  and	  Bank	  1988;	  Howley	  and	  Livingston	  2009).	  The	  ability	  of	   retroviruses	   to	  efficiently	   transduce	  mammalian	   cells	   and	  integrate	  their	  genomes	  made	  them	  a	  strong	  candidate	  for	  gene	  therapy	  vectors.	  In	  1990,	  the	  first	  gene	  therapy	  trial	  was	  approved.	  The	  therapy	  was	  tested	  in	  two	  young	   patients	   with	   severe	   combined	   immunodeficiency	   (ADA-­‐SCID)	   who	  received	   a	   reinfusion	   of	   peripheral	   blood	   T	   cells	   transduced	   with	   a	   retroviral	  vector	  carrying	  the	  adenosine	  deaminase	  cDNA	  (Blaese	  et	  al.	  1995).	  Although	  the	  therapeutic	   benefit	   to	   the	   patients	   was	   modest,	   the	   demonstration	   that	   gene	  therapy	   could	   be	   safely	   conducted	   led	   to	   an	   increased	   number	  of	  clinical	  trials	  for	  a	  broad	  range	  of	   inherited	  disorders	  and	  cancers.	  However,	   in	  1999	  the	  field	  had	  a	  major	  clinical	  setback	  after	  the	  death	  of	  a	  young	  patient	  due	  to	   vector-­‐associated	   toxicity.	   A	   young	  man	   received	   a	   recombinant	   adenoviral	  vector	  to	  treat	  ornithine	  transcarbamylase	  deficiency	  (OTCD),	  the	  most	  common	  metabolic	   disorder	   of	   the	   urea	   cycle,	   and	   died	   98	   hours	   later	   due	   to	   an	   acute	  systemic	   inflammation	   and	   multi-­‐organ	   failure	   caused	   by	   a	   strong	   immune	  response	  to	  the	  adenoviral	  vector	  (Raper	  et	  al.	  2003).	  Not	  much	  later,	  in	  a	  gene	  therapy	  trial	  for	  X-­‐linked	  severe	  combined	  immunodeficiency	  (X-­‐linked	  SCID),	  5	  out	   of	   20	   treated	   children	   developed	   leukaemia,	   one	   of	   whom	   died,	   due	   to	  insertional	  mutagenesis	   caused	  by	   the	  Moloney	  murine	   leukaemia	   virus–based	  gammaretroviral	  vector	  (Cavazzana-­‐Calvo	  et	  al.	  2000;	  Gaspar	  et	  al.	  2004;	  Howe	  et	  al.	  2008;	  Hacein-­‐Bey-­‐Abina	  et	  al.	  2008;	  Hacein-­‐Bey-­‐Abina	  et	  al.	  2010;	  Gaspar	  et	  al.	  2011).	  Notwithstanding	  this	  fatal	  case,	  the	  X-­‐linked	  SCID	  trial	  was	  regarded	  as	   successful,	   with	   cure	   and	   survival	   rates	   similar	   to	   those	   associated	   with	  matched-­‐sibling	  donor	  allogeneic	  hematopoietic	  stem	  cell	  transplantation.	  In	  the	  past	   decade	   a	   variety	   of	   gene	   delivery	   strategies	   have	   been	   developed	   and	  approved	   for	   clinical	   trials,	   some	   of	   them	   leading	   to	   the	   effective	   treatment	   of	  diseases	  such	  as	  haemophilia	  B	  (Nathwani	  et	  al.	  2011),	  sickle-­‐cell	  disease,	  beta-­‐thalassemia	   (Negre	   et	   al.	   2016),	   lipoprotein	   lipase	   deficiency	   (LPLD)	   (Ylä-­‐Herttuala	  2012)	  and	  inoperable	  melanoma	  (Goins	  et	  al.	  2014).	  Although	   gene	   therapy	  was	   first	   conceived	   as	   a	   strategy	   to	   treat	   hereditary	  monogenic	   disorders,	   the	   notion	   that	   gene	   therapy	   can	   be	   used	   to	   treat	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degenerative	   and	   even	   infectious	   diseases	   in	   humans	   has	   now	   long	   been	  accepted	  in	  the	  scientific	  and	  public	  policy	  circles.	  Nowadays,	  medical	  conditions	  including	   cancer,	   cardiovascular	   diseases,	   infectious	   diseases	   and	  neurodegenerative	  disorders	  are	  also	  considered	  for	  gene	  therapy.	  	  New	  technologies	  have	  expanded	  the	  potential	  of	  gene	  therapy	  with	  tools	  that	  allow	  for	  in	  vivo	  gene	  editing.	  Tools	  such	  as	  transcription	  activator–like	  effector	  nucleases	   (TALENs)	   have	   recently	   been	   used	   to	   successfully	   cure	   a	   new-­‐born	  from	   leukaemia	   (Reardon	   2015).	   Furthermore,	   the	   clustered	   regularly	  interspaced	   short	   palindromic	   repeat	   (CRISPR)-­‐associated	   nuclease	   Cas9,	  although	   not	   yet	   tested	   in	   humans,	   holds	   great	   potential	   for	   future	   genetic	  therapies	  (Sterneckert	  et	  al.	  2014).	  	  
1.1.2 Forms	  of	  Gene	  Delivery	  The	  main	  goal	  of	  gene	  therapy	  is	  to	  safely	  achieve	  stable	  expression	  of	  a	  gene	  of	  interest	  in	  the	  appropriate	  tissue.	  In	  this	  pursuit,	  different	  strategies	  for	  gene	  delivery	   have	   been	  developed,	   each	  with	   particular	   characteristics	   as	   to	  which	  type	  of	  cells	  they	  target	  and	  for	  how	  long	  the	  transgene	  is	  expressed.	  Delivery	  of	  transgenes	  can	  be	  divided	  in	  two	  forms:	  non-­‐viral	  and	  viral.	  	  
1.1.2.1 Non-­‐viral	  Mediated	  Gene	  Delivery	  Non-­‐viral	  vectors	  for	  gene	  delivery	  generally	  consist	  of	  double-­‐stranded	  DNA	  plasmids	   associated	  with	   cationic	   liposomes	   to	   allow	   passage	   through	   the	   cell	  membrane	  (Pedroso	  de	  Lima	  et	  al.	  2001;	  Wong	  et	  al.	  2007).	  However,	  physical	  methods,	  such	  as	  electroporation	  or	  propulsion,	  can	  also	  be	  used	  to	  deliver	  DNA	  into	   a	   cell	   (Gehl	   2003).	   Non-­‐viral	   vectors	   are	   cheap,	   easy	   to	   produce	   and	  generally	   trigger	   a	   minimal	   immune	   response,	   however	   they	   still	   face	   the	  problem	   of	   low	   efficiency	   of	   gene	   delivery	   and	   expression	   in	   a	   therapeutic	  context	  (Lechardeur	  et	  al.	  2005).	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1.1.2.2 Viral	  Mediated	  Gene	  Delivery	  Viral	   vectors	   are	   the	  main	   tool	   for	   gene	  delivery	   in	   gene	   therapy	   strategies.	  The	  ability	  of	  viruses	  to	  efficiently	  transfer	  and	  express	  their	  genetic	  information	  in	   different	   hosts	   and	   tissues	   has	   been	   exploited	   and	   viral	   vectors	   have	   been	  engineered	  to	  package	  a	  modified	  genome	  carrying	  a	  gene	  of	  interest	  in	  place	  of	  the	  viral	  genes.	  Viral	   vectors	   can	   be	   subdivided	   in	   two	   categories:	   integrating	   and	   non-­‐integrating	   vectors.	   Integrating	   vectors	   insert	   their	   genetic	   material	   in	   the	  recipient’s	   genome	   ensuring	   that	   their	   genes	   are	   passed	   on	   to	   future	   cell	  generations	   and	   are	   therefore	   used	   to	   transduce	   actively	   dividing	   cells.	   Non-­‐integrating	  vectors,	  on	  the	  other	  hand,	  do	  not	  insert	  themselves	  in	  the	  recipient’s	  genome	  and	  are	  generally	  used	   to	   transduce	  post-­‐mitotic	  or	  non-­‐dividing	  cells.	  While	   integrating	   vectors	   are	   stably	   inherited,	   their	   insertion	   into	   the	   human	  genome	  is	  never	  completely	  devoid	  of	  the	  risk	  of	  insertional	  mutagenesis.	  	  To	  date	  different	  vectors	   for	  gene	  therapy	  have	  been	  developed	  which	  differ	  mainly	   in	   the	  mode	   and	   type	   of	   cells	   they	   transduce,	   their	   packaging	   capacity,	  gene	  expression	  profile	  and	  ability	  to	  elicit	  immune	  responses.	  These	  differences,	  together	   with	   the	   diversity	   of	   diseases	   that	   are	   potentially	   treatable	   by	   gene	  therapy,	   make	   it	   impossible	   to	   have	   one	   single	   vector	   that	   is	   suitable	   for	   all	  applications.	  The	  viral	  vectors	  most	  commonly	  used	  in	  gene	  therapy	  are	  derived	  from	   gammaretroviruses,	   lentiviruses,	   adenoviruses,	   adeno-­‐associated	   viruses	  (AAV)	  and	  herpes	  simplex-­‐1	  viruses	  (HSV-­‐1).	  Because	  some	  of	   these	  viruses	  are	  pathogenic	   in	   their	  wild-­‐type	   forms,	   their	  formation	  and	  replication	  in	  a	  therapeutic	  context	  is	  highly	  undesired.	  To	  avoid	  pathogenicity	  and	  increase	  their	  safety	  profile,	  mechanisms	  are	  employed	  during	  vector	  production	  to	  ensure	  the	  generation	  of	  replicative	  defective	  vectors.	  This	  can	   be	   achieved	   through	   the	   replacement	   of	   viral	   genes	   by	   the	   therapeutic	  transgene	   and	   the	   separation	   of	   cis	   and	   trans	   elements.	   Cis	   elements	   are	   the	  nucleic	   acid	   sequences	   that	   are	   biologically	   active,	   while	   trans	   elements	   are	  protein-­‐coding	   sequences	   that	   act	   through	   the	   expressed	   proteins.	   This	  separation	  is	  a	  very	  important	  safety	  mechanism	  in	  vector	  production	  to	  impose	  a	  barrier	  for	  the	  formation	  of	  replication	  competent	  wild-­‐type	  virus.	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The	  popularity	  of	  AAV	  as	  a	  gene	  therapy	  vector	  has	  significantly	  grown	  in	  the	  last	   decades	   owing	   mainly	   to	   its	   ability	   to	   achieve	   long-­‐term	   transgene	  expression,	   its	   low	   immunogenicity	   and	   the	   lack	  of	  pathogenicity	   associated	   to	  viral	   infection.	   Although	   a	   debate	   on	   the	   oncogenic	   potential	   of	   AAV	   has	   been	  recently	   sparked	   by	   a	   study	   linking	   AAV	   infection	   with	   the	   development	   of	  hepatocellular	   carcinoma	   (Nault	   et	   al.	   2015),	   this	   study	   was	   resoundingly	  rejected	   by	   leading	   researchers	   in	   the	   fields	   of	   gene	   therapy	   and	   molecular	  genetics	  and	  more	  recent	  data	   refute	   the	  proposed	   link	  between	  AAV	   infection	  and	  hepatocellular	  carcinoma	  (Berns	  et	  al.	  2015;	  Gil-­‐Farina	  et	  al.	  2016).	  Since	  the	  study	  described	  in	  this	  thesis	  made	  use	  of	  AAV	  vectors,	  its	  biology	  and	  application	  in	  gene	  therapy	  will	  be	  discussed	  in	  further	  detail.	  	  
1.2 Adeno-­‐Associated	  Virus	  AAV	  belongs	   to	   the	  Parvoviridae	   family	   and	   is	   classified	   in	   the	  Dependovirus	  genus	  due	  to	  its	  dependence	  on	  helper	  functions	  provided	  by	  other	  DNA	  viruses	  such	  as	  adeno-­‐	  or	  herpes	  virus	  to	  complete	  a	  productive	  replication	  cycle.	  AAV	  is	  a	  nonenveloped,	  small	  virus	  (25nm)	  with	  a	  linear	  single-­‐stranded	  DNA	  (ssDNA)	  genome	  of	  4.7kb.	  The	  viral	  genome	  can	  be	  either	  sense	  or	  antisense	  and	  contains	  two	  main	   open	   reading	   frames	   (ORF):	   rep	   and	   cap.	   The	   rep	  ORF	   codes	   for	   the	  non-­‐structural	   proteins	   Rep78,	   Rep68,	   Rep52	   and	   Rep40,	   while	   the	   cap	   ORF	  codes	   for	   the	   structural	   proteins	   VP1,	   VP2	   and	   VP3	   (Srivastava	   et	   al.	   1983).	  Within	  the	  VP2	  coding	  sequence,	  a	  cryptic	  ORF	  is	  present	  that	  codes	  for	  a	  protein	  involved	   in	   capsid	  assembly	   called	  assembly-­‐activating	  protein	   (AAP)	   (Sonntag	  et	  al.	  2010).	  The	  expression	  of	  a	  variety	  of	  proteins	  from	  such	  a	  limiting	  coding	  capacity	   is	  achieved	  by	  combining	  different	  promoters,	  alternative	  splicing	  and	  non-­‐conventional	  start	  codons	  (Lusby	  et	  al.	  1980;	  Marcus	  et	  al.	  1981;	  Qiu	  et	  al.	  2006).	  The	  viral	  genome	  is	  further	  characterised	  by	  the	  presence	  of	  inverted	  terminal	  repeats	   (ITRs),	   145bp	   imperfect	   palindromic	   sequences	   that	   flank	   the	   open	  reading	  frames	  and	  that	  self-­‐anneal	  to	  form	  T-­‐shaped	  hairpins.	  The	  ITRs	  provide	  all	   the	   cis-­‐acting	   elements	   necessary	   for	   replication	   and	   packaging	   of	   the	   viral	  genome	  (Samulski	  et	  al.	  1989)	  (Figure	  1).	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Figure	  1:	  AAV	  genome,	  genes,	  transcriptional	  units	  and	  proteins.	  
There	  are	  three	  promoters,	  identified	  by	  their	  relative	  position	  in	  the	  genome:	  p5,	  p19	  and	  
p40.	   The	   p5	   promoter	   controls	   the	   expression	   of	   the	   large	  Rep	   proteins	   Rep78	   and	   the	  
spliced	  variant	  Rep68.	  The	  p19	  gives	  rise	  to	  the	  small	  Rep	  proteins	  Rep52	  and	  Rep40.	  The	  
p40	  promoter	  controls	   the	  expression	  of	   the	  three	  capsid	  proteins	  VP1,	  VP2	  and	  VP3,	  as	  
well	   as	   of	   AAP.	   There	   is	   a	   single	   splice	   donor	   site	   and	   two	   splice	   acceptor	   sites,	   one	   of	  
which	   (2228)	   is	   used	   most	   frequently.	   Alternative	   splicing	   and	   non-­‐conventional	   start	  
codons	  (for	  VP2	  and	  AAP)	  allow	  the	  generation	  of	  8	  proteins	  (coloured	  boxes).	  All	  the	  AAV	  
mRNAs	  use	  a	  single	  polyA	  tail	  located	  at	  the	  right	  end	  of	  the	  genome.	  	  The	  4.7kb	  genome	  is	  packaged	  in	  an	  icosahedral	  capsid	  formed	  by	  a	  total	  of	  60	  copies	  of	  VP1,	  VP2	  and	  VP3,	  in	  a	  ratio	  of	  1:1:10,	  respectively.	  The	  capsid	  proteins	  provide	  vital	   functions	   for	   the	  virus	   life	  cycle,	  such	  as	  host	  cell	   recognition	  and	  binding,	  entry	  and	  trafficking	   to	   the	  nucleus,	   release	  of	   the	  viral	  genome	  at	   the	  appropriate	  time	  and	  place,	  egress	  from	  the	  host	  cell,	  and	  escape	  from	  immune	  surveillance	   (Agbandje-­‐McKenna	   &	   Kleinschmidt	   2011).	   In	   total,	   13	   AAV	  serotypes	  have	  been	  isolated	  (AAV1-­‐13),	  with	  AAV2	  being	  the	  most	  extensively	  studied	   and	   best	   known.	  Among	   the	   differences	   between	   the	   13	   serotypes	   are	  the	   variations	   in	   their	   cap	   gene	   sequences	   that	   reflect	   their	   evolutionary	  relationship	   and	   phylogenetic	   proximity	   to	   each	   other.	   These	   variations	   play	  important	   roles	   in	   viral	   host	   cell	   binding,	   tissue	   tropism	   and	   determination	   of	  capsid	  antigenicity	  (Srivastava	  et	  al.	  1983;	  Muramatsu	  et	  al.	  1996;	  Chiorini	  et	  al.	  1997;	  Rutledge	  et	  al.	  1998;	  Chiorini	  et	  al.	  1999;	  Gao	  et	  al.	  2002;	  Gao	  et	  al.	  2004;	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Mori	  et	  al.	  2004;	  Schmidt	  et	  al.	  2006;	  Schmidt,	  Voutetakis,	  et	  al.	  2008;	  Schmidt,	  Govindasamy,	  et	  al.	  2008;	  Drouin	  &	  Agbandje-­‐McKenna	  2013).	  	  	  
1.2.1 AAV	  Life	  Cycle	  and	  Biological	  Barriers	  for	  Cell	  Transduction	  AAV	   has	   a	   complex	   and	   tightly	   regulated	   life	   cycle	   characterised	   by	   the	  presence	   of	   a	   productive	   replicative	   and	   a	   latent	   phase.	   Under	   permissive	  conditions,	   such	  as	  co-­‐infection	  with	  adeno-­‐	  or	  herpes	  virus,	   the	  AAV	  DNA	  will	  undergo	  several	  rounds	  of	  replication	  before	  being	  packaged	  into	  newly	  formed	  capsids.	   Under	   non-­‐permissive	   conditions,	   however,	   AAV	  will	   remain	   latent	   in	  the	   cell,	   either	   episomally	   or	   integrated	   in	   the	   host	   genome	   (Henckaerts	   &	  Linden	  2010).	  Infection	   begins	   with	   the	   attachment	   of	   the	   virus	   to	   the	   host	   cell	   surface.	  Following	  attachment,	  AAV	  interacts	  with	  the	  AAV	  receptor	  (AAVR)	  before	  being	  internalised	   through	   endocytosis	   and	   trafficked	   to	   the	   trans-­‐Golgi	   network	  (Pillay	  et	  al.	  2016).	  	  The	   intricacies	   of	   AAV	   intracellular	   trafficking	   to	   the	   nucleus	   are	   not	  completely	  understood	  but	  AAV	  has	  been	  shown	  to	  co-­‐localise	  with	  markers	  of	  early,	  late,	  recycling	  endosomes	  as	  well	  as	  lysosomes	  after	  internalisation	  and	  it	  is	  known	  that	  endosomal	  processing,	  which	   leads	  to	  conformational	  changes	  to	  the	  AAV	  capsid,	  is	  necessary	  for	  efficient	  AAV	  infection	  (Nonnenmacher	  &	  Weber	  2011).	  Whether	  AAV	  uncoating	  occurs	  inside	  the	  nucleus	  or	  immediately	  prior	  to	  nuclear	  entry	   is	  still	  a	  matter	  of	  debate	  with	  existing	  evidence	  supporting	  both	  interpretations	  (Bartlett	  et	  al.	  2000;	  Sanlioglu	  et	  al.	  2000;	  Xiao	  et	  al.	  2002;	  Lux	  et	  al.	  2005).	  Following	  genome	  release,	  the	  single-­‐stranded	  DNA	  must	  be	  converted	  into	   a	   double-­‐stranded	   DNA	   genome	   for	   gene	   expression	   and	   replication.	   The	  essential	  elements	  required	  for	  AAV	  DNA	  replication	  are	  the	  viral	  ITRs,	  the	  large	  Rep	  proteins	  (Rep78	  or	  Rep68)	  and	  a	  subset	  of	  helper-­‐virus	  factors	  such	  as	  the	  adenoviral	   E1,	   E2A,	   E4orf6	   proteins	   and	   the	   adenoviral	   non-­‐coding	   VA1	   RNA	  (Hauswirth	  and	  Berns	  1977;	  Geoffroy	  and	  Salvetti	  2005;	  Vogel	  et	  al.	  2013).	  The	  model	   for	   AAV	   replication	  was	   described	   several	   decades	   ago	   and	   it	   is	  often	  referred	  to	  as	  rolling	  hairpin	  replication	  (Kerr	  et	  al.	  2005).	  It	  consists	  of	  a	  modified	   version	   of	   the	   plasmid	   rolling	   circle	   replication	   mechanism	   and	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involves	  a	  strand	  displacement	  process.	  Replication	  of	  the	  AAV	  genome	  is	  shown	  in	  Figure	  2	  and	  begins	  with	  the	  synthesis	  of	  the	  second	  DNA	  strand	  with	  the	  self-­‐annealed	   ITR	   on	   the	   3’	   end	   of	   the	   genome	   functioning	   as	   a	   primer	   for	  unidirectional	  DNA	  synthesis.	  The	  extension	  from	  the	  3’	  end	  results	  in	  a	  double-­‐stranded	  molecule	  covalently	  attached	  at	  one	  side.	  The	  replication	  of	  the	  ITR	  that	  originally	   served	   as	   a	   primer	   is	   called	   terminal	   resolution	   and	   it	   requires	   the	  binding	   of	   Rep	   to	   a	   region	   of	   the	   ITR	   called	   Rep	   binding	   site	   (RBS)	   and	  subsequent	  nicking	  at	  the	  terminal	  resolution	  site	  (TRS)	  to	  generate	  a	  new	  free	  3’-­‐OH.	   DNA	   replication	   is	   resumed	   from	   the	   newly	   generated	   3’-­‐OH	   and	   the	  second	   ITR	   is	   copied.	  At	   the	   end	  of	   this	   process	   a	   double-­‐stranded	   linear	  DNA	  molecule	  with	  palindromic	  ends	  is	  generated,	  which	  can	  fold	  back	  into	  T-­‐shaped	  structures,	  thereby	  allowing	  a	  new	  round	  of	  replication	  by	  strand	  displacement	  to	  begin.	  	  	  
	  
Figure	  2:	  Rolling	  hairpin	  replication	  of	  AAV	  DNA.	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The	   free	   3’-­‐OH	   provided	   by	   the	   self-­‐annealed	   ITR	   (a)	   serves	   as	   the	   primer	   for	   DNA	  
replication	  mediated	  by	  the	  cellular	  machinery	  (b).	  The	  right	  ITR	  is	  replicated	  by	  strand	  
displacement,	  generating	  a	  double-­‐stranded	  molecule	  covalently	  linked	  by	  the	  left	  ITR	  (c).	  
Rep	  binds	  at	   the	  RBS	  in	  the	   left	   ITR	  (d)	  and	  nicks	  at	   the	  nearby	  TRS	  site	  (e)	  to	  allow	  the	  
terminal	  resolution	  of	  the	  left	  ITR	  (f).	  The	  complementary	  ITR	  sequences	  at	  the	  right	  end	  
of	   the	   genome	   fold	   back	   (g),	   freeing	   a	   new	  3’-­‐OH	   that	   can	  be	  used	   for	   another	   round	  of	  
replication	  by	  strand	  displacement	  (h)	  that	  generates	  a	  new	  single-­‐stranded	  AAV	  genome	  
and	   a	   double-­‐stranded	  molecule	   covalently	   linked	   by	   the	   right	   ITR	   (i).	   These	  molecules	  
can	  then	  be	  used	  for	  another	  round	  of	  replication	  (grey	  arrows)	  or	  potentially	  could	  serve	  
as	   packaging	   templates.	   If	   the	   refolding	   of	   the	   right	   ITR	   occurs	   prior	   to	   the	   terminal	  
resolution	   of	   the	   left	   ITR	   (j)	   followed	   by	   replication	   by	   strand	   displacement,	   a	   dimeric	  
replication	   intermediate	  can	  be	   formed	  (k).	  By	  subsequent	  RBS	  binding	  and	  TRS	  nicking	  
the	  dimeric	  intermediate	  can	  re-­‐enter	  the	  replication	  cycle.	  	  Packaging	  occurs	  by	   inserting	  the	  newly	  synthesised	  AAV	  genomes	   into	  pre-­‐assembled	   capsids,	   formed	   rapidly	   in	   the	   nucleus	   with	   help	   of	   the	   assembly	  activating	  protein	  (Sonntag	  et	  al.	  2010).	  Packaging	  is	  known	  to	  be	  a	  slow	  reaction	  and	   the	   only	   cis	   acting	   elements	   necessary	   for	   this	   process	   are	   the	   AAV	   ITRs	  (McLaughlin	   et	   al.	   1988).	   Experiments	   have	   demonstrated	   the	   interaction	  between	  Rep	  and	  capsids	  during	  genome	  packaging	  and	  that	  part	  of	  the	  capsid-­‐associated	  Rep	  is	  covalently	  attached	  to	  the	  5’	  end	  of	  replicated	  DNA	  (Wistuba	  et	  al.	  1995;	  Prasad	  &	  Trempe	  1995).	  AAV	   encounters	   several	   biological	   barriers	   that	   appear	   to	   limit	   its	   ability	   to	  efficiently	   transduce	   certain	   tissues.	   The	   first	   one	   is	   the	   viral	   attachment	   and	  interaction	  with	  different	  factors	  present	  at	  the	  host	  cell	  surface.	  This	  step	  has	  a	  particular	   significance	   in	  defining	   tissue	   tropism	  and	   transduction	  efficiency	  of	  different	   serotypes.	   Successful	   AAV	   entry	   into	   the	   cell	   is	   greatly	   affected	   by	  attachment	   factor	   and	   co-­‐receptor	   recognition.	   Heparan	   sulphate	   proteoglycan	  (HSPG)	  has	  been	   identified	   as	  one	  of	   the	  primary	   attachment	   factors	   for	  AAV2	  and	  AAV3	  (Summerford	  &	  Samulski	  1998;	  Handa	  et	  al.	  2000;	  Wong	  et	  al.	  2015).	  In	  contrast,	  sialic	  acid	  has	  been	  identified	  as	  a	  primary	  attachment	  receptor	  for	  AAV4	  and	  AAV5	  (Kaludov	  et	  al.	  2001;	  Walters	  et	  al.	  2001).	  AAV7	  and	  AAV8	  were	  rescued	   from	   non-­‐human	   primate	   tissues	   and	   their	   distinct	   tissue	   tropisms	  suggest	   that	   they	  use	  different	  cell	   surface	  receptors	   than	  other	  AAV	  serotypes	  (Summerford	  et	   al.	   1999;	  Qing	  et	   al.	   1999).	  AAV	  also	   requires	   co-­‐receptors	   for	  efficient	   infection.	   For	   example,	   although	   both	   AAV2	   and	   AAV3	   use	   HSPG	   to	  attach	   to	   cells,	   AAV3	   can	   transduce	   hematopoietic	   cells,	   which	   are	   not	  susceptible	   to	   transduction	  with	  AAV2,	  suggesting	   that	  co-­‐receptors	  on	   the	  cell	  surface	  are	  required	  for	  infection	  and	  can	  influence	  the	  tropism	  of	  different	  AAV	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serotypes.	   The	   integrin	   αVβ5	   and	   the	   fibroblast	   growth	   factor	   receptor	   have	  been	   identified	   as	   co-­‐receptors	   for	   AAV2.	   Similarly,	   platelet-­‐derived	   growth	  factor	  receptor	  (PDGFR)	  has	  been	  identified	  as	  a	  co-­‐receptor	  for	  AAV5	  (Pilz	  et	  al.	  2012).	  The	  abundance	  of	  AAV	  co-­‐receptors	  on	  the	  surface	  of	  target	  cells	  and	  the	  activation	   of	   cellular	   pathways	   that	   trigger	   endocytosis	   can	   also	   be	   a	   rate-­‐limiting	  factor	  in	  AAV	  infection	  (Duan,	  Yue,	  et	  al.	  1998).	  Viral	   trafficking,	   endosomal	   escape	   and	   nuclear	   import	   are	   interrelated	  processes	  and	  appear	  to	  be	  rate-­‐limiting	  for	  many	  AAV	  serotypes.	  It	  has	  become	  increasingly	   recognised	   that	   following	   endocytosis,	   processing	   of	   AAV	   virions	  through	   the	   endosomal	   compartment	   is	   intricately	   linked	   to	   transduction.	   For	  example,	  when	  directly	  injected	  into	  the	  cytoplasm,	  AAV2	  fails	  to	  accumulate	  in	  the	  nucleus,	  suggesting	  the	  necessity	  of	  endosomal	  processing	  for	  viral	  infection.	  Further,	   endosomal	   processing	   of	   AAV	   has	   been	   shown	   to	   lead	   to	   the	  externalisation	   of	   the	   phospholipase	   A2	   catalytic	   domain,	   a	   functional	   domain	  relevant	  for	  viral	  infection	  (Sonntag	  et	  al.	  2006).	  In	  addition,	  different	  serotypes	  might	   be	   distinctively	   affected	   by	   endosomal	   acidification	   depending	   on	   the	  stability	  of	  their	  capsid	  proteins	  (Ding	  et	  al.	  2005;	  Nam	  et	  al.	  2011;	  Horowitz	  et	  al.	  2013).	  	  The	  final	  steps	  for	  AAV	  transduction	  include	  viral	  uncoating	  and	  conversion	  of	  the	  single-­‐stranded	  AAV	  genome	  to	  double-­‐stranded	  DNA	  capable	  of	  expressing	  its	   genes.	   Although	   still	   an	   elusive	   matter,	   it	   is	   generally	   believed	   that	   AAV	  particles	   are	   transported	   into	   the	   nucleus	   prior	   to	   uncoating	   and	   that	   both	  processes	   represent	   rate-­‐limiting	   steps	   for	   AAV	   infection	   (Seisenberger	   et	   al.	  2001;	  Xiao	  et	  al.	  2002).	  In	  the	  absence	  of	  co-­‐infection	  with	  a	  helper	  virus,	  AAV	  is	  not	  able	  to	  replicate	  and	   enters	   the	   latent	   phase	   of	   its	   life	   cycle	   by	   integrating	   into	   the	   host	   cell	  genome.	   Integration	  was	   first	  mapped	   to	  one	   locus	   in	   the	  human	   chromosome	  19,	   termed	  AAVS1,	  and	  was	  shown	  to	  be	  a	  Rep	  dependent	  mechanism	  (Kotin	  &	  Siniscalco	   1990;	   Kotin	   et	   al.	   1991;	   Samulski	   et	   al.	   1991;	   Surosky	   et	   al.	   1997).	  More	  recently,	   several	  other	   integration	  hotspots	  were	   identified	   in	   the	  human	  genome	  but	  the	  AAVS1	  locus	  remains	  by	  far	  the	  most	  frequently	  targeted	  by	  AAV	  (Hüser	  et	  al.	  2014;	  Petri	  et	  al.	  2015).	  A	  schematic	  representation	  of	  the	  AAV	  life	  cycle	  is	  shown	  in	  Figure	  3.	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Figure	  3:	  The	  AAV	  life	  cycle.	  
The	  AAV	  life	  cycle	  is	  divided	  between	  productive	  infection	  in	  the	  presence	  of	  helper	  virus	  
(adenovirus	  in	  the	  picture)	  and	  latent	  infection	  in	  its	  absence.	  (I)	  The	  AAV	  particle	  enters	  
the	   cell	   by	   receptor-­‐mediated	   endocytosis	   and	   (II)	   is	   trafficked	   through	   the	   endosomal	  
system	   to	   (III)	   the	   nuclear	  membrane.	   (IV)	   After	   translocation	   to	   the	   nucleus,	   the	   viral	  
DNA	   is	   released	   and	   (V)	   undergoes	   several	   rounds	   of	   replication	   before	   being	   (VI)	  
packaged	  in	  pre-­‐formed	  capsids	  and	  (VII)	  egressing	  from	  the	  cell.	  In	  the	  absence	  of	  helper	  
functions,	   the	   AAV	   particle	   reaches	   the	   nucleus	   where	   it	   can	   establish	   latency	   by	   (A)	  
forming	   a	   stable	   circular	   episome	   or	   (B)	   by	   integrating	   into	   the	   human	   genome.	   In	   the	  
event	  of	  helper	  virus	   superinfection,	   (C)	   the	  AAV	  genome	  can	  be	   rescued	   from	   its	   latent	  
state	   and	   undergo	   productive	   replication.	   The	   relative	   sizes	   of	   the	   elements	   of	   this	  
diagram	  are	  not	  in	  scale	  but	  are	  adapted	  for	  clarity.	  	  
1.3 Recombinant	  AAV	  Vectors	  Integrated	   AAV	   has	   been	   shown	   to	   be	   rescued	   from	   the	   host	   genome	   upon	  infection	  with	  helper	  viruses	   (Hoggan,	  M.	  D.,	  Thomas,	  G.	  F.	   and	   Johnson	  1973).	  This	   observation	   suggested	   that	   rescue	   of	   the	   AAV	   genome	   from	   a	   plasmid	  should	  be	  possible	  if	  a	  helper	  virus	  was	  present.	  Indeed,	  when	  the	  AAV	  genome	  was	  cloned	  into	  a	  bacterial	  plasmid	  and	  exposed	  to	  a	  helper	  virus	  in	  culture	  cells,	  it	  was	  able	   to	   replicate	  and	   infect	   in	  a	  manner	   that	  was	   indistinguishable	   from	  wild-­‐type	  virions.	  This	  breakthrough	  promoted	  rapid	  progress	   in	   the	  AAV	   field	  by	   facilitating	   the	  manipulation	   of	   its	   genome	   for	   the	   study	   of	   replication	   and	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gene	  expression	  (Samulski	  et	  al.	  1982;	  Laughlin	  et	  al.	  1983).	  With	  this	  new	  tool	  to	  study	  AAV,	  it	  was	  quickly	  noticed	  that	  the	  ITRs	  were	  cis-­‐acting	  elements,	  while	  the	  genes	  between	  them	  -­‐	  later	  discovered	  to	  code	  for	  the	  Rep	  and	  Cap	  proteins	  -­‐	  had	  a	  trans-­‐acting	  function	  in	  AAV	  replication.	  This	  notion	  paved	  the	  way	  for	  the	  generation	  of	  recombinant	  AAV	  vectors	  (rAAV):	  by	  retaining	  the	  cis-­‐acting	  ITRs	  and	  providing	   the	   trans-­‐acting	  Rep	  and	  Cap	   functions	  by	  complementation,	   the	  whole	   AAV	   genome	   could	   be	   deleted	   (except	   for	   the	   ITRs)	   and	   a	   vector	  containing	  a	  foreign	  DNA	  sequence	  of	  up	  to	  4.5kb	  could	  be	  produced	  (Figure	  4).	  	  
	  
Figure	  4:	  Genomic	  structures	  of	  wild-­‐type	  and	  recombinant	  AAV.	  
rAAV	  is	  generated	  by	  removing	  the	  trans-­‐acting	  elements	  rep	  and	  cap	   from	  the	  wild-­‐type	  
virus	   (top)	   and	   replacing	   them	   by	   a	   transgene	   cassette	   consisting	   of	   a	   promoter	   and	   a	  
transgene	   (bottom).	   The	   only	   viral	   elements	   present	   in	   rAAV	   are	   the	   cis-­‐acting	   ITRs,	  
responsible	  for	  the	  packaging	  of	  the	  transgene	  cassette	  into	  AAV	  capsids.	  The	  rep	  and	  cap	  
ORF	  are	  depicted	  in	  red	  and	  blue,	  respectively.	  The	  transgene	  cassette	  is	  depicted	  by	  the	  
orange	   and	   green	   lines	   and	   they	   represent	   the	   promoter	   and	   the	   transgene	   under	   its	  
control,	  respectively.	  	  	  Because	   the	   rAAV	   generated	   by	   Rep	   and	   Cap	   trans-­‐complementation	   are	  devoid	  of	  all	  wild-­‐type	  genes,	  these	  vectors	  are	  unable	  to	  replicate	  or	  to	  integrate	  and	   their	   recombinant	   genomes	   form	   concatemers,	   which	   are	   able	   to	   stably	  express	  their	  transgenes	  in	  transduced	  cells.	  Also	  important	  for	  the	  development	  of	   rAAV	   were	   studies	   that	   analysed	   mutations	   in	   the	   adenovirus	   genome	   and	  identified	  the	  subset	  of	  adenoviral	  genes,	   including	  E1,	  E2A,	  E4orf6	  and	  the	  VA	  RNA	   as	   necessary	   and	   sufficient	   to	   establish	   the	   helper	   functions	   required	   for	  AAV	  replication	  (Matsushita	  et	  al.	  1998).	  This	  discovery	  led	  to	  the	  development	  
rep cap 
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of	  plasmids	  harbouring	  helper	  function	  genes,	  which	  allowed	  for	  the	  production	  of	  rAAV	  using	  helper	  virus-­‐free	  methods	  (Streck	  et	  al.	  2005).	  Another	   important	   advance	   in	   the	   generation	   of	   rAAV	   vectors	   was	   the	  development	  of	  double-­‐stranded	  AAV	  vectors	   (dsAAV	  -­‐	  also	  referred	   to	  as	  self-­‐complementary	  AAV),	  which	  are	  able	  to	  achieve	  a	  more	  rapid	  onset	  of	  transgene	  expression	   (Wang	   et	   al.	   2003).	  Double-­‐stranded	  AAV	   is	   generated	  by	  mutating	  the	  TRS	   in	  one	   ITR,	   thereby	  abolishing	   the	   terminal	   resolution	  step	  of	   the	  AAV	  replication	   and	   resulting	   in	   a	   sense	   and	   antisense	   strand	   covalently	   linked	  (Figure	  2j).	  The	  rapid	  transgene	  expression	  of	  dsAAV	  occurs	  because	  they	  bypass	  the	   rate-­‐limiting	   second-­‐strand	   synthesis	   step	   once	   the	   genome	   is	   uncoated	   in	  the	   cell	   (McCarty	   2008).	   Gene	   therapy	   strategies	   have	   taken	   advantage	   of	   the	  rapid	   onset	   of	   transgene	   expression	   in	   dsAAV,	   however	   the	   packaging	   of	   a	  dimeric	  genome	  limits	  the	  loading	  capacity	  of	  dsAAV	  to	  half	  of	  the	  length	  of	  the	  ssAAV	  genome.	  This	  size	  restriction	   limits	   the	  application	  of	  dsAAV	  vectors	   for	  gene	   therapy	  but	   the	  ability	  of	  AAV	   to	   form	  concatemers	   in	   vivo	   has	   led	   to	   the	  development	  of	  dual	  vector	  strategies	   in	  order	   to	  overcome	  this	  size	   limitation	  (Yang	  et	  al.	  1999;	  Yan	  et	  al.	  2000;	  Ghosh	  &	  Duan	  2007).	  Concatemerisation	  of	   the	  AAV	  genome	   is	   important	  not	  only	   for	  dual	   vector	  strategies	   in	   gene	   therapy;	   it	   is	   also	   the	   underlying	  mechanism	   through	  which	  rAAV	  is	  able	  to	  stably	  express	  its	  transgenes.	  Concatemerisation	  occurs	  through	  intramolecular	  recombination	  of	  independent	  monomer	  circular	  vector	  genomes	  mostly	   in	   a	   head-­‐to-­‐tail	   configuration	   (Duan,	   Sharma,	   et	   al.	   1998;	   Yang	   et	   al.	  1999;	  Nakai	  et	  al.	  2001).	  	  
1.3.1 Production	  of	  recombinant	  AAV	  Production	  of	  rAAV	  vectors	  can	  be	  achieved	  in	  culture	  by	  supplying	  cells	  with	  (1)	  a	  plasmid	  containing	  a	   transgene	  cassette	   flanked	  by	   the	  AAV	   ITRs,	   (2)	   the	  AAV	  rep	  and	  cap	  coding	  sequences	  and	  (3)	  the	  helper	  functions.	  Several	  methods	  have	  been	  developed,	  which	  use	  different	  forms	  of	  delivery	  of	  each	  of	  these	  three	  elements	   necessary	   for	   rAAV	   production.	   The	   most	   common	   one	   consists	   of	  double	   or	   triple	   transfection	   of	   the	   human	   embryonic	   kidney	   derived	   cell	   line	  HEK293.	  Triple	  transfection	  is	  performed	  when	  the	  three	  items	  mentioned	  above	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are	  provided	  in	  separate	  plasmids,	  however	  the	  combination	  of	  elements	  2	  and	  3	  into	  one	  single	  plasmid	  is	  also	  possible	  and	  allows	  for	  a	  double	  transfection	  for	  rAAV	  production.	  Transfection-­‐based	  production	  commonly	  uses	  adherent	  cells,	  which	  can	  render	  the	  production	  of	  rAAV	  a	  laborious	  task	  when	  very	  high	  yields	  are	  desired.	  However,	  HEK293	   cells	   have	  been	   adapted	   to	   suspension	   cultures	  and	   protocols	   have	   been	   optimised	   for	   the	   production	   of	   large-­‐scale	   good	  manufacturing	   practices	   (GMP)-­‐compliant	   vectors	   (Grieger	   et	   al.	   2015).	  Alternative	  rAAV	  production	  methods	  consist	  of	  suspension	  cell	  culture	  systems	  of	   either	   insect	   cells,	   to	   which	   all	   three	   components	   mentioned	   above	   are	  provided	   by	   baculovirus	   infection	   or	   stable	  mammalian	   packaging	   (containing	  
rep	   and	   cap)	   or	   producer	   (containing	   the	   transgene	   flanked	   by	   AAV	   ITRs)	   cell	  lines,	   to	  which	  certain	  components	  are	  provided	  by	  adenovirus	   infection.	   rAAV	  production	  protocols	   are	   continuously	   improving	  and	   the	  HEK293	   transfection	  system	   has	   been	   optimised	   to	   yield	   enough	   vector	   for	   preclinical	   and	   clinical	  trials,	   however	   further	   advances	   in	   rAAV	  production	  protocol	   are	   still	   desired.	  Regardless	  of	  the	  production	  system	  adopted,	  the	  yield	  of	  rAAV	  is	  usually	  10-­‐fold	  lower	   than	   that	   of	   wtAAV,	   possibly	   due	   to	   differences	   between	   providing	   the	  
trans-­‐acting	   elements	   by	   complementation	   vs.	   within	   the	   AAV	   genome.	  Furthermore,	   the	  ratio	  between	  empty-­‐	  and	  genome	  containing	  particles	  varies	  between	  different	  purification	  systems	  but	  it	  is	  usually	  higher	  for	  rAAV	  than	  for	  wtAAV	  (Aucoin	  et	  al.	  2008).	  High-­‐yielding	   and	   scalable	   rAAV	   purification	   methods	   are	   of	   paramount	  importance	   for	   the	   application	   of	   rAAV	   in	   large-­‐scale	   preclinical	   and	   clinical	  studies.	  	  
1.3.2 Purification	  of	  recombinant	  AAV	  Traditional	  purification	  methods	  include	  density	  gradient	  centrifugation,	  most	  commonly	   using	   iodixanol	   or	   caesium	   chloride,	   and	   chromatography,	   such	   as	  ion-­‐exchange,	   receptor-­‐specific	   affinity	   purification	   and	  AVB	   sepharose	   affinity	  purification.	   Gradient	   centrifugation	   purification	   results	   in	   a	   smaller	   ratio	   of	  empty/genome	  containing	  particles	  due	  to	  the	  density	  difference	  between	  empty	  and	  full	  particles,	  which	  are	  separated	  during	  the	  centrifugation.	  The	  downside	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of	   this	   method	   is	   the	   difficulty	   to	   adapt	   it	   for	   large-­‐scale	   productions.	   The	  opposite	   is	   true	   for	   chromatography	   purification	   methods:	   while	   they	   are	  relatively	   easy	   to	   upscale,	   they	   do	   not	   distinguish	   between	   empty	   and	   full	  particles.	  Thus,	   if	  a	  small	  ratio	  of	  empty/full	  particles	  is	  desired	  in	  a	  large-­‐scale	  production,	  a	  combination	  of	  both	  purification	  methods	  must	  be	  used.	  However,	  for	   the	   majority	   of	   routine	   laboratory	   research	   and	   preclinical	   studies,	   either	  purification	   method	   is	   suitable.	   In	   recent	   years,	   AVB	   sepharose	   affinity	  chromatography	   has	   gained	   increased	   popularity.	   In	   contrast	   to	   the	   other	  chromatography	   methods,	   its	   AAV	   affinity	   ligand	   -­‐	   a	   14kDa	   fragment	   from	   a	  single	   chain	   antibody	   expressed	   in	   yeast	   and	   conjugated	   to	   the	   sepharose	   -­‐	  allows	   for	   one-­‐step	   purification	   compatible	   with	   multiple	   AAV	   serotypes	  (Snyder,	  Richard	  O.,	  Moullier	  2011).	  Accurate	   quantification	   of	   rAAV	   is	   important	   to	   ensure	   correct	   and	  reproducible	   dosing	   in	   both	   preclinical	   and	   clinical	   settings.	   Despite	   of	   its	  relevance	  there	  is	  no	  single	  method	  that	  is	  consistently	  used	  across	  laboratories	  to	  quantify	  rAAV.	  The	  most	  common	  method	  for	  AAV	  titration	  is	  based	  on	  real-­‐time	  quantitative	  PCR	  (qPCR).	  It	  relies	  on	  the	  generation	  of	  a	  standard	  curve	  in	  which	  the	  copy	  numbers	  of	  the	  primer	  target	  sequence	  -­‐	  generally	  the	  transgene	  -­‐	  are	  known	  for	  each	  dilution	  point.	  This	  standard	  curve	  is	  then	  used	  to	  estimate	  the	  rAAV	  titre	  by	  linear	  regression.	  It	  is	  therefore	  extremely	  important	  to	  avoid	  contamination	   of	   the	   samples	   and	   to	   set	   up	   a	   negative	   control	   for	   the	   PCR	  reaction.	  Equally	  important	  is	  to	  make	  sure	  that	  DNAse	  treatment	  of	  the	  rAAV	  is	  done	  prior	  to	  titration	  as	  reminiscent	  DNA	  from	  the	  transfection	  can	  stick	  to	  the	  outside	   of	   the	   capsid	   and	   lead	   to	   an	   overestimation	   of	   the	   genome	   titre.	   The	  advantages	   of	   qPCR	   titration	   over	   other	  methods	   are	   its	   practicality,	   relatively	  low	   cost	   and	   speed	   in	   obtaining	   the	   results.	   Other	   genome	   titration	   methods,	  each	   with	   their	   up	   and	   down	   sides,	   are	   also	   available.	   ELISA,	   while	   a	   very	  sensitive	   method,	   is	   costly	   and	   cannot	   distinguish	   between	   empty	   and	   full	  capsids.	  Slot	  blot	  is	  the	  most	  reliable	  titration	  method	  but	  its	  disadvantage	  lies	  in	  the	   fact	   that	   it	   takes	   about	   two	  days	   to	   complete	   (Snyder,	  Richard	  O.,	  Moullier	  2011).	  Alkaline	  gel	  electrophoresis	  is	  a	  cheap	  method	  for	  AAV	  genome	  titration	  and	   is	   based	   on	   the	   quantification	   of	   the	   DNA	   loaded	   on	   a	   gel	   relative	   to	   a	  standard	   curve	   generated	   with	   known	   amounts	   of	   reference	   DNA.	   Another	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advantage	   of	   the	   alkaline	   agarose	   gel	   method	   is	   that	   it	   also	   allows	   the	  visualisation	   of	   the	   DNA	   species.	   A	   standard	   curve	   based	   titration	   can	   also	   be	  done	  to	  quantify	  total	  particle	  titre	  in	  a	  preparation	  by	  running	  purified	  rAAV	  in	  a	  polyacrylamide	  gel	  (PAGE)	  alongside	  BSA	  samples	  of	  known	  concentration	  and	  quantifying	  the	  AAV	  VP3	  protein	  (Kohlbrenner	  et	  al.	  2012).	  	  
	  
Figure	  5:	  Recombinant	  AAV	  production	  process.	  
rAAV	  is	  generally	  produced	  by	  transfection	  of	  HEK293	  cells	  with	  plasmids	  that	  provide	  the	  
transgene	   flanked	  by	  AAV	   ITRs,	  helper	   virus	   functions	  and	  Rep	  and	  Cap	  proteins.	  While	  
the	   ITR	   sequence	   and	   Rep	   are	   always	   from	   AAV2,	   the	   Cap	   protein	   used	   can	   vary	   and	  
determines	   the	   serotype	   of	   the	   produced	   rAAV.	   The	   separation	   of	   the	   trans-­‐acting	  
elements	   (Rep	   and	   Cap)	   from	   the	   cis-­‐acting	   ITRs	   is	   a	   security	   measure	   to	   avoid	   the	  
generation	  of	  replication	  competent	  AAV.	  72h	  post-­‐transfection	  the	  virus	  can	  be	  harvested	  
from	   the	   supernatant	   through	   protein	   precipitation	   and	   from	   the	   cells	   through	   freeze-­‐
and-­‐thaw	   cycles	   to	   disrupt	   the	   cell	   membrane.	   Purification	   of	   rAAV	   is	   done	   either	   by	  
density	  gradient	  centrifugation	  or	  chromatography,	  after	  which	  the	  titre	  is	  determined	  by	  
real-­‐time	  qPCR	  and/or	  alkaline	  agarose	  gel	  electrophoresis.	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vectors	   were	   based	   on	   AAV2	   but	   nowadays	   most	   of	   the	   vectors	   used	   are	  pseudotyped	  i.e.	  they	  are	  packaged	  in	  a	  capsid	  of	  some	  serotype	  other	  than	  AAV2	  but	   contain	   their	   transgenes	   flanked	   by	   AAV2	   ITRs.	   The	  most	   commonly	   used	  pseudotyped	  vectors	  include	  AAV1,	  AAV5,	  AAV8,	  AAV9	  and	  AAVrh10	  because	  of	  their	  different	  capsid	  properties,	  tropism	  and	  biodistribution	  profiles	  (Zincarelli	  et	  al.	  2008).	  In	  addition,	  emerging	  technologies	  allow	  the	  design	  of	  AAV	  vectors	  with	  enhanced	  tropism	  to	  certain	  organs	  or	  cell-­‐types	  (Lisowski	  et	  al.	  2014;	  Zinn	  &	  Vandenberghe	  2014).	  Accumulating	   evidence	   from	   studies	   using	   different	   serotypes	   show	   that	   in	  general	  AAV1,	  AAV6	  and	  AAV9	  are	  efficient	  in	  transducing	  muscle	  (Hauck	  &	  Xiao	  2003;	  Rivière	  et	  al.	  2006;	  Tabebordbar	  et	  al.	  2015),	  AAV5,	  AAV9	  and	  AAVrh10	  present	  a	  broad	  distribution	  in	  the	  brain	  (Davidson	  et	  al.	  2000;	  Lin	  et	  al.	  2005;	  Meadows	  et	   al.	  2015),	  while	  AAV8	   is	  particularly	  efficient	   in	   liver,	   skeletal	   and	  cardiac	  muscle	  transduction	  (Wang	  et	  al.	  2005;	  Nakai	  et	  al.	  2005).	  Overall,	  AAV8	  is	   the	   vector	   that	   most	   efficiently	   crosses	   the	   blood	   vessel	   barrier,	   leading	   to	  systemic	  gene	  transfer	  in	  liver,	  skeletal	  and	  cardiac	  muscles.	  	  Interestingly,	   gender	   has	   shown	   to	   be	   a	   factor	   influencing	   AAV8-­‐mediated	  transduction	   in	   the	   liver,	   with	   males	   being	   more	   permissible	   than	   females	  (Davidoff	   et	   al.	   2003).	   It	   is	   clear	   that	   one	   serotype	   can	   have	   tropism	   for	  more	  than	  one	   tissue	  and	   thus,	   in	  order	   to	  achieve	  a	  higher	  degree	  of	  specificity	  and	  avoid	   transduction	   of	   undesired	   organs	   or	   cell	   types,	   vectors	   of	   a	   particular	  serotype	   are	   usually	   combined	   with	   a	   tissue-­‐specific	   promoter.	   This	   strategy	  ensures	   that	   only	   particular	   cell-­‐types	   are	   able	   to	   express	   the	   transgene	  delivered	  by	  AAV.	  The	  transduction	  profile	  of	  different	  serotypes	  after	  systemic	  delivery	  has	  been	  thoroughly	  evaluated	  in	  mice	  and	  overall	  it	  can	  be	  ranked	  as:	  AAV9	   >	   AAV8	   =	   AAVrh.10	   >	   AAV7	   >	   AAV6	   >	   AAV1	   >	   AAV5	   >	   AAV2	   >	   AAV3	  (Zincarelli	  et	  al.	  2008;	  Pañeda	  et	  al.	  2009).	  	  Not	  only	  mice	  but	  also	  larger	  animal	  models	  have	  shown	  long-­‐term	  transgene	  expression	  following	  AAV	  administration.	   In	  dogs,	  AAV1-­‐,	  AAV2-­‐,	  AAV6-­‐,	  AAV8-­‐	  and	  AAV9-­‐mediated	  gene	  transfer	  led	  to	  phenotype	  correction	  in	  haemophilia	  A	  and	  B,	  while	  AAV5	   led	   to	   behavioural	   recovery	   in	   a	  NHP	  model	   of	   Parkinson’s	  disease	   (Muramatsu	   et	   al.	   2002;	   Sarkar	   et	   al.	   2006;	   Niemeyer	   et	   al.	   2009).	  Furthermore,	   successful	   transduction	   of	   NHP	   retina	   by	   AAV5	   vectors	   has	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provided	  strong	  support	  for	  the	  treatment	  of	  retinal	  degenerative	  retinopathies,	  such	  as	  Leber	  congenital	  amaurosis	  (Stieger	  et	  al.	  2009).	  
	  
1.4.1 Clinical	  Trials	  Using	  Recombinant	  AAV	  Vectors	  To	  date,	  the	  most	  promising	  results	  from	  in	  vivo	  gene	  therapy	  trials	  have	  been	  achieved	  using	  AAV.	  Because	  AAV2	  was	  the	  first	  serotype	  discovered,	  the	  greater	  knowledge	   about	   it	   serotype	   led	   to	   it	   being	   the	   first	   one	   to	   be	   used	   as	   a	   gene	  therapy	  vector.	  With	   the	   isolation	  of	  new	  serotypes	  and	  the	  characterisation	  of	  their	   different	   tropism	   profiles	   and	   transduction	   efficiencies,	   AAV2	   was	   soon	  replaced	  in	  the	  clinic	  by	  serotypes	  that	  more	  closely	  fit	  the	  specific	  transduction	  profile	  required	  for	  each	  gene	  transfer	  approach.	  Challenges	  to	  the	  clinical	  use	  of	  AAV	  are	  generally	   tissue-­‐specific	   and	  vary	   from	   immune	   responses	  against	   the	  vector	  to	  the	  optimal	  mode	  of	  gene	  delivery	  in	  each	  tissue.	  Exciting	   progress	   has	   been	  made	   using	   AAV	   in	   diseases	   such	   as	   congenital	  blindness	   and	   haemophilia	   and	   gene	   therapy	   to	   treat	   these	   conditions	   are	  moving	  closer	  to	  clinical	  application.	  	  
1.4.1.1 AAV-­‐Mediated	   Gene	   Transfer	   for	   the	   Treatment	   of	   Leber’s	  
Congenital	  Amaurosis	  One	  of	  the	  most	  compelling	  examples	  of	  success	  in	  clinical	  gene	  transfer	  using	  AAV	  vectors	  are	  the	  trials	  for	  the	  treatment	  of	  the	  retinal	  degenerative	  disorder	  Leber’s	   congenital	   amaurosis	   (LCA).	   This	   disease,	   characterised	   by	   early-­‐onset	  blindness	  due	  to	  retinal	  degeneration,	  can	  result	  from	  mutations	  in	  14	  different	  genes.	   Following	   successful	   AAV-­‐mediated	   expression	   of	  RPE65,	   one	   of	   the	   14	  possible	   genes	   affected,	   in	   animal	   models,	   three	   clinical	   trials	   for	   RPE65	  deficiency	  were	   initiated	   in	  2007	   (Koenekoop).	  Very	   little	   immune	  response	   to	  the	   vector	   and	   the	   transgene	   product	   were	   observed	   and	   no	   serious	   adverse	  events	   among	   the	   >25	   subjects	   injected	   was	   reported.	   Three	   years	   post-­‐AAV	  injection,	   all	   three	   trials	   reported	   success	   as	   determined	   by	   psychophysical	  measures	  of	  visual	  function	  (visual	  acuity	  and	  visual	  fields),	  objective	  measures	  (such	   as	   pupillary	   light	   response	   or	   full	   field	   light	   sensitivity)	   and	   functional	  measures	  (such	  as	  the	  ability	  to	  navigate	  an	  obstacle	  course	  in	  dim	  light),	  with	  at	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least	  some	  parameters	   improving	   in	  nearly	  all	  subjects	  (Bainbridge	  et	  al.	  2008;	  Maguire	   et	   al.	   2008;	   Hauswirth	   et	   al.	   2008;	   Pierce	   &	   Bennett	   2015).	  Demonstration	  of	   proof-­‐of-­‐concept	   in	   this	   disease	  has	   laid	   the	   groundwork	   for	  trials	  for	  a	  host	  of	  more	  common	  inherited	  retinal	  degenerative	  disorders,	  such	  as	  Leber’s	  hereditary	  optic	  neuropathy,	  choroideraemia	  and	  age-­‐related	  macular	  degeneration.	  
	  
1.4.1.2 AAV-­‐Mediated	  Gene	  Delivery	  for	  the	  Treatment	  of	  Haemophilia	  B	  The	  clinical	  trials	  for	  the	  treatment	  of	  haemophilia	  B	  are	  another	  example	  of	  successful	   AAV	   gene	   therapies	   that	   have	   brought,	   alongside	   the	   cure	   of	   some	  patients,	  enormous	  advancement	  in	  the	  understanding	  of	  AAV	  tolerance	  and	  its	  interaction	   with	   the	   human	   immune	   system.	   Haemophilia	   B	   is	   a	   bleeding	  diathesis	  caused	  by	  mutations	   in	   the	  gene	   that	  codes	   for	   the	  blood	  coagulation	  factor	   IX.	   When	   left	   untreated,	   the	   disease	   leads	   to	   death	   in	   childhood	   or	  adolescence	   and	   current	   treatment	   by	   intravenous	   infusion	   of	   clotting	   factor	  concentrates	   remains	   unaffordable	   for	   the	   majority	   of	   the	   people	   affected.	  Haemophilia	  B	   is	   an	  attractive	   target	   for	  gene	   therapy	  approaches	  because	   the	  therapeutic	  window	  is	  wide.	  Increasing	  factor	  IX	  levels	  to	  >2%	  already	  leads	  to	  phenotype	   correction	   and	   levels	   up	   to	   150%	   are	   still	   considered	   normal.	   In	  addition,	   endpoints	   are	   easy	   to	  measure	   and	   small	   and	   large	   animal	  models	  of	  the	  disease	  exist.	  The	   first	   AAV	   clinical	   trial	   to	   treat	   haemophilia	   B	   was	   done	   using	   AAV2	   at	  relatively	   low	   doses	   as	   a	   precaution	   prompted	   by	   the	   death	   of	   a	   young	   man	  seven	  years	  earlier,	  who	  received	  liver-­‐directed	  gene	  therapy	  with	  an	  adenoviral	  vector	   (Gelsinger	   &	   Shamoo	   2008).	   This	   haemophilia	   B	   trial	   showed	   clear	  efficacy	  in	  one	  subject,	  with	  circulating	  factor	  IX	  levels	  in	  the	  range	  of	  10–12%	  of	  normal	   at	   the	  highest	  dose	   tested.	  However,	   elevated	   factor	   IX	   levels	  persisted	  for	  only	  ~10	  weeks	  and	  were	  followed	  by	  a	  rise	  in	  transaminase	  levels.	  Further	  investigation	  demonstrated	  that	  the	  transaminase	  elevation	  and	  the	  decrease	  in	  factor	  IX	  levels	  were	  due	  to	  a	  selective	  CD8+	  T	  cell	  response	  against	  transduced	  hepatocytes	  triggered	  by	  the	  AAV	  capsid.	  A	  second	  subject	  showed	  no	  evidence	  of	  factor	  IX	  expression	  or	  transaminase	  elevation	  and	  this	   lack	  of	  response	  was	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attributed	   to	   the	   presence	   of	   pre-­‐existing	   neutralising	   antibodies	   against	   AAV,	  which	  blocked	  the	  transduction	  of	  the	  vector.	  These	  issues,	  not	  observed	  in	  any	  preclinical	   studies	   in	   animals,	   led	   to	   a	   better	   understanding	   of	   the	   AAV	  interaction	  with	  the	  immune	  system	  and	  to	  the	  optimisation	  of	  vectors	  and	  trial	  protocols	  (Manno	  et	  al.	  2006).	  A	  subsequent	  clinical	  trial	  made	  use	  of	  a	  double-­‐stranded	  AAV	   genome	  packaged	   in	   the	   liver-­‐tropic	   capsid	   of	   AAV8	   in	   order	   to	  achieve	   a	  more	   rapid	   and	  potent	   transgene	   expression	  using	   a	   smaller	  dose.	  A	  dose-­‐dependent	  immune	  response	  was	  also	  observed	  when	  using	  AAV8	  but	  this	  was	   addressed	   with	   a	   short	   course	   corticoid	   administration	   to	   the	   patients,	  which	  temporarily	  suppressed	  their	  immune	  system	  and	  assured	  a	  steady	  rise	  in	  factor	   IX	   plasma	   levels.	   Interestingly,	   no	   transaminase	   elevation	   has	   been	  observed	   since	   the	   corticoid	   treatment	   was	   terminated,	   indicating	   that	   capsid	  antigens	   presented	   at	   the	   surface	   of	   hepatocytes	  might	   be	   degraded	   over	   time	  (Nathwani	  et	  al.	  2014).	  This	  second	  trial	  has	  exceeded	  all	  expectations	  and	  today,	  more	  than	  6	  years	  post-­‐AAV	  administration,	  the	  six	  high-­‐dose	  patients	  (out	  of	  10	  recruited)	   are	   still	   expressing	   FIX	   at	   ~5%	   of	   normal	   levels.	   At	   present,	   three	  other	  trials	  are	  ongoing	  for	  AAV	  gene	  therapy	  for	  the	  treatment	  of	  haemophilia	  B	  (High	  et	  al.	  2014).	  Two	  of	  them	  have	  not	  reported	  any	  results	  yet	  and	  the	  third	  one	  has	  sent	  out	  a	  press	  release	  stating	  that	  AAV	  treatment	  has	  led	  to	  the	  cure	  of	  patients.	  	  	  
1.4.1.3 AAV-­‐Mediated	  Gene	  Delivery	  to	  the	  CNS	  The	  progress	  in	  the	  development	  of	  AAV	  gene	  therapies	  for	  the	  treatment	  of	  conditions	   affecting	   the	   CNS	   has	   been	   slower	   than	   for	   diseases	   affecting	  peripheral	   organs.	   Particularly	   challenging	   has	   been	   the	   issue	   of	   broad	   versus	  local	   delivery.	   To	   date,	   several	   early-­‐stage	   clinical	   trials	   using	   AAV	   in	   the	   CNS	  have	  been	  carried	  out	  showing	  good	  vector	  tolerability	  and	  long-­‐term	  transgene	  expression,	   however	   clear	   evidence	   of	   efficacy	   in	   controlled	   Phase	   II/III	   trials	  still	  remains	  to	  be	  shown	  (O’Connor	  &	  Boulis	  2015).	  For	   some	   conditions	   such	   as	   Parkinson’s	   disease	   local	   delivery	   to	   specific	  brain	   areas	   can	   provide	   therapeutic	   relief	   of	   motor	   symptoms	   however	   most	  neurodegenerative	  disorders	  require	  a	  broad	  delivery	  to	  the	  CNS.	  In	  these	  cases,	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access	   to	   large	   areas	   of	   the	   brain	   and	   the	   blood-­‐brain-­‐barrier	   (BBB)	   impose	  limitations	  for	  vector	  delivery.	  Some	  serotypes	  such	  as	  AAV9	  and	  AAVrh10	  have	  been	  shown	  to	  be	  able	  to	  cross	  the	  BBB,	  but	  systemic	  delivery	  of	  AAV	  must	  take	  into	  consideration	  potential	  problems	  of	  off-­‐target	  transduction	  and	  neutralising	  antibodies	  (Inagaki	  et	  al.	  2006;	  Wolf	  et	  al.	  2015).	  In	  addition,	  the	  choice	  of	  AAV	  serotype,	   delivery	   techniques	   must	   be	   considered	   carefully.	   Overall,	   although	  much	  progress	  has	  been	  made	  in	  achieving	  widespread	  transduction	  of	  the	  CNS	  in	   animal	   models	   and	   several	   studies	   have	   confirmed	   the	   safety	   profile	   and	  tolerability	  of	  AAV	  gene	   therapy,	   its	   efficacy	   in	   the	   treatment	  of	  CNS	  disorders	  remains	  to	  be	  proven.	  	  1.4.1.3.1 AAV	  Gene	  Therapy	  for	  Alzheimer’s	  Disease	  Alzheimer’s	   disease	   is	   a	   progressive	   neurodegenerative	   disorder	  characterised	   by	   the	   loss	   of	   memory	   and	   cognitive	   functions	   and	   disease	  progression	  has	  been	  associated	  with	  accumulation	  of	  amyloid	  β	  plaques	  and	  the	  loss	   of	   cholinergic	   neurons.	   A	   Phase	   I	   clinical	   trial	   using	   AAV2	   to	   express	   the	  nerve	  growth	  factor	  (NGF)	  in	  the	  brain	  showed	  that	  therapy	  was	  well	  tolerated,	  with	   post-­‐mortem	   analysis	   of	   brain	   tissue	   identifying	   expression	   of	   NGF	   in	   an	  active	  form	  (Rafii	  et	  al.	  2014).	  The	  data	  supported	  the	   initiation	  of	  a	  controlled	  Phase	  II	  trial	  to	  rigorously	  assess	  the	  effectiveness	  of	  AAV2-­‐NGF,	  however	  it	  was	  eventually	  announced	  that	  the	  trial	  failed	  to	  meet	  its	  primary	  endpoints.	  	  	  1.4.1.3.2 AAV	  Gene	  Therapy	  for	  Spinal	  Muscular	  Atrophy	  Spinal	  muscular	  atrophy	  (SMA)	  is	  a	  motor	  neuron	  disease	  caused	  by	  the	  loss	  of	  the	  survival	  motor	  neuron	  1	  (SMN1)	  gene	  and	  is	  the	  leading	  genetic	  cause	  of	  infantile	  death.	  Because	  SMA	   is	  a	  monogenic	  disease,	   it	   is	  a	  good	  candidate	   for	  gene	  replacement	  strategies	  and	  a	  Phase	  I	  clinical	  study	  with	  AAV9	  is	  currently	  ongoing	  with	  the	  aim	  to	  test	  safety	  and	  efficacy	  of	  intravenous	  AAV	  delivery	  for	  the	  correction	  of	  a	  disease	  affecting	   the	  CNS	  (Faravelli	  et	  al.	  2015;	  Duque	  et	  al.	  2015).	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1.4.1.3.3 AAV	  Gene	  Therapy	  for	  Lysosomal	  Storage	  Diseases	  Lysosomal	   storage	  diseases	   encompass	   over	   50	  different	   diseases	   that	   arise	  from	   defective	   catabolism	   of	   some	   molecules	   leading	   to	   their	   accumulation	  within	  lysosomes	  and	  cell	  toxicity.	  The	  standard	  treatment	  for	  these	  diseases	  is	  trough	   enzyme	   replacement	   that	   leads	   to	   the	   degradation	   of	   the	   accumulated	  macromolecules.	   However,	   some	   of	   these	   diseases	   such	   as	   metachromic	  leukodystrophy	   (MLD)	   and	   mucopolysaccharidosis	   type	   III	   A	   (MPSIIIA)	  encompass	   a	   neurological	   component	   that	   cannot	   be	   treated	   by	   enzyme	  replacement	  due	  to	  the	  inability	  of	  the	  enzymes	  to	  cross	  the	  BBB	  (Bradbury	  et	  al.	  2015;	  Pastores	  &	  Hughes	  2015).	  Metachromic	  leukodystrophy	  (MLD)	  is	  a	  disease	  that	  is	  still	  untreatable	  and	  it	  is	  caused	  by	  an	  inherited	  mutation	  in	  the	  arylsulfatase	  A	  (ARSA)	  gene	  resulting	  in	  the	   accumulation	   of	   sulphatide	   in	   Schwann	   cells,	   oligodendrocytes	   and	   brain	  neurons.	  The	  first	  Phase	  I	  gene	  therapy	  clinical	  trial	  is	  underway	  using	  AAVrh10	  to	  deliver	  ARSA	  intracerebrally	  to	  early-­‐stage	  or	  presymptomatic	  MLD	  patients.	  Preclinical	  studies	  in	  animal	  models	  of	  the	  disease	  showed	  phenotype	  correction	  but	  results	  from	  the	  human	  trial	  have	  not	  been	  published	  yet	  (Piguet	  et	  al.	  2012).	  	  Another	   lysosomal	   storage	  disease	  with	  a	  neurological	   component	   currently	  being	  tested	  in	  Phase	  I/II	  trials	  is	  MPSIIIA,	  also	  known	  as	  Sanfilippo	  type	  A.	  This	  disorder	   is	  caused	  by	  a	  mutation	   in	   the	   lysosomal	  heparan-­‐N-­‐sulfamidase	  gene	  (SGSH),	   which	   leads	   to	   cognitive	   delay,	   abnormal	   behaviour,	   and	   seizures	  (Valstar	  et	  al.	  2010).	  Both	  trials	  are	  testing	  the	  efficacy	  of	  AAVrh10	  intracranial	  transgene	  delivery	  and	  reports	  have	  shown	  no	  safety	  issues	  associated	  with	  the	  vector.	  Preliminary	  efficacy	  data	  with	  regard	  to	  brain	  atrophy	  for	  some	  patients	  and	  possible	  improvements	  in	  behaviour	  and	  sleep	  have	  been	  reported	  (Tardieu	  et	  al.	  2014).	  	  
1.4.1.4 AAV-­‐Mediated	  Gene	  Transfer	  to	  Skeletal	  Muscle	  	  The	  muscle	  is	  an	  attractive	  target	  tissue	  for	  gene	  transfer	  strategies	  aimed	  at	  correcting	  neuromuscular	  and	  metabolic	  diseases	  (Mendell	  et	  al.	  2009;	  Manno	  et	  al.	   2003).	   In	   fact,	   the	   only	   gene	   therapy	   currently	   approved	   for	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commercialisation	   is	   based	   on	   the	   intramuscular	   delivery	   of	   AAV1	   to	   treat	  lipoprotein	  lipase	  (LPL)	  deficiency	  (Morrison	  2015).	  Intramuscular	  AAV	  administration	  is	  the	  preferred	  route	  for	  muscle	  targeting.	  Ease	  of	  delivery	  and	   local	   retention	  of	   the	  vector	  are	  among	   the	  advantages	  of	  intramuscular	   delivery.	   However,	   this	   route	   of	   administration	   has	   been	  associated	   with	   a	   higher	   risk	   of	   triggering	   an	   immune	   response	   against	   the	  transgene	   compared	   to	   systemic	   delivery	   (Mendell	   et	   al.	   2010).	   Although	  evidence	   suggests	   that	   intravascular	   AAV	   vector	   delivery	   is	   less	   prone	   than	  intramuscular	  administration	  to	  trigger	   immune	  responses	  directed	  against	  the	  transgene	   product,	   it	   increases	   the	   exposure	   of	   the	   vector	   to	   neutralisation	   by	  pre-­‐existing	  antibodies.	  	  
	  
1.5 Future	  Perspectives	  of	  AAV	  Gene	  Therapy	  To	  date,	  one	   rAAV	  product	  has	   reached	   the	  market	   in	  Europe	  and	   following	  the	  many	  preclinical	  studies	  reporting	  promising	  results	  with	  AAV	  gene	  therapy,	  numerous	  rAAV	  vectors	  have	  entered	  clinical	   trials	   (Morrison	  2015).	  As	  of	   July	  2015,	   137	   clinical	   trials	   were	   conducted	   using	   AAV	   (Anon	   2015).	   Although	  representing	   only	   6.2%	   of	   the	   gene	   therapy	   trials	   conducted	   to	   this	   date,	   this	  number	  is	  expected	  to	  grow	  as	  protocols	  of	  AAV	  production	  are	  improved,	  more	  potent	   and	   optimised	   vectors	   are	   developed	   and	   investment	   from	   the	   private	  sector	  and	  the	  pharmaceutical	  industry	  increases.	  	  
1.6 Parkinson’s	  Disease	  In	  1817	  the	  English	  physician	  James	  Parkinson	  described	  the	  symptoms	  of	  the	  “shaky	  palsy”,	  a	  condition	  that	  was	   later	  described	   in	  greater	  detail	  and	  named	  after	  him	   (Parkinson	  2002).	   Parkinson’s	  disease	   (PD)	   symptoms	  might	  be	   first	  noticed	   as	   a	   twitching	   in	   the	   fingers	   that	   instead	   of	   going	   away	   turns	   into	   a	  tremor	   of	   the	   hand	   and	   eventually	   of	   the	   entire	   arm.	   Affected	   people	   typically	  assume	   a	   bent	   posture,	   have	   a	   short	   gait,	   slow	   speech	   and	   a	   face	   lacking	  expressions	  or	  emotions.	  With	  time,	  these	  symptoms	  worsen	  and	  spread	  out	  and	  essential	   routine	   activities	   such	   as	   standing,	   walking	   and	   swallowing	   become	  hugely	   cumbersome.	   These	   difficulties	   are	   a	   consequence	   of	   resting	   tremor,	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cogwheel	   rigidity,	   akinesia	   (loss	   or	   impairment	   of	   the	   power	   of	   voluntary	  movement),	   bradykinesia	   (slowness)	   and	   postural	   instability,	   the	   motor	  hallmarks	   of	   PD.	   Although	   motor	   symptoms	   are	   typically	   associated	   with	   PD,	  affected	  people	   also	   suffer	   from	  wide	   a	   range	  of	   non-­‐motor	   symptoms	   such	   as	  depression,	   apathy,	   pain,	   sexual	   difficulties,	   bowel	   incontinence,	   visual	  impairment,	   hallucinations	   and	   insomnia,	   all	   of	   which	   still	   remain	   under-­‐recognised	   and,	   consequently,	   under-­‐treated	   (Chaudhuri	  &	   Schapira	   2009).	   PD	  affects	  around	  1-­‐2%	  of	  the	  population	  above	  the	  age	  of	  55.	  It	  is	  the	  most	  common	  movement	  disorder	  and	  the	  second	  most	  common	  neurodegenerative	  disease	  of	  the	  human	  brain	  after	  Alzheimer’s	  disease	  with	  a	  higher	   incidence	  expected	   to	  follow	  the	  increase	  in	  life	  expectancy	  (de	  Lau	  &	  Breteler	  2006).	  	  Nearly	  200	  years	  after	  it	  was	  first	  described,	  the	  ultimate	  cause	  of	  the	  disease	  development	   still	   remains	   unknown.	   PD	   seems	   to	   be	   a	   complex	  multifactorial	  disorder	   with	   variable	   contributions	   of	   environmental	   factors	   and	   genetic	  susceptibility.	  Genetic	  predisposition	  accounts	  for	  10%	  of	  the	  cases	  but	  the	  other	  90%	   remain	   described	   as	   idiopathic	   (also	   known	   as	   sporadic),	  with	   age	   being	  one	  of	   the	  main	   risk	   factors.	  Most	  of	   the	  progress	   in	  PD	  research	  pathogenesis	  has	   been	   made	   in	   understanding	   the	   neuronal	   death	   that	   leads	   to	   the	   typical	  motor	   complications	   of	   the	   disease.	   Cellular	   death	   occurs	   in	   a	   group	   of	  dopamine-­‐synthetic	  neurons	  that	  populate	  the	  area	  near	  the	  brainstem	  known	  as	  substantia	   nigra	   pars	   compacta	   (SNc)	   and	   innervate	   the	   subcortical	   nucleus	   of	  the	   basal	   ganglia	   known	   as	   striatum	   supplying	   it	   with	   the	   neurotransmitter	  dopamine	  for	  the	  fine-­‐tuning	  of	  movement.	  It	  is	  not	  until	  70%	  of	  the	  nigral	  cells	  are	   lost	   that	   dopamine	   levels	   reach	   a	   clinically	   significant	   threshold	   and	   a	  cascade	  of	  motor	  complications	  start	  to	  manifest.	  Neuronal	  death	  in	  the	  SNc	  has	  been	  associated	  with	  the	  presence	  of	  protein	  aggregates	  known	  as	  Lewy	  bodies	  and	   Lewy	   neurites.	   Although	   these	   neurons	   are	   the	   most	   vulnerable,	   PD	  pathology	   seems	   to	   start	   at	   the	   olfactory	   system	   and	   the	   gut-­‐connected	   dorsal	  motor	  nucleus	  of	  the	  vagus.	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1.6.1 α-­‐synuclein	  Aggregation	  and	  Parkinson’s	  Disease	  
α-­‐synuclein,	   a	   hydrophilic	   protein	   abundant	   in	   presynaptic	   terminals,	   is	   a	  major	   component	   of	   the	   Lewy	   bodies	   and	   Lewy	   neurites.	   For	   reasons	   still	  unknown,	   it	   can	   leave	   its	   binding	   site	   within	   the	   synaptic	   terminals	   and	   start	  forming	  toxic	  insoluble	  aggregates	  that	  spread	  to	  different	  regions	  of	  the	  nervous	  system.	   Studies	   have	   shown	   that	   sporadic	   PD,	   the	   most	   common	   form	   of	   the	  disease,	   is	   an	  α-­‐synucleinopathy	   that	   can	   be	   classified	   into	   six	   different	   stages	  according	   to	   its	  degree	  of	   spread	   in	   the	   central	  nervous	   system.	  The	  abnormal	  deposition	   of	   α-­‐synuclein	   starts	   at	   lower	   regions	   of	   the	   brain	   and	   spreads	  gradually	  towards	  the	  cortex	  in	  a	  predictable	  pattern.	  After	  its	  occurrence	  in	  the	  olfactory	  system	  and	  the	  gut-­‐connected	  dorsal	  motor	  nucleus	  of	  the	  vagus,	  which	  characterises	   stage	   1,	  α-­‐synuclein	   aggregates	   spread	   to	   the	  medulla	   oblongata	  and	   the	   pontine	   tegumentum	   (stage	   2).	   It	   is	   only	   at	   stage	   three,	   when	   the	  pathology	   reaches	   the	   amygdala	   and	   the	   substantia	   nigra	   that	   the	   motor	  symptoms	  of	  PD	  begin	   to	   appear.	  The	  pathology	  worsens	  when	   the	  aggregates	  reach	   the	   temporal	   cortex	   (stage	   4)	   but	   it	   is	   at	   stages	   5	   and	   6,	   when	   the	  neocortex	   is	  affected,	   that	  many	  of	   the	  cognitive	   impairment	  symptoms	  appear	  (Braak	   et	   al.).	   It	   is	   important	   to	   note	   that	   this	   rating	   scale	   is	   based	   on	   the	  progression	  of	  the	  α-­‐synucleinopathy	  and	  that	  other	  scales	  based	  on	  the	  severity	  of	   PD	   symptoms	   (most	   commonly	   the	   motor	   ones)	   are	   more	   practical	   in	   the	  management	  of	  the	  disease	  and	  are	  therefore	  used	  by	  physicians	  to	  rate	  disease	  progression	  and	  to	  decide	  upon	  a	  treatment.	  Furthermore,	  post-­‐mortem	  analysis	  of	  brains	  from	  people	  who	  had	  suffered	  from	  genetic	  and	  sporadic	   forms	  of	  PD	  showed	  distinct	  patterns	  of	  α-­‐synucleinopathy,	  bringing	   into	  question	  whether	  all	   forms	   of	   PD	   are	   the	   same	   (Doherty	   et	   al.	   2013).	   Nonetheless,	   the	   clear	  abnormal	  deposition	  of	  α-­‐synuclein	   in	  most	  people	   suffering	   from	  PD	   suggests	  that	   it	   might	   fall	   under	   the	   category	   of	   the	   so-­‐called	   amyloid	   diseases.	   The	  common	   feature	  of	   these	  diseases	   is	   the	  presence	  of	  proteins	   that	  assume	  a	  β-­‐sheet	   conformation	   and	   aggregate	   into	   insoluble	   forms.	   Despite	   affecting	  different	  kinds	  of	  proteins,	  these	  aggregates	  exhibit	  the	  same	  subatomic	  pattern	  in	   different	   amyloid	   diseases:	   α-­‐synuclein	   in	   Parkinson’s	   disease,	   Lewy	   body	  dementia	  and	  multiple	  system	  atrophy;	  amyloid-­‐β	  and	  tau	  protein	  in	  Alzheimer’s	  disease;	   polyglutamine	   protein	   in	   Huntington’s	   disease;	   and	   amylin	   protein	   in	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type	  2	  diabetes	   (Chiti	  &	  Dobson	  2006).	   Strengthening	   the	  notion	   that	  PD	   is	   an	  amyloid	  disease	  is	  the	  observation	  from	  a	  trial	  in	  which	  people	  with	  PD	  received	  a	  transplantation	  of	  dopamine-­‐producing	  neurons	  in	  the	  striatum.	  Some	  patients	  showed	   only	   a	   temporary	   improvement	   of	   the	   motor	   symptoms	   and	   post-­‐mortem	  autopsy	  revealed	  that	  the	  disease	  had	  spread	  from	  the	  patients’	  brain	  to	  many	  of	  the	  transplanted	  neurons	  in	  a	  prion-­‐like	  fashion	  (Li	  et	  al.	  2008).	  Overall,	  there	  is	  strong	  evidence	  that	  suggest	  that	  the	  aberrant	  α-­‐synuclein	  deposition	  is	  the	  driving	  force	  in	  PD	  pathogenesis	  (Stefanis	  2012).	  	  
1.6.2 Mitochondrial	  Dysfunction	  and	  Parkinson’s	  Disease	  Aberrant	   mitochondrial	   function	   and	   increased	   oxidative	   stress	   have	   also	  been	   implicated	   in	   the	   pathogenesis	   of	   PD.	   The	   first	   evidence	   for	   this	   link	  appeared	  when,	  in	  the	  late	  70’s,	  heroin	  users	  developed	  PD	  symptoms	  a	  few	  days	  after	  injecting	  an	  impure	  batch	  of	  the	  drug.	  It	  was	  soon	  discovered	  that	  the	  drug	  contained	   the	   contaminant	   MPTP,	   which	   is	   preferentially	   taken	   up	   by	   the	  dopaminergic	  neurons	  in	  the	  SNc.	  Once	  inside	  the	  dopaminergic	  neurons,	  MPTP	  is	   catalysed	   into	   a	   toxic	   molecule	   that	   functions	   as	   an	   inhibitor	   of	   the	  mitochondrial	   complex	   I	   leading	   to	   oxidative	   stress	   followed	   by	   cell	   death	  (Bajpai	   et	   al.	   2013).	   Further	   evidence	   providing	   a	   link	   between	   abnormal	  mitochondrial	   function	   and	   PD	   pathology	   came	   from	   brain	   autopsies	   from	   PD	  affected	  people,	  which	  revealed	  a	  deficiency	  in	  mitochondrial	  complex	  I	  activity.	  In	  addition,	  ground	  breaking	  advances	  in	  PD	  research	  led	  to	  the	  identification	  of	  genes	  that	  are	  responsible	  for	  the	  less	  common	  genetic	  forms	  of	  the	  disease.	  It	  is	  now	   known	   that	   mutations	   in	   the	   genes	   encoding	   α-­‐synuclein	   and	   LRRK2	  (leucine-­‐rich	  repeat	  kinase	  2)	  are	  responsible	  for	  the	  autosomal	  dominant	  forms	  of	   PD,	   whilst	   mutations	   in	   the	   genes	   encoding	   parkin,	   PINK1	   (PTEN-­‐induced	  putative	  kinase	  1),	  HTRA2	  (high	  temperature	  requirement	  protein	  A2)	  and	  DJ-­‐1	  mediate	   autosomal	   recessive	   forms	   of	   PD.	   These	   genes	   have	   been	   shown	   to	  directly	  or	   indirectly	   affect	  mitochondrial	   integrity,	   thereby	  providing	  a	   link	   to	  further	  pathophysiological	  alterations	  observed	  in	  sporadic	  PD.	  Because	   sporadic	   and	   genetic	   forms	   of	   PD	   share	   important	   clinical,	  pathological	   and	   biochemical	   features,	   in	   particular	   the	   progressive	   loss	   of	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dopaminergic	  neurons	  in	  the	  SNc,	  insight	  into	  the	  function	  of	  PD-­‐associated	  gene	  products	  can	  help	  to	  elucidate	  the	  primary	  mechanisms	  leading	  to	  neuronal	  cell	  death.	  	  
1.6.3 Dopamine	  Metabolism	  in	  the	  Central	  Nervous	  System	  Dopamine	   is	   a	   catecholamine	   neurotransmitter	   found	   predominantly	   in	   the	  central	   nervous	   system	   (CNS);	   it	   is	   involved	   in	   different	   pathways	   related	   to	  reward-­‐motivated	   behaviour,	   memory,	   attention,	   mood,	   circadian	   rhythm	   and	  motor	  control.	  Dopamine	  also	  functions	  in	  the	  peripheral	  nervous	  system	  and	  in	  organs	  such	  as	  the	  kidneys,	  pancreas	  and	  the	  upper	  gastrointestinal	  tract,	  where	  it	  is	  synthesised	  and	  acts	  in	  a	  paracrine	  manner	  (Ustione	  et	  al.	  2013).	  Dopamine	  is	  also	  synthesised	  in	  the	  adrenal	  medulla,	  where	  it	  is	  used	  as	  precursor	  for	  the	  synthesis	   of	   the	   hormones	   and	   neurotransmitter	   epinephrine	   and	  norepinephrine	  (Daubner	  et	  al.	  2011).	  In	   the	   CNS,	   the	   four	   major	   neural	   pathways	   that	   use	   dopamine	   as	   a	  neurotransmitter	   are	   the	   mesolimbic,	   mesocortical,	   tuberoinfundibular	   and	  nigrostriatal	   (Figure	   6).	   The	   mesolimbic	   and	   mesocortical	   pathways	   contain	  neuronal	   projections	   that	   connect	   a	   structure	   located	   in	   the	   midbrain,	   called	  ventral	   tegmental	   area	   (VTA),	   to	   the	   limbic	   system	   and	   the	   frontal	   cortex,	  respectively.	   Both	   pathways	   are	   essential	   for	   reward-­‐motivated	   behaviour,	  cognitive	   control,	   motivation	   and	   emotional	   response	   and	   disorders	   in	   these	  pathways	   are	   associated	   with	   schizophrenia	   and	   addiction.	   The	  tuberoinfundibular	  pathway	  transmits	  dopamine	  from	  the	  hypothalamus	  to	  the	  pituitary	   gland	   and	   it	   regulates	   the	   secretion	   of	   the	   hormone	   prolactin.	   The	  nigrostriatal	  pathway	  connects	  the	  SNc	  with	  the	  dorsal	  striatum	  and	  is	  involved	  in	  motor	   control.	   The	   selective	   degeneration	   of	   the	   nigrostriatal	   dopaminergic	  neurons	  is	  responsible	  for	  the	  motor	  complications	  of	  PD.	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Figure	  6:	  The	  four	  major	  dopaminergic	  pathways	  in	  the	  CNS.	  
The	   pathways	   that	   use	   dopamine	   as	   a	   neurotransmitter	   are	   the	   mesolimbic	   pathway	  
(orange);	  the	  mesocortical	  pathway	  (red);	  the	  tuberoinfundibular	  pathway	  (pink)	  and	  the	  
nigrostriatal	   pathway	   (blue).	   Together,	   the	   caudate	   nucleus	   and	   the	   putamen	   form	   the	  
dorsal	   striatum,	  which	   is	   involved	  with	  motor	  control.	  The	  selective	  degeneration	  of	   the	  
nigrostriatal	  dopaminergic	  neurons	  is	  the	  responsible	  for	  the	  motor	  complications	  of	  PD.	  
(Adapted	  from:	  https://www.wikimedia.org).	  	  Dopamine	   is	   synthesised	   from	   the	   amino	   acid	   tyrosine	   through	   a	   tightly	  regulated	   pathway	   (Figure	   7).	   The	   first	   step	   in	   its	   biosynthesis	   is	   the	  hydroxylation	  of	  the	  amino	  acid	  tyrosine	  to	  L-­‐DOPA	  by	  the	  rate-­‐limiting	  enzyme	  tyrosine	   hydroxylase	   (TH),	   which	   uses	   tetrahydrobiopterin	   (BH4)	   as	   cofactor.	  The	   second	   reaction	   is	   the	   removal	   of	   the	   carboxyl	   group	   from	  L-­‐DOPA	  by	   the	  enzyme	   aromatic	   amino	   acid	   decarboxylase	   (AADC)	   to	   form	   dopamine.	  Immediately	   after	   it	   is	   synthesised,	   dopamine	   is	   relocated	   from	   the	   cytoplasm	  into	   synaptic	   vesicles	   by	   the	   protein	   vesicular	   monoamine	   transporter	   2	  (VMAT2),	  where	   it	   is	   up	   to	   1000	   times	  more	   concentrated	   than	   in	   the	   cytosol	  (Elsworth	  &	  Roth	  1997;	  Eiden	  et	  al.	  2004).	  Upon	  arrival	  of	  an	  action	  potential,	  calcium	   influx	   leads	   to	   the	   fusion	   of	   the	   synaptic	   vesicles	   with	   the	   neuronal	  membrane	   and	   release	   of	   dopamine	   into	   the	   synaptic	   cleft	   by	   exocytosis.	   The	  extent	  of	  dopamine	  release	  is	  dependent	  on	  the	  neuron’s	  firing	  rate	  and	  pattern	  and	  once	  released,	  dopamine	  exerts	  its	  effect	  through	  interaction	  with	  dopamine	  D1–5	  receptors.	  Dopamine	  can	  be	  taken	  up	  by	  the	  membrane	  protein	  dopamine	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transporter	  (DAT)	  of	  the	  presynaptic	  neuron	  where	  it	  can	  either	  be	  recycled	  into	  the	   vesicles	   via	  VMAT2	  or	   degraded.	   DAT	   is	   the	   primary	  mechanism	  by	  which	  dopamine	   is	   cleared	   from	   the	   synaptic	   cleft	   and	   it	   controls	   the	   spatial	   and	  temporal	   dynamics	   of	   dopamine	   neurotransmission	   (Vaughan	  &	   Foster	   2013).	  Degradation	  of	  dopamine	  can	  occur	  via	  the	  monoamine	  oxidase	  (MAO)	  and	  the	  catechol-­‐O-­‐methyl	   transferase	   (COMT)	   enzymes	   into	   its	   main	   end-­‐product	  homovanillic	  acid	  (HVA).	  MAO	  exists	   in	  two	  isoforms	  (A	  and	  B),	  which	  catalyse	  the	   oxidative	   deamination	   of	   dopamine	   into	   3,4-­‐dihydroxyphenylacetic	  acid	  (DOPAC),	   which	   is	   then	   further	   converted	   into	   HVA.	   This	   is	   the	   main	  pathway	  of	  dopamine	  inactivation	  in	  the	  striatum.	  In	  other	  regions	  of	  the	  brain,	  dopamine	  is	  preferentially	  methylated	  by	  COMT	  to	  form	  3-­‐methoxytyramine	  (3-­‐MT),	  which	  is	  in	  turn	  converted	  into	  HVA	  by	  MAO.	  The	  end	  product	  HVA	  has	  no	  known	  biological	  activity	  and	  is	  excreted	  (Leonard	  1993).	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1.6.4 L-­‐DOPA	  Pharmacotherapy	  in	  Parkinson’s	  Disease	  Although	   extensive	   research	   has	   brought	   a	   deeper	   understanding	   of	   the	  genetic	   and	   environmental	   factors	   affecting	   the	   susceptibility	   for	   PD	   and	   the	  molecular	  processes	  that	  lead	  to	  neuronal	  loss,	  the	  ultimate	  cause	  of	  the	  disease	  remains	  unknown.	  The	   severity	  of	   the	  disease	   seems	   to	  be	  proportional	   to	   the	  loss	   of	   dopamine	   input	   in	   the	   striatum	   and	   existing	   therapies	   focus	   on	   the	  restoration	   and	  preservation	  of	   the	  brain’s	   dysfunctional	   dopaminergic	   system	  (Hohen	  &	  Yahr	  1967;	  Kish	  et	  al.	  1988;	  Feng	  &	  Maguire-­‐Zeiss	  2011).	  	  The	  discovery	  in	  1958	  that	  dopamine	  acts	  as	  a	  neurotransmitter	  that	  controls	  movement	   led	  to	  the	  development	  of	  treatments	  that	  aim	  for	  the	  restoration	  of	  dopamine	  neurotransmission.	   L-­‐DOPA,	   the	  precursor	  of	   dopamine,	   entered	   the	  clinical	  scene	  as	  a	  direct	  consequence	  of	  this	  discovery	  and,	  because	  of	  its	  ability	  to	   provide	   powerful	   symptomatic	   relief	   in	   PD	   patients,	   it	   was	   regarded	   as	   a	  miracle	  drug	  (Degkwitz	  et	  al.	  1960;	  Birkmayer	  &	  Hornykiewicz	  1961).	  In	  the	  first	  years	  after	  its	  discovery	  as	  an	  antiparkinsonian	  agent,	  L-­‐DOPA	  was	  administered	  without	   a	   peripherally	   acting	   AADC	   inhibitor	   (e.g.	   benserazide)	   and	   the	  peripheral	   conversion	   of	   L-­‐DOPA	   to	   dopamine	   caused	   problems	   such	   as	  hypotension,	   nausea,	   vomiting,	   and	   anorexia.	   The	   administration	   of	   AADC	  inhibitors	  together	  with	  L-­‐DOPA	  allowed	  for	  a	  reduction	  in	  the	  dose	  by	  as	  much	  as	  60–80%	  and	  a	  faster	  onset	  of	  L-­‐DOPA’s	  antiparkinsonian	  effects	  without	  any	  loss	  in	  therapeutic	  efficacy	  (Birkmayer	  et	  al.	  1974;	  Nutt	  et	  al.	  1985).	  In	  addition	  to	   benserazide,	   COMT	   inhibitors,	   such	   as	   tolcapone	   and	   entacapone,	   are	  commonly	   used	   in	   the	   clinic	   to	   avoid	   peripheral	   degradation	   of	   L-­‐DOPA	   and	  extend	   the	   duration	   of	   its	   antiparkinsonian	   effects	   (Ruottinen	   &	   Rinne	   1996;	  Napolitano	  et	  al.	  1999).	  The	  absorption	  of	  L-­‐DOPA	  happens	  in	  the	  duodenum	  and	  proximal	   jejunum	  by	   active	   transport	   via	   the	   large	   neutral	   amino	   acid	   (LNAA)	  system.	  This	  same	  system	  is	  responsible	  for	  its	  transport	  across	  the	  blood-­‐brain-­‐barrier	   and	   is	   present	   in	   endothelial	   cells	   and	   astrocytes	   (Wade	   et	   al.	   1973;	  Kageyama	  et	   al.	   2000).	  Because	  L-­‐DOPA	   relies	  on	  active	   transport	   to	   enter	   the	  gut	  and	  the	  brain,	  meals	  rich	   in	  protein	   interfere	  with	   its	  absorption	  and	  affect	  peak	  plasma	  levels	  after	  oral	  medication	  (Nutt	  et	  al.	  1984).	  L-­‐DOPA	   is	   an	   amino	   acid	   that	   has	   proven	   to	   be	   very	   difficult	   to	   manage	  clinically.	   Its	   half-­‐life	   is	   very	   short	   (60	   minutes)	   and	   its	   pharmacodynamics	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interaction	   with	   the	   disease	   progression	   is	   poorly	   understood.	   Despite	   an	  increased	  half-­‐life	  and	  bioavailability	  achieved	  with	  AADC	  and	  COMT	  inhibitors,	  prolonged	  treatment	  with	  L-­‐DOPA	  will	  inevitably	  lead	  to	  side	  effects	  in	  over	  80%	  of	   the	   patients	   within	   the	   first	   5-­‐10	   years	   of	   treatment.	   L-­‐DOPA	   induced	   side	  effects	   are	   disabling	   and	   include	   severe	   involuntary	   movements	   known	   as	  dyskinesias	   and	   swings	   between	   mobility	   and	   immobility	   known	   as	   ON–OFF	  phenomena,	  which	  are	  characterised	  by	  improved	  mobility	  (ON)	  due	  to	  L-­‐DOPA	  followed	   by	   sudden	   unpredictable	   impaired	   mobility	   (OFF).	   Other	   L-­‐DOPA	  induced	   side	   effects	   may	   include	   hypotension,	   sexual	   dysfunction,	   and	  psychiatric	  disorders.	  The	  introduction	  of	  L-­‐DOPA	  as	  a	  medicine	  to	  treat	  the	  symptoms	  of	  PD	  more	  than	   50	   years	   ago	   was	   so	   revolutionary	   that	   better	   drugs	   have	   yet	   to	   be	  developed	  and	  most	  of	  the	  research	  focus	  has	  revolved	  around	  ways	  to	  maximise	  L-­‐DOPA’s	  therapeutic	  benefit	  without	  triggering	  side	  effects	  (Abbott	  2010).	  	  	  
1.7 L-­‐DOPA	  Induced	  Dyskinesia	  Oral	  medication	  with	  L-­‐DOPA	   is	   the	   gold-­‐standard	   treatment	   for	  PD.	  During	  the	  early	  years	  of	  PD,	  when	  motor	  complications	  are	  the	  predominant	  symptoms,	  L-­‐DOPA	   provides	   enormous	   symptomatic	   relief	   and	   substantially	   improves	  quality	  of	  life	  of	  patients	  (Kordower	  &	  Goetz	  1999).	  However,	  chronic	  treatment	  with	   L-­‐DOPA	   to	   manage	   parkinsonian	   symptoms	   leads	   to	   the	   development	   of	  side	   effects,	   most	   remarkably	   the	   so-­‐called	   L-­‐DOPA	   induced	   dyskinesia	   (LID).	  Dyskinesia	  is	  the	  medical	  term	  for	  any	  involuntary	  movement	  other	  than	  tremor	  and	   the	   spectrum	   of	   LID	   includes	   a	   variety	   of	   movements,	   such	   as	   chorea,	  dystonia,	  athetosis,	  and	  ballism.	  Choreic	  movements	  are	  non-­‐rhythmic,	   irregular,	   spasmodic,	  and	   involuntary	  movements	   that	   appear	   to	   flow	   from	   one	   muscle	   to	   the	   next.	   It	   occurs	   more	  commonly	   in	  distal	  muscles	  and	  is	  best	  seen	  in	  the	  fingers,	   toes,	  wrists,	  and/or	  the	  ankles.	  Chorea	  can	  also	  affect	   the	   craniofacial	  muscles	  and	   the	  neck	  but	   its	  prevalence	  in	  these	  muscles	  is	  less	  common	  in	  PD	  patients.	  	  Dystonia	   means	   “bad	   tone”	   and	   is	   medically	   defined	   as	   sustained	   or	  intermittent	   involuntary,	   patterned,	   and	   often	   repetitive	   contractions	   of	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opposing	  muscles.	  Dystonia	   is	  often	   initiated	  or	  worsened	  by	  voluntary	  actions	  and	  it	  causes	  twisting	  movements	  or	  abnormal	  postures,	  or	  both.	  In	  PD	  patients	  that	  developed	  LID,	  dystonia	  is	  caused	  either	  by	  the	  wearing	  “OFF”	  of	  L-­‐DOPA	  or	  during	   the	   “ON”	   phase.	   Dystonic	   symptoms	   can	   be	   disabling	   and	   result	   in	  significant	  pain	  (Fabbrini	  et	  al.	  2007).	  Athetoid	   movements	   are	   slow,	   involuntary,	   writhing	   movements	   of	   the	  fingers,	  hands,	  toes,	  and	  feet	  and	  in	  some	  cases	  can	  affect	  the	  arms,	  the	  legs,	  the	  neck,	  and	  the	  tongue.	  Ballistic	   movements	   manifest	   through	   muscle	   contractions	   that	   exhibit	  maximum	   speed	   and	   acceleration	   over	   a	   short	   period	   of	   time.	   Clinically	   the	  movements	   affect	   mainly	   proximal	   muscles,	   i.e.,	   sudden	   abrupt	   violent	  movement	  of	  the	  whole	  arm	  or	  leg.	  	  Phenotypically,	  LID	  manifests	  as	  any	  of	  the	  involuntary	  movements	  described	  above	  but	  most	  often	  it	  is	  characterised	  by	  mixtures	  of	  dystonia	  and	  chorea.	  Once	  established,	   dyskinesia	   tends	   to	   remain	  persistent	   and	  with	   the	  progression	  of	  the	  disease	   it	  becomes	   increasingly	  more	  difficult	   to	  deliver	  L-­‐DOPA	  doses	  that	  control	  the	  parkinsonian	  features	  without	  triggering	  dyskinesia	  (Moskovitz	  et	  al.	  1978;	  Olanow	  et	  al.	  2000).	  Although	  it	  can	  be	  reduced	  by	  some	  pharmacological	  manipulations	   and	   surgical	   procedures,	   LID	   is	   a	   significant	   source	   of	   disability	  and	   is	   difficult	   to	   treat,	   therefore	   efforts	   are	  made	   to	  minimise	   or	   prevent	   its	  appearance.	  Among	  the	  factors	  that	  affect	  the	  induction	  of	  LID	  is	  the	  pulsatile	  stimulation	  of	  dopamine	  receptors	  by	  oral	  administration	  of	  L-­‐DOPA.	  Supporting	  this	  notion	  is	   the	   observation	   that	   intravenous	   administration	   of	   L-­‐DOPA	   shows	   a	   more	  prolonged	   and	   stable	   clinical	   response	   with	   minimal	   side	   effects,	   including	  improvement	   in	   dyskinesia	   (Schuh	   &	   Bennett	   1993).	   However,	   practical	  considerations	  hinder	  its	  clinical	  use	  and	  intravenously	  administered	  L-­‐DOPA	  is	  only	   used	   in	   research	   studies.	   More	   recently,	   a	   new	   therapy	   for	   continuous	  stimulation	  of	  dopamine	  receptors	  by	  continuous	  duodenal	  L-­‐DOPA	  delivery	  was	  developed.	   Continuous	   duodenal	   infusion	   by	   a	   surgically	   implanted	   pump	  circumvents	   the	   problem	   of	   supra-­‐physiological	   dopamine	   swings	   associated	  with	  intermittent	  oral	  medication	  with	  L-­‐DOPA;	  this	  continuous	  mode	  of	  delivery	  has	  been	  shown	  to	  improve	  not	  only	  motor	  fluctuations	  in	  PD	  but	  also	  to	  reduce	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the	   severity	   and	  duration	  of	   dyskinesias	   (Olanow	  et	   al.	   2000;	  Nutt	   et	   al.	   2000;	  Nyholm	  et	  al.	  2005).	  As	  continuous	  duodenal	  L-­‐DOPA	  infusion	  is	  not	  employed	  in	  early	   stages	   of	   PD,	   it	   is	   not	   known	   whether	   its	   early	   use	   could	   prevent	   the	  development	   of	   dyskinesia.	   Because	   L-­‐DOPA	   is	   still	   the	   best	   known	  antiparkinsonian	   drug,	   the	   development	   of	   LID	   is	   still	   an	   major	   issue	   in	   the	  management	   of	   PD.	   Therefore,	   research	   on	   PD	   has	   focused	   in	   developing	  strategies	  to	  avoid	  LID.	  	  
1.7.1 Basal	  Ganglia	  Circuitry	  and	  L-­‐DOPA	  Induced	  Dyskinesia	  The	   basal	   ganglia	   are	   a	   group	   of	   subcortical	   nuclei	   that	   comprise	   the	  substantia	  nigra,	   the	  striatum,	  the	   internal	  and	  external	  segments	  of	   the	  globus	  pallidus	  (GPi	  and	  GPe,	  respectively)	  and	  the	  subthalamic	  nucleus	  (STN)	  (Obeso	  et	  al.	   2000).	   The	   striatum	   is	   divided	   into	   a	   ventral	   and	   a	   dorsal	   sub-­‐region.	   The	  ventral	   striatum	   functions	  as	  a	  part	  of	   the	   reward	   system	  and	   is	   comprised	  by	  the	   nucleus	   accumbens	   and	   the	   olfactory	   tubercle,	   whilst	   the	   dorsal	   striatum	  plays	  a	  major	  role	  in	  movement	  control	  and	  is	  composed	  of	  the	  caudate	  nucleus	  and	   the	  putamen.	   In	   rodents	   there	   is	   no	   clear	   separation	  between	   the	   caudate	  nucleus	   and	   the	   putamen	   and	   both	   structures	   are	   collectively	   called	   striatum.	  Among	   the	   functions	   of	   the	   basal	   ganglia	   is	   the	   control	   of	  movement,	  which	   is	  accomplished	   through	   a	   complex	   intercommunication	   between	   the	   different	  nuclei	   that	   ultimately	   leads	   to	   the	   inhibition	   of	   the	   thalamus.	   The	   thalamus	   is	  normally	  kept	  under	  inhibition	  and	  only	  upon	  release	  it	  stimulates	  the	  motor	  and	  premotor	  cortices	  leading	  to	  body	  movement.	  The	   major	   inputs	   into	   the	   basal	   ganglia	   are	   dopaminergic,	   from	   the	  nigrostriatal	  pathway,	  and	  glutamatergic,	  acetylcholinergic,	  serotonergic	  and	  to	  a	  lesser	   extent	   noradrenergic	   from	   other	   pathways.	   The	   output	   from	   the	   basal	  ganglia	   is	  mainly	   gamma-­‐aminobutyric	   acid	   (GABA)-­‐ergic	   (which	   is	   inhibitory)	  and	  projects	  from	  the	  GPi	  to	  the	  thalamus.	  In	  the	  classical	  model	  of	  basal	  ganglia	  circuitry,	  the	  striatum	  projects	  neurons	  to	   the	  other	  nuclei	   through	  a	  direct	  and	  an	   indirect	  pathway,	  which	  are	  named	  according	  to	  how	  they	  synapse	  with	  the	  GPi.	  As	  the	  name	  suggests,	  in	  the	  direct	  pathway	   neuronal	   projections	   synapse	   directly	   with	   the	   GPi,	   which	   sends	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inhibitory	  projections	  to	  the	  thalamus.	  The	  neurons	  of	  the	  direct	  output	  pathway	  have	  D1	  dopamine	  receptors	  on	  their	  cell	  bodies.	  The	  striatal	  projections	  in	  the	  indirect	  pathway	  reach	  the	  GPi	  through	  synapses	  with	  the	  GPe,	  from	  where	  they	  send	  inhibitory	  projections	  to	  the	  STN,	  which	  in	  turn	  makes	  excitatory	  synapses	  with	   the	  GPi	   (Figure	  8A).	  The	  output	  neurons	  of	   the	   indirect	  pathway	  have	  D2	  dopamine	  receptors	  in	  their	  cell	  bodies.	  While	  stimulation	  of	  D1	  receptors	  leads	  to	   an	   increase	   in	   the	   intracellular	   levels	   of	   the	   secondary	   messenger	   cAMP,	  stimulation	  of	  D2	   receptors	   leads	   to	   its	  decrease,	   therefore	   the	  direct	  pathway	  has	  excitatory	  receptors	  and	  its	  activation	  stimulates	  the	   inhibitory	  GABA-­‐ergic	  output	   to	   the	  GPi.	   The	  GPi	   also	   sends	   inhibitory	  GABA-­‐ergic	   projections	   to	   the	  thalamus,	   therefore	   inhibition	  of	   the	  GPi	   leads	   to	  a	  decreased	   inhibitory	  action	  on	   the	   thalamus,	   which	   becomes	   more	   active	   and	   stimulates	   the	   motor	   and	  premotor	  cortices.	  Therefore,	  dopamine	  stimulation	  of	  the	  direct	  pathway	  leads	  to	  decreased	  GPi	  activity,	  which	  leads	  to	  increased	  thalamic	  activity,	  culminating	  in	  increased	  activity	  of	  the	  motor	  cortex.	  In	   the	   striatal	   indirect	   pathway,	   stimulation	   of	   the	   D2	   receptors	   leads	   to	   a	  decreased	   activity	   of	   the	   inhibitory	   GABA-­‐ergic	   neurons	   that	   synapse	  with	   the	  GPe.	  Because	   the	  GPe	  also	   sends	   inhibitory	  GABA-­‐ergic	  projections	   to	   the	  STN,	  inhibition	   of	   the	   GPe	   leads	   to	   increased	   activity	   of	   the	   STN.	   The	   STN	   sends	  excitatory	   projections	   to	   the	   GPi,	   which	   in	   turn	   increases	   its	   inhibition	   of	   the	  thalamus.	  Thus,	  dopamine	  stimulation	  of	  the	  indirect	  pathway	  leads	  to	  increased	  GPi	  activity,	  which	  inhibits	  the	  thalamus	  leading	  to	  decreased	  stimulation	  of	  the	  motor	   and	   premotor	   cortices.	   Although	   already	   quite	   complex,	   the	   classical	  model	   of	   the	   basal	   ganglia	   circuitry	   is	   even	  more	   complicated	   than	   presented	  here.	  Reciprocal	  pathways	  between	  the	  basal	  ganglia	  nuclei	  add	  further	  layers	  of	  complexity	  to	  their	  structure	  and	  organisation.	  The	   degeneration	   of	   the	   nigral	   dopaminergic	   neurons	   that	   innervate	   the	  striatum	  leads	  to	  an	  imbalance	  in	  the	  activity	  of	  the	  direct	  and	  indirect	  pathways	  resulting	   in	   voluntary	   movement	   decline	   and	   the	   motor	   features	   that	  characterise	  PD	   (Figure	  8B).	  However,	   the	  mechanisms	   through	  which	  L-­‐DOPA	  treatment	   leads	   to	   the	   development	   of	   dyskinesia	   are	   not	   completely	  understood.	  According	  to	  the	  classical	  model	  presented	  here,	  L-­‐DOPA	  treatment	  overstimulates	   D1	   and	   D2	   receptors	   leading	   to	   underactivity	   of	   the	   indirect	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pathway	   and	   overactivity	   of	   the	   direct	   pathway.	   As	   a	   consequence,	   the	   GABA-­‐ergic	  repression	  of	  the	  thalamus	  is	  released	  and	  its	  increased	  firing	  rates	  lead	  to	  involuntary	  movements	  (Figure	  8C).	  	  
	  
Figure	  8:	  Classical	  model	  of	  the	  basal	  ganglia	  circuitry	  and	  LID	  in	  PD.	  
A.	  Basal	  ganglia	  circuitry	  in	  the	  healthy	  brain.	  Dopaminergic	  input	  from	  the	  nigrostriatal	  
pathway	   (1)	   synapses	   with	   the	   striatal	   output	   neurons	   that	   make	   up	   the	   indirect	   and	  
direct	  GABA-­‐output	  pathways.	   In	   the	   striatal	   indirect	  pathway	   (2),	   stimulation	  of	   the	  D2	  
receptors	  leads	  to	  a	  decreased	  activity	  of	  the	  inhibitory	  GABA-­‐ergic	  neurons	  that	  synapse	  
with	   the	   GPe.	   The	   GPe	   also	   sends	   inhibitory	   GABA-­‐ergic	   projections	   to	   the	   STN	   and	  
inhibition	   of	   the	   GPe	   leads	   to	   increased	   activity	   of	   the	   STN.	   The	   STN	   sends	   excitatory	  
projections	  to	  the	  GPi,	  thereby	  increasing	  the	  inhibition	  of	  the	  thalamus.	  The	  direct	  output	  
pathway	   (3)	   has	   excitatory	   D1	   dopaminergic	   receptors	   on	   its	   surface	   and	   dopamine	  
stimulation	  from	  the	  SNc	  (1)	  leads	  to	  excitation	  of	  the	  inhibitory	  GABA-­‐ergic	  neurons	  that	  
synapse	  with	   the	   GPi.	   The	   inhibited	   GPi	   in	   turn	   releases	   is	   repression	   of	   the	   thalamus.	  
Another	  major	   input	   to	   the	   striatum	   comes	   from	   the	   frontal	   cortex	   (4).	   B.	   According	   to	  
classical	   thinking	   about	   PD,	   loss	   of	   dopaminergic	   input	   from	   the	   SNc	   leads	   to	   reduced	  
voluntary	   movement	   through	   the	   overactivity	   of	   the	   indirect	   output	   pathway	   and	  
underactivity	  of	  the	  direct	  output	  pathway.	  C.	  Treatment	  with	  oral	  L-­‐DOPA	  was	  thought	  to	  
bring	  about	  changes	  in	  the	  opposite	  directions,	  with	  underactivity	  of	  the	  indirect	  pathway	  
and	   overactivity	   of	   the	   direct	   pathway.	   However	   this	   view	   has	   been	   challenged	   and	   the	  
precise	  mechanism	  through	  which	  LID	  occurs	  is	  not	  fully	  understood.	  (From:	  Jenner,	  P;	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of the GPi — which, according to the model, should 
increase dyskinesia — actually reduces dyskinesia in 
PD25.This illustrates the complexity of dyskinesia and the 
simplicity and perhaps naivety of some of the proposed 
models. It is probable that many of the changes that are 
currently proposed to be c uses of dyskinesia ac ually 
arise as a consequence of drug treatment or from the 
involuntary movements themselves.
Recent studies also suggest that PD models that were 
made by simply looking at overall changes in the activ-
ity of basal ganglia pathways fail to reflect the complex 
changes in firing patterns that occur. For example, loss of 
dopamine in PD and in experimental models of PD leads 
to synchronized low-frequency oscillatory burst firing in 
GPi and STN neurons that is reversed by L-DOPA26–28. 
The activity of specific neurons in these nuclei is linked 
to movement in specific body parts, and this might 
be critical for determining whether the expression of 
dyskinesia is localized or generalized. A more detailed 
understanding of the changes that occur in the activity 
of specific basal ganglia pathways is required, and dys-
kinesia should not be thought of as being a homogene-
ous single disorder or as resulting from global changes 
in the activity of basal ganglia nuclei.
The cl s ical vi w of t e dir ct and indirect output 
pathways of the basal ganglia can also be challenged29. 
This organizational plan of the basal ganglia is a clas-
sical view, and newer anatomical data suggest that it 
might not be entirely accurate. For example, axons pro-
jecting from the striatum in primates send collaterals to 
virtually every basal ganglia target. This alternative way 
to view the organization of the basal ganglia might alter 
our understanding of its relationship to the control of 
voluntary movement and the changes that occur in PD 
and dyskinesia. This issue is raised merely to prevent 
the reader from thinking that either the models of basal 
ganglia function or the models of their involvement in 
motor disorders are set in stone.
Figure 2 | Classical model of the basal ganglia changes that underlie L-DOPA-induced dyskinesia.  
a | Interconnections in the healthy basal ganglia. Dopaminergic input from the nigrostriatal pathway (1) synapses on to 
the striatal output neurons that make up the indirect and direct GABA (G-aminobutyric acid)-ergic output pathways.The 
indirect pathway (2) has inhibitory D2 dopaminergic receptors on its cell bodies and localizes enkephalin, whereas  
the direct output pathway (3) has excitatory D1 dopaminergic receptors on its surface and localizes substance P and 
dynorphin. The indirect output pathway projects to the external globus pallidus (GPe), where it synapses on to the 
GABAergic pathway that projects to the subthalamic nucleus (STN). The glutamatergic neurons of the STN project to  
the internal globus pallidus (GPi), where they synapse on to GABAergic output to the thalamus. The direct output 
pathway projects to the GPi, where it too synapses on to GABAergic output to the thalamus. Another major input to the 
striatum comes from the frontal cortex (4). b | According to classical thinking about Parkinson’s disease, loss of 
dopaminergic input from the substantia nigra leads to overactivity of the indirect output pathway and underactivity of 
the direct output pathway. The number of dendritic spines on medium spiny neurons in the striatum is reduced. Cortical 
glutamatergic input to the striatum is also altered. c | Administration of L-DOPA (l-3,4-dihydroxyphenylalanine)  was 
thought to bring about changes in the opposite directions, with underactivity of the indirect pathway and overactivity  
of the direct pathway (this is the view that is illustrated); however, there is evidence that this is not the case. As a 
consequence, a reciprocal link between the GPi and the STN was introduced to the model in an attempt to make it fit  
the experimental data (not shown).
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reduction	  of	  dyskinesia	   in	  40%	  of	   the	  participants.	  These	  observations	  suggest	  that	   alternative	   views	   need	   to	   be	   considered	   when	   looking	   at	   the	   connection	  between	   basal	   ganglia	   function,	   PD	   and	   dyskinesia	   (Leblois	   et	   al.	   2006;	   Jenner	  2008).	   Despite	   our	   poor	   understanding	   of	   the	   mechanisms	   underlying	   the	  development	   of	   LID,	   clinical	   observations	   suggest	   that	   the	   extent	   of	   nigral	  denervation	   and	   the	  mode	   of	   L-­‐DOPA	   administration	   play	   central	   roles	   in	   the	  manifestation	  of	  dyskinesia.	  	  
1.8 Gene	   Therapy	   Strategies	   for	   the	   Treatment	   of	   Parkinson’s	  
Disease	  PD	   is	   a	  well-­‐suited	   candidate	   for	   gene	   therapy	   and	  different	   strategies	   have	  been	  explored	  as	  a	  treatment.	  One	  factor	  that	  makes	  PD	  a	  well-­‐suited	  candidate	  for	  gene	  therapy	  is	  that	  viral	  vectors	  enable	  the	  targeting	  and	  the	  expression	  of	  complex	   molecules	   or	   enzymes	   in	   specific	   areas	   of	   the	   brain	   affected	   by	   the	  disease.	   Furthermore,	   while	   improvement	   in	   the	   treatment	   of	   the	   motor	  symptoms	  of	  PD	  has	  been	  achieved	  trough	  the	  introduction	  of	  compounds	  such	  as	  long	  lasting	  dopamine	  agonists	  and	  enzyme	  inhibitors	  that	  increase	  the	  half-­‐life	   and	   the	   bioavailability	   of	   oral	   L-­‐DOPA,	   the	   cost	   of	   these	   treatments	  represents	  a	  significant	  financial	  burden	  on	  patients.	  Gene	  therapy,	  on	  the	  other	  hand,	  has	   the	  potential	   to	   alleviate	   this	  burden	  by	   reducing	  or	   even	  abolishing	  the	   necessity	   for	   some	  medicines	   because	   it	   is	   based	   on	   a	   single	   intervention	  principle	   with	   life-­‐long	   effects.	   In	   total,	   nine	   gene	   therapy	   trials	   have	   been	  initiated	   to	   treat	   PD.	   Their	   therapeutic	   strategies	   are	   based	   on	   a	   number	   of	  preclinical	  and	  clinical	  observations	  and	  can	  be	  divided	   in	   three	  categories:	   (1)	  modification	   of	   disease	   progression	   by	   neuroprotection;	   (2)	  modulation	   of	   the	  activity	   in	  the	  basal	  ganglia	  downstream	  of	   the	  striatum;	  and	  (3)	  restoration	  of	  dopamine	  synthesis	  in	  the	  striatum.	  
	  
1.8.1 Modification	  of	  Disease	  Progression	  by	  Neuroprotection	  Because	   PD	   is	   a	   progressive	   neurodegenerative	   disorder,	   attempts	   to	   delay	  and	   even	   halt	   disease	   progression	   have	   been	   extensively	   pursued.	   In	   the	   90’s	  molecules	  known	  as	  neurotrophic	  factors	  were	  identified	  that	  showed	  promising	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neuroprotective	  potential.	  Two	  of	  them,	  glial	  derived	  neurotropic	  factor	  (GDNF)	  and	   neurturin	   (NTN)	   were	   shown	   to	   promote	   the	   survival	   of	   dopaminergic	  neurons	   in	   the	  midbrain	  both	   in	  vitro	  and	   in	  vivo	  and	  the	  promising	  preclinical	  data	  prompted	  rapid	  clinical	   testing	  soon	  after	   their	  discovery	  (Lin	  et	  al.	  1993;	  Björklund	  et	  al.	  1997;	  Horger	  et	  al.	  1998;	  Tseng	  et	  al.	  1998).	  AAV-­‐mediated	  gene	  transfer	  of	  NTN	   into	   the	  putamen	  and	   the	   substantia	  nigra	  of	  patients	  met	   the	  safety	  endpoints	  of	  Phase	  I	  clinical	  trials	  but	  subsequent	  Phase	  II	  trials	  showed	  no	   efficacy	   over	   control	   groups	   (Marks	   et	   al.	   2016).	   The	   project	   leaders	  hypothesised	  that	  possible	  reasons	  for	  the	  trial	  failures	  is	  that	  benefits	  in	  animal	  models	   might	   not	   translate	   into	   benefits	   in	   patients	   because	   they	   do	   not	  recapitulate	   the	   pathology,	   more	   specifically	   the	   accumulation	   of	   α-­‐synuclein	  found	   in	   PD.	   Another	   factor	   is	   that	   the	   trials	  were	   performed	   in	   advanced	   PD	  patients,	  which	  could	  have	  had	  an	  impact	  on	  the	  probability	  of	  the	  study	  to	  meet	  its	  endpoints.	  Since	  the	  strategy	  is	  based	  on	  the	  assumption	  of	  a	  neuroprotective	  action,	  efficacy	  might	  only	  be	  seen	   if	  patients	  with	  a	   less	  advanced	   form	  of	   the	  disease,	  and	  therefore	  with	  a	  greater	  residual	  dopaminergic	  system	  still	  present,	  are	  enrolled	  (Warren	  Olanow	  et	  al.	  2015).	  A	  Phase	  I	  clinical	  trial	  to	  test	  the	  safety	  and	   tolerability	   of	   AAV2-­‐mediated	   GDNF	   delivery	   to	   the	   putamen	   is	   currently	  recruiting	  patients,	  however	   its	  protocol	  has	  been	  criticised	   for	  not	  addressing	  some	  of	  the	  issues	  raised	  by	  the	  AAV2-­‐NTN	  trials	  (Bartus	  et	  al.	  2014).	  Overall,	  no	  neuroprotection	   study	   has	   yet	   been	   able	   to	   demonstrate	   positive	   results	   in	   a	  double	  blind	  trial	  to	  support	  advancing	  to	  a	  Phase	  III	  trial.	  	  
	  
1.8.2 Modulation	   of	   the	  Activity	   in	   the	  Basal	   Ganglia	  Downstream	  of	   the	  
Striatum	  Neurosurgical	   intervention	   to	   reduce	   motor	   complications	   in	   PD	   has	   been	  successfully	  accomplished	  by	  a	  technique	  called	  deep	  brain	  stimulation	  (DBS).	  It	  consists	  of	  the	  implantation	  of	  intracranial	  electrodes	  in	  the	  internal	  segment	  of	  the	   globus	   pallidus	   (Gpi)	   and	   the	   subthalamic	   nucleus	   (STN),	   which	   send	  electrical	   impulses	   to	   the	  brain	   in	  an	  attempt	   to	  better	  control	  dyskinesia.	  DBS	  works	   as	   a	   “brain	   pacemaker”	   and	   although	   its	   mechanism	   of	   action	   is	   not	  completely	  understood,	   it	   is	   thought	   to	  act	  by	   inhibiting	  hyperactive	  regions	   in	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the	   basal	   ganglia.	   DBS	   can	   mitigate	   motor	   symptoms	   of	   PD	  and/or	   directly	  diminish	  the	  side	  effects	  induced	  by	  L-­‐DOPA	  pharmacotherapy,	  thereby	  allowing	  a	   decrease	   in	   medication	   dose	   allowing	   for	   a	   better	   management	   of	   motor	  symptoms.	  The	   success	   of	   DBS	   has	   driven	   the	   gene	   therapy	   strategy	   of	   AAV-­‐mediated	  expression	  of	  glutamic	  acid	  decarboxylase	  (GAD)	  in	  the	  STN,	  which	   is	  based	  on	  the	   assumption	   that	   ectopic	   GAD	   will	   catalyse	   the	   synthesis	   of	   gamma-­‐aminobutyric	   acid	   (GABA),	   the	   major	   inhibitory	   neurotransmitter	   in	   the	   CNS,	  thereby	  providing	   lost	   inhibitory	   control	   in	   the	   STN	  and	   restoring	   appropriate	  synaptic	  balance.	  A	  Phase	  I	  clinical	  trial	  showed	  safety	  and	  tolerability	  to	  AAV2-­‐mediated	  GAD	  gene	  transfer	  to	  the	  STN	  but	  after	  a	  Phase	  II	  randomised,	  multi-­‐center,	   double	   blind,	   placebo	   control	   study,	   the	   programme	   was	   suspended	  because	  the	  results,	  although	  encouraging,	  did	  not	  surpass	  the	  current	  standard	  of	  care	  (Kaplitt	  et	  al.	  2007;	  Bartus	  et	  al.	  2014).	  	  
1.8.3 Restoration	  of	  Dopamine	  Synthesis	  in	  the	  Striatum	  Since	   the	   discovery	   of	   dopamine	   as	   a	   neurotransmitter	   involved	   in	   the	  manifestation	  of	  PD	  pathology,	  the	  focus	  of	  pharmacological	  therapies	  has	  been	  on	  restoring	  the	  dopaminergic	  tone	  in	  the	  brain.	  Therapeutic	  strategies	  pursuing	  this	   goal	   follow	   one	   of	   three	   approaches,	   which	   are	   distinct	   in	   their	  interpretation	  as	  to	  which	  enzymes	  must	  be	  ectopically	  expressed	  to	  restore	  the	  imbalanced	  dopaminergic	  tone	  in	  the	  brain	  (Figure	  9).	  	  
	   57	  
	  
total systemic L-DOPA would be converted to DA in this part of the
brain. As a result, the dose of oral L-DOPA could be decreased with
maintained efﬁcacy, whereas the effects due to extra-striatal DA
synthesis may be minimized. This strategy is also known as the pro-
drug approach. The ﬁrst proof-of-principle for this therapy was
demonstrated in primates with a unilateral MPTP (1-methyl 4-
phenyl 1,2,3,6-tetrahydropyridine) lesion that received an injection
of rAAV2 vectors coding for the human AADC gene. These animals
showed increased conversion efﬁcacy of peripheral L-DOPA to DA as
seen by biochemical analysis of tissue punches from the transduced
striatum [29].
When applied to MPTP lesioned non-human primates, rAAV
mediated AADC delivery resulted in an increased accumulation of
[18F]-MT (ﬂuoro-L-m-tyrosine), in the transduced striatum compared
to lesion controls [29]. FMT is an L-DOPA analog that cannot be
methylated by catechol-O-methyltransferase (COMT) in peripheral
organs and erythrocytes but is still a valid substrate for the AADC
enzyme. Thus, the background signal in the brain is less then that of
[18F]-DOPA but with maintained speciﬁcity for neurons that display
decarboxylase activity [30]. [18F]-MT retention in the brain correlates
well with the total concentration of AADC (present in dopamine,
serotonin and norepinephrine containing neurons) but is not
dependent on vesicular monoamine transporter (VMAT2) function
[30]. In a follow-up study, Bankiewicz and colleagues presented long-
term behavioral improvement and in vivo AADC enzyme activity for
up to 6 years after rAAV-AADC transduction of MPTP treated
monkeys [31]. The animals displayed a 50% improvement in the
clinical rating scale after a single injection of L-DOPA at a dose that
was not sufﬁcient to induce a signiﬁcant improvement in control
vector injected animals. However the duration of action for
peripheral L-DOPA in these rAAV-AADC transduced primates was
not reported. Nevertheless, the behavioral effects were coupled with
a normalized striatal [18F]-MT uptake that was stable for the full
duration of the study [31].
The pro-drug approach is often touted as attractive from a safety
point of view because it enables peripheral regulation. In case of
adverse events, the peripheral supply of L-DOPA can be discontinued
and the ectopic AADC enzyme would be rendered inactive. However,
one point of concern is if the ectopic release of DA from transduced
cells were too efﬁcient, the extracellular levels of DA after an oral L-
DOPA intake might increase too rapidly. Thus the therapy could
increase the ﬂuctuations of DA supply and aggravate dyskinesias. In
fact, it has been shown in primates that even AADC over-expression
alone can potentiate L-DOPA-induced dyskinesias if the transduction
is heterogeneous [32]. If this were to happen, the daily L-DOPA dose
would have to be decreased or even discontinued until the adverse
events disappear. However, as oral L-DOPA is the main, most
efﬁcacious pharmacotherapy for the patients, this would leave them
worse off than before the intervention.
Fig. 1. Schematic drawings of viral vector-mediated enzyme replacement strategies in
the parkinsonian brain. (A) Pro-drug approach for enhanced DA synthesis. rAAV
mediated gene transfer of AADC results in expression of the enzyme at high levels in
striatal neurons from an episomal plasmid. L-DOPA from oral pharmacotherapy enters
the brain over the blood–brain barrier. It is taken up by the transduced striatal neuron
and converted by the ectopic AADC to DA that probably accumulates in the cytoplasm
and diffuses towards the post-synaptic DA receptors providing symptomatic relief. (B)
Dopamine replacement. The multi-cistronic EIAV vector infects the striatal neuron
where the genes are integrated in the host genome. As the vector carries all three genes
required for DA synthesis (TH, GCH1 and AADC), dietary tyrosine can be used to
synthesize DA within the striatal neuron at a constant rate. This DA then exits the
neuron and reaches the DA receptors in the same way as in panel A. (C) Continuous
DOPA delivery strategy. rAAV mediated gene transfer of TH and GCH1 results in
transduced striatal neurons that can synthesize DOPA form dietary Tyrosine at a
constant rate. However, as the cells do not possess the decarboxylase activity, the DOPA
exits the cell and ends up in spared DA ﬁbers or Serotonergic terminals. There it is
converted by endogenous AADC enzyme into DA and stored in vesicles by the VMAT2
transporter. The ectopically derived DA (in blue) therefore competes with endogenous
5-HT or DA (in red) for storage and release.
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Figure	   9:	   Schematic	   representation	   of	   viral	   vector-­‐mediated	   enzyme	   replacement	  
strategies	  for	  the	  restoration	  of	  the	  dopaminergic	  tone	  in	  the	  brain.	  
(A)	   Pro-­‐drug	   approach	   for	   enhanced	   dopamine	   synthesis.	   L-­‐DOPA	   from	   oral	  
pharmacotherapy	   enters	   the	   brain	   over	   the	   BBB,	   is	   taken	   up	   by	   the	   transduced	   striatal	  
neuron	   and	   is	   converted	   by	   the	   ectopic	   AADC	   to	   dopamine.	   The	   newly	   synthesised	  
dopamine	  probably	  accumulates	  in	  the	  cytoplasm	  and	  diffuses	  towards	  the	  post-­‐synaptic	  
dopamine	  receptors	  providing	  symptomatic	  relief.	  (B)	  Dopamine	  replacement.	  Lentiviral-­‐
based	   expression	   of	   TH,	   GCH1	   and	   AADC	   for	   dopamine	   synthesis.	   (C)	   Continuous	   DOPA	  
delivery	   strategy.	   rAAV	   mediated	   gene	   transfer	   of	   TH	   and	   GCH1	   results	   in	   transduced	  
striatal	   neurons	   that	   can	   synthesise	   DOPA	   form	   dietary	   tyrosine	   at	   a	   constant	   rate.	  
However,	   as	   the	   cells	  do	  not	  express	  AADC,	  L-­‐DOPA	  exits	   the	   cell	   and	  ends	  up	   in	   spared	  
dopaminergic	  fibres	  or	  serotonergic	  terminals,	  where	  it	  is	  converted	  by	  endogenous	  AADC	  
into	   dopamine	   and	   stored	   in	   vesicles	   by	   the	   VMAT2	   transporter.	   DA:	   dopamine;	   5-­‐HT:	  
serotonin;	   TH:	   tyrosine	   hydroxylase;	   GCH:	   GTP-­‐cyclohydrolase;	   AADC:	   aromatic	   amino	  
acid	   decarboxylase;	   BH4:	   tetrahydrobiopterin;	   Tyr:	   tyrosine.	   (From:	   Björklund	   T.	   and	  
Kirik	  D.	  Biochim	  Biophys	  Acta.	  2009	  Jul;1792(7):703-­‐13).	  	  The	   first	   approach,	   which	   proposes	   enhanced	   dopamine	   synthesis	   by	   the	  ectopic	  expression	  of	  AADC	  is	  known	  as	  the	  pro-­‐drug	  approach.	  This	  approach	  is	  based	  on	  the	  clinical	  observation	  that	  PD	  patients	  have	  decreased	  AADC	  levels	  in	  their	  striatum	  and	  predicts	  that	  ectopic	  expression	  of	  AADC	  at	  high	  levels	  in	  the	  striatal	  neurons	   can	   restore	   the	  dopaminergic	   tone	   in	   the	  brain	  when	   the	  pro-­‐drug	   (L-­‐DOPA)	   is	   provided	   orally.	   This	   strategy	   has	   shown	   long-­‐lasting	  therapeutic	  benefit	  in	  MPTP-­‐lesioned	  NHP	  for	  up	  to	  6	  years	  after	  injection	  of	  an	  AAV2	   vector	   expressing	   AADC	   in	   the	   putamen	   and	   is	   regarded	   a	   safe	   strategy	  because	   it	  allows	   for	  peripheral	  regulation	  of	  L-­‐DOPA	  (Bankiewicz	  et	  al.	  2006).	  So	   far,	   this	   approach	   has	   been	   successfully	   tested	   in	   two	  Phase	   I	   clinical	   trials	  (Christine	  et	  al.	  2009;	  Muramatsu	  et	  al.	  2010).	  However,	  a	   long-­‐term	  follow-­‐up	  study	  of	  the	  subjects	  enrolled	  in	  one	  of	  the	  trials	  demonstrated	  that	  following	  an	  improvement	  in	  the	  Unified	  Parkinson's	  Disease	  Rating	  Scale	  (UPDRS)	  in	  the	  first	  year,	  rating	  scores	  slowly	  deteriorated	  over	  the	  subsequent	  years	  (Mittermeyer	  et	  al.	  2012).	  In	  response	  to	  this	  observation,	  delivery	  techniques	  were	  improved	  in	  order	  to	  achieve	  increased	  vector	  coverage	  in	  the	  putamen	  (San	  Sebastian	  et	  al.	  2012).	  At	  the	  moment	  a	  Phase	  II	  AAV2-­‐AADC	  trial	   is	  in	  progress	  but	  no	  data	  have	  been	  released	  yet.	  The	   second	   approach	   to	   restore	   the	   dopaminergic	   tone	   in	   the	   brain	   is	   the	  dopamine	  replacement	  approach,	  which	  is	  based	  on	  the	  intrastriatal	  delivery	  of	  the	   three	   enzymes	   required	   for	   dopamine	   synthesis:	   TH,	   GCH1	   and	   AADC.	  Ectopic	   dopamine	   production	   in	   the	   striatum,	   however,	   raises	   some	   concerns.	  Since	   the	   complete	  dopamine-­‐synthetic	  machinery	  will	   be	  expressed	   in	   striatal	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neurons	  that	  lack	  a	  dopamine	  vesicular	  storage	  system,	  dietary	  tyrosine	  reaching	  transduced	  neurons	  will	  be	  readily	  converted	  into	  free	  cytosolic	  dopamine.	  This	  has	  two	  potential	  undesired	  effects:	  firstly,	  the	  TH	  enzyme	  in	  the	  cytoplasm	  can	  be	   strongly	   inhibited	   by	   dopamine	   through	   its	   end-­‐product	   negative	   feedback	  mechanism,	   thus	   compromising	   the	   therapeutic	   efficacy	   (Zigmond	   et	   al.	   1989;	  Daubner	   et	   al.	   2011).	   Secondly,	   cytosolic	   dopamine	   can	   cause	   severe	   oxidative	  stress	  and	  lead	  to	  cell	  death.	  This	  approach	  was	  tested	  in	  rodents	  and	  NHP	  using	  an	  integrating	  lentiviral	  vector	  to	  deliver	  the	  three	  enzymes	  to	  the	  striatum.	  The	  feedback	   inhibition	   issue	   was	   addressed	   by	   using	   a	   truncated	   form	   of	   the	   TH	  enzyme	   lacking	   its	   N-­‐terminal	   regulatory	   domain,	   which	   abolishes	   its	   end-­‐product	   inhibition	  mechanism.	  The	  NHP	  study	  showed	  efficacy	  of	   the	   lenti-­‐TH-­‐AADC-­‐GCH1	  gene	  transfer	  without	  triggering	  OFF	  drug	  dyskinesias	  as	  had	  been	  seen	   in	   previous	   studies	   with	   foetal	   grafting	   to	   treat	   PD	   (Freed	   et	   al.	   2001;	  Olanow	   et	   al.	   2003;	   Rylander	   Ottosson	   &	   Lane	   2016).	   However,	   in	   an	  uncontrolled,	   open	   label	   Phase	   I/II	   clinical	   trial,	   this	   lentiviral	   gene	   transfer	  approach	   showed	   only	   modest	   efficacy,	   which	   was	   within	   the	   placebo	   range	  observed	  in	  the	  AAV2-­‐NTN	  and	  AAV2-­‐AADC	  trials	  (Marks	  et	  al.	  2008;	  Christine	  et	  al.	  2009).	  Nevertheless,	  the	  strategy	  was	  deemed	  as	  safe,	  with	  no	  adverse	  effects	  reported	   related	   to	   the	   gene	   therapy	   intervention.	   This	   observation	   is	   of	  paramount	   importance	  given	   that	   this	  was	   the	   first	   report	  of	  a	   lentiviral-­‐based	  vector	  used	  to	  treat	  a	  condition	  affecting	  the	  CNS.	  Because	  of	  the	  modest	  efficacy	  seen	   in	   the	   trial	   and	   the	   failure	   of	   other	   gene	   therapies	   to	   meet	   the	   primary	  endpoints	  for	  efficacy	  in	  double-­‐blind	  placebo	  controlled	  trials,	  the	  study	  leaders	  decided	   to	   continue	   only	   once	   their	   delivery	   strategy	   and	   vector	   have	   been	  optimised.	  The	   third	   approach	   is	   an	   alternative	   to	   the	   dopamine	   delivery	   strategy	   and	  consists	  of	  continuous	  L-­‐DOPA	  delivery	  to	  the	  striatum.	  At	   first,	  both	  strategies	  might	   look	   similar	   but	   in	   fact	   they	   differ	   in	   a	   number	   of	   key	   points.	   A	   first	  difference	   is	   in	   regard	   to	   the	   enzymes	   that	   are	   delivered	   by	   the	   viral	   vectors.	  Instead	  of	  providing	  the	  whole	  dopamine-­‐synthetic	  machinery,	  the	  continuous	  L-­‐DOPA	  synthesis	  approach	  delivers	  TH	  and	  GCH1,	  the	  two	  rate-­‐limiting	  enzymes	  in	  L-­‐DOPA	  synthesis	  and	  relies	  on	  endogenous	  AADC	  dopamine	  synthesis.	  This	  strategy	   addresses	   the	   potential	   issues	   raised	   for	   the	   dopamine	   replacement	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approach	  by	   separating	   the	   compartment	   in	  which	  L-­‐DOPA	   is	   synthesised	   (the	  transduced	   striatal	   neurons)	   and	   the	   compartment	   where	   it	   is	   converted	   into	  dopamine	   (the	   spared	   dopaminergic	   and	   serotonergic	   neurons	   expressing	  AADC).	   Through	   this	   separation,	   dopamine	   synthesis	   is	   restricted	   to	   neurons	  that	   naturally	   express	   AADC	   and	   are	   able	   to	   store	   the	   neurotransmitter	   in	  vesicles	  for	  controlled	  release.	  Although	  it	  might	  sound	  counter-­‐intuitive	  to	  rely	  on	  the	  endogenous	  expression	  of	  AADC	  in	  a	  cell	  population	  that	  is	  affected	  by	  the	  progressive	   character	   of	   the	   disease,	   the	   gold-­‐standard	   treatment	  with	   oral	   L-­‐DOPA	  pharmacotherapy	  suggests	  that	  the	  endogenous	  levels	  of	  AADC	  expressed	  in	  spared	  neurons	  are	  sufficient	   to	  convert	  L-­‐DOPA	   into	  dopamine.	   In	  addition,	  the	  progression	  of	  PD	  affects	  the	  serotonergic	  neurons	  (another	  source	  of	  AADC	  in	  the	  striatum)	  to	  a	  much	  lesser	  extent	  than	  the	  dopaminergic	  neurons	  and	  can	  therefore	   be	   regarded	   as	   a	   long-­‐term	   source	   of	   AADC	   (Kish	   et	   al.	   2008).	  Preclinical	   studies	   using	   AAV-­‐mediated	   TH	   and	   GCH1	   continuous	   L-­‐DOPA	  synthesis	   in	   the	   striatum	   have	   shown	   improvement	   in	   motor	   tests	   as	   well	   as	  decrease	   in	   dyskinesia	   (Carlsson	   et	   al.	   2005).	   Furthermore,	   dopamine	  synthesised	  after	  this	  gene	  therapy	  approach	  reaches	  post-­‐synaptic	  receptors	  on	  striatal	  neurons	  in	  a	  physiological	  manner	  (Leriche	  et	  al.	  2009).	  The	  potential	  advantages	  of	  AAV-­‐mediated	  continuous	  L-­‐DOPA	  synthesis	  over	  direct	   dopamine	   synthesis	   lay	   the	   scientific	   rationale	   for	   studies	   done	   in	   this	  thesis:	   the	   expansion	   of	   this	   approach	   from	   the	   CNS	   to	   the	   periphery	   and	   the	  safety	  and	  efficacy	  studies	  in	  NHP	  following	  promising	  preclinical	  results	  in	  a	  rat	  model	  of	  PD.	  	  
1.9 Aims	  of	  the	  Thesis	  Chronic	  intermittent	  oral	  L-­‐DOPA	  pharmacotherapy	  leads	  to	  the	  development	  of	   side	   effects	   such	   as	   motor	   fluctuations	   and	   LID.	   Although	   the	   underlying	  pathophysiology	  of	  LID	  development	  remains	  elusive,	   the	  relationship	  between	  swings	   in	   the	   levels	  of	   circulating	  L-­‐DOPA	  and	  LID	   is	   indisputable	  and	  patients	  under	   continuous	  dopamine	   receptor	   stimulation	  present	   significantly	   reduced	  dyskinesia	   compared	   with	   the	   standard	   intermittent	   oral	   L-­‐DOPA	   therapy.	  Continuous	  L-­‐DOPA	  synthesis	  can	  be	  achieved	  by	  gene	   transfer	  of	   the	  L-­‐DOPA-­‐
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synthetic	   genes	   TH	   and	   GCH1	   to	   the	   CNS,	   as	   shown	   in	   a	   rodent	   model	   of	   PD,	  resulting	  in	  decreased	  parkinsonism	  and	  L-­‐DOPA	  induced	  side	  effects.	  This	   thesis	   evaluates	   two	   novel	   gene	   therapy	   strategies	   that	   propose	   a	  combination	   treatment	  of	  oral	  L-­‐DOPA	  and	  a	  one-­‐time	  AAV	   injection	   to	  deliver	  TH	  and	  GCH1	  in	  order	  to	  achieve	  a	  continuous	  and	  basal	  L-­‐DOPA	  supply,	  thereby	  diminishing	   the	   fluctuations	   inherent	   to	   oral	   treatment	   alone	   and	   improving	  management	   of	   L-­‐DOPA	   induced	   side	   effects.	   The	   main	   aims	   of	   the	   proposed	  study	  are	  to:	  1) Test	  whether	  elevated	  L-­‐DOPA	  levels	  can	  be	  detected	  in	  the	  periphery	  of	  healty	  mice	  upon	  AAV-­‐mediated	  delivery	  of	  the	  GCH1	  and	  TH	  genes	  to	  the	  liver.	  2) Test	  the	  preclinical	  efficacy	  and	  safety	  of	  a	  candidate	  AAV	  vector	  in	  a	  NHP	  model	  of	  PD	  as	  well	  as	  develop	  and	  test	  improved	  versions	  thereof.	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Chapter	  2 Materials	  and	  Methods	  	  
2.1 Standard	  Molecular	  Biology	  Techniques	  	  
2.1.1 Molecular	  Cloning	  
2.1.1.1 Standard	  Polymerase	  Chain	  Reaction	  (PCR)	  This	   is	   the	  basic	  PCR	   reaction	   that	  was	  used	   for	   colony	  screening	  and	  other	  tests.	   The	   polymerase	   kit	   used	   is	   the	   standard	   GoTaq®	   DNA	   polymerase	  (Promega).	  PCR	  reactions	  were	  carried	  out	  in	  a	  total	  volume	  of	  25µl	  containing	  (final	   concentrations):	   200µM	   dNTPs	   (NEB),	   1X	   Colourless	   GoTaq	   Reaction	  Buffer,	  1.25U	  GoTaq	  DNA	  polymerase,	  1µM	  each	  of	  the	  primers,	  ~50ng	  DNA,	  and	  ddH2O	   to	  a	   final	  25µl	  volume.	  0.01μmol	  of	  unmodified	  oligonucleotide	  primers	  for	   PCR	   amplification	   were	   obtained	   from	   Eurofins	   MWG	   Operon	   and	  resuspended	  with	  ddH2O	  to	  make	  stock	  solutions	  at	  100µM.	  Forward	  (sense)	  and	  reverse	   (anti-­‐sense,	   reverse	   complement)	   oligonucleotide	   primers	   were	  designed	  following	  the	  manufacturer’s	  instructions:	  15-­‐30	  nucleotides	  in	  length,	  40-­‐60%	  GC	  content,	  and	  terminating	  in	  at	  least	  one	  G/C	  base.	  For	  information	  on	  the	   primers	   used	   in	   this	   thesis	   see	   table	   (Appendix	   A	   p.	   217).	   PCRs	   were	  performed	  using	  an	  Eppendorf	  Mastercycler	  ep	  gradient	  thermocycler.	  A	  typical	  PCR	  reaction	  initiated	  with	  a	  2	  minute	  denaturing	  step	  at	  95˚C	  followed	  by	  25-­‐35	  cycles	  including	  a	  denaturing	  step	  of	  20	  seconds	  at	  95˚C,	  an	  annealing	  step	  of	  45	  seconds	  at	  the	  optimal	  temperature	  for	  each	  primer	  pair	  and	  an	  extension	  step	  of	  1	  minute	  per	  kb	  at	  72°C.	  A	  final	  5	  minutes	  extension	  at	  72°C	  followed	  the	  cycles.	  Reactions	  were	  kept	  at	  4°C	  until	  use.	  	  
2.1.1.2 High	  Fidelity	  PCR	  For	   all	   PCR	   reactions	   performed	   to	   amplify	   DNA	   fragments	   for	   cloning,	   the	  Phusion	   High	   Fidelity	   polymerase	   kit	   (Thermo	   Scientific)	   was	   used	   to	   ensure	  high	  fidelity	  amplification	  of	  target	  sequences.	  PCR	  reactions	  were	  carried	  out	  in	  a	  total	  volume	  of	  25μl,	  in	  a	  mixture	  containing	  (final	  concentrations)	  10-­‐50ng	  of	  DNA	   template,	   0.5µM	  of	   forward	   and	   reverse	   primers,	   10mM	  of	   dNTPs	   (NEB),	  0.02u/μl	   Phusion®	   High-­‐Fidelity	   DNA	   polymerase	   (Thermo	   Scientific),	   1X	  
	   63	  
Phusion®	   HF	   or	   GC	   Buffer	   and	   brought	   to	   the	   final	   volume	  with	   ddH2O.	   PCRs	  were	   performed	   using	   an	   Eppendorf	   Mastercycler	   ep	   gradient	   thermocycler.	  Phusion	   GC	   buffer	   was	   used	   in	   reactions	   that	   initially	   did	   not	   work	   with	   HF	  buffer,	   as	   it	   is	   indicated	   for	   GC-­‐rich	   templates	   or	   those	   that	   form	   secondary	  structures.	  Reaction	  conditions	  varied	  depending	  on	  the	  size	  and	  GC	  content	  of	  the	   fragment	   to	   be	   amplified.	   A	   typical	   PCR	   reaction	   initiated	   with	   a	   30s	  denaturing	  step	  at	  98°C	  followed	  by	  25-­‐35	  cycles	  including	  a	  denaturing	  step	  of	  10s	  at	  98°C,	  an	  annealing	  step	  of	  20s	  at	  the	  optimal	  temperature	  for	  the	  primer	  pair	   and	   an	   extension	   step	   of	   30s/kb	   at	   72°C.	   A	   final	   5	  min	   extension	   at	   72°C	  followed	   the	   cycles.	   Reactions	   were	   kept	   at	   4°C	   until	   use.	   The	   annealing	   step	  temperature	  was	   adjusted	   to	   the	  melting	   temperature	   of	   the	   primers.	   Primers	  were	   designed	   and	   obtained	   from	   Eurofins	   MWG	   Operon.	   For	   some	   cloning	  strategies,	  primers	  were	  designed	  with	  external	  overhangs	  containing	  restriction	  endonuclease	  sites	  matching	  those	  in	  the	  destination	  construct.	  For	  information	  on	  the	  primers	  used	  in	  this	  thesis	  see	  table	  (Appendix	  A,	  p.	  217).	  	  
2.1.1.3 Site-­‐directed	   Mutagenesis	   for	   the	   Generation	   of	   LP1-­‐mutated	  
Constructs	  Side-­‐directed	   mutagenesis	   was	   used	   to	   insert	   point	   mutations	   in	   the	   LP1	  promoter	   sequence.	   Mutagenesis	   primers	   were	   ~40nt	   long	   and	   included	   a	  central	  mismatched	   nt	   flanked	   by	   ~20nt	   homologous	   to	   the	   parental	   plasmid.	  Reactions	   were	   done	   in	   a	   total	   volume	   of	   50µl	   using	   30ng	   of	   template	   DNA,	  200μM	  dNTPs	  (NEB),	  8μl	  5M	  betaine	  solution	  (Sigma),	  125ng	  of	  each	  primer	  and	  1.25μl	   Phusion	   High	   Fidelity	   Polymerase	   (Fischer	   Scientific)	   in	   appropriate	  buffer.	  Conditions	  of	  the	  PCR	  amplification	  were	  as	  follows:	  98°C	  (30s),	  followed	  by	   12	   cycles	   of	   98°C	   (10s)/	   55°C	   (60s)/	   72°C	   (3min),	   and	   a	   final	   extension	   at	  72°C	   for	   10min.	   For	   information	   on	   the	   primers	   used	   in	   this	   thesis	   see	   table	  (Appendix	  A,	  p.	  217).	  	  
	  
2.1.1.4 Agarose	  Gel	  Electrophoresis	  Amplified	  DNA	  PCR	  products	  or	  DNA	  fragments	  from	  restriction	  endonuclease	  digestions	   were	   diluted	   with	   5X	   DNA	   loading	   dye	   (NEB).	   Agarose	   gels	   were	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prepared	  by	  dissolving	  agarose	  powder	  (UltraPureTM	  Agarose,	  Life	  Technologies)	  in	   1X	   TAE	   buffer	   (10X:	   Tris-­‐Base	   48.4g/L,	   Acetic	   acid	   11.4ml/L,	   EDTA	   3.7g/L)	  and	  heating	  until	   dissolved.	   The	   agarose	  percentage	  was	   varied	  between	  0.8%	  and	  1.5%	  depending	  on	   the	   size	  of	   the	   fragment	   to	  be	  observed/isolated,	  with	  higher	  percentages	  used	  to	  achieve	  better	  separation	  of	  smaller	  fragments.	  After	  allowing	   the	   dissolved	   agarose	   to	   cool	   down,	   1μg/ml	   of	   Ethidium	   bromide	  solution	  (Sigma)	  was	  added	  and	  the	  mixture	  was	  poured	  into	  an	  electrophoresis	  tank	  (BioRad).	  Once	  solidified,	  the	  gel	  was	  immersed	  in	  1X	  TAE	  buffer	  and	  DNA	  samples	  were	  loaded	  in	  the	  wells	  of	  the	  gel.	  Gels	  were	  run	  at	  120V	  for	  about	  30-­‐90	  minutes,	   depending	   on	   the	   separation	   required	   between	   bands.	   Band	   sizes	  were	  monitored	  with	  the	  100bp	  or	  the	  1kb	  DNA	  ladder	  (NEB),	  which	  was	  run	  in	  parallel	   to	   the	   samples.	   Ethidium	   bromide-­‐stained	   DNA	   fragments	   were	  visualised	   under	   a	   ultra-­‐violet	   trans-­‐illuminator	   using	   a	   ChemiDocTM	   XRS+	  System	  (BioRad).	  
	  
2.1.1.5 Extraction	  and	  Purification	  od	  DNA	  Fragments	  from	  Agarose	  Gels	  DNA	  fragments	  of	  interest	  were	  excised	  from	  agarose	  gels	  and	  purified	  using	  the	   Qiagen	   Gel	   Extraction	   Kit.	   Three	   volumes	   of	   solubilisation	   and	   binding	   QG	  buffer	  were	  added	  to	  the	  agarose	  gel	  slice,	  the	  mixture	  was	  heated	  to	  50°C	  for	  10	  minutes	  and	  mixed	  to	  dissolve	  the	  slice.	  One	  volume	  of	  isopropanol	  was	  added	  to	  the	  mixture,	  which	  was	  subsequently	  loaded	  onto	  a	  QIAquick	  spin-­‐column.	  DNA	  was	  bound	  to	  the	  column	  by	  centrifugation	  at	  13000	  rpm	  for	  1	  min,	  after	  which	  flow-­‐through	  was	  discarded	  and	  the	  column	  was	  washed	  with	  750μl	  of	  ethanol-­‐containing	   PE	   buffer	   and	   centrifuged	   twice	   to	   completely	   remove	   ethanol.	   The	  DNA	  was	  finally	  eluted	  into	  a	  sterile	  eppendorf	  tube	  with	  30μl	  of	  ddH2O.	  	  A	   similar	   procedure	   was	   used	   to	   purify	   restriction	   endonuclease	   digestion	  products	   that	   were	   not	   run	   on	   agarose	   gels.	   The	   same	   kit	   and	   protocol	   were	  used,	  with	  the	  exception	  that	  the	  restriction	  endonuclease	  digestion	  mixture	  was	  directly	  mixed	  with	  the	  QG	  buffer	  and	  isopropanol.	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2.1.1.6 DNA	  Digestion	  with	  Restriction	  Endonucleases	  For	   analytical	   restriction	   endonuclease	   (RE)	   digestions,	   0.5μl	   of	   RE	   (NEB)	  were	  used	  to	  digest	  500ng	  of	  plasmid	  DNA	  in	  a	  1X	  solution	  of	  the	  manufacturer’s	  supplied	  buffer,	  and	  total	  reaction	  volume	  was	  adjusted	  to	  50μl	  with	  ddH2O.	  For	  RE	  digestions	  to	  generate	  fragments	  for	  cloning,	  1µl	  of	  RE	  was	  used	  to	  digest	  2-­‐5µg	  of	  DNA.	  All	   reactions	  were	  performed	  at	   the	   indicated	   temperature	   for	   the	  used	   RE	   (generally	   at	   37˚C)	   for	   2	   hours.	   When	   double	   digestions	   with	   two	  different	  restriction	  enzymes	  were	  performed,	  a	  compatible	  reaction	  buffer	  was	  used	   as	   indicated	   by	  manufacturer.	   After	   single-­‐enzyme	  digestions	   to	   generate	  plasmid	   fragments	   for	   cloning,	   vector	   DNA	   was	   treated	   with	   calf	   intestinal	  phosphatase	   (CIP,	   NEB)	   to	   remove	   the	   5’	   phosphate	   group	   from	   the	   digested	  vector	   and	   to	   prevent	   re-­‐circularisation	  between	   compatible	   ends.	   0.5µl	   of	   CIP	  were	   added	   directly	   to	   the	   RE	   digestion	  mixture	   and	   incubated	   at	   37˚C	   for	   30	  minutes	  and	  further	  purified	  as	  described	  above.	  	  
2.1.1.7 DNA	  Ligations	  The	  purified	  DNA	  insert	  and	  vector	  were	  mixed	  at	  a	  3:1	  ratio	  with	  1μl	  of	  10X	  T4	   ligase	  buffer	   (NEB)	  and	  0.5μl	  of	  T4	   ligase	  enzyme	  (NEB),	   in	  a	   total	   reaction	  volume	   adjusted	   to	   10μl	   with	   ddH2O.	   Reactions	   were	   incubated	   at	   room	  temperature	  for	  2	  hours	  or	  overnight	  at	  16˚C.	  	  
2.1.1.8 Competent	  Bacterial	  Cells:	  Media	  and	  Maintenance	  	  For	   DNA	   transformations	   and	   plasmid	   DNA	   amplification	   two	   strains	   of	  chemically	   competent	   bacteria	   were	   used.	   The	   Escherichia	   coli	   SURE	  supercompetent	   cells	   (Stratagene),	   that	   have	   reduced	   recombination	   potential,	  were	  used	  for	  transformation	  and	  amplification	  of	  plasmids	  containing	  AAV	  ITRs	  and	  grown	  at	  30˚C.	  The	  Escherichia	  coli	  DH10B	  competent	  cells	  (Thermo	  Fisher)	  were	   used	   for	   all	   other	   plasmids	   and	   cultured	   at	   37˚C.	   Competent	   cells	   were	  stored	  at	  -­‐80˚.	  Autoclaved	  LB	  (Fisher	  Scientific,	  20g/L	  ddH20)	  was	  used	  for	  liquid	  cultures.	  Autoclaved	  LB	  agar	  (37g/L	  ddH20)	  set	  in	  Sterilin	  10cm	  Petri	  dishes	  was	  used	   for	   solid	   phase	   growth	   cultures.	   Antibiotics	   were	   added	   to	   room	  temperature	   autoclaved	   broth	   or	   autoclaved	   agar	   cooled	   to	   50°C.	   Ampicillin	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(Sigma,	  100μg/ml	  in	  dH2O)	  or	  Kanamycin	  Sulphate	  (Fisher	  Scientific,	  50μg/ml	  in	  ddH2O)	   were	   used	   for	   selection.	   Stock	   preparations	   of	   transformed	   bacteria	  were	  kept	  as	  glycerol	  stocks	  (bacterial	  pellet	  resuspended	  in	  LB	  containing	  10%	  glycerol)	  at	  -­‐80˚C.	  	  
2.1.1.9 Transformation	  of	  Competent	  Bacteria	  5μl	  of	  the	  DNA	  insert-­‐vector	  ligation	  reaction	  or	  10-­‐50ng	  of	  plasmid	  DNA	  was	  used	   for	   transformation	   into	   competent	   cells	   following	   the	   manufacturer’s	  protocol.	   For	   SURE	   competent	   cells,	   50μl	   of	   competent	   bacteria	   cells	   were	  initially	  incubated	  with	  1µl	  of	  β-­‐mercaptoethanol	  for	  10	  minutes	  on	  ice.	  DNA	  was	  then	  added	  and	  incubated	  for	  30	  minutes	  on	  ice,	  followed	  by	  a	  heat	  shock	  at	  42°C	  for	  45	  seconds	  and	  further	  2	  minutes	  on	  ice.	  For	  DH10B	  competent	  cells,	  50µl	  of	  cells	  were	  mixed	  with	  DNA	  and	  incubated	  for	  30	  minutes	  on	  ice,	  followed	  by	  a	  30	  second	  heat	  shock	  at	  42˚C	  and	  a	  final	  2	  minutes	  incubation	  on	  ice.	  In	  both	  cases,	  reactions	  were	  then	  incubated	  with	  250μl	  of	  LB	  at	  30˚C	  for	  1	  hour	  and	  plated	  on	  LB	   agar	   plates	   containing	   the	   appropriate	   antibiotic.	   Plates	   were	   incubated	  upside	  down	  at	  30˚C	  or	  37°C	  overnight.	  	  
2.1.1.10 Plasmid	  DNA	  Amplification	  and	  Purification	  –	  Mini	  Preps	  Single	  colonies	   from	  transformed	  or	   re-­‐streaked	  bacteria	  were	   inoculated	   in	  3ml	   of	   LB	   containing	   antibiotic	   and	   incubated	   at	   the	   appropriate	   temperature	  overnight	  in	  a	  shaking	  incubator.	  On	  the	  following	  day,	  2ml	  of	  the	  culture	  were	  transferred	   to	   an	   eppendorf	   tube	   and	   cells	   were	   pelleted	   in	   a	   bench-­‐top	  centrifuge	  at	  8000rpm	  for	  4	  minutes.	  DNA	  was	  extracted	  using	  the	  Qiagen	  mini	  prep	   kit.	   Briefly,	   cells	   were	   re-­‐suspended	   Qiagen	   P1	   buffer	   and	   then	   lysed	   in	  250μl	   of	   P2	   lysis	   buffer	   and	   mixed	   by	   inverting	   the	   tube.	   After	   a	   3-­‐minutes	  incubation	   at	   room	   temperature,	   P3	   neutralisation	   buffer	   was	   added	   to	   the	  mixture	  and	  DNA	  was	  separated	  from	  bacterial	  debris	  by	  centrifugation	  at	  14000	  rpm	  for	  10	  minutes	  in	  a	  bench-­‐top	  centrifuge.	  Supernatant	  containing	  DNA	  was	  then	   transferred	   to	   a	   QIAprep	   spin	   column	   to	   bind	   DNA	   followed	   by	   washing	  with	  ethanol	  containing	  PE	  buffer	  and	  elution	  in	  30µl	  of	  ddH2O.	  DNA	  was	  kept	  at	  4˚C	  for	  short	  term	  storage	  or	  at	  -­‐20˚C	  for	  longer	  storage.	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2.1.1.11 Plasmid	   DNA	   Amplification	   and	   Purification	   –	   Midi/Maxi	  
Preps	  One	  ml	  of	   transformed	  bacteria	  culture	  or	  a	  10µl	   from	  a	  glycerol	  stock	  were	  inoculated	  overnight	  in	  100ml	  (400-­‐600ml	  for	  maxi	  preps)	  of	  LB	  with	  antibiotic	  selection.	  Cells	  were	  harvested	  by	  centrifugation	  at	  6000	  g	  for	  15	  min	  at	  4°C	  and	  DNA	   extraction	   was	   performed	   using	   the	   NucleoBond®	   Xtra	   Midi/Maxi	   kit	  (Macherey-­‐Nagel),	   following	   the	  manufacturer’s	  protocol.	  The	  general	  principle	  behind	   this	  plasmid	  purification	  protocols	   is	  based	  on	  a	  modified	  alkaline	   lysis	  procedure,	   followed	   by	   plasmid	   DNA	   binding	   to	   a	   NucleoBond	   resin	   under	  appropriate	  low	  salt	  and	  pH	  conditions.	  RNA,	  proteins,	  dyes	  and	  low	  molecular–weight	  impurities	  are	  removed	  by	  several	  washing	  steps,	  and	  the	  plasmid	  DNA	  is	  finally	   eluted	   in	   a	   high-­‐salt	   buffer,	   concentrated	   and	   desalted	   by	   isopropanol	  precipitation	  and	  washed	  in	  ethanol.	  Finally,	  the	  clean	  DNA	  pellet	  was	  allowed	  to	  air	  dry	  before	  re-­‐suspension	  in	  100-­‐1000μl	  ddH2O	  depending	  on	  the	  amount	  of	  purified	   DNA	   and	   the	   desired	   final	   concentration.	   DNA	   concentration	   was	  subsequently	  measured	  (see	  below).	  Preparations	  obtained	  by	  this	  method	  were	  typically	   at	   a	   concentration	   of	   0.5-­‐1μg/μl	   and	   stored	   short-­‐term	   at	   4˚C	   or	   for	  long-­‐term	  at	  -­‐20˚C.	  	  
2.1.1.12 Determining	  DNA	  Concentration	  DNA	   concentration	   was	   determined	   using	   a	   Nanodrop	   ND-­‐100	  Spectrophotometer	   (Labtech	   International).	   Following	   a	   blank	   measurement	  with	  the	  solvent	  solution,	  1μl	  of	  undiluted	  DNA	  preparation	  was	  loaded	  onto	  the	  measuring	  pedestal.	  The	  Nanodrop	  calculates	  the	  DNA	  concentration	  measuring	  the	   sample	   absorbance	   at	   260nm	   (OD260)	   and	   assuming	   that	   1	   OD260	   unit	  corresponds	  to	  50μg/ml	  of	  double-­‐stranded	  DNA.	  The	  purity	  of	  the	  DNA	  sample	  can	  be	  assessed	  by	  the	  OD260/OD280	  ratio,	  which	  at	  ~1.8	  is	  considered	  free	  from	  protein	  contamination.	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2.1.1.13 DNA	  Sequencing	  DNA	   sequencing	   was	   performed	   by	   Eurofins	   MWG	   Operon	   from	   1.5µg	   of	  plasmid	   DNA	   in	   15μl	   ddH2O	   pre-­‐mixed	   with	   2µl	   of	   the	   appropriate	   primer	   at	  10pmol/μl.	   Sequencing	   was	   performed	   using	   the	   Value	   Read	   service	   in	   tube	  format,	   results	  were	   returned	  online	  and	  subsequently	  analysed	  using	   the	  APE	  DNA	  analysis	  software	  and	  the	  NCBI	  Blast	  tool.	  	  
2.1.2 Total	  DNA	  Extraction	  For	  total/genomic	  DNA	  extraction	  the	  Qiagen	  DNeasy	  Blood	  &	  Tissue	  Kit	  was	  used	   as	   per	   manufacturer’s	   instructions.	   Cells	   are	   first	   washed	   in	   PBS	   and	  pelleted	   (~30mg	   frozen	   tissue	   was	   cut	   and	   weighed),	   followed	   by	   lysis	   and	  proteinase	  K	  digestion	  to	  remove	  all	  proteins.	  The	  DNA	  isolation/purification	  is	  performed	   using	   a	   silica-­‐based	   DNA	   purification	   in	   spin-­‐columns	   using	   the	   kit	  buffers.	  	  
2.1.3 Total	  RNA	  Extraction	  RNA	  extraction	  was	  performed	  using	  the	  RNeasy	  mini	  Kit	  (Qiagen),	  following	  the	   manufacturer’s	   instructions.	   Cells	   were	   first	   washed	   in	   PBS	   and	   pelleted,	  followed	  by	  lysis	  in	  the	  supplied	  buffer,	  homogenization	  using	  a	  syringe	  and	  a	  21	  gauge	   needle,	   and	   column	  purification.	   RNA	  was	   eluted	   using	   50µl	   RNAse-­‐free	  water	   (supplied)	   and	   the	   concentration	   determined	   using	   the	   Nanodrop	  spectrophotometer	  in	  a	  procedure	  analogous	  to	  that	  used	  for	  DNA.	  The	  RNA	  was	  diluted	  in	  a	  total	  volume	  of	  85µl	  RNAse-­‐free	  water	  and	  mixed	  with	  10	  μl	  Buffer	  RDD	   and	   5μl	   of	   DNase	   I	   stock	   solution	   and	   incubated	   for	   20	   min	   at	   room	  temperature.	  The	  DNAse	  I-­‐treated	  RNA	  was	  then	  re-­‐cleaned	  using	  the	  RNeasy	  kit	  (following	  the	  RNA	  clean-­‐up	  protocol).	  The	  DNase	  I	  stock	  solution	  was	  prepared	  by	  dissolving	  the	  lyophilised	  DNase	  I	  (1500	  Kunitz	  units,	  QIAGEN)	  in	  550μl	  of	  the	  RNase-­‐free	  water	  provided.	  RNA	  was	  stored	  at	  -­‐80˚C.	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2.1.4 Total	  Protein	  Extraction	  Volumes	  indicated	  are	  for	  a	  well	  of	  a	  24	  well	  plate.	  Cells	  were	  harvested	  and	  washed	   in	   PBS	   and	   pelleted.	   The	   cell	   pellet	  was	   then	   dissolved	   in	   50µl	   NP-­‐40	  lysis	  buffer	  (150mM	  NaCl,	  1%	  NP-­‐40,	  50mM	  Tris	  HCl	  pH	  8)	  containing	  2µl	  of	  25X	  protease	   inhibitor	  cocktail	   (Complete,	  Roche),	  and	   incubated	  on	   ice	   for	  10	  min.	  For	  tissues,	  ~30mg	  were	  mixed	  with	  450	  µl	  NP-­‐40	  lysis	  buffer,	  sonicated	  4x	  10s	  and	  mixed	  for	  2h	  at	  4˚C.	  Lysates	  were	  then	  spun	  at	  13000	  rpm	  for	  10	  min	  at	  4˚C	  and	  the	  supernatant	  transferred	  to	  a	  clean	  1.5ml	  tube.	  Proteins	  were	  stored	  at	  -­‐80˚C.	  	  
2.1.5 DNA	  and	  RNA	  Detection	  and	  Analysis	  
	  
2.1.5.1 Reverse	  Transcription	  For	   gene	   expression	   analysis,	   RNA	  was	   reverse-­‐transcribed	   using	   the	   High-­‐Capacity	   cDNA	   Reverse	   Transcription	   Kit	   (Applied	   Biosystems)	   following	   the	  manufacturer’s	   instructions.	  First,	  a	  2X	  RT	  master	  mix	  was	  prepared	  by	  mixing	  (volumes	   for	  one	  reaction)	   the	   following	  provided	  reagents:	  2µl	  10X	  RT	  buffer,	  0.8µl	   dNTP	   mix	   (100mM),	   2µl	   10X	   RT	   random	   primers,	   1µl	   MultiScribeTM	  Reverse	   Transcriptase,	   4.2µl	   nuclease-­‐free	   ddH2O.	   10µl	   of	   2X	   RT	   master	   mix	  were	   then	   mixed	   with	   10µl	   RNA	   at	   the	   desired	   concentration.	   Reverse	  transcription	  was	  performed	  using	  a	  thermal	  cycler	  with	  the	  following	  program:	  10	  min	  at	  25˚C,	  2h	  at	  37˚C,	  5	  min	  at	  85˚C.	  The	  obtained	  cDNA	  was	  stored	  at	  4˚C	  for	   short-­‐term	   storage	   or	   at	   -­‐20˚C	   for	   long-­‐term	   storage,	   and	   was	   used	   for	  relative	  quantification	  by	  qPCR	  (see	  below).	  
	  
2.1.5.2 Real-­‐time	  quantitative	  PCR:	  relative	  quantification	  3’FAM-­‐5’MGB-­‐conjugated	  qPCR	  probes	  and	  qPCR	  primers	  designed	  to	  bind	  to	  the	  TH,	  GCH1	  or	  the	  β-­‐actin	  genes	  were	  obtained	  from	  Thermo	  Fischer.	  qPCR	  was	  performed	   on	   cDNA	   using	   the	   TaqMan	   Universal	   PCR	   master	   mix	   (Life	  Technologies)	  and	  the	  custom	  primer-­‐probe	  mix	  of	  choice;	  primers	  were	  used	  at	  a	  final	  concentration	  of	  900nM,	  and	  probes	  at	  250mM.	  Relative	  expression	  levels	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were	  determined	  by	  the	  comparative	  threshold	  cycle	  (Ct)	  method	  (Schmittgen	  &	  Livak	  2008).	  	  
2.1.6 Protein	  Detection	  and	  Analysis	  	  
2.1.6.1 SDS-­‐PAGE	  10µl	  of	  protein	  extracts	  in	  NP-­‐40	  lysis	  buffer	  were	  mixed	  with	  2µl	  of	  loading	  buffer	  (0.8g	  SDS,	  5ml	  Tris	  pH	  6.8,	  5ml	  glycerol,	  4mg	  bromophenol	  blue,	  5%	  beta-­‐mercaptoethanol)	   and	  denatured	  by	  boiling	   for	  15	  min.	   Subsequently,	  proteins	  were	   separated	   in	   10%	   or	   12%	   polyacrylamide	   gels.	   The	   percentage	   was	  determined	  by	  altering	  the	  volume	  of	  40%	  Acrylamide	  solution	  (Acrylamide:Bis-­‐Acrylamide	  29:1,	  Fisher	  Scientific)	  and	  ddH2O	  to	  a	  reaction	  mixture	  of	  1.5M	  Tris-­‐HCl	  pH	  8.8,	  0.4%	  SDS,	  3.3μl/ml	  10%	  ammonium	  persulphate	   (APS,	  Sigma)	  and	  0.6μl/ml	   of	   N,N,N’N’-­‐	   Tetramethylethylenediamine	   (TEMED,	   Sigma).	   The	  stacking	  gels	  were	  made	  using	  0.5M	  Tris-­‐Cl	  pH	  6.8,	  0.4%	  SDS,	  5μl/ml	  10%	  APS,	  1μl/ml	   TEMED	   and	   ddH2O.	   Polymerised	   gels	   were	   transferred	   to	   the	   running	  tank	   and	   immersed	   in	   running	   buffer	   (100ml	   10X	   Tris-­‐glycine	   and	   10ml	   10%	  SDS	  and	  ddH2O	   to	  1L).	  10X	  Tris-­‐glycine	  was	  prepared	  by	  mixing	  61g	  Tris	  base	  and	  288g	  glycine	  in	  2L	  ddH2O.	  Gels	  were	  typically	  run	  at	  120V	  until	  the	  blue	  dye	  front	   had	   migrated	   to	   the	   bottom	   of	   the	   gel,	   using	   the	   Protean	   II	   mini	   gel	  electrophoresis	  kit	  (BioRad).	  2µl	  of	  Precision	  Plus	  Protein	  Dual	  Colour	  Standards	  (Bio-­‐Rad)	  was	  used	  as	  a	  guide	  for	  molecular	  weights	  in	  all	  gels.	  	  
2.1.6.2 Western	  Blot	  Proteins	   resolved	   in	   SDS-­‐PAGE	   were	   transferred	   onto	   pure	   nitrocellulose	  0.45μm	  membrane	  (VWR	  International).	  Gel	  to	  membrane	  transfer	  was	  achieved	  using	   a	   BioRad	  Mini	   Trans-­‐Blot®	   transfer	   system	  with	   transfer	   buffer	   (100ml	  10X	  Tris-­‐glycine,	  200ml	  methanol,	  700	  ml	  ddH2O)	  at	  16V	  overnight	  or	  at	  100V	  on	   ice	   for	   60	  min.	   After	   transfer,	  membranes	  were	   removed	   from	   the	   transfer	  tank	   and	   blocked	  with	   5%	   (w/v)	   skimmed	   dried	  milk	   in	   PBS-­‐Tween	   (1X	   PBS,	  0.1%	   Tween	   20,	   Sigma)	   for	   1h.	   Membranes	   were	   then	   incubated	   with	   the	  
	   71	  
indicated	   primary	   antibody	   in	   5%	   milk	   in	   PBS-­‐Tween	   for	   3h	   at	   room	  temperature	  or	  overnight	  at	  4˚C.	  Next,	  membranes	  were	  washed	  3	  times	  for	  15	  min	   in	   PBS-­‐Tween	   and	   subsequently	   incubated	   with	   the	   corresponding	  horseradish	   peroxidase	   (HRP)-­‐conjugated	   secondary	   antibody	   for	   1h.	   Finally,	  membranes	  were	  washed	  three	  times	  for	  15	  min	  in	  PBS-­‐Tween	  and	  developed.	  The	  signal	  of	  membranes	   incubated	  with	  HRP-­‐conjugated	  secondary	  antibodies	  was	   detected	   using	   the	   SuperSignal	   West	   Pico	   chemiluminescene	   substrate	  (Thermo	  Scientific),	  prepared	  according	   to	   the	  manufacturers’	   instructions	  and	  applied	   on	   the	  membrane	   for	   5	  min.	   The	  membrane	  was	   then	  placed	  between	  two	   clear	   plastic	   sheets	   and	   imaged	   using	   a	   Image	   Quant	   LAS4000	   (GE	  Healthcare)	  chemiluminescence	  imaging	  technology.	  	  
2.1.7 Engineering	  of	  Recombinant	  AAV	  Producer	  Plasmids	  	  
2.1.7.1 AAV	  Plasmids	  for	  Brain	  Targeting	  Vectors	  	  2.1.7.1.1 pAAV-­‐SYN-­‐GCH1-­‐SYN-­‐TH	  (pGPT002)	  The	   AAV	   producer	   plasmid	   pAAV-­‐SYN-­‐GCH1-­‐SYN-­‐TH-­‐WPRE	   (pGPT002)	  expresses	  both	   enzymes,	  GCH1	  and	  TH,	   from	  a	   single-­‐vector	   genome	  with	   two	  identical	   and	   independent	   promoters.	   The	   organisation	   of	   the	   expression	  cassettes	   is	   identical	   to	   the	  one	  used	  by	  Cederfjäll	   et	  al	   (Cederfjäll	   et	  al.	  2012).	  Expression	  of	  GCH1	  and	  TH	  genes	   is	   under	   the	   control	   of	   the	  human	   synapsin	  promoter	   (SYN)	   and	   a	   modified	   posttranscriptional	   regulatory	   element	   of	   the	  woodchuck	   hepatitis	   virus	   (WPRE),	   in	   which	   expression	   of	   the	   putative	  oncogenic	  woodchuck	  hepatitis	  virus	  X	  protein	   (WHX)	  was	   silenced,	   is	  present	  between	  the	  TH	  coding	  sequence	  and	  the	  SV40	  polyA.	  The	  expression	  cassettes	  were	   synthesised	   with	   flanking	   BglII	   restriction	   endonuclease	   sites	   (p65050),	  which	  were	   then	  used	   to	   subclone	   them	   into	   the	  AAV2	   ITR-­‐containing	  plasmid	  pTRUF11.	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2.1.7.1.2 pAAV-­‐SYN-­‐GCH1-­‐SYN-­‐tTH	  (pLA109)	  The	   AAV	   producer	   plasmid	   pAAV-­‐SYN-­‐GCH1-­‐SYN-­‐tTH-­‐WPRE	   (pLA109)	   is	  almost	   identical	   to	   GPT002,	   with	   the	   difference	   being	   the	   absence	   of	   the	   first	  465nt	  of	   the	  TH	  gene	  (correspondent	  to	  the	   first	  155	  N-­‐terminus	  amino	  acids).	  This	   truncation,	   that	   renders	   a	   constitutively	   active	   TH,	   was	   generated	   by	  isothermal	  assembly	   followed	  by	  PCR	  and	   replacement	  of	   the	   full	   length	  TH	   in	  GPT002	   by	   the	   truncated	   PCR	  product.	   In	   brief,	   a	   first	   PCR	  was	   carried	   out	   to	  generate	  a	  ~2050bp	  fragment	  of	  the	  SYN-­‐GCH1-­‐SYN	  sequence	  containing	  a	  BglII	  restriction	  endonuclease	  site	  on	  the	  5’	  end	  and	  a	  3’	  overhang	  with	  a	  start	  codon	  followed	  by	  a	  sequence	  overlapping	  the	  18nt	  correspondent	  to	  amino	  acids	  157	  to	   163	   in	   the	   TH	   protein.	   Fragment	   one	   was	   amplified	   using	   Phusion	   High	  Fidelity	   Polymerase	   (Fischer	   Scientific)	   in	   appropriate	   buffer,	   200μM	   dNTPs	  (NEB),	   p65050	   as	   a	   DNA	   template	   and	   primer	   pair	   LA43/LA44.	   The	   cycling	  conditions	  were:	  98°C	   (30s),	   followed	  by	  30	   cycles	  of	   98°C	   (10s)/	  63°C	   (30s)/	  72°C	  (60s),	  and	  a	  final	  extension	  at	  72°C	  for	  10	  min.	  A	  second	  PCR	  was	  done	  on	  p65050	   to	   amplify	   the	   TH	   gene	  without	   the	   465nt	   immediately	   after	   the	   start	  codon	  using	   the	  same	  cycling	  conditions	  as	  above	  and	  primer	  pair	  LA45/LA46.	  This	  generated	  a	  product	  of	  ~1850bp	  in	  which	  the	  first	  18bp	  of	  the	  5’	  end	  were	  complementary	   to	   the	   last	   18bp	   at	   the	   3’	   end	   of	   fragment	   one,	   allowing	   their	  combination	   by	   isothermal	   assembly	   (Gibson	   et	   al.	   2009).	   The	   isothermal	  assembly	  was	   done	   by	  mixing	   equimolar	   amounts	   (~100ng)	   of	   fragments	   one	  and	  two,	  isothermal	  assembly	  buffer	  and	  1M	  betaine	  solution	  (Sigma)	  in	  a	  total	  volume	  of	  20µl.	  The	  mix	  was	  incubated	  for	  1h	  at	  50°C,	  after	  which	  5µl	  were	  used	  as	  a	  template	  for	  a	  PCR	  reaction.	  Because	  the	  length	  of	  the	  assembled	  fragment	  obtained	  in	  the	  reaction	  (~4kb)	  could	  be	  difficult	  to	  amplify,	  a	  new	  primer	  pair	  was	  designed	  (LA47/LA48),	  which	  led	  to	  the	  amplification	  of	  a	  ~1.5kb	  fragment	  comprised	  of	  the	  GCH1	  polyA	  followed	  by	  the	  SYN	  and	  approximately	  half	  of	  the	  newly	   truncated	   TH	   gene.	   The	   PCR	   was	   done	   using	   Phusion	   High	   Fidelity	  Polymerase	  (Fischer	  Scientific)	   in	  appropriate	  buffer	  and	  200μM	  dNTPs	  (NEB).	  The	   cycling	   conditions	  were:	   98°C	   (30s),	   followed	   by	   30	   cycles	   of	   98°C	   (10s)/	  63°C	  (30s)/	  72°C	  (60s),	  and	  a	   final	  extension	  at	  72°C	   for	  10	  min.	  The	  resulting	  fragment	  was	  cloned	  into	  pGPT002	  digested	  with	  the	  restriction	  endonucleases	  NsiI	  and	  EcoNI	  (NEB),	  thereby	  creating	  pLA109.	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2.1.7.1.3 pAAV-­‐SYN-­‐GCH1-­‐CMV-­‐TH	  (pGPT004)	  The	  AAV	  producer	  plasmid	  pAAV-­‐SYN-­‐GCH1-­‐CMV-­‐TH-­‐WPRE	  (pGPT004)	  was	  created	   by	   amplifying	   the	   CMV-­‐TH	   cassette	   from	   the	   vector	   pAAV-­‐TH	  (Muramatsu	   et	   al.	   2002)	   and	   cloning	   it	   in	   pGPT002	   in	   place	   of	   the	   SYN-­‐TH	  sequence	   .	   The	  CMV-­‐TH	   fragment	  was	   amplified	   in	   a	   20µl	   reaction	  using	   50ng	  pAAV-­‐TH	  as	  a	  template,	  200μM	  dNTPs	  (NEB),	  Phusion	  High	  Fidelity	  Polymerase	  (Fischer	   Scientific)	   in	   appropriate	   buffer	   and	   primer	   pair	   AA133/AA134.	  Conditions	  of	  the	  PCR	  amplification	  were	  as	  follows:	  98°C	  (30s),	  followed	  by	  30	  cycles	  of	  98°C	  (10s)/	  59°C	  (15s)/	  72°C	  (80s),	  and	  a	  final	  extension	  at	  72°C	  for	  10	  min.	  The	  ~3.2	  kb	  fragment	  was	  digested	  and	  ligated	  into	  pGPT002	  digested	  with	  the	   restriction	   endonucleases	  MfeI	   and	   partially	   digested	   with	   BglII	   (NEB),	   so	  that	   only	   the	   SYN-­‐TH	   sequence	   was	   removed.	   The	   partial	   digestion	   was	  necessary	   due	   to	   the	   presence	   of	   a	   second	   BglII	   endonuclease	   restriction	   site	  present	   immediately	   downstream	   of	   the	   L-­‐ITR	   in	   pGPT002.	   This	   bicistronic	  construct	  was	  named	  pGPT004.	  	  
2.1.7.2 AAV	  plasmid	  for	  Liver	  Targeting	  Vectors	  	  2.1.7.2.1 pdsAAV-­‐LP1-­‐GCH1	  and	  pdsAAV-­‐LP1-­‐tTH	  (pAA009	  and	  pAA010)	  The	  AAV	  producer	   plasmids	  pdsAAV-­‐LP1-­‐GCH1	   (pAA009)	   and	  pdsAAV-­‐LP1-­‐tTH	   (pAA010)	  were	   used	   to	   produce	   the	   double-­‐stranded	   rAAV2/8-­‐LP1-­‐GCH1	  and	   rAAV2/8-­‐LP1-­‐tTH,	   respectively.	   Briefly,	   pAA009	   and	   pAA010	   were	  constructed	   by	   digesting	   scAAV-­‐LP1-­‐hFIXco	  with	   XbaI	   and	   SpeI	   and	   ligating	   it	  after	   NheI	   digestion	  with	   either	   the	   GCH1	   or	   tTH	   PCR	   fragment	   isolated	   from	  pLA100	  (ssAAV-­‐SYN-­‐GCH1-­‐SYN-­‐TH-­‐WPRE)	  and	  pLA109	  (ssAAV-­‐SYN-­‐GCH1-­‐SYN-­‐tTH),	   respectively.	   The	   scAAV-­‐LP1-­‐GCH1	   (pAA009)	   and	   scAAV-­‐LP1-­‐tTH	  (pAA010)	   vectors	   were	   constructed	   as	   follows:	   The	   992bp	   GCH1	   fragment	   of	  pLA100	  (AAV-­‐SYN-­‐GCH1-­‐SYN-­‐TH)	  was	  amplified	  using	  primer	  pair	  AA16/AA17	  at	   a	   concentration	   of	   0.75pmol/μl	  with	   25ng	   template	   pLA100,	   200μM	   dNTPs	  (NEB)	  and	  GoTaq	  Polymerase	  (Promega)	  in	  appropriate	  buffer.	  Conditions	  of	  the	  PCR	  amplifications	  were	  as	  follows:	  95°C	  (2min),	   followed	  by	  30	  cycles	  of	  95°C	  (30s)/	   65°C	   (30s)/	   72°C	   (30s),	   and	   a	   final	   extension	   at	   72°C	   for	   5	   min.	   The	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1858bp	   tTH-­‐WPRE	   fragment	   of	   pLA109	   (AAV-­‐SYN-­‐GCH1-­‐SYN-­‐tTH)	   was	  amplified	   using	   primer	   pair	   AA33/AA34	   0.4pmol/μl,	   25ng	   template	   pLA109,	  200μM	  dNTPs	  (NEB)	  and	  Phusion	  Polymerase	  (Thermo	  Scientific)	  in	  appropriate	  buffer.	   Conditions	   of	   the	   PCR	   amplifications	   were	   as	   follows:	   98°C	   (30s),	  followed	   by	   30	   cycles	   of	   98°C	   (10s)/	   63°C	   (30s)/	   72°C	   (1min),	   and	   a	   final	  extension	  at	  72°C	  for	  10	  min.	  	  The	   final	   transgene	   constructs	   are	   two	   plasmids	   for	   dsAAV	   production	  containing	  either	  the	  human	  GCH1	  or	  the	  tTH	  gene	  under	  the	  control	  of	  the	  liver-­‐specific	  LP1	  enhancer/promoter,	  all	  flanked	  by	  AAV2	  ITRs.	  
	  2.1.7.2.2 pAAV-­‐LP1-­‐GCH1-­‐LP1-­‐tTH	  (pAA019)	  AAV	  producer	   plasmid	   pAAV-­‐LP1-­‐GCH1-­‐LP1-­‐tTH-­‐WPRE	   (pAA019)	  was	   used	  to	   generate	   the	   single-­‐stranded	   rAAV2/8-­‐LP1-­‐GCH1-­‐LP1-­‐tTH-­‐WPRE	   and	   its	  recombination	   by-­‐product	   rAAV2/8-­‐LP1-­‐tTH.	   Briefly,	   the	   expression	   cassettes	  LP1-­‐GCH1-­‐LP1-­‐tTH-­‐WPRE	   were	   subcloned	   into	   pBluescript	   II	   SK(+)	   to	   make	  pAA018	   prior	   to	   cloning	   into	   the	   AAV	   ITR	   containing	   backbone	   pSUB201	  (pAA019).	  The	  first	  LP1	  promoter	  was	  amplified	  using	  scAAV-­‐LP1-­‐hFIXco	  (Nathwani	  et	  al.	  2006)	  as	  a	  template	  and	  cloned	  into	  pTRUF11	  (ATCC®	  MBA-­‐331™)	  between	  the	  BlpI	   and	   SbfI	   restriction	   sites,	   thereby	   generating	   pAA001.	  Next,	   the	  GCH1	  gene	   was	   amplified	   from	   pLA100	   (pAAV-­‐SYN-­‐GCH1-­‐SYN-­‐TH-­‐WPRE)	   as	   a	  template	  and	  subsequently	  cloned	  into	  pAA001	  using	  the	  SbfI	  and	  Tth111I	  sites,	  thereby	   forming	   pAA002.	   Next,	   the	   LP1-­‐GCH1	   fragment	   was	   amplified	   from	  pAA002	  using	  the	  primer	  pair	  AA37/AA38,	  which	  contained	  5’	  XbaI/BlpI	  and	  3’	  XbaI/SphI/BstBI/Tth111I	   multiple	   cloning	   site	   overhangs	   to	   allow	   the	  construction	  of	  a	  modular	  vector.	  The	  LP1-­‐GCH1	   fragment	  was	   ligated	   into	   the	  AAV	   backbone	   pSUB201	   (Samulski	   et	   al.	   1987)	   through	   XbaI	   restriction	   sites,	  thereby	   forming	   pAA003.	   To	   avoid	   cloning	   difficulties	   due	   to	   the	   presence	   of	  ITRs	   in	   psub201,	   the	   LP1-­‐GCH1	   cassette	  was	   transferred	   to	   the	   cloning	   vector	  pUC18	   (Thermo	  Scientific)	   through	   the	  XbaI	   sites,	   thereby	   generating	  pAA004.	  The	   second	   LP1	   promoter	   was	   amplified	   from	   pAA010	   with	   the	   primer	   pair	  AA006/AA07	  and	  cloned	  into	  pAA004	  using	  BstBI	  and	  Tth111I	  restriction	  sites,	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thereby	  generating	  pAA005.	   In	  order	   to	  add	   the	   tTH	  gene	   to	   the	  construct,	   the	  LP1-­‐GCH1-­‐LP1	  fragment	  had	  to	  be	  transferred	  to	  the	  pBluescript	  II	  SK(+)	  vector	  due	  to	  the	  presence	  of	  an	  extra	  SphI	  site	  in	  the	  pUC18	  backbone.	  The	  backbone	  transfer	  was	  done	  by	  cutting	  LP1-­‐GCH1-­‐LP1	  out	  of	  pAA005	  using	  the	  XbaI	  sites	  and	  ligating	  it	  into	  pBluescript	  II	  SK(+).	  The	  new	  construct	  was	  named	  pAA006.	  Next,	   the	   tTH-­‐WPRE	   fragment	   was	   amplified	   from	   pLA109	   (pAAV-­‐SYN-­‐GCH1-­‐SYN-­‐tTH-­‐WPRE)	   using	   primer	   pair	   AA53/AA65.	   The	   tTH-­‐WPRE	   sequence	   was	  inserted	   into	   pAA006	   through	   the	   restriction	   sites	   SphI	   and	   BstBI,	   thereby	  forming	   pAA017.	   After	   sequencing	   of	   pAA018,	   a	  mutation	   on	   the	   Tth111I	   site	  was	   found	  and	   fixed	  by	  recloning	   the	  GCH1-­‐LP1	  sequence.	  At	   this	  point,	  a	  new	  primer	  set	  was	  designed	  to	  add	  a	  BglII	  restriction	  site	  immediately	  downstream	  of	   the	   Ttth111I	   site	   and,	   additionally,	   to	   allow	   the	   incorporation	   of	   the	   GCH1	  Kozak	   sequence	   as	   in	   pLA100	   and	   pLA109.	   Primer	   pairs	   AA73/AA84	   and	  AA85/AAA07	  were	  used	  to	  amplify	  the	  new	  GCH1	  sequence	  and	  the	  second	  LP1	  promoter,	   respectively.	   An	   overlapping	   PCR	  was	   done	   to	   fuse	   GCH1-­‐LP1	   using	  primer	   pair	   AA73/AA07,	   which	   was	   subsequently	   cloned	   into	   pAA017	   using	  restriction	  sites	  SbfI	  and	  BstBI,	  thereby	  forming	  pAA018.	  Finally,	  the	  bicistronic	  LP1-­‐GCH1-­‐LP1-­‐tTH	   expression	   cassette	   was	   transferred	   back	   to	   the	   AAV	  backbone	  psub201.	  This	   final	  plasmid	  was	  called	  pAA019	  and	  was	  used	  for	  the	  production	   of	   a	   rAAV	   containing	   both	   human	   GCH1	   and	   tTH	   genes	   under	   the	  control	  of	  the	  liver-­‐specific	  LP1	  enhancer/promoter,	  all	  flanked	  by	  AAV2	  ITRs.	  The	  568bp	  LP1	  fragment	  of	  the	  first	  LP1	  promoter	  for	  pAA001	  generation	  was	  amplified	  in	  a	  20µl	  PCR	  reaction	  using	  12.5ng	  scAAV-­‐LP1-­‐hFIXco	  template	  DNA,	  200μM	  dNTPs	  (NEB),	  0.5µM	  of	  primer	  pair	  AA01/AA02	  and	  GoTaq	  Polymerase	  (Promega)	   in	   appropriate	   buffer.	   Conditions	   of	   the	   PCR	   amplification	   were	   as	  follows:	   95°C	   (2min),	   followed	   by	   30	   cycles	   of	   95°C	   (30s)/	   65°C	   (30s)/	   72°C	  (35s),	  and	  a	  final	  extension	  at	  72°C	  for	  5	  min.	  The	   ~1kb	   GCH1	   fragment	   for	   pAA002	   generation	  was	   amplified	   in	   3x	   25µl	  PCR	  reactions	  using	  27ng	  pLA100	  template	  DNA,	  200μM	  dNTPs	  (NEB),	  0.5µM	  of	  primer	   pair	   AA03/AA004	   and	   GoTaq	   Polymerase	   (Promega)	   in	   appropriate	  buffer.	   Conditions	   of	   the	   PCR	   amplification	   were	   as	   follows:	   95°C	   (2min),	  followed	   by	   30	   cycles	   of	   95°C	   (30s)/	   68°C	   (30s)/	   72°C	   (35s),	   and	   a	   final	  extension	  at	  72°C	  for	  5	  min.	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The	  ~1.5kb	  LP1-­‐GCH1	   fragment	   for	  pAA003	  generation	  was	  amplified	   in	  5x	  20µl	   PCR	   reactions	   using	   20ng	   pAA002	   template	   DNA,	   200μM	   dNTPs	   (NEB),	  0.5µM	  of	  primer	  pair	  AA37/AA38,	  4μl/reaction	  of	  5M	  betaine	  solution	   (Sigma)	  and	  Phusion	  High	  Fidelity	  Polymerase	  (Fischer	  Scientific)	  in	  appropriate	  buffer.	  Conditions	  of	  the	  PCR	  amplification	  were	  as	  follows:	  98°C	  (30s),	  followed	  by	  30	  cycles	  of	  98°C	  (10s)/	  56°C	  (30s)/	  72°C	  (45s),	  and	  a	  final	  extension	  at	  72°C	  for	  10	  min.	  The	   ~550bp	   LP1	   fragment	   of	   the	   second	   LP1	   promoter	   for	   pAA005	  generation	  was	   amplified	   in	   a	   20µl	   PCR	   reaction	   using	   50ng	   pAA010	   template	  DNA,	  200	  μM	  dNTPs	  (NEB),	  0.5µM	  of	  primer	  pair	  AA006/AA07	  and	  Phusion	  High	  Fidelity	  Polymerase	  (Fischer	  Scientific)	   in	  appropriate	  buffer.	  Conditions	  of	   the	  PCR	   amplification	   were	   as	   follows:	   98°C	   (30s),	   followed	   by	   30	   cycles	   of	   98°C	  (10s)/	  65°C	  (15s)/	  72°C	  (9s),	  and	  a	  final	  extension	  at	  72°C	  for	  10	  min.	  The	  ~1.8kb	   tTH-­‐WPRE	   fragment	   for	   pAA017	   generation	  was	   amplified	   in	   a	  20µl	   PCR	   reaction	   using	   50ng	   pLA109	   template	   DNA,	   200μM	   dNTPs	   (NEB),	  0.5µM	  of	  primer	  pair	  AA53/AA65	  and	  Phusion	  High	  Fidelity	  Polymerase	  (Fischer	  Scientific)	   in	   appropriate	   buffer.	   Conditions	   of	   the	   PCR	   amplification	   were	   as	  follows:	  98°C	  (30s),	  followed	  by	  30	  cycles	  of	  98°C	  (10s)/	  60°C	  (15s)/	  72°C	  (60s),	  and	  a	  final	  extension	  at	  72°C	  for	  10	  min.	  The	  ~1	  kb	  GCH1	  sequence	  to	  be	  used	  as	  a	  template	  for	  the	  overlapping	  PCR	  with	  the	  second	  LP1	  was	  amplified	  in	  a	  20µl	  PCR	  reactions	  using	  25ng	  pLA109	  template	   DNA,	   200μM	   dNTPs	   (NEB),	   0.5µM	   of	   primer	   pair	   AA73/AA84	   and	  GoTaq	   Polymerase	   (Promega)	   in	   appropriate	   buffer.	   Conditions	   of	   the	   PCR	  amplification	  were	  as	  follows:	  95°C	  (2min),	  followed	  by	  30	  cycles	  of	  95°C	  (30s)/	  65°C	  (30s)/	  72°C	  (35s),	  and	  a	  final	  extension	  at	  72°C	  for	  5	  min.	  The	  ~550	  bp	  LP1	  sequence	   to	   be	   used	   as	   a	   template	   for	   the	   overlapping	   PCR	   with	   GCH1	   was	  amplified	   in	   a	   20µl	   PCR	   reaction	   using	   25ng	   pAA010	   template	   DNA,	   200μM	  dNTPs	   (NEB),	   0.5µM	   of	   primer	   pair	   AA85/AA07	   and	   Phusion	   High	   Fidelity	  Polymerase	   (Fischer	   Scientific)	   in	   appropriate	   buffer.	   Conditions	   of	   the	   PCR	  amplification	  were	  as	   follows:	  98°C	  (30s),	   followed	  by	  30	  cycles	  of	  98°C	  (10s)/	  65°C	  (15s)/	  72°C	  (20s),	  and	  a	  final	  extension	  at	  72°C	  for	  10	  min.	  The	  overlapping	  PCR	  to	  fuse	  the	  GCH1	  to	  the	  second	  LP1	  was	  done	  in	  a	  20µl	  reaction	  using	  100ng	  and	  50ng	  of	  GCH1	  and	  LP1,	  respectively	  as	  template	  DNA,	  200μM	  dNTPs	  (NEB),	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0.5µM	  of	  primer	  pair	  AA73/AA07	  and	  Phusion	  High	  Fidelity	  Polymerase	  (Fischer	  Scientific)	   in	   appropriate	   buffer.	   Conditions	   of	   the	   PCR	   amplification	   were	   as	  follows:	  98°C	  (30s),	  followed	  by	  30	  cycles	  of	  98°C	  (10s)/	  65°C	  (15s)/	  72°C	  (45s),	  and	  a	  final	  extension	  at	  72°C	  for	  10	  min.	  	  
2.1.7.3 AAV	  Plasmids	  for	  Systemic	  Vectors	  	  2.1.7.3.1 pAAV-­‐EF1α-­‐tTH-­‐IRES-­‐PTPS-­‐2A-­‐GCH1-­‐WPRE-­‐miR208aT	  (pAA062)	  AAV	   producer	   plasmid	   pAAV-­‐EF1α-­‐tTH-­‐IRES-­‐PTPS-­‐2A-­‐GCH1-­‐WPRE-­‐miR208aT	  (pAA062)	  was	  constructed	  as	  follows.	  The	  short	  EF1α	  promoter	  was	  amplified	   using	   pMB13	   as	   a	   template	   and	   cloned	   in	   place	   of	   the	   first	   LP1	  promoter	   in	   pAA018	   between	   the	   BlpI	   and	   SbfI	   restriction	   sites,	   thereby	  generating	  pAA057.	  Next,	   the	   tTH	  gene	  without	   the	  WPRE	  was	   amplified	   from	  pAA016	  (pscAAV-­‐HLP-­‐tTH-­‐WPRE)	  and	  subsequently	  cloned	  in	  place	  of	  the	  of	  the	  GCH1	  gene	  in	  pAA057	  using	  the	  SbfI	  and	  BglII	  sites,	  generating	  pAA058.	  Next,	  the	  encephalomyocarditis	   virus	   (EMCV)	   internal	   ribosome	   entry	   site	   (IRES)	  sequence	   was	   amplified	   from	   pCSIG	   (Matheson	   et	   al.	   2015)	   and	   cloned	   into	  pAA058	   using	   BglII	   and	   BstBI	   sites	   in	   place	   of	   the	   LP1	   promoter,	   generating	  pAA059.	  Next,	   the	   EF1α-­‐tTH-­‐IRES-­‐tTH-­‐WPRE	   sequence	  was	   removed	   from	   the	  pBluescript	   II	   SK(+)	   backbone	   using	   XbaI	   (NEB)	   and	   ligated	   into	   the	   AAV	  backbone	  pSUB201,	  forming	  pAA060.	  The	  6-­‐Pyruvoyl-­‐tetrahydropterin	  synthase	  (PTPS)	  and	  GCH1	  genes	  were	  amplified	   from	  pAA020	  and	   cloned	   into	  pAA060	  using	  BstBI	  and	  SpeI	   restriction	  endonuclease	   sites	   in	  place	  of	   the	   second	   tTH,	  thereby	  generating	  pAA061.	   In	   a	   final	   step,	   two	   in	   tandem	  copies	  of	   the	   target	  sequence	   of	   the	   cardiac-­‐specific	   microRNA-­‐208a	   (Roudaut	   et	   al.	   2013)	   were	  added	  to	  the	  cassette.	  The	  42nt	  tandem	  sequence,	  that	  was	  originally	  synthesised	  and	  cloned	  into	  pAA056,	  was	  amplified	  and	  subsequently	  inserted	  into	  pAA061	  through	  the	  restriction	  sites	  SalI	  and	  SpeI.	  This	  final	  plasmid	  was	  called	  pAA062	  and	   it	   supports	   the	   production	   of	   a	   rAAV	   containing	   a	   truncated	   form	   of	   the	  human	   TH,	   the	   human	   PTPS	   and	   GCH1	   under	   the	   control	   of	   the	   short	   EF1α	  promoter.	  The	  IRES	  sequence	  allows	  for	  the	  expression	  of	  the	  three	  genes	  from	  the	  same	  mRNA.	  The	  PTPS	  and	  GCH1	  genes	  are	  linked	  in	  frame	  through	  the	  foot-­‐
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and-­‐mouth	   disease	   virus	   (FMDV)	   2A	   sequence,	   which,	   though	   a	   ribosomal	  skipping	   mechanism	   (Donnelly	   et	   al.	   2001),	   leads	   to	   equimolar	   translation	   of	  both	  proteins.	  The	  268bp	  EF1α	  promoter	  sequence	  for	  pAA057	  generation	  was	  amplified	  in	  a	   20µl	   PCR	   reaction	   using	   75ng	   pMB13	   template	   DNA,	   200μM	   dNTPs	   (NEB),	  0.5µM	   of	   primer	   pair	   AA150/AA151	   and	   Phusion	   High	   Fidelity	   Polymerase	  (Fischer	   Scientific)	   in	   appropriate	   buffer.	   Conditions	   of	   the	   PCR	   amplification	  were	   as	   follows:	   98°C	   (30s),	   followed	  by	   30	   cycles	   of	   98°C	   (10s)/	   59°C	   (15s)/	  72°C	  (10s),	  and	  a	  final	  extension	  at	  72°C	  for	  10	  min.	  The	  ~2.5kb	  tTH	  fragment	  for	  pAA058	  generation	  was	  amplified	  in	  a	  50µl	  PCR	  reactions	   using	   25ng	   pAA016	   template	   DNA,	   200μM	   dNTPs	   (NEB),	   0.4µM	   of	  primer	   pair	   AA152/AA153	   and	   Phusion	   High	   Fidelity	   Polymerase	   (Fischer	  Scientific)	   in	   appropriate	   buffer.	   Conditions	   of	   the	   PCR	   amplification	   were	   as	  follows:	  98°C	  (30s),	  followed	  by	  30	  cycles	  of	  98°C	  (10s)/	  59°C	  (15s)/	  72°C	  (30s),	  and	  a	  final	  extension	  at	  72°C	  for	  10	  min.	  The	  ~600bp	   IRES	   sequence	   for	   pAA059	   generation	  was	   amplified	   in	   a	   20µl	  PCR	  reaction	  using	  30ng	  pCSIG	  template	  DNA,	  200μM	  dNTPs	  (NEB),	  0.25µM	  of	  primer	   pair	   AA154/AA155	   and	   Phusion	   High	   Fidelity	   Polymerase	   (Fischer	  Scientific)	   in	   appropriate	   buffer.	   Conditions	   of	   the	   PCR	   amplification	   were	   as	  follows:	  98°C	  (3	  s),	   followed	  by	  30	  cycles	  of	  98°C	  (10s)/	  53°C	  (30s)/	  72°C	  (9s),	  and	  a	  final	  extension	  at	  72°C	  for	  10	  min.	  The	  ~1.3kb	  PTPS-­‐2A-­‐GCH1	  fragment	  for	  pAA061	  generation	  was	  amplified	  in	  a	   20µl	   PCR	   reaction	   using	   30ng	   pAA020	   template	   DNA,	   200μM	   dNTPs	   (NEB),	  0.125µM	   of	   primer	   pair	   AA156/AA157	   and	   Phusion	   High	   Fidelity	   Polymerase	  (Fischer	   Scientific)	   in	   GC	   buffer.	   Conditions	   of	   the	   PCR	   amplification	   were	   as	  follows:	  98°C	  (30s),	  followed	  by	  30	  cycles	  of	  98°C	  (10s)/	  53°C	  (30s)/	  72°C	  (10s),	  and	  a	  final	  extension	  at	  72°C	  for	  10	  min.	  The	   42nt	   tandem	   copy	   of	  microRNA-­‐208a	   sequence	  was	   amplified	   together	  with	   the	  WPRE	   sequence	   in	   a	   20µl	   PCR	   reaction	   using	   40ng	   pAA056	   template	  DNA,	   200μM	   dNTPs	   (NEB),	   0.25µM	   of	   primer	   pair	   AA60/AA158	   and	   Phusion	  High	   Fidelity	   Polymerase	   (Fischer	   Scientific)	   in	   appropriate	   buffer.	   The	   PCR	  cycling	   conditions	   were	   as	   follows:	   98°C	   (30s),	   followed	   by	   30	   cycles	   of	   98°C	  (10s)/	  55°C	  (30s)/	  72°C	  (14s),	  and	  a	  final	  extension	  at	  72°C	  for	  10	  min.	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  2.1.7.3.2 pAAV-­‐EF1α-­‐TH-­‐IRES-­‐PTPS-­‐2A-­‐GCH1-­‐WPRE-­‐miR208aT	  (pAA063)	  AAV	   producer	   plasmid	   pAAV-­‐EF1α-­‐TH-­‐IRES-­‐PTPS-­‐2A-­‐GCH1-­‐WPRE-­‐miR208aT	   (pAA063)	   was	   constructed	   as	   follows.	   The	   543bp	   fragment	   that	  corresponds	   to	   the	   regulatory	   N-­‐terminus	   portion	   of	   TH	   was	   removed	   from	  pGPT002	   using	   the	   restriction	   endonuclease	   sites	   BstEII	   and	   ligated	   with	   the	  7919bp	  fragment	  of	  pAA062	  digested	  with	  the	  same	  enzyme.	  
	  
2.2 Cell	  Culture	  and	  Transfections	  
	  
2.2.1 Maintenance	  of	  Cell	  Cultures	  All	   cell	   culture	   work	   was	   performed	   in	   assigned	   mycoplasma-­‐free	   tissue	  culture	   hoods.	   Human	   embryonic	   kidney	   293T	   cells	   (HEK293T)	   and	   human	  neuroblastoma	   cells	   (SH-­‐SY5Y),	   obtained	   from	   the	   American	   Tissue	   Culture	  Collection	   (ATCC),	  were	   grown	   in	   Dulbecco’s	  modified	   Eagle	  medium	   (DMEM)	  +4.5g/L	  Glucose,	  +L-­‐	  Glutamine,	  +Pyruvate	  (GIBCO	  41966,	  Invitrogen),	  and	  10%	  heat	  inactivated	  (56°C	  for	  30	  min)	  foetal	  bovine	  serum	  (FBS,	  Invitrogen).	  Human	  hepatocellular	   carcinoma	   cells	   (Huh7.5)	   were	   obtained	   from	   ATCC	   and	  maintained	  in	  DMEM	  with	  10%	  FCS	  and	  supplemented	  with	  non-­‐essential	  amino	  acids	   (100X	   NEAA;	   Life	   Technologies)	   to	   a	   final	   concentration	   of	   1X.	   All	   Cells	  were	  cultured	  at	  37°C	  and	  5%	  CO2	  in	  10cm	  dishes	  (Corning).	  Unless	  otherwise	  required,	   cells	   were	   regularly	   passaged	   using	   1ml	   TrypLETM	   Express	   (GIBCO	  12605,	   Invitrogen).	  To	  passage	   them,	  cells	  were	   incubated	  with	   trypsin	   for	  1-­‐3	  min	   at	   37°C,	   re-­‐suspended	   by	   repeated	   pipetting	   and	   the	   required	   proportion	  was	   transferred	   to	   a	   new	   10cm	   dish	   containing	   pre-­‐warmed	   fresh	   complete	  DMEM.	  	  
2.2.2 Freezing	  and	  Thawing	  of	  Cell	  Lines	  Stocks	  of	  frozen	  cells	  were	  long-­‐term	  stored	  in	  liquid	  nitrogen.	  To	  freeze	  cells,	  at	   least	   2-­‐3	   confluent	   10cm	  dishes	   of	   each	   cell	   line	  were	   prepared.	   Cells	  were	  detached	  using	  1ml	  of	  trypsin	  and	  washed	  in	  5-­‐10ml	  fresh	  culture	  medium.	  After	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harvesting	   the	   cells	   by	   centrifugation	   at	   1200	   rpm	   for	   5	   min,	   cells	   were	   re-­‐suspended	  in	  1ml	  of	  freezing	  medium	  containing	  10%	  DMSO	  (Sigma),	  50%	  FBS	  (Invitrogen)	   and	  40%	  culture	  medium	  and	   immediately	   transferred	   to	   a	   1.8ml	  labelled	  cryovial.	  Cryovials	  were	   initially	   stored	  at	   -­‐80˚C	  and	  after	  24-­‐48	  hours	  moved	  to	  a	  liquid	  nitrogen	  tank.	  To	  later	  recover	  the	  cryo-­‐preserved	  cells,	  vials	  were	   thawed	   rapidly	   at	   37°C,	   cells	   were	   pelleted	   at	   1200	   rpm	   for	   5	   min	   and	  rapidly	  resuspended	  into	  10ml	  of	  pre-­‐warmed	  DMEM	  with	  10%	  FBS.	  Cells	  were	  left	  to	  recover	  in	  10cm	  dish	  for	  at	  least	  24-­‐48h.	  	  
2.2.3 Mycoplasma	  Testing	  Standard	  mycoplasma	  testing	  was	  performed	  regularly	  on	  all	  cells	  cultured	  in	  the	   mycoplasma-­‐free	   tissue	   culture	   room	   using	   the	   MycoAlertTM	   Mycoplasma	  Detection	  Kit	   (Lonza)	  and	   the	  controls	   from	  the	  MycoAlertTM	  Assay	  Control	  Set	  (Lonza)	  following	  the	  manufacturer’s	  protocol.	  This	  test	  is	  based	  on	  the	  activity	  of	  mycoplasmal	   enzymes	   that	   are	   found	   in	   all	   six	  of	   the	  main	  mycoplasma	   cell	  culture	  contaminants	  but	  are	  not	  present	  in	  eukaryotic	  cells,	  which	  convert	  ADP	  present	   in	   the	  Mycoalert	   substrate	   to	   ATP.	   The	   ATP	   is	   then	   transferred	   into	   a	  light	  signal	  via	  the	  luciferase	  enzyme	  in	  the	  MycoAlert	  Reagent.	  By	  measuring	  the	  level	   of	   ATP	   in	   a	   sample	   both	   before	   (read	   A)	   and	   after	   the	   addition	   of	   the	  MycoAlert	  Substrate	  (read	  B),	  a	  ratio	  can	  be	  obtained	  which	  is	   indicative	  of	  the	  presence	  or	  the	  absence	  of	  mycoplasma.	  	  
2.2.4 Transient	  Transfection	  of	  DNA	  Plasmids	  For	   regular	   plasmid	   DNA	   transfection,	   HEK	   293T	   cells	   were	   seeded	   and	  transfected	  24	  h	   later	  using	  polyethylinimine	  (PEI,	  Polysciences).	  On	  the	  day	  of	  transfection,	   DNA	   and	   PEI	   (3.5µl/µg	   DNA,	   pH	   7)	   were	   separately	   diluted	   in	  serum-­‐free	   DMEM	   before	   being	   mixed	   together	   and	   incubated	   for	   20	   min	   at	  room	   temperature	   before	   being	   added	   to	   the	   cells.	   The	   final	   volume	   of	   the	  transfection	   mix	   was	   1/10	   the	   volume	   of	   the	   final	   culture	   vessel	   cells	   were	  grown	  in.	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2.2.5 Recombinant	  AAV	  Production	  and	  Titration	  	  
2.2.5.1 Transfection	  with	  Producer	  Plasmids	  and	  Harvesting	  To	  prepare	  rAAV	  vector	  stocks,	  HEK	  293T	  cells	  were	  seeded	   in	  10-­‐stack	  cell	  chambers	   (6360	   cm2/chamber)	   (Corning)	   in	   a	   density	   of	   5x108	   cells/chamber.	  Twenty-­‐four	   hours	   later,	   the	   cells	   were	   60-­‐70%	   confluent	   and	   ready	   to	   be	  transfected.	  Transfection	  mixes	  were	  set	  up	  as	  shown	  in	  Table	  1:	  	  
Reagent/Plasmid	   Amount/chamber	  Transgene	  plasmid	   160	  μg	  pLT2-­‐AAV8	  (Rep	  and	  Cap)	   160	  μg	  HGTI	  helper	  plasmid	   480	  μg	  DMEM	  Serum	  Free	   120	  ml	  PEI	  Max,	  pH	  7	   2.8	  ml	  
	  
Table	   1:	   Reagents	   and	   plasmids	   used	   in	   triple	   transfection	   schemes	   for	   rAAV2/8	  
production.	  	  pLT2-­‐AAV8	   codes	   for	   serotype	   2	   Rep78	   and	   serotype	   8	   VP1,	   VP2	   and	   VP3	  capsid	  proteins;	  HGTI	  codes	  for	  the	  adenoviral	  proteins	  E2a	  and	  E4orf6	  and	  the	  VA	  RNAs	  (	  Matsushita	  et	  al.	  2004;	  McIntosh	  et	  al.	  2013),	  which	  together	  provide	  the	   helper	   functions.	   HEK293T	   cells	   express	   the	   additional	   adenoviral	   helper	  proteins	   required	   for	   rAAV	   production.	   rAAV	   produced	   following	   this	   triple	  transfection	  scheme	  was	  a	  pseudotyped	  AAV8	  vector	  containing	  AAV2	  ITRs	  and	  AAV8	   capsid	   proteins	   (AAV2/8).	   AAV8	   has	   a	   tropism	   for	   the	   liver	   and	   was	  therefore	  used	  in	  this	  study	  (Nakai	  et	  al.	  2005).	  After	  20	  min	  incubation	  at	  room	  temperature,	   the	  transfection	  mix	  was	  added	  to	  1L	  pre-­‐warmed	  DMEM	  (Gibco)	  supplemented	  with	  10%	  FBS.	  This	   transfection	  media	  was	  subsequently	  added	  to	   the	   10-­‐stack	   cell	   chamber	   in	   replacement	   of	   the	   old	   media.	   After	   72h	  incubation,	  media	  from	  the	  chamber	  was	  collected;	  attached	  cells	  were	  washed	  with	  PBS	  and	  harvested	  with	  trypsin.	  The	  cells	  were	  subsequently	  spun	  at	  2000g	  for	   10	  min,	   the	  pellets	  washed	  with	  PBS,	   spun	   again	   at	   2000g	   for	   10	  min,	   and	  resuspended	  in	  15ml	  of	  lysis	  buffer	  (150mM	  NaCl,	  50mM	  Tris	  pH	  8.5).	  Cell	  lysis	  was	  done	  by	  three	  freeze/thaw	  cycles	  (alternating	  -­‐	  80	  ̊C	  to	  37	  ̊C	  water	  bath).	  The	  virus	   present	   in	   the	   media	   was	   precipitated	   with	   ammonium	   sulphate	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(31.3g/100ml	  media)	  and	  the	  pellet	  resuspended	  in	  15	  ml	  lysis	  buffer.	  The	  crude	  lysate	  and	  supernatant	  precipitate	  were	  then	  treated	  with	  5000	  units/chamber	  of	   benzonase	   (Sigma)	   in	   the	   presence	   of	   1mM	  MgCl2,	   and	   incubated	   in	   a	  37	  ̊C	  water	   bath	   for	   30	   min	   before	   further	   purification	   either	   by	   AVB	   sepharose	  affinity	  column	  or	  iodixanol	  density	  gradient.	  	  
2.2.5.2 Recombinant	  AAV	  Purification	  on	  AVB	  Sepharose	  Column	  AVB	  Sepharose	  is	  an	  affinity	  medium	  with	  affinity	  for	  several	  AAV	  serotypes	  and	  enables	  its	  purification	  in	  one	  step	  with	  high	  purity.	  Crude	   lysate	  was	   filtered	   through	  a	  0.2µm	  filter	  before	   loading	   into	   the	  AVB	  sepharose	  column	  equilibrated	  with	  PBS	  at	  pH	  7.0.	  In	  a	  second	  step,	  the	  column	  was	  washed	  with	  PBS	  to	  eliminate	  unbound	  particles.	  AAV	  was	  eluted	  in	  50mM	  glycine	  solution	  pH	  2.7	  and	  collected	  in	  1ml	  fractions	  into	  tubes	  containing	  30µl	  Tris	  buffer	  pH	  8.8	  to	  neutralise	  the	  glycine	  elution	  buffer.	  Tubes	  corresponding	  to	  the	  260mm	  and	  280mm	  graph	  peaks	  are	  the	  ones	  containing	  the	  virus.	  They	  were	  pooled	  together	  (~2.5ml)	  and	  injected	  into	  10000	  MWCO	  dialysis	  cassettes	  (Thermo	  Scientific).	  Dialysis	  cassettes	  containing	  the	  purified	  virus	  were	  stirred	  overnight	   in	   1L	   PBS	   at	   4°C.	   Finally,	   the	   dialysed	   virus	   was	   removed	   from	   the	  cassette	  and	  stored	  at	  4°C	  until	  titration.	  	  
2.2.5.3 Recombinant	  AAV	  Purification	  by	  Iodixanol	  Density	  Gradient	  Following	  benzonase	  treatment,	  the	  lysis	  buffer	  containing	  the	  lysed	  cells	  and	  the	  respuspended	  proteins	  from	  the	  supernatant	  were	  spun	  at	  4200	  rpm	  for	  30	  min.	  The	  supernatant	  was	  loaded	  onto	  ULTRA-­‐Clear	  14	  x	  89mm	  ultracentrifuge	  tubes	  (Beckman	  Coulter)	  containing	  1.55ml,	  1.55	  ml,	  1.88	  ml	  and	  2.8ml	  of	  60%,	  40%,	  25%,	  15%	  iodixanol	  solution	  layers,	  respectively.	  This	  gradient	  was	  spun	  at	  40000	  rpm	  for	  3h	  at	  18°C	  in	  a	  Sorvall	  Discovery	  90SE	  ultracentrifuge	  using	  a	  TH-­‐641	  rotor.	  The	  virus	  fraction	  was	  collected	  by	  piercing	  the	  gradient	  tube	  between	  the	  60%	  and	   the	  40%	  fractions	  with	  a	  19G	  11/2	  needle.	  Approximately	  1ml	  of	  virus	  was	  collected	  per	  tube	  and	  pooled	  together	  for	  buffer	  exchange.	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2.2.5.4 Recombinant	  AAV	  Buffer	  Exchange/Concentration	  After	   purification,	   viruses	   were	   buffered/concentrated	   using	   a	   Vivaspin	   20,	  100KDa	  cut	  off	  concentrator	  (Vivascience).	  First,	  5ml	  of	  PBS	  were	  added	  to	  the	  concentrator,	   which	   was	   shaken	   well	   to	   remove	   any	   debris.	   The	   PBS	   was	  discarded	  and	  another	  10ml	  PBS	  were	  added	  to	  the	  concentrator	  and	  spun	  5	  min	  at	   2000	   rpm	   to	   clean	   the	   membrane	   from	   any	   trace	   of	   glycerine	   and	   sodium	  azide,	   after	   which	   the	   bucket	   was	   emptied	   and	   the	   remaining	   PBS	   in	   the	  concentrator	  was	  discarded.	  Iodixanol	  samples	  were	  diluted	  at	  least	  3	  times	  into	  PBS	   and	   spun	   at	   1000g	   until	   the	   volume	   in	   the	   concentrators	   reduced	   to	   1ml.	  Next,	   the	  concentrator	  was	   filled	  up	   to	  20ml	  with	  PBS	  and	  spun	  at	  1000g	  until	  the	  volume	  in	  the	  concentrators	  reduced	  to	  1ml.	  This	  process	  was	  repeated	  once	  again	   and	   spun	   to	   a	   final	   volume	   of	   500	   to	   800μL.	   Finally,	   the	   virus	   prep	  was	  transferred	  from	  the	  concentrator	  to	  a	  new	  eppendorf	  tube.	  
	  
2.2.5.5 Determination	   of	   Recombinant	   AAV	   Genome	   Titre	   by	   Real-­‐Time	  
Quantitative	  PCR	  Real-­‐time	   quantitative	   PCR	   (qPCR)	   was	   used	   to	   determine	   the	   genome-­‐containing	  particle	  (gcp)	  titre	  of	  rAAV	  preparations.	  The	  SYBR	  Green	  Jump	  Start	  Taq	  ready	  mix	  without	  MgCl2	  (Sigma)	  was	  used	  according	  to	  the	  manufacturer’s	  instructions	   on	   an	   ABI	   Prism	   cycler	   (AB	   Applied	   Biosystems)	   for	   absolute	   gcp	  titre	   quantification.	   The	   MgCl2	   and	   primer	   concentrations	   were	   optimised	  previously	   to	   4mM	   and	   0.25µM,	   respectively.	   Linearised	   transgene	   plasmids	  were	  used	  to	  prepare	  standard	  curves,	  using	  concentrations	  ranging	  from	  108	  to	  103	  genome	  copies.	  One	  µl	  of	  the	  viral	  stock	  prep	  and	  dilutions	  thereof	  were	  used	  as	   sample.	   The	   following	   specific	   primer	   pairs	   were	   used	   for	   the	   titrations:	  AA39/AA40	   for	   viruses	   containing	   the	   GCH	   gene	   and	   AA41/AA42	   for	   viruses	  containing	   the	  TH	  gene.	  The	  cycling	  parameters	  were	  as	   follows:	  2	  min	  at	  94	  ̊C	  followed	  by	  40	  times	  15s	  at	  94	  ̊C,	  15s	  at	  58	  ̊C	  and	  1	  min	  at	  72	  ̊C.	  The	  amount	  of	  genome	  containing	  particles	   (gcp)	   in	   the	  viral	  samples	  was	  calculated	   from	  the	  amount	  of	  DNA	  detected	  relative	  to	  the	  standard	  curve.	  Each	  standard,	  negative	  control	  and	  virus	  sample	  was	  loaded	  in	  duplicate.	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2.2.5.6 Alkaline	   Gel	   Electrophoresis	   for	   Recombinant	   AAV	   Genome	  
Titration	  and	  Quality	  Control	  AAV	  samples	  were	   loaded	  on	  an	  alkaline	  agarose	  gel	  made	  of	  0.8%	  agarose,	  2ml	  50x	  alkaline	  running	  buffer	  (2.5M	  NaOH,	  50mM	  EDTA)	  were	  added	  to	  98ml	  of	  dissolved	  agarose	  (0.8%	  w/v)	  and	  allowed	  to	  set.	  The	  alkaline	  agarose	  gel	  was	  run	  at	  18V	  overnight	  in	  a	  cold	  room.	  Prior	  to	  loading,	  25μl	  AAV	  were	  mixed	  with	  8.5μl	  alkaline	  loading	  buffer	  (20%	  glycerol,	  4x	  alkaline	  running	  buffer,	  1.2%	  SDS	  and	   xylene	   cyanol).	   On	   the	   following	   day,	   the	   gel	   was	   gently	   rocked	   in	   3	   gel	  volumes	   of	   0.1M	   Tris	   pH	   8.0	   for	   1h	   and	   subsequently	   transferred	   to	   a	   1	   gel	  volume	  solution	  of	  4X	  Gelred	   (Cambridge	  Bioscience)	   in	  0.1M	  NaCl	  and	  rocked	  gently	  for	  2h.	  Finally,	  the	  gel	  was	  rinsed	  briefly	  2X	  in	  tap	  water	  and	  was	  imaged	  using	  a	  UV	  transilluminator.	  Hyperladder	  I	  (Bioline)	  was	  used	  as	  a	  size	  reference	  and	  for	  quantification	  of	  the	  AAV	  titre	  by	  relative	  quantification	  of	  the	  intensities	  of	  the	  DNA	  bands.	  	  
2.2.5.7 Determination	   of	   rAAV	   Capsid	   Titre	   by	   Sodium	   Dodecyl	   Sulphate	  
Polyacrylamide	  Gel	  Electrophoresis	  (SDS-­‐PAGE)	  Protein	  Gel	  12%	   SDS-­‐PAGE	   protein	   gels	   were	   used	   to	   determine	   the	   rAAV	   capsid	   titre.	  The	   viral	   protein	   concentrations	   were	   determined	   using	   a	   Bovine	   Serum	  Albumin	   (BSA)	   standard	   curve.	   To	  prepare	   the	  BSA	   curve,	   10μl	   of	   appropriate	  BSA	  dilution	  was	  mixed	  with	  5μl	  of	  water	  and	  3μl	  of	  6X	  loading	  buffer	  (0.8g	  SDS,	  5%	  β-­‐mercaptoethanol,	  5ml	  Tris	  pH	  6.8,	  5ml	  glycerol,	  4mg	  bromophenol	  blue).	  For	   viral	   samples,	   15μl	   of	   purified	   virus	   were	   mixed	   with	   3μl	   of	   6X	   loading	  buffer.	  All	  samples	  were	  boiled	  at	  95°C	  for	  5	  min	  before	  loading.	  5μl	  of	  Precision	  Plus	  Protein	  Dual	  Colour	  Standards	  (Bio-­‐Rad)	  was	  used	  as	  ladder.	  The	  gel	  was	  run	   in	  1X	  Tris-­‐Glycine	  running	  buffer	  (1	   in	  5	  dilution	  from	  a	  5X	  stock	   solution	   containing	  15.1g	  Tris	   base,	   94g	   glycine,	   50ml	   SDS	  10%	  and	  add	  ddH2O	   to	   a	   total	   volume	   of	   1L)	   at	   80V	   until	   the	   samples	   had	   reached	   the	  separating	  gel,	  then	  the	  voltage	  was	  increased	  to	  120V	  and	  the	  gel	  run	  until	  the	  blue	  dye	  front	  ran	  out	  of	  the	  gel.	  The	  gel	  was	  removed	  from	  the	  glass	  plates	  and	  fixed	   in	   a	   solution	   of	   50%	  ethanol	   and	   15%	  acetic	   acid	   in	  water,	  washed	  with	  water,	   and	   stained	   with	   the	   KryptonTM	   Infrared	   Protein	   Stain	   (Thermo	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Scientific)	   for	   at	   least	  2h	   in	   a	   shaking	   tray.	  The	  gel	  was	  distained	   in	   a	   solution	  made	  of	  5%	  acetic	   acid	  and	  0.1%	  Tween®20	   (Sigma-­‐Aldrich)	   in	  water.	  The	  gel	  was	   finally	  scanned	  using	  a	  LI-­‐COR	  Odyssey®	  Infrared	  Imaging	  system,	  and	  the	  band	  showing	  the	  viral	  VP3	  protein	  quantified	  using	  the	  Odyssey	  software.	  The	  protein	   content	   of	   the	   VP3	   band	   (in	   ng)	   was	   deduced	   from	   the	   BSA	   standard	  curve	  and	  the	  viral	  particle	  titre	  was	  calculated	  based	  on	  the	  known	  amount	  of	  VP3	   proteins	   per	   capsid	   (4.986868	   x	   10-­‐9ng/capsid)	   and	   the	   volume	   of	   virus	  loaded.	  	  
2.2.6 Recombinant	  AAV	  Infection	  and	  Transduction	  The	  cells	  to	  be	  infected	  were	  grown	  to	  70%	  confluency,	  incubated	  with	  rAAV	  in	   a	   low	   volume	   (200µl	   for	   a	   well	   of	   24-­‐well	   plate,	   volumes	   adjusted	  proportionally	  to	  the	  size	  of	  the	  culture	  vessel)	  and	  incubated	  for	  1h	  at	  37˚C.	  This	  adsorption	  step	  ensures	  maximal	  infection/transduction	  efficiency.	  After	  1h,	  the	  medium	  was	  replenished	   to	   the	  normal	  culture	  volume	  (i.e.	  500µl	   for	  a	  well	  of	  24-­‐well	   plate).	   Cells	   were	   harvested	   after	   48	   h	   for	   further	   analysis	   (RNA	   and	  protein	  expression).	  	  
2.3 Animal	  Studies	  	  
2.3.1 Mouse	  Experiments	  	  
2.3.1.1 Study	  Design	  Mouse	   work	   was	   carried	   out	   at	   the	   Biological	   Services	   Unit	   from	   King’s	  College	  London	  in	  the	  United	  Kingdom	  and	  performed	  under	  the	  authority	  of	  the	  UK	   Home	   Office	   Project	   and	   Personal	   Licences	   regulations	   and	  was	   compliant	  with	   the	   guidelines	   of	   King’s	   College	   London	   ethical	   review	   committee.	   CD1®	  mice	  were	  obtained	  from	  Charles	  River	  Laboratories	  Inc.	  (Wilmington,	  MA,	  USA).	  This	   is	   a	   suitable	   rodent	   model	   for	   toxicity	   testing,	   for	   which	   extensive	  background	  data	  are	  available	  and	  is	  acceptable	  as	  a	  model	  for	  toxicity	  testing	  by	  regulatory	  authorities.	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AAV	   vector	   genomes	   diluted	   in	   phosphate-­‐buffered	   saline	   were	   slowly	  administered	   by	   tail	   vein	   injection	   at	   doses	   indicated	   in	   table	   2.	   Animals	  were	  also	  dosed	  with	  benserazide	  hydrochloride	  and	  either	  tolcapone	  or	  entacapone.	  Benserazide	   is	   a	   DOPA	   decarboxylase	   inhibitor	   that	   is	   frequently	   used	   in	  combination	   with	   other	   treatments	   for	   PD,	   to	   inhibit	   the	   carboxylation	   of	   L-­‐DOPA,	  which	  diminishes	  its	  therapeutic	  efficacy.	  Tolcapone	   and	   entacapone	   are	   catechol-­‐O-­‐methyl	   transferase	   (COMT)	  inhibitors	  that	  are	  co-­‐administered	  with	  decarboxylase	  inhibitors	  and	  L-­‐DOPA	  to	  minimise	  peripheral	  L-­‐DOPA	  catabolism	  and	  to	  increase	  its	  bioavailability	  to	  the	  brain.	  In	   studies	   one	   and	   two,	   test	   animals	   were	   given	   a	   single	   dose	   of	   the	   AAV	  vectors	  on	  day	  1	  (Table	  2).	  The	  animals	  were	  then	  maintained	  until	  day	  28	  when	  three	   intraperitoneal	   benserazide	   hydrochloride	   injections	   (sub-­‐doses	   of	   2.4	  mg/kg)	  and	  oral	  doses	  of	  tolcapone	  (sub-­‐doses	  of	  10	  mg/kg)	  were	  administered	  at	   approximately	   4	   hour	   intervals	   to	   all	   test	   groups.	   In	   studies	   one	   and	   two,	  control	  animals	  received	  the	  same	  dosing	  regimen	  of	  benserazide	  hydrochloride	  and	   tolcapone	   as	   described	   above	   on	   day	   15	   to	   ensure	   its	   suitability	   for	  administration	  to	  the	  test	  groups	  and	  sacrificed	  4	  hours	  after	  the	  last	  sub-­‐dose.	  In	   study	   three,	   test	   and	   control	   animals	   received	   a	   single	   intraperitoneal	  injection	  of	  benserazide	  and	  entacapone	  on	  day	  28	  one	  hour	  prior	  to	  sacrifice.	  From	  each	  animal,	  750µl	  blood	  samples	  were	  obtained	  4	  hours	  (studies	  1	  and	  2)	  or	  1	  hour	  (study	  3)	  after	  the	  final	  dose	  administration	  of	  benserazide	  and	  the	  COMT	   inhibitor.	  Animals	  were	   then	  sacrificed	  and	  a	   section	   from	   the	   liver	  was	  taken,	  washed	  with	  saline	  and	  either	  snap-­‐frozen	  and	  stored	  in	  liquid	  nitrogen	  or	  fixed	  in	  4%	  paraformaldehyde	  for	  further	  analysis	  (studies	  1	  and	  2)	  or	  perfused	  first	  with	  PBS	  to	  wash	  out	  the	  blood	  and	  then	  with	  4%	  paraformaldehyde	  (study	  3).	  A	  schematic	  time	  course	  of	  all	  three	  studies	  is	  shown	  in	  Figure	  10.	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Figure	  10:	  Time	  course	  scheme	  of	  the	  three	  mouse	  studies.	  
Animals	  were	  dosed	  with	  AAV	  vectors	  at	  day	  0.	  In	  study	  1,	  control	  animals	  received	  three	  
intraperitoneal	  benserazide	  injections	  and	  oral	  doses	  of	  tolcapone	  at	  4	  hours	  intervals	  in	  
a	   total	  dose	  of	  12	  and	  30	  mg/kg,	   respectively,	   at	  day	  15	   to	  ensure	   the	   suitability	  of	   this	  
regimen	   for	   administration	   to	   the	   test	   groups.	   At	   day	   28	   the	   same	   dosing	   regimen	   of	  
benserazide	  and	  tolcapone	  was	  administered	  to	  the	  test	  groups.	  Animals	  were	  sacrificed	  4	  
hours	  after	  the	  final	  sub-­‐dose.	  In	  study	  2,	  all	  animals	  received	  a	  single	  dose	  of	  benserazide	  
and	   COMT	   inhibitor	   at	   the	   day	   of	   sacrifice,	   while	   in	   study	   3,	   three	   sub-­‐doses	   were	  
administered	   4	   hours	   apart.	   Total	   dose	   was	   10	   mg/kg	   for	   benserazide	   and	   30	   mg/kg	  
COMT	  inhibitor	  in	  all	  studies.	  
	  
Treatment	  of	  Test	  Groups	  with	  AAV	  (Studies	  1-­‐3)	  
Treatment	  of	  Control	  Group	  with	  benserazide	  and	  COMT	  inhibitor	  and	  sacrifice	  (Study	  1)	   Benserazide	  and	  COMT	  inhibitor	  treatment	  of	  Test	  (Studies	  1	  -­‐	  3)	  and	  Control	  Groups	  (Studies	  2	  and	  3);	  sacrifice	  
28	  15	  0	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1	   6	   M	   PBS	   -­‐	   4	   10	   3	   4	  
1	   6	   M	   scLP1-­‐tTH	   3.51x1010	   4	   10	   3	   4	  scLP1-­‐GCH1	   3.51x1010	  
1	   6	   M	   scLP1-­‐tTH	   7.02x1010	   4	   10	   3	   4	  
2	   3	   F	   PBS	   -­‐	   12	   30	   1	   1	  
2	   3	   F	   ssLP1-­‐GCH1-­‐LP1-­‐tTH	   3.6x1012	   12	   30	   1	   1	  
2	   3	   F	   ssLP1-­‐GCH1-­‐LP1-­‐tTH	   1.3x1012	   12	   30	   1	   1	  
3	   3	   M	   PBS	   -­‐	   4	   10	   3	   1	  
3	   5	   M	   ssLP1-­‐GCH1-­‐LP1-­‐tTH	   1.3x1012	   4	   10	   3	   1	  
3	   3	   M	   Oral	  L-­‐DOPA	   10	  mg/kg	   4	   10	   3	   1	  	  
Table	  2:	  Treatment	  scheme	  in	  all	  three	  mouse	  studies.	  
Mice	  dosed	  with	  two	  self-­‐complementary	  (sc)	  vectors	  received	  a	  50/50	  mix	  of	  each.	  In	  study	  1,	  untreated	  control	  animals	  were	  maintained	  untreated	  
throughout	  the	  study	  until	  day	  15,	  when	  they	  were	  dosed	  with	  benserazide	  and	  tolcapone	  4	  hours	  prior	  to	  sacrifice.	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2.3.1.2 Mouse	  Liver	  Analysis	  For	   immunostaining	  analysis,	  6µm	   thick	   sections	  of	  paraffin	  embedded	   liver	  were	   cut	   and	   blocked	   in	   PBS	   containing	   10%	  BSA.	   Before	   incubation	  with	   the	  primary	  antibody,	   tissue	  sections	  were	  blocked	   for	  endogenous	  biotin	   in	  100µl	  avidin	  (0.1mg/ml)	  for	  1	  min,	  washed	  three	  times	  for	  5	  min,	  then	  incubated	  with	  100µl	  biotin	  (0.5mg/ml)	  and	  washed	  three	  times	  for	  5	  min	  with	  PBS.	  Biotin	   is	   particularly	   enriched	   in	   the	   liver	   and	   the	   immunodetection	   system	  used	   here	   is	   based	   upon	   avidin-­‐biotin	   coupling.	   Thus,	   the	   endogenous	   biotin	  needs	   to	  be	  blocked	  prior	   to	   immunostaining	   to	  prevent	   the	   avidin-­‐peroxidase	  conjugate	  binding	  to	  it.	  Biotin	  can	  bind	  to	  only	  one	  molecule	  of	  avidin,	  whereas	  avidin	   can	   bind	   four	   molecules	   of	   biotin.	   Avidin	   is	   applied	   to	   the	   section	   in	  excess,	  so	  that	  all	  endogenous	  biotin	  molecules	  are	  bound	  to	  one	  of	  each	  of	  the	  avidin	  biotin-­‐binding	  sites.	  Excess	  Biotin	  is	  then	  applied	  and	  this	  will	  bind	  to	  the	  remaining	   three	   biotin	   –	   binding	   sites	   of	   the	   bound	   avidin.	   All	   avidin-­‐biotin	  binding	  sites	  are	  thus	  saturated.	  After	   blocking	   endogenous	   biotin,	   primary	   antibodies	  were	   used	   as	   follows:	  2h	  goat	  monoclonal	  anti-­‐human	  GCH1	  (1:350,	  Sigma;	  2h	  rabbit	  polyclonal	  anti-­‐human	  TH	  (1:1000,	  Abcam	  #ab137869).	  Samples	  were	  washed	  3x	  with	  PBS	  and	  then	   incubated	   with	   biotinylated	   species-­‐specific	   secondary	   antibody	   at	   room	  temperature	   for	   30	   min.	   Finally,	   samples	   were	   developed	   in	   ABC-­‐Peroxidase	  solution	  for	  30	  min	  at	  room	  temperature.	  The	   haematoxylin	   and	   eosin	   staining	   (H&E)	   was	   performed	   on	   6µm	   thick	  sections	   of	   paraffin	   embedded	   liver	   sections.	   Haematoxylin	   stains	   the	   nucleus,	  while	   eosin	   stains	   the	   cytoplasm	   of	   the	   cells.	   Sections	  were	   cut,	   mounted	   and	  dried	  in	  an	  oven	  at	  60°C	  overnight.	  Next,	  they	  were	  de-­‐waxed	  in	  100%	  xylene	  for	  3	  min	   3x	   and	  washed	   in	   100%	   industrial	  methylated	   spirit	   (IMS).	   Slides	  were	  then	   incubated	   in	  haematoxylin	   for	  5	  min,	  washed	  under	   running	   tap	  water	   to	  remove	   excesses	   and	   differentiated	   in	   0.5	   HCl/70%	   IMS	   and	   washed	   under	  running	   tap	  water.	  Next,	   sections	  were	   incubated	   for	  10s	   in	   eosin	   and	  washed	  under	  running	  tap	  water	  to	  remove	  excesses.	  Sections	  were	  then	  dehydrated	  4x	  for	  30s	   in	  100%	  IMS	  and	  2x	   for	  30s	   in	  100%	  xylene.	  Finally,	   slides	  were	  cover	  slipped	  with	  DePeX	  mounting	  medium	  and	  dried	  overnight	  at	  room	  temperature	  before	  imaging	  using	  a	  fluorescence	  phase	  contrast	  microscope	  (Zeiss	  Axioskop).	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2.3.1.3 Cell	  Count	  in	  Histological	  Liver	  Sections	  To	  evaluate	   the	  number	  of	   transduced	  cells	   in	   the	   liver,	  10	  random	  sections	  per	  animal	  stained	  for	  GCH1	  and	  TH	  were	  manually	  counted	  at	  20x	  magnification	  with	  a	  fluorescence	  phase	  contrast	  microscope	  (Zeiss	  Axioskop).	  
	  
2.3.2 HPLC	   System	   and	   Determination	   of	   L-­‐DOPA	   and	   its	   Metabolites	   in	  
the	  Plasma	  and	  Liver	  	  
2.3.2.1 HPLC	  System	  The	   HPLC	   system	   consisted	   of	   a	   pump,	   an	   autosampler,	   a	   column	  compartment	  (UltiMate	  3000	  series;	  all	   from	  Dionex,	  UK),	  a	  Spherisorb	  ODS(2)	  3µm	  particle	  size	  HPLC	  column	  (SpheriClone	  0.46cm	  x	  13cm;	  Phenomenex,	  UK)	  and	   the	   INTRO	   electrochemical	   detector	   with	   a	   VT-­‐03	   flow	   cell	   potassium	  chloride	  reference	  electrode	  (Antec,	  UK).	  The	  electrode	  contained	  a	  50µm	  thick	  spacer	  (Aquilant	  Scientific	  (Presearch),	  UK).	  The	  mobile	  phase	  consisted	  of	  0.1M	  NaH2PO4	   buffer	   containing	   1mM	   EDTA	   disodium,	   0.01-­‐0.02%	   OSA	   and	   12%	  methanol	   at	   pH2.9-­‐3.2	   (pH	   adjusted	   with	   3.0M	   orthophosphoric	   acid),	   as	  appropriate	   (Table	   3).	   The	   mobile	   phase	   was	   filtered	   (polyamide	   membrane	  filters,	  0.2µm	  pore	  size;	  Sartorius,	  Germany)	  and	  degassed	  during	  HPLC	  analysis.	  Isocratic	  elution	  was	  performed	  with	  a	  ﬂow	  rate	  of	  0.8ml/min.	  The	  samples	  and	  standard	  solutions	  were	  maintained	  at	  9ºC	  in	  the	  autosampler.	  The	  column	  was	  maintained	   at	   30ºC	   in	   the	   column	   compartment.	   A	   potential	   of	   0.72V	   was	  maintained	  across	  the	  glassy	  carbon	  working	  electrode.	  A	  volume	  of	  10µl	  sample	  or	   standards	  was	   injected	   into	   the	   system.	  A	   range	  of	   sensitivity	   (2	  –	  50nA/V)	  was	  set	  to	  obtain	  optimum	  peak	  height	  as	  appropriate	  (Table	  3).	  The	  system	  was	  calibrated	   using	   a	   standard	   solution	   at	   a	   concentration	   of	   either	   200ng/mL,	  10µg/mL	   or	   5µM	   as	   appropriate	   (Table	   3).	   The	   samples	   and	   standards	   were	  analysed	  for	  15	  min	  each.	  A	   range	   of	   standards	   containing	   L-­‐DOPA	   and	   3-­‐OMD	   were	   prepared	   in	  homogenising	   acid	   (0.4M	   perchloric	   acid	   (PCA)	   containing	   0.01%	   sodium	  metabisulfite	   and	   1mM	   Na2-­‐EDTA.	   This	   homogenising	   acid	   is	   referred	   as	   PC	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solution),	  as	  appropriated	  (Table	  4).	  An	  internal	  standard	  (either	  AMD	  or	  DHBA)	  was	  also	  prepared	  separately.	  	  Peak	  height	  of	   the	  analytes	  and	   internal	  standards	  were	  measured	  using	  the	  Chromeleon	   6.8	   Chromatographic	   Data	   System	   (Dionex,	   UK).	   Sample	  concentrations	  were	  determined	  by	   the	  comparison	  of	  peak	  height	  ratio	   (PHR)	  between	  the	  internal	  standard	  peak	  and	  analytes	  using	  the	  following	  equation:	  	  𝐴𝑚𝑜𝑢𝑛𝑡  𝑖𝑛  𝑠𝑎𝑚𝑝𝑙𝑒   =    !"   !"#$%&  !!!"#$ !   !"! !  !"  (!"#$%"&'  !"#  !"  !"#)!"   !"#$%"&'  !"#  !"  !"#$%& !  !"  (!"#  !!!"#$) ,	  where	  PH	  =	  peak	  height	  and	  STD	  =	  standard.	  	  Calibration	  curves	  were	  calculated	  using	  PHR	  to	  the	  internal	  standard.	  	  
2.3.2.2 Determination	  of	  Plasma	  L-­‐DOPA	  Concentrations	  Blood	  plasma	  samples	  were	  analysed	  by	  HPLC	  with	  electrochemical	  detection	  (ED).	  The	   first	   set	  of	  plasma	  samples	  was	  analysed	  by	  ABS	  Laboratories,	  while	  the	  second	  set	  of	  plasma	  samples	  was	  analysed	  at	  King’s	  College	  London.	  In	  this	  section,	  the	  protocol	  for	  the	  outsourced	  samples	  is	  described.	  The	  protocol	  used	  at	  King’s	  College	  London	  is	  described	  in	  the	  following	  section.	  For	  each	  sample,	  20µl	  were	  injected	  by	  a	  cooled	  autosampler	  (Spark	  Holland	  Midas)	  into	  an	  electrochemical	  detector	  (ESA	  Coulochem	  III)	  coupled	  to	  a	  guard	  cell	   (ESA	   5020)	   and	   a	   glass-­‐carbon	   electrode	   analytical	   cell	   (ESA	   5011).	   For	  DOPA	   detection,	   a	   reverse-­‐phase	   C18	   column	   (3µm	   ReproSil-­‐pur,	   4.6mm	   Ø,	  150mm	  length,	  Chrompack)	  was	  used	  for	  compound	  separation.	  The	  mobile	  phase	  for	  DOPA	  detection	  contained	  100mM	  NaH2PO4	  adjusted	  to	  pH	  3.0	  with	  H3PO4,	  90µM	  Na2-­‐EDTA	  and	  2.8mM	  1-­‐octanesulfonic	  acid	   (OSA)	   in	  10%	  methanol.	  The	  mobile	  phases	  were	  delivered	  at	  a	  ﬂow	  rate	  of	  500µl/min.	  Peak	   identiﬁcation	   and	   quantiﬁcation	   were	   conducted	   using	   the	   Clarity	  Chromatographic	  software	  package	  (DataApex,	  Prague,	  Czech	  Republic).	  
2.3.2.3 Determination	  of	  L-­‐DOPA	  and	  3-­‐OMD	  Concentrations	  in	  the	  Liver	  A	  range	  of	  standards	  containing	  L-­‐DOPA	  and	  3-­‐OMD	  (25	  –	  1000ng/mL)	  were	  prepared	   in	   the	   0.4M	   PCA	   solution.	   AMD	   or	   DHBA	   was	   also	   added	   to	   the	  standards	  at	  a	  final	  concentration	  of	  200ng/mL	  or	  10µg/mL,	  respectively.	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In	   order	   to	   determine	   plasma	   and	  hepatic	   concentrations	   of	   L-­‐DOPA	   and	  3-­‐OMD,	   blood	   plasma	   and	   liver	   samples	   were	   thawed	   at	   4ºC	   on	   ice.	   The	   blood	  plasma	  samples	  were	  homogenised	  (9:1	  volume/volume	  ratio)	  in	  the	  0.4M	  PCA	  solution	   containing	   AMD	   as	   an	   internal	   standard	   at	   a	   final	   concentration	   of	  200ng/ml.	   PCA	   (70%;	   3:10	   volume/volume	   ration)	   was	   further	   added	   to	   the	  plasma	   samples	   to	   deproteinise.	   The	   liver	   samples	   were	   homogenised	   (1:8	  weight/volume	  ratio)	   in	   the	  0.4M	  PCA	  solution	  containing	  DHBA	  as	  an	   internal	  standard	   at	   a	   final	   concentration	   of	   10µg/ml.	   The	   liver	   samples	   were	   filtered	  using	  Vivaspin	  500	   tubes	   (10000	  MWCO;	  GE	  Healthcare,	  UK)	  by	   centrifuge,	  30	  min	  at	  4ºC	  at	  13000	  rpm.	  Both	  plasma	  and	  liver	  samples	  were	  sonicated	  using	  a	  Microson	  ultrasonic	  tissue	  disruptor	  to	  further	  progress	  acidification	  of	  proteins.	  The	   samples	   were	   then	   centrifuged	   at	   14000rpm	   for	   10	   min	   at	   4ºC	   and	   the	  supernatant	  was	   collected	   and	   analysed	   by	  HPLC-­‐ED	   as	   described	   above.	   Data	  were	  expressed	  as	  µg/mL/10µL	  sample.	  	  
2.3.2.4 Hepatic	  TH	  Activity	  Alumina	   was	   prepared	   before	   the	   start	   of	   the	   assays.	   Aluminum	   oxide	   was	  added	  to	  HCl	  (2N;	  1:5	  weight/volume	  ratio)	  and	  heated	  at	  90ºC	  for	  45	  min	  with	  continuous	  and	  rapid	  stirring.	  The	  supernatant	  was	  removed	  and	  the	  precipitate	  was	  washed	  twice	  with	  HCl	  (2N)	  at	  70ºC	  for	  10	  min	  and	  twice	  with	  HCl	  (2N)	  at	  50ºC	  for	  10	  min.	  Alumina	  was	  further	  washed	  with	  distilled	  water	  to	  increase	  its	  pH	  to	  3.4.	  Alumina	  was	  then	  dried	  in	  an	  oven	  at	  120ºC	  for	  1h	  and	  at	  200ºC	  for	  2h.	  The	  dried	  alumina	  was	  stored	  in	  an	  aluminum	  foil-­‐covered	  tube	  with	  desiccants	  until	  use.	  Mouse	   liver	   tissue	   was	   homogenised	   in	   0.32M	   sucrose	   (1:9	   weight/volume	  ratio)	  using	  the	  Microson	  ultrasonic	  tissue	  disruptor.	  This	  homogenate	  was	  used	  as	  a	  source	  for	  the	  enzyme.	  The	  reaction	  medium	  contained	  hepatic	  homogenate	  (equivalent	   to	   approximately	   3mg	   of	   tissue),	   6,7-­‐dimethyl-­‐5,6,7,8-­‐tetrahydropterine	   (DMPH4,	   enzymatic	   cofactor,	   final	   concentration	   1mM;	  dissolved	   in	   1M	   2-­‐mercaptoethanol),	   ferrous	   ammonium	   sulphate	   (final	  concentration	  1mM)	  and	  acetate	  buffer	  (final	  concentration	  100mM)	  (Table,	  see	  below).	   The	   reaction	   was	   initiated	   by	   the	   addition	   of	   2mM	   L-­‐tyrosine	   (final	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concentration	  of	  0.4mM),	   followed	  by	  30	  min	   incubation	  at	  37	  °C.	  The	  reaction	  was	   terminated	   by	   the	   addition	   of	   100µl	   0.4M	   PCA	   solution	   containing	   10µM	  AMD	   as	   an	   internal	   standard	   and	   the	   mixture	   was	   centrifuged	   for	   10	   min.	   L-­‐DOPA	   and	   AMD	  were	   extracted	   onto	   acid	  washed	   alumina	   (140–150mg)	   from	  150µl	  of	   the	  resultant	  supernatant.	  Tris	  buffer	  (pH8.6,	  1ml)	  was	  added	  and	  the	  mixture	   was	   vigorously	   shaken	   for	   10	   min	   at	   room	   temperature.	   The	  supernatant	  was	   aspirated	   and	   the	   alumina	   residue	  washed	   twice	  with	  water.	  After	   the	   second	   wash,	   200µl	   of	   0.4M	   PCA	   solution	   were	   added	   and	   shaken	  vigorously	  for	  10	  min	  to	  elute	  the	  L-­‐DOPA	  and	  AMD	  from	  the	  alumina.	  Following	  centrifugation	   at	   14000	   rpm	   for	   10	  min	   at	   4ºC,	   the	   resultant	   supernatant	  was	  used	   for	   HPLC–ECD	   analysis	   to	   determine	   the	   concentration	   of	   L-­‐DOPA.	   The	  assay	   was	   performed	   in	   triplicate.	   Non–enzymatic	   formation	   of	   L-­‐DOPA	   was	  determined	   by	   the	   addition	   of	   D-­‐tyrosine	   and	   3-­‐iodotyrosine	   (tyrosine	  hydroxylase	   inhibitor)	   instead	   of	   L-­‐tyrosine	   (a	   blank;	   Table	   4,	   see	   below).	   The	  concentration	  of	  L-­‐DOPA	  was	  calculated	  as	  described	  above.	  The	  concentration	  of	   L-­‐DOPA	   in	   the	   blank	   was	   subtracted	   from	   the	   sample.	   This	   difference	  corresponded	   to	   the	   final	   concentration	   of	   L-­‐DOPA	   in	   the	   samples.	   Data	   were	  expressed	  as	  L-­‐DOPA	  formed/30min/3mg	  tissue.	  The	  rates	  of	  alumina	  extraction	  for	  L-­‐DOPA	  and	  AMD	  were	  38%	  and	  40%,	  respectively.	  	  
	  
Table	  3:	  List	  of	  HPLC	  settings	  used	  in	  the	  mouse	  studies.	  	  
Experiment	   Determination	  of	  L-­‐DOPA	  and	  3-­‐
OMD	  Concentrations	  
TH	  Activity	  






















s	   Internal	  standard	  used	   AMD	  (200ng/mL)	   DHBA	  (10µg/mL)	   AMD	  (10µM)	  A	  range	  of	  standard	  concentrations	  used	  for	  calibrations	   25–1000ng/mL	   0.01–100µg/mL	   0.1-­‐50	  µM	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TH	  reactions	   Blank	  
30µ l	  tissue	  homogenate	   30µl	  tissue	  homogenate	  
10µ l	  DMPH4	  (10mM)	  in	  mercaptoethanol	   10µl	  DMPH4	  (10mM)	  in	  mercaptoethanol	  
20µ l	  distilled	  water	   20µl	  distilled	  water	  
10µ l	  Ferrous	  ammonium	  sulphate	  (10mM)	   10µl	  distilled	  water	  
10µ l	  Acetate	  buffer	  (1M)	   10µl	  Acetate	  buffer	  (1M)	  
20µ l	  L-­‐tyrosine	  (1M)	   20µl	  D-­‐tyrosine	  (2mM)/	  3-­‐iodotyroine	  (2mM)	  
	  
Table	  4:	  Reaction	  mixtures	  used	  in	  the	  hepatic	  TH	  activity	  assay.	  	  
2.3.3 Rat	  Experiments	  	  
2.3.3.1 Animal	  Selection	  Female	  Sprague-­‐Dawley	  or	  Hodded	  rats	  weighing	  225–250g	  were	  purchased	  from	  Charles	  River	   (Schweinfurt,	  Germany)	   and	  were	  housed	   in	   groups	  of	   2–3	  animals	  per	  cage	  with	  free	  access	  to	  food	  (except	  during	  the	  corridor	  tests)	  and	  water	  under	  a	  12h	  light/12h	  dark	  cycle.	  All	  experimental	  procedures	  performed	  in	   this	   study	   were	   approved	   by	   the	   Ethical	   Committee	   for	   use	   of	   Laboratory	  Animals	  in	  the	  Lund-­‐Malmö	  region.	  	  	  
2.3.3.2 Surgical	  Procedures	  All	   surgical	   procedures	   were	   conducted	   under	   anaesthesia	   induced	   by	   an	  intraperitoneal	   injection	   of	   a	   20:1	   mixture	   of	   Fentanyl	   and	   medetomidine	  (Dormitor;	   Apoteksbolaget,	   Sweden)	   in	   ~6ml/kg.	   The	   stereotactic	   injections	  were	   conducted	   with	   a	   Hamilton	   syringe	   with	   the	   animal	   mounted	   in	   a	  stereotactic	   frame	   (Stoelting,	   Wood	   Dale,	   US).	   The	   anteroposterior	   (AP)	   and	  mediolateral	   (ML)	   coordinates	   were	   calculated	   from	   bregma	   and	   the	  dorsoventral	  (DV)	  coordinates	  from	  the	  dural	  surface	  (Pinxos	  &	  Watson	  1986).	  	  
2.3.3.3 6-­‐OHDA	  Lesions	  The	  neurotoxin	  6-­‐OHDA	  (Sigma-­‐Aldrich	  AB,	  Stockholm,	  Sweden)	  was	  injected	  unilaterally	   into	   the	   left	   medial	   forebrain	   bundle	   to	   lesion	   the	   ascending	  dopamine	   (DA)	   projections	   (Ungerstedt	   &	   Arbuthnott	   1970).	   Fourteen	  microgram	  free	  base	  6-­‐OHDA	  was	  administered	  in	  ascorbate-­‐saline	  (0.02%)	  at	  a	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concentration	   of	   3.5μg/μl	   into	   one	   deposit	   along	   the	   fibre	   bundle	   to	   ensure	   a	  specific	   lesion	  of	   the	  dopamine	   fibres,	   sparing	   the	   serotonin	  projection	   system	  (Carta	  et	  al.	  2007).	  The	  injection	  was	  conducted	  at	  the	  following	  coordinate:	  AP:	  –4.4mm;	  ML:	  –1.2mm	  and	  DV:	  –7.8mm	  with	  the	  tooth	  bar	  set	  to	  -­‐2.4mm	  with	  a	  26-­‐gauge	  needle	   attached	   to	   the	  Hamilton	   syringe.	   The	   toxin	  was	   injected	   at	   a	  speed	  of	  1μl/	  min	  and	  the	  needle	  was	  kept	  in	  place	  for	  an	  additional	  3	  min	  before	  it	  was	  slowly	  retracted	  from	  the	  brain	  parenchyma.	  	  	  
2.3.3.4 AAV	  Vector	  Injections	  The	  animals	   treated	  with	  vectors	  received	   intrastriatal	   injections	  of	  5μl	  AAV	  vector	   in	   PBS.	   The	   injections	   were	   performed	   at	   two	   sites	   with	   two	   deposits	  each,	  1.5μl	  in	  the	  more	  ventral	  site	  and	  1μl	  in	  the	  more	  dorsal,	  delivered	  with	  a	  pulled	  glass	  capillary	  (outer	  diameter	  60–80μm)	  mounted	  on	  a	  22-­‐gauge	  needle	  attached	   to	   the	   Hamilton	   syringe.	   The	   injection	   coordinates	   were:	   (i)	   AP:	  +1.0mm;	  ML:	  –2.8mm,	  and	  DV:	  –4.5,	  –3.5mm	  and	  (ii)	  AP:	  0.0mm;	  ML:	  –4.0mm,	  and	  DV:	  –5.0,	  –4.0mm	  with	  the	  tooth	  bar	  set	  to	  –2.4mm.	  The	  injection	  rate	  was	  0.4μl/minute	  and	  the	  needle	  was	  kept	  in	  place	  for	  1	  min	  after	  the	  first	  and	  3	  min	  after	  the	  second	  deposit,	  before	  it	  was	  slowly	  retracted.	  	  	  
2.3.3.5 Behavioural	  Tests	  	  
	  2.3.3.5.1 Drug-­‐induced	  Rotation	  Drug-­‐induced	   rotation	   tests	   were	   performed	   by	   measuring	   full-­‐body	   turns	  with	   automated	   rotometer	   bowls	   (AccuScan	   Instruments,	   Columbus,	   US),	   after	  an	   injection	   of	   d-­‐amphetamine	   sulphate	   (2.5mg/kg,	   intraperitoneal;	  Apoteksbolaget,	   Sweden)	   and	   quantified	   continuously	   for	   90	   min.	   Rotational	  asymmetry	  scores	  are	  presented	  as	  net	   full	  body	  turns/minute.	  The	  drug-­‐naïve	  spontaneous	   rotation	   test	   was	   performed	   with	   the	   same	   setup	   with	   the	  exception	  of	  the	  drug	  challenge.	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2.3.3.5.2 Cylinder	  Test	  Cylinder	  test	  assessing	  exploratory	  forelimb	  use	  asymmetry	  was	  performed	  as	  described	  by	  Kirik	  et	   al.	   (Kirik	   et	   al.	   2001),	  with	  minor	  modifications.	  Each	   rat	  was	  placed	  in	  a	  20cm	  in	  diameter	  glass	  cylinder	  and	  exploratory	  behaviour	  was	  recorded	  with	   a	   digital	   video	   camera.	   Two	   perpendicular	  mirrors	  were	   placed	  behind	  the	  glass	  cylinder,	  which	  allowed	  the	  complete	  surface	  of	  the	  cylinder	  to	  be	   clearly	   visible	  on	   the	   recording.	  The	   animal	  was	   left	   in	   the	   cylinder	  until	   at	  least	   20	   forelimb	   touches	   on	   the	   cylinder	   wall	   were	   observed.	   Forelimb	  placement	   and	   use	   on	   the	   cylinder	   wall	   was	   scored	   post-­‐hoc	   with	   frame-­‐by-­‐frame	   analysis	   by	   an	   observer	   blinded	   to	   the	   group	   treatment.	   The	   paw	   used	  during	  each	  of	  the	  20	  contacts	  with	  the	  cylinder	  walls	  during	  rearing	  was	  scored	  and	  presented	  as	  right	   forepaw	  touches	  as	  a	  percentage	  of	   the	   total	  number	  of	  touches.	  	  	  2.3.3.5.3 Stepping	  Test	  The	  stepping	  test	  was	  initially	  described	  by	  Schallert	  et	  al.;	  its	  modified	  side-­‐stepping	  version	  was	  performed	  in	  the	  this	  study	  (Schallert	  et	  al.	  1979;	  Olsson	  et	  al.	   1995).	   Forelimb	   akinesia	   was	   assessed	   by	   an	   investigator	   blinded	   to	   the	  animal’s	  group	  identity	  by	  holding	  the	  rat	  with	  two	  hands	  only	  allowing	  one	  fore-­‐	  paw	   to	   reach	   the	   table	   surface.	   The	   animal	   was	   then	   moved	   sideways	   over	   a	  defined	  distance	  of	  90cm	  at	  a	  constant	  pace	  over	  4–5s.	  The	   investigator	  scored	  the	   numbers	   of	   adjusting	   side	   steps	   in	   both	   forehand	   and	   backhand	   direction	  twice,	   and	   the	   average	   was	   calculated.	   The	   animals	   were	   trained	   for	   6	   days	  during	   the	   seventh	   week	   post-­‐AAV	   injection	   and	   then	   scored	   by	   taking	   the	  average	   of	   their	   performance	   during	   days	   7–9,	   when	   the	   daily	   variability	   had	  minimised.	   For	   the	   12-­‐week	   post-­‐AAV	   injection	   time	   point,	   the	   animals	   only	  needed	   habituation	   for	   1	   or	   2	   days	   and	   were	   then	   scored	   during	   three	  consecutive	  days.	  	  	  2.3.3.5.4 Corridor	  test	  The	   corridor	   test	   was	   performed	   8	   and	   12	   weeks	   post-­‐AAV	   injections,	   as	  previously	   described,	   to	   study	   lateralised	   sensorimotor	   response	   selection	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(Dowd	  et	  al.	  2005).	  Briefly,	  the	  rats	  were	  placed	  in	  the	  end	  of	  a	  corridor	  (1,500	  ×	  70	  ×	  230mm)	  with	  10	  adjacent	  pairs	  of	   lids,	  evenly	  distributed	  along	   the	   floor.	  Each	  lid	  was	  filled	  with	  approximately	  five	  sugar	  pellets.	  Retrieval	  was	  defined	  as	  each	  time	  the	  rat	  poked	  its	  nose	  into	  a	  unique	  cup,	  regardless	  of	  whether	  it	  ate	  any	  pellets.	  Revisits	  without	  interleaving	  other	  retrievals	  were	  not	  scored.	  Each	  rat	   was	   tested	   until	   20	   retrievals	   were	   made	   or	   a	   maximum	   time	   of	   5	   min	  elapsed.	   The	   rats	   were	   food	   restricted	   prior	   and	   throughout	   testing	   and	  habituated	   for	   10	  min	   for	   2	   days	   in	   the	   corridor,	   with	   sugar	   pellets	   scattered	  along	   the	   floor.	   To	   reduce	   exploratory	   behaviour	   the	   rats	   were	   placed	   in	   an	  empty	   corridor	   before	   scoring.	   The	   rats	   were	   then	   scored	   for	   4	   days	   and	   the	  results	   were	   presented	   as	   an	   average	   of	   the	   last	   2	   days	   of	   the	   number	   of	  contralateral	  retrievals	  (right)	  as	  a	  percentage	  of	  total	  retrievals.	  	  	  
2.3.4 Non-­‐human	  Primate	  Experiments	  	  
2.3.4.1 Animal	  Selection	  Male	   F2	   captive	   bred	   Macaca	   mulatta	   or,	   whenever	   specified,	   Macaca	  
fascicularis,	   were	   purchased	   by	   Motac	   from	   the	   contracted	   provider	   (Xierxin	  Laboratory	  Co.	  Ltd.,	  Beijing,	  China).	  Animals	  underwent	  a	  period	  of	  quarantine	  (40	   days)	   according	   to	   the	   test	   facility	   vendor	  management	   program.	   Animals	  were	   inspected	  daily	   for	  signs	  of	   illness	  and	   further	  clinical	  examinations	  were	  performed	   if	  necessary.	  Two	  parasitological	   treatments	  were	  given	   for	   internal	  and	   external	   parasites	   over	   the	   quarantine	   period	   prior	   to	   delivery.	   Animals	  were	   identified	   by	   a	   neck	   collar.	   Cage	   labels	   indicated	   the	   individual	   animal	  identification	  numbers.	  	  
2.3.4.2 Housing	  and	  Acclimatisation	  Animals	  were	   housed	   in	   pairs	   in	   an	   air-­‐conditioned	   animal	   room	  with	   non-­‐recycled	  air	  that	  was	  changed	  at	  least	  eight	  times	  per	  hour.	  An	  artificial	  12	  hour	  (h)	   day/night	   cycle	   with	   lights	   on	   at	   8.00	   a.m.	   was	   provided.	   Animals	   were	  acclimatised	   for	   a	   minimum	   of	   21	   days	   in	   the	   facility	   where	   behavioural	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assessments	   were	   conducted.	   During	   this	   period,	   daily	   inspections	   for	   illness	  were	   carried	   out	   for	   each	   animal	   and	   further	   clinical	   examinations	   were	  performed	   if	   necessary.	   Animals	   were	   reported	   to	   be	   free	   of	   enterobacteria.	  Animals	  underwent	  a	  serological	  test	  for	  viral	  herpes	  B.	  However,	  they	  were	  not	  required	  to	  be	  negative	  to	  be	  included	  in	  the	  study.	  	  	  
2.3.4.3 Diet	  and	  Drinking	  Water	  Housing	   conditions:	   SAUE	   Ltd	   Old	  World	  Monkey	   pellets	   were	   available	   ad	  
libitum	  and	  were	  distributed	  in	  the	  morning	  and	  afternoon.	  The	  batch	  used	  was	  not	   quality	   controlled	   and	   no	   certificate	   of	   analysis	   is	   available.	   The	   diet	   was	  supplemented	  daily	  with	  fresh	  fruit	  and	  vegetables.	   If,	  at	  any	  point,	  an	  animal’s	  condition	  required	  supplemental	   feeding,	  nutritional	  milk	  (Heinz)	  was	  given	  by	  gavage	   (up	   to	   three	   times	   100	   ml	   per	   day).	   Drinking	   water	   was	   available	   ad	  
libitum.	  	  	  
2.3.4.4 Preparation	   of	   the	  MPTP-­‐lesioned	  Macaque	  Model	   of	   Parkinson’s	  
Disease	  Forty	  macaques	  were	  injected	  once	  daily	  with	  a	  low	  dose	  (0.2	  mg/kg,	   i.v.)	  of	  MPTP	  to	  induce	  parkinsonism	  (Bezard	  et	  al.	  2001).	  MPTP	  treatment	  was	  carried	  out	  until	  the	  animal	  reached	  a	  parkinsonian	  disability	  score	  of	  6	  on	  the	  validated	  parkinsonian	  macaque	  clinical	  rating	  scale	  (Benazzouz	  et	  al.	  1993).	  A	  score	  of	  6	  was	   chosen	   as	   this	   level	   of	   parkinsonism	   permitted	   forthcoming	   surgical	  procedures	   to	   commence	   under	   general	   anaesthesia,	   with	   a	   reduced	   risk	   in	  compromising	  animal	  recovery	  and	  post-­‐surgical	  health.	  The	  degree	  of	  parkinsonism	  was	  assessed	  daily	   from	  the	  beginning	  of	  MPTP	  administration	   using	   a	   parkinsonian	   macaque	   clinical	   rating	   scale,	   which	   has	  been	  validated	  for	  direct	  observational	  studies	  (Imbert	  et	  al.	  2000).	  	  
	  
2.3.4.5 Tailoring	  of	  L-­‐DOPA	  Dose	  Following	   stabilisation	   of	   parkinsonian	   motor	   symptoms,	   animals	   were	  primed	  with	  L-­‐DOPA	  over	  2	  weeks.	  Each	  animal	  was	  treated	  twice	  daily,	  with	  a	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tailored	   dose	   of	   Madopar	   (L-­‐DOPA/benserazide,	   ratio	   4:1,	   p.o.)	   based	   on	   the	  animal’s	   weight.	   This	   dose	   was	   selected	   to	   maximally	   reverse	   parkinsonian	  motor	  symptoms	  and	  cause	  hyperactivity	  in	  animals,	  which	  has	  been	  associated	  with	  the	  development	  of	  dyskinesia.	  L-­‐DOPA	  was	  administered	  until	  dyskinesia	  stabilised.	  After	  this	  L-­‐DOPA	  priming	  treatment	  regimen,	  the	  so	  called	  ‘treatment	  dose’	   (treatment	  dose	  =	  100%;	  priming	  dose	  =	  133%	  of	   ‘treatment	  dose’)	  was	  defined	   as	   the	   lowest	   dose	   that	   produced	   complete	   reversal	   of	   parkinsonian	  motor	  symptoms.	  
	  
2.3.4.6 Pre-­‐operative	  Procedures	  On	  the	  day	  prior	  to	  surgery,	  each	  animal	  was	  given	  duphamox	  (15mg/kg;	  s.c.)	  for	  infection	  prophylaxis.	  	  On	  the	  day	  of	  surgery,	  each	  animal	  was	  given	  atropine	  SO4	  (0.04mg/kg;	  i.m.)	  before	   surgery.	   The	   non-­‐steroid	   anti-­‐inflammatory	   drug	   ketophen	   was	   also	  administered	   (2mg/kg;	   s.c.).	   There	   was	   a	   minimum	   of	   10	   min	   before	   animals	  received	  general	  anaesthesia	  (ketamine	  HCl;	  10mg/kg,	   i.m.)	  following	  ketophen	  administration.	  	  Xylocaine	   cream	   was	   applied	   topically	   as	   a	   local	   anaesthetic	   lubricant.	   The	  animal	  was	   then	   intubated	   and	  maintained	   under	   anaesthesia	  with	   isoflurane,	  which	  was	  delivered	  through	  a	  volume-­‐regulated	  respirator.	  The	  heart	  rate	  and	  oxygen	   saturation	   of	   the	   animal	   was	   monitored	   and	   recorded	   within	   30	   min	  intervals	   throughout	   the	   surgical	  procedure.	  Animals	  were	  placed	  on	  a	  heating	  pad	  during	  surgery.	  The	  core	  body	  temperature	  of	  the	  animal	  was	  also	  measured	  within	  30	  min	   intervals	   throughout	   the	  surgical	  procedure,	  with	  a	   temperature	  probe	  placed	  in	  the	  rectum.	  A	  second	  heat	  pad	  was	  used	  to	  maintain	  core	  body	  temperature	  when	  required.	  Other	   drugs	   for	   appropriate	   anaesthetic	   and	   clinical	   management	   of	   the	  animal	  were	  used	   if	  required.	  Each	  drug,	  dose,	  route	  and	  site	  of	  administration	  was	   documented	   in	   the	   surgical	   records.	   All	   vital	   signs	   recorded	   were	  documented	  in	  the	  surgical	  records.	  During	   surgery,	   ophthalmic	   ointment	   was	   applied	   to	   each	   eye	   (Liposic	  ophthalmic	   gel).	   The	   hair	   was	   clipped	   from	   the	   cranium	   and	   cranio-­‐dorsal	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portion	  of	  the	  neck	  and	  sides.	  Each	  animal	  was	  then	  positioned	  in	  a	  stereotactic	  apparatus.	  The	   surgical	   site	  was	  made	   aseptic	   by	   cleaning	  with	  70%	   isopropyl	  alcohol	   scrub.	   A	   drape	   was	   placed	   on	   each	   animal	   to	   maintain	   strict	   aseptic	  surgery.	  	  
2.3.4.7 AAV	  Vector	  Injections	  For	  the	  location	  of	  injection	  sites,	  intracerebral	  sites	  were	  identified	  for	  each	  individual	  macaque	  by	  using	  the	  standard	  Horsley	  Clarke	  stereotaxic	  technique.	  Sagittal	  and	  frontal	  ventriculography	  was	  used	  to	  locate	  the	  borders	  of	  the	  third	  ventricles,	   and	   also	   the	   edges	   of	   the	   anterior	   and	   posterior	   commissures	   to	  improve	  the	  accuracy	  of	  site	  location.	  	  Firstly,	   a	   hole	  was	   drilled	   (Dremel)	   into	   the	   skull	   of	   each	  macaque	  without	  damaging	   the	   dura	   matter.	   A	   ventriculographic	   cannula	   mounted	   on	   a	   glass	  syringe	  was	  then	  placed	  into	  the	  anterior	  horn	  of	  the	  lateral	  ventricle,	   followed	  by	   injection	   of	   contrast	  medium	   (Omnipaque,	   Nycomed,	   Norway).	   The	   precise	  neuroanatomical	   location	   of	   the	   ventricles	   was	   identified	   with	   referral	   to	   a	  stereotaxic	   atlas	   (François	   et	   al.	   1996).	   Coordinates	  were	   then	   adjusted	  before	  further	   insertions	   into	   the	   skull.	   Ventriculography	   was	   used	   to	   locate	   the	  anterior	   commissure.	   The	   defined	   position	   of	   anterior	   commissure	   was	   then	  combined	   with	   a	   stereotaxic	   population-­‐based	   historical	   atlas	   of	   the	   basal	  ganglia	  to	  locate	  the	  position	  of	  the	  left	  and	  right	  putamen.	  An	  infusion	  cannula	  for	  delivery	  of	  the	  test	  item	  was	  then	  placed	  into	  position	  as	  described	  below.	  The	  drilled	  area	  was	  cleaned	  with	  sterile	  saline.	  Stereotactic	  injections	  of	  the	  test	   item	   were	   made	   into	   the	   striatum	   (putamen).	   Theoretical	   targets	   were	  defined	   based	   upon	   the	   atlas	   of	   François	   and	   Percheron	   but	   were	   also	  determined	   practically	   in	   individual	   animals,	   based	   on	   the	   findings	   from	  stereotactic	  ventriculography.	  The	  delivery	  of	  the	  test	  item	  was	  made	  along	  three	  tracks	  in	  each	  hemisphere,	  with	  two	  to	  four	  deposits	  per	  track.	  Deposit	  coordinates	  had	  been	  validated	  from	  a	  previous	  pilot	  study	  using	  an	  inactive	  AAV2/5	  GFP	  vector.	  	  	  
	   101	  
Track	   Anteroposterior	  




(relative	  to	  AC-­‐PC	  line)	  
1	   AC+1	  mm	   14	  mm	   0	  mm	   +3mm	  
2	   AC-­‐1	  mm	   14	  mm	   0	  mm	   +3mm	  
3	   AC-­‐4	  mm	   15	  mm	   0	  mm	   +3mm	  	  
Table	   5:	   Theoretical	   deposit	   coordinates	   for	   the	   stereotactic	   injection	   of	   the	   AAV2/5	  
vectors	  in	  the	  putamen	  of	  MPTP-­‐lesioned	  NHP.	  
Theoretical	   targets	   were	   defined	   based	   upon	   the	   atlas	   of	   François	   and	   Percheron	   and	  
determined	   practically	   in	   individual	   animals.	   AC:	   anterior	   commissure;	   PC:	   posterior	  
commissure.	  	  The	  infusions	  were	  made	  at	  a	  rate	  of	  2µl/min	  with	  a	  Hamilton	  syringe	  (needle	  gauge	  28).	  Following	  completion	  of	  all	  stereotactic	  injections,	  skin	  wounds	  were	  closed	   in	   layers	   with	   a	   continuous	   suture	   using	   absorbable	   suturing	   material.	  Animals	  were	  then	  monitored	  until	  recovery	  from	  general	  anaesthesia.	  	  	  
2.3.4.8 Post-­‐operative	  Care	  Each	  animal	  was	  extubated	  and	  then	  closely	  monitored	  during	  post-­‐operative	  care.	   Animals	   were	   kept	   warm	   until	   swallowing	   and	   righting	   reflexes	   were	  regained.	   Care	   was	   provided	   for	   the	   animals	   by	   experienced	   technicians	   and	  veterinary	  support	  was	  available	  at	  any	  time.	  	  	  
2.3.4.9 Post-­‐operative	  Therapy	  One	   day	   post-­‐surgery,	   animals	   were	   given	   duphamox	   (15mg/kg;	   s.c.)	   for	  infection	  prophylaxis.	  Analgesia	  (ketophen,	  2mg/kg;	  s.c.)	  was	  administered	  over	  the	   first	   three	   days	   post-­‐surgery.	   If	   required,	   a	   stronger	   analgesic	   drug	   was	  provided	   following	   veterinary	   advice	   and	   documented	   in	   the	   surgical	   record	  sheets.	  Other	  drugs	  were	  administered	  for	  clinical	  management	  if	  required.	  Each	  drug,	   dose,	   route	   and	   site	   of	   administration	   was	   documented	   in	   the	   surgical	  records.	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2.3.4.10 Behavioural	  tests	  2.3.4.10.1 Locomotor	  activity	  	  A	   quantitative	   assessment	   of	   the	   amount	   of	  movement	   for	   each	   animal	  was	  obtained	  in	  5	  min	  time	  bins	  for	  the	  duration	  of	  the	  experiment.	  Recordings	  were	  made	  using	  computer-­‐based	  activity	  monitors.	  	  	  2.3.4.10.2 	  Parkinsonian	  disability	  Parkinsonian	  disability	  was	  assessed	  using	  non-­‐parametric	  measurements	  of	  video	  recorded	  behaviour.	  Behaviour	  subtypes	  and	  rating	  scales	  were	  as	  follows:	  a) Motor	  (range	  of	  movement):	  0	  =	  no	  movement	  	  1	  =	  movement	  of	  head	  only	  2	  =	  movement	  of	  head,	  limbs	  and/or	  trunk,	  without	  locomotion,	  for	  >30%	  of	  the	  observation	  period	  3	  =	  walking	  on	  the	  floor	  and/or	  climbing	  on	  the	  walls	  of	  the	  cage	  for	  <30%	  of	  the	  observation	  period	  4	  =	  walking	  on	  the	  floor	  and	  /or	  climbing	  on	  the	  walls	  of	  the	  cage	  for	  >30%	  of	  the	  observation	  period	  The	   score	   given	   was	   the	   maximum	   achieved	   in	   each	   10	   min	  observation	  period.	  	  b) Bradykinesia:	  0	  =	  initiation	  of	  movement	  and	  normal	  speed	  of	  movement	  1	  =	  mild,	  slowing	  of	  movement	  2	   =	   moderate	   slowing,	   difficulty	   initiating	   and	   maintaining	  movement,	  marked	  freezing	  3	  =	  akinetic,	  unable	  to	  move,	  with	  prolonged	  freezing	  episodes	  The	   score	   given	   was	   representative	   of	   behaviour	   over	   the	  observation	  period.	  	  c) Postural	  abnormality:	  	  0	  =	  normal,	  upright,	  holds	  head	  up,	  normal	  balance	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1	  =	  hunched	  body,	  holds	  head	  up	  2	  =	  hunched	  body	  and	  neck,	  face	  down,	  may	  lose	  balance.	  	  The	   score	   given	   was	   representative	   of	   behaviour	   over	   the	  observation	  period.	  	  d) Tremor:	  0	  =	  absent	  1	  =	  present	  	  The	   score	   given	   was	   representative	   of	   behaviour	   over	   the	  observation	  period.	  	  	  e) Parkinsonian	  disability:	  (4	  -­‐	  Range	  of	  movement)	  +	  bradykinesia	  +	  postural	  abnormality	  +	  tremor.	   This	   score	   was	   a	   maximum	   global	   parkinsonian	   disability	  score	  out	  of	  10.	  	  2.3.4.10.3 Dyskinesia	  Non-­‐parametric	   measurements	   of	   video	   recorded	   behaviour.	   Behaviour	  subtypes	  and	  rating	  scales	  were	  as	  follows:	  a) Chorea:	  0	  =	  Absent	  1	  =	  Mild,	  fleeting,	  present	  <30%	  of	  the	  observation	  period	  2	  =	  Moderate,	  not	  interfering	  with	  normal	  activity,	  present	  >30%	  of	  the	  observation	  period	  3	  =	  Marked,	  at	  times	  interfering	  with	  normal	  activity;	  present	  <70%	  of	  the	  observation	  period	  4	  =	  Severe,	  continuous,	  replacing	  normal	  activity,	  present	  >70%	  of	  the	  observation	  period.	  	  
b) Dystonia:	  0	  =	  Absent	  1	  =	  Mild,	  fleeting,	  present	  <30%	  of	  the	  observation	  period	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2	  =	  Moderate,	  not	  interfering	  with	  normal	  activity,	  present	  >30%	  of	  the	  observation	  period	  3	  =	  Marked,	  at	  times	  interfering	  with	  normal	  activity,	  present	  <70%	  of	  the	  observation	  period	  4	  =	  Severe,	  continuous,	  replacing	  normal	  activity,	  present	  >70%	  of	  the	  observation	  period.	  	  Following	  L-­‐DOPA	  treatment	  with	  priming	  or	  treatment	  doses,	  behaviour	  was	  assessed	  for	  4h	  post	  administration.	  In	  the	  OFF	  state,	  behaviour	  was	  assessed	  for	  1h.	   For	   assessment	   of	   locomotor	   activity,	   scores	   were	   recorded	   in	   5	   min	  intervals.	   For	   assessment	   of	   parkinsonian	   disability	   and	   dyskinesia,	   video-­‐recorded	  behaviour	  was	  scored	  over	  10	  min	  intervals	  by	  an	  observer	  blinded	  to	  treatment.	  
2.3.4.11 Analysis	  of	  Data	  All	   statistical	   analyses	  were	   carried	  out	  using	  Graphpad	  Prism	   (versions	  5.0	  and	   later	   version	   5.04c).	   The	   data	   were	   analysed	   with	   the	   non-­‐parametric	  equivalent	  of	   the	   t-­‐test	  Wilcoxon	  matched	  pairs	   test,	  Mann-­‐Whitney	   test	  or	   the	  non-­‐parametric	  equivalent	  of	  the	  one-­‐way	  ANOVA	  Kruskal-­‐Wallis	  or	  Friedman’s	  test,	  followed	  by	  Dunn’s	  multiple	  comparisons.	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Chapter	  3 AAV-­‐mediated	   Continuous	   L-­‐DOPA	   Synthesis	   in	   the	  
Periphery	  	  
3.1 Introduction	  The	   study	   described	   in	   this	   chapter	   is	   aimed	   to	   test	   a	   proof-­‐of-­‐principle	  therapeutic	   strategy	   to	   improve	   treatment	   of	   PD.	   It	   proposes	   a	   combination	  therapy	  of	  oral	  L-­‐DOPA	  and	  a	  one-­‐time	  intravenous	  AAV	  injection	  to	  deliver	  TH	  and	  GCH1	  to	  the	  liver	  in	  order	  to	  achieve	  a	  continuous	  and	  basal	  hepatic	  L-­‐DOPA	  synthesis,	   thereby	   potentially	   diminishing	   the	   fluctuations	   inherent	   to	   oral	  treatment	   alone	   and	   improving	   management	   of	   L-­‐DOPA	   induced	   side	   effects	  (Figure	  11).	  The	  question	  being	   tested	  here	   is	  whether	  elevated	  L-­‐DOPA	   levels	  can	  be	  detected	  in	  the	  periphery	  of	  healty	  mice	  upon	  AAV-­‐mediated	  delivery	  of	  the	  GCH1	  and	  TH	  genes	  to	  the	  liver.	  Since	   the	   discovery	   of	   dopamine	   as	   a	   neurotransmitter	   and	   its	   role	   in	   PD,	  restoration	   of	   the	   dopaminergic	   tone	   in	   the	   brain	   has	   been	   the	   focus	   of	  pharmacological	   therapies	   for	   PD.	   The	   oral	   administration	   of	   L-­‐DOPA	   together	  with	  an	  aromatic	  amino	  acid	  decarboxylase	  (AADC)	  inhibitor	  is	  one	  of	  the	  most	  effective	  therapies	  and	  is	  currently	  the	  gold	  standard	  treatment	  for	  the	  disease.	  During	   the	   early	   years	   of	   PD,	  when	  motor	   complications	   are	   the	   predominant	  symptoms,	   L-­‐DOPA	   oral	   treatment	   provides	   enormous	   symptomatic	   relief	   and	  substantially	   improves	   life	   quality	   of	   patients	   (Kordower	   &	   Goetz	   1999).	  However,	  over	  80%	  of	  the	  patients	  develop	  side	  effects	  to	  L-­‐DOPA	  treatment	  5-­‐10	   years	   after	   initiation	   of	   the	   therapy.	   L-­‐DOPA	   induced	   side	   effects	   can	   be	  disabling	   and	   include	   dyskinesias	   and	   motor	   fluctuations	   such	   as	   freezing	  episodes.	  Once	  established,	  dyskinesia	   tends	   to	   remain	  persistent	  and	  with	   the	  progression	   of	   the	   disease	   it	   becomes	   increasingly	  more	   difficult	   to	   deliver	   L-­‐DOPA	   doses	   that	   control	   the	   parkinsonian	   features	   without	   triggering	   side	  effects.	   It	   is	   thought	   that	   L-­‐DOPA	   induced	   dyskinesia	   (LID)	   develops	   as	   a	  consequence	   of	   the	   pulsatile	   stimulation	   of	   dopamine	   receptors	   by	   oral	  administration	   of	   L-­‐DOPA.	   As	   a	   corollary,	   stabilising	   L-­‐DOPA	   plasma	   levels	   by	  continuous	  duodenal	   infusion	  has	  been	  shown	   to	  delay	   the	  onset	  and	  diminish	  the	   severity	   of	   LID.	   The	   efficacy	   of	   continuous	   duodenal	   L-­‐DOPA	   infusion	   has	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been	   demonstrated	   in	   a	   12-­‐week	   Phase	   III	   double	   blind	   and	   a	   52-­‐week	   open-­‐label	  trial.	  The	  results	  showed	  improvement	  in	  the	  ON-­‐time	  without	  troublesome	  dyskinesia	  and	   reduced	  OFF-­‐time.	  However,	   the	  need	   for	  an	   invasive	   intestinal	  surgical	   procedure	   and	   permanent	   tube	   maintenance	   poses	   limits	   to	   a	   wider	  application	   of	   this	   therapy.	   Furthermore,	   those	   eligible	   for	   duodenal	   L-­‐DOPA	  infusion	   experience	   adverse	   effects	   related	   to	   the	   implanted	   device	   such	   as	  intestinal	   tube	   dislocation,	   intestinal	   tube	   occlusion,	   pump	   malfunction	   and	  stoma	   leakage	   in	   89%	   of	   the	   cases	   (Olanow	   et	   al.	   2000;	   Nyholm	   et	   al.	   2005;	  Seeberger	  &	  Hauser	  2015).	  	  
	  
Figure	  11:	  Rationale	  for	  continuous	  systemic	  L-­‐DOPA	  delivery.	  
Providing	  a	  continuous	  basal	  supply	  of	  systemic	  L-­‐DOPA	  has	  the	  potential	  to	  increase	  the	  
efficacy	   of	   the	   standard	   oral	   medication	   treatment	   by	   facilitating	   the	   management	   of	  
parkinsonian	  features	  without	  transcending	  the	  therapeutic	  window.	  	  The	  liver	  is	  a	  suitable	  candidate	  organ	  for	  this	  gene	  therapy	  strategy	  because	  it	   provides	   the	   amino	   acid	   tyrosine,	   which	   is	   produced	   by	   the	   enzyme	  phenylalanine	  hydroxylase	  (PAH)	  and	   is	   the	  substrate	   for	  L-­‐DOPA	  synthesis,	  as	  well	   as	   BH4,	   the	   cofactor	   required	   by	   PAH	   and	   TH	   for	   their	   catalytic	   activity	  (Figure	  12).	  GCH1	  codes	  for	  the	  rate-­‐limiting	  enzyme	  in	  the	  biosynthesis	  of	  BH4	  and	  its	  expression	  together	  with	  TH	  was	  shown	  to	  be	  sufficient	  and	  necessary	  for	  L-­‐DOPA	   synthesis	   in	   vivo	   (Mandel	   et	   al.	   1998).	   Although	   the	   liver	   synthesises	  BH4,	   GCH1	   was	   delivered	   through	   the	   vector	   to	   ensure	   robust	   TH	   activity	  without	  the	  risk	  of	  depleting	  it	  from	  the	  liver.	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Figure	  12:	  Therapeutic	  strategy	  for	  AAV-­‐mediated	  L-­‐DOPA	  synthesis	  in	  the	  liver.	  
This	  strategy	  can	  benefit	  from	  the	  presence	  of	  endogenous	  hepatic	  tyrosine	  and	  BH4.	  AAV-­‐
mediated	   gene	   addition	   of	  TH	   and	  GCH1	   will	   lead	   to	   hepatic	   synthesis	   of	   L-­‐DOPA.	   PAH:	  
phenylalanine	   hydroxylase;	   BH4:	   tetrahydrobiopterin;	   TH:	   tyrosine	   hydroxylase;	   GCH1:	  
GTP-­‐Cyclohydrolase-­‐1.	  	  The	   proposed	   gene	   therapy	  was	   tested	   following	   two	   different	   approaches.	  The	  first	  one	  attempted	  to	  achieve	  co-­‐linear	  expression	  of	  the	  L-­‐DOPA-­‐synthetic	  enzymes	   GCH1	   and	   TH	   from	   two	   separate	   vectors.	   In	   the	   second	   approach,	  expression	  of	  TH	  and	  GCH1	  was	  achieved	   from	  a	  single	  AAV	  vector	   in	  order	   to	  guarantee	  equal	  transduction	  efficiencies	  of	  both	  genes	  in	  the	  liver.	  	  
3.2 Results	  	  
3.2.1 Generation	  and	  Titration	  of	  the	  Monocistronic	  Liver	  Vectors	  In	   the	   first	   approach	   double-­‐stranded	   AAV	   (dsAAV)	   was	   used	   to	   take	  advantage	   of	   its	   rapid	   onset	   of	   transgene	   expression	   (Wang	   et	   al.	   2003).	   The	  double-­‐stranded	   monocistronic	   vectors	   were	   designed	   to	   express	   the	   rate-­‐limiting	   enzymes	   in	   L-­‐DOPA	   synthesis,	   TH	   and	   GCH1,	   from	   separate	   vectors.	  Transgene	   expression	   in	   each	   vector	   was	   controlled	   by	   the	   liver-­‐specific	   LP1	  promoter,	  which	  was	   constructed	  by	   joining	   core	   liver-­‐specific	   elements	  of	   the	  human	   apolipoprotein	   hepatic	   control	   region	   (HCR),	   the	   human	   alpha-­‐1-­‐antitrypsin	   (hAAT)	  gene	  promoter	  and	  a	  modified	  SV40	  small	  T	  antigen	   intron	  (Nathwani	   et	   al.	   2006).	   This	   synthetic	   promoter	   has	   been	   shown	   to	   achieve	  strong	   liver-­‐specific	   transgene	  expression	   in	  animal	  models	  and	  has	  been	  used	  successfully	   in	   clinical	   trials	   using	   AAV	   for	   the	   treatment	   of	   haemophilia	   B	  (Nathwani	  et	  al.	  2012).	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The	  monocistronic	  TH	  vector	  expresses	  a	   truncated	  TH	   lacking	   the	   first	  155	  N-­‐terminal	   amino	   acids.	   This	   truncation	   eliminates	   the	   regulatory	   domain	  thereby	   rendering	   the	   enzyme	   constitutively	   active	   and	   allowing	   L-­‐DOPA	  synthesis	  to	  reach	  maximum	  levels	  in	  vivo	  (Daubner	  et	  al.	  2011).	  Downstream	  of	  the	   TH	   coding	   sequence,	   the	   woodchuck	   hepatitis	   virus	   post-­‐transcriptional	  regulatory	  element	  (WPRE)	  was	  introduced,	  a	  cis-­‐acting	  sequence	  that	  functions	  by	   enhancing	   mRNA	   trafficking	   to	   the	   ribosome	   thereby	   increasing	   its	  translation	   (Zanta-­‐Boussif	   et	   al.	   2009).	   Enhanced	   expression	   of	   TH	   had	   been	  shown	   to	   be	   important	   for	   the	   achievement	   of	   the	   optimal	   5:1	   stoichiometric	  ratio	   of	   TH:GCH1	   (Björklund	   et	   al.	   2009).	   The	   monocistronic	   GCH1	   vector	  contains	  the	  GCH1	  gene	  under	  the	  control	  of	  the	  liver-­‐specific	  promoter	  LP1.	  A	   schematic	   representation	   of	   both	  monocistronic	   liver	   vectors	   is	   shown	   in	  Figure	  13.	  	  	  
	  
Figure	  13:	  Schematic	  of	  monocistronic	  liver	  vectors.	  
The	  monocistronic	   liver	   vectors	   harbour	   the	  GCH1	   gene	   (A)	   and	   the	   truncated	  TH	   gene	  
(tTH)	   (B)	  under	   the	   control	  of	   the	   liver-­‐specific	  LP1	  promoter.	  The	  WPRE	  sequence	  was	  
introduced	  downstream	  of	  the	  TH	  coding	  sequence	  to	  enhance	  its	  expression.	  The	  shaded	  
area	  in	  the	  TH	  gene	  indicates	  the	  truncated	  region	  (t).	  	  Once	   the	   construction	   of	   each	   vector	   was	   finalised,	   they	   were	   verified	   by	  sequencing	   and	   the	   integrity	   of	   the	   ITRs	   was	   confirmed	   by	   restriction	  endonuclease	  analysis.	  The	  AAV	  ITRs	  are	  the	  viral	  cis-­‐elements	  required	  for	  viral	  replication	   and	   their	   integrity	   is	   therefore	   extremely	   important	   for	   the	  production	  of	  rAAV.	  However,	  due	  to	  their	  palindromic	  nature,	  the	  AAV	  ITRs	  are	  very	   recombinogenic.	   Because	   each	   ITR	   contains	   two	   SmaI	   endonuclease	   sites,	  digestion	  of	  an	  ITR-­‐containing	  plasmid	  with	  this	  enzyme	  is	  suitable	  to	  assess	  ITR	  integrity.	   ITR	   recombination	   leads	   to	   a	   partial	   deletion	   of	   one	   ITR	   with	   the	  consequent	   elimination	   of	   two	   SmaI	   sites	   from	   the	   AAV	   plasmid;	   this	   can	   be	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easily	   diagnosed	   by	   endonuclease	   digestion	   followed	   agarose	   gel	  electrophoresis.	  Production	  of	   the	  recombinant	  vectors	  AAV2/8-­‐LP1-­‐GCH1	  and	  AAV2/8-­‐LP1-­‐tTH-­‐WPRE	  was	  done	  by	   triple	   transfection	  of	  HEK293T	  cells;	   the	  vectors	  were	  purified	   by	   FPLC	   using	   an	  AVB	   sepharose	   affinity	   column	   (Grieger	  &	   Samulski	  2012).	  The	  annotation	  AAV2/8	  indicates	  that	  the	  transgene	  cassette	  was	  flanked	  by	  AAV2	  ITRs	  and	  packaged	  into	  an	  AAV8	  capsid.	  Serotype	  8	  was	  chosen	  for	  this	  study	   due	   to	   its	   strong	   tropism	   for	   the	  mouse	   liver	   (Nakai	   et	   al.	   2005).	   Since	  AAV8	   is	   also	   able	   to	   efficiently	   transduce	  muscle	   tissue,	   the	   liver-­‐specific	   LP1	  promoter	  was	  used	  in	  the	  vector	  to	  ensure	  liver-­‐specific	  transduction	  (Nathwani	  et	  al.	  2006).	  Titration	  of	  the	  AAV	  vectors	  was	  done	  by	  total	  particle	  and	  genome	  containing	  particles	  (gcp)	  quantification.	  The	  particle	  titration	  combined	  with	  real	  time	  PCR	  and/or	  alkaline	  agarose	  gel	  electrophoresis	  for	  genome	  titration	  provides	  a	  good	  estimate	  of	  vector	  production	  and	  packaging	  efficiency.	  The	  particle	  titre	  of	  both	  vectors	  was	  determined	  by	  SDS-­‐PAGE	  quantification	  of	   the	  AAV	  capsid	  protein	  VP3	  relative	  to	  a	  BSA	  standard	  curve	  (Kohlbrenner	  et	  al.	  2012)	  (Figure	  14);	  the	  genome	  titre	  was	  determined	  by	  the	  adapted	  real-­‐time	  quantitative	  PCR	  method	  for	  genome	  quantification	  of	  double-­‐stranded	  AAV	  vectors	  (Fagone	  et	  al.	  2011).	  SDS-­‐PAGE	   for	   the	   particle	   titration	   demonstrated	   that	   the	   purification	   of	   both	  dsAAV	   vectors	   led	   to	   high-­‐purity	   preparations,	   with	   only	   AAV	   capsid	   proteins	  VP1,	  VP2	  and	  VP3	  being	  detected.	  	  	  
	  
Figure	  14:	  SDS-­‐PAGE	  capsid	  titration	  of	  monocistronic	  liver	  vectors.	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Viral	   proteins	   VP1,	   VP2,	   VP3	   (top	   to	   bottom)	   were	   the	   absolute	   majority	   of	   proteins	  
detected	  on	  the	  gel,	  indicating	  the	  purity	  of	  the	  preparation.	  Particle	  titres	  calculated	  from	  
this	  gel	  are	  shown	  in	  Table	  6.	  	  Total	  particle	  titres	  were	  8.25x1012	  and	  1.84x1013	  particles/ml,	  while	  genome	  titres	   were	   4.88x1012	   and	   3.97x1011	   gcp/ml	   for	   GCH1	   and	   TH	   vectors,	  respectively.	   In	   an	   efficient	   rAAV	   preparation,	   the	   ratio	   between	   particle	   and	  genome	  titres	  does	  not	  exceed	  10.	  While	  the	  particle:genome	  ratio	  for	  the	  GCH1	  vector	   was	   around	   2,	   the	   ratio	   for	   the	   TH	   vector	   was	   approximately	   46,	  indicating	   that	  packaging	  of	   the	   latter	  was	  very	   inefficient	   (Table	  6).	  This	   issue	  most	  likely	  arose	  as	  a	  result	  of	  its	  oversized	  2.6kb	  genome,	  which	  exceeded	  the	  optimal	  packaging	  capacity	  of	  dsAAV	  by	  0.25kb.	  The	  optimal	  packaging	  size	  for	  dsAAV	  is	  2.35kb	  –	  half	  of	  that	  of	  the	  single-­‐stranded	  4.7kb	  wild-­‐type	  genome.	  	  






LP1-­‐GCH1	   4.88	  x	  1012	   8.25	  x	  1012	   1.7	  
LP1-­‐tTH	   3.97	  x	  1011	   1.84	  x	  1013	   46.3	  	  
Table	  6:	  Genome	  and	  particle	  titres	  of	  monocistronic	  liver	  vectors.	  
Titres	  were	  determined	  by	  real	  time	  PCR	  and	  SDS-­‐PAGE.	  Packaging	  efficiency	  is	  indicated	  
in	   the	   last	   column.	   A	   particle:genome	   ratio	   >10	   is	   indicative	   of	   inefficient	   genome	  
packaging.	  
	  
3.2.2 In	  vivo	  Efficacy	  of	  the	  Monocistronic	  Liver	  Vectors	  To	   evaluate	   the	   in	   vivo	   efficacy	   of	   both	  monocistronic	   liver	   vectors,	   a	   study	  was	  designed	  with	   the	  aim	  to	  assess	   their	   transduction	  efficiency	   in	   the	  mouse	  liver	  and	  to	  evaluate	  their	  ability	  to	  raise	  systemic	  levels	  of	  L-­‐DOPA	  after	  a	  single	  systemic	   injection.	   Two	   different	   vector	   treated	   groups	   (TH	   vector	   +/-­‐	   GCH1	  vector)	   were	   used	   to	   investigate	   whether	   ectopic	   expression	   of	   both	   genes	   is	  necessary	  to	  support	  L-­‐DOPA	  synthesis	  in	  the	  liver.	  Since	  BH4	  is	  a	  co-­‐factor	  for	  the	   naturally	   occurring	   liver	   enzyme	   PAH,	   the	   necessity	   for	   ectopic	   BH4	   to	  support	  L-­‐DOPA	  synthesis	   in	   the	   liver	   is	  not	  known.	  Male	  mice	   received	  a	   tail-­‐vein	   injection	   of	   7.02x1010	   gcp	   total,	  with	   the	   group	   treated	  with	   both	   vectors	  receiving	  a	  50/50	  mix	  of	  each	  (n=	  6/group)	  (Table	  7).	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Treatment	  Group	   Dose	  (gcp/mouse)	   n	  
Vehicle	   -­‐	   6	  
dsAAV2/8-­‐LP1-­‐tTH	   7.02x1010	   6	  
dsAAV2/8-­‐LP1-­‐tTH	  +	   3.51x1010	   6	  
dsAAV2/8-­‐LP1-­‐GCH1	   3.51x1010	  
	   	   	  Table	  7:	  Treatment	  groups	  and	  doses	  of	  monocistronic	  dsAAV vectors	  injected	  into	  mice.	  
	  The	   total	   dose	  used	   in	   the	   study	  was	   limited	  by	   the	   genome	   titre	   of	   the	  TH	  vector	  due	  to	  its	  lower	  genome	  titre.	  Immediately	  prior	  to	  the	  termination	  of	  the	  study,	   plasma	   from	   each	   animal	   was	   collected	   after	   a	   three-­‐dose	   regimen	  treatment	  with	  the	  AADC	  and	  COMT	  inhibitors	  benserazide	  and	  tolcapone,	  which	  were	   given	   to	   block	  peripheral	   conversion	   of	   L-­‐DOPA	   to	   dopamine	   and	   inhibit	  COMT-­‐mediated	  L-­‐DOPA	  degradation	  (Figure	  15).	  
	  
	  
Figure	  15:	  Timeline	  of	  the	  first	  mouse	  study.	  
Male	  mice	  (n=6/group)	  were	  dosed	  with	  AAV	  vectors	  at	  day	  0.	  At	  day	  15,	  vehicle-­‐treated	  
animals	  received	   three	   intraperitoneal	   injections	  of	  benserazide	  and	   three	  oral	  doses	  of	  
tolcapone	   in	   approximately	   4-­‐hour	   intervals	   in	   a	   total	   dose	   of	   12	   and	   30	   mg/kg,	  
respectively.	  Vehicle-­‐treated	  animals	  were	  sacrificed	  at	  an	  earlier	   time-­‐point	   in	  order	   to	  
ensure	   benserazide	   and	   tolcapone’s	   suitability	   for	   administration	   to	   the	   test	   groups.	   At	  
day	  28	   the	   same	  dosing	   regimen	  of	   benserazide	   and	   tolcapone	  was	   administered	   to	   the	  
vector-­‐treated	  groups.	  Animals	  were	  sacrificed	  4	  hours	  after	  the	  final	  sub-­‐dose.	  
	  Transduction	   of	   both	   monocistronic	   vectors	   was	   assessed	   by	  immunohistochemistry	   (IHC)	   of	   paraffin	   embedded	   liver	   sections.	  As	   shown	   in	  Figure	  16,	   transgene	  expression	  of	   both	  GCH1	  and	  TH	  vectors	  was	  detected	   in	  <1%	  of	  hepatocytes.	   In	  the	   liver	  sections	  of	  animals	  treated	  with	  the	  TH	  vector	  only,	  an	  average	  of	  2.8±2.4	  cells/field	  were	  positive.	  The	  average	  number	  of	  cells	  per	  field	  was	  857.	  	  
	   
Injection	  with	  7.02x1010	  gcp	  AAV	  or	  vehicle 
  
Administration	  of	  3x	  dose-­‐regimen	  of	  benserazide	  and	  tolcapone	  to	  vehicle-­‐treated	  group,	  bleeding,	  sacrifice	  and	  harvesting	  of	  the	  liver 
Administration	  of	  3x	  dose-­‐regimen	  of	  benserazide	  and	  tolcapone	  to	  vector-­‐treated	  groups,	  bleeding,	  sacrifice	  and	  harvesting	  of	  the	  liver 
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Figure	  16:	  Transduction	  efficiency	  of	  the	  TH	  and	  GCH1	  vectors	  in	  the	  mouse	  liver.	  
Transduction	  levels	  15	  days	  (Vehicle)	  or	  28	  days	  (TH	  Vector	  and	  TH+GCH1	  Vectors)	  post-­‐
injection.	   No	   transgene	   expression	   was	   observed	   in	   the	   vehicle-­‐treated	   animals.	  
Transgene	  expression	  was	  detected	  in	  a	  very	  low	  number	  of	  hepatocytes	  in	  vector-­‐treated	  
animals	   (brown	  cells).	   Liver	   sections	   stained	  without	  primary	  antibody	   incubation	  were	  
used	  as	  a	  control	  for	  unspecific	  staining.	  
	  	  The	   plasma	   levels	   of	   L-­‐DOPA	   after	   treatment	   with	   the	   monocistronic	   AAV	  vectors	  were	  quantified	  by	  HPLC	  coupled	  with	  electrochemical	  detection.	  At	  the	  time	   this	   first	   animal	   study	   was	   performed,	   a	   protocol	   for	   in-­‐house	   L-­‐DOPA	  detection	  had	  not	  been	  established	  yet	  and	  the	  assay	  was	  therefore	  outsourced	  to	  ABS	  Laboratories	   (London,	  UK).	  No	   significant	   difference	   in	   L-­‐DOPA	  plasma	  levels	   between	   vehicle-­‐	   and	   vector-­‐treated	   animals	   was	   observed:	   vehicle	  treated	   animals	   had	   0.75±0.2nmol/ml,	   whereas	   animals	   treated	   with	   the	   TH	  vector	   only	   and	   both	   vectors	   together	   showed	   0.8±0.11nmol/ml	   and	  0.86±0.13µg/ml	  of	  circulating	  L-­‐DOPA,	  respectively	  (Table	  8).	  	   	  
Group	   Day	  of	  Sacrifice	   L-­‐DOPA	  	  
	  plasma	  (nmol/ml)	  
Vehicle	   15	   0.75±0.2	  
TH	  Vector	   28	   0.80±0.11	  
TH+GCH1	  Vectors	   28	   0.86±0.13	  
	  
Table	  8:	  L-­‐DOPA	  plasma	  levels	  of	  animals	  treated	  with	  the	  monocistronic	  liver	  vectors.	  
L-­‐DOPA	   plasma	   levels	   28	   days	   post-­‐injection	   measured	   by	   HPLC	   with	   electrochemical	  
detection.	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The	   results	   of	   this	   first	   animal	   study	   indicate	   that	   transduction	   efficiency	  of	  both	  vectors	  has	  to	  be	  greatly	  optimised	  in	  order	  to	  increase	  the	  potential	  for	  a	  therapeutic	  benefit	   from	  this	  gene	  therapy	  strategy.	   It	   is	  particularly	   important	  to	  ensure	   that	  both	  vectors	   transduce	  with	  equal	  efficiency	   in	  case	  TH	  alone	   is	  not	   sufficient	   to	   sustain	   L-­‐DOPA	   synthesis	   in	   the	   liver.	   In	   order	   to	   achieve	   a	  higher	  transduction	  with	  both	  vectors	  a	  much	  higher	  dose	  would	  be	  necessary.	  However,	   as	   seen	   from	   the	   capsid:genome	   titres	   ratio	   for	   the	   TH	   vector,	   its	  genome	   packaging	   was	   very	   inefficient	   due	   to	   its	   oversized	   genome.	   As	   a	  consequence,	  upscaling	  the	  production	  of	  this	  vector	  proved	  to	  be	  cumbersome	  and	   impractical.	   Thus,	   to	   address	   the	   scalability	   problem	   and	   to	   guarantee	  efficient	  and	  equal	  transduction	  levels	  for	  both	  genes,	  the	  dual-­‐vector	  approach	  was	  abandoned	  and	  a	  bicistronic	  vector	  was	  designed,	  which	  combines	  both	  the	  
GCH1	  and	  TH	  genes	  in	  a	  single	  AAV	  genome.	  
	  
3.2.3 Generation	  and	  Titration	  of	  the	  Bicistronic	  Liver	  Vector	  The	  bicistronic	  liver	  vector	  used	  in	  this	  study	  was	  designed	  to	  combine	  both	  the	  GCH1	  and	  TH	  genes	  in	  a	  single	  AAV	  vector,	  with	  each	  gene	  being	  expressed	  from	  an	  independent	  cassette	  controlled	  by	  the	  liver-­‐specific	  LP1	  promoter.	  The	  rationale	   for	   using	   two	   identical	   promoters	   in	   a	   single	   vector	   stems	   from	  successful	  preclinical	  studies	  carried	  out	  in	  a	  rodent	  model	  of	  PD.	  Cederfjäll	  et	  al.	  showed	   that	   injection	   of	   a	   vector	   expressing	   both	  GCH1	   and	  TH	   genes	   from	   a	  single	  AAV	  genome	   into	   the	  rat’s	   striatum	  resulted	   in	  widespread	   transduction	  and	  continuous	  L-­‐DOPA	  synthesis	  in	  the	  CNS	  (Cederfjäll	  et	  al.	  2012;	  Cederfjäll	  et	  al.	  2013).	  Similarly	  to	  the	  monocistronic	  TH	  vector,	  the	  TH	  gene	  in	  the	  bicistronic	  vector	  was	  truncated	  (lacking	  the	  nucleotides	  correspondent	  to	  the	  first	  155	  N-­‐terminal	  amino	  acids)	  and	  cloned	  immediately	  upstream	  of	  the	  WPRE	  sequence.	  This	  genome	  configuration	  had	  been	  shown	  to	  lead	  to	  an	  optimal	  TH:GCH1	  ratio	  for	  in	  vivo	  L-­‐DOPA	  synthesis	  (Cederfjäll	  et	  al.	  2012).	  A	  schematic	  representation	  of	  the	  singe-­‐stranded	  bicistronic	  vector	  is	  shown	  in	  Figure	  17.	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Figure	  17:	  Schematic	  of	  the	  single-­‐stranded	  bicistronic	  liver	  vector	  
The	  vector	  harbours	  the	  GCH1	  and	  the	  truncated	  TH	  (tTH)	  gene.	  Each	  expression	  cassette	  
is	   independently	  controlled	  by	  the	   liver-­‐specific	  LP1	  promoter.	  The	  WPRE	  sequence	  was	  
introduced	  downstream	  of	  the	  tTH	  coding	  sequence	  to	  enhance	  its	  expression.	  The	  shaded	  
area	  in	  the	  TH	  gene	  indicates	  the	  truncated	  region.	  	  	  The	   cloning	   strategy	   for	   the	   generation	   of	   the	   bicistronic	   liver	   vector	   was	  designed	   in	   a	   way	   to	   result	   in	   a	   modular	   construct	   in	   which	   each	   gene	   and	  regulatory	   element	   was	   flanked	   by	   a	   unique	   restriction	   endonuclease	   site	   to	  allow	  for	  future	  modifications	  if	  necessary.	  Therefore,	  both	  LP1	  promoters,	  both	  transgenes	   and	   the	  WPRE	  were	   cloned	   individually	   one	   after	   another	   into	   the	  AAV	  ITR-­‐containing	  backbone	  pSub201	  (Samulski	  et	  al.	  1987).	  The	  plasmid	  was	  quality	   controlled	  by	   restriction	  endonuclease	   analysis	   followed	  by	   sequencing	  after	  the	  completion	  of	  each	  cloning	  step.	  Once	  the	  construction	  of	  the	  modular	  vector	  was	  finalised,	  the	  integrity	  of	  the	  ITRs	  was	  confirmed	  by	  SmaI	  restriction	  endonuclease	  analysis.	  Production	  of	  the	  recombinant	  vector	  AAV2/8-­‐LP1-­‐GCH1-­‐LP1-­‐tTH-­‐WPRE	  was	  done	  by	  triple	  transfection	  of	  HEK293T	  cells;	  purification	  was	  done	  by	  iodixanol	  density	   gradient	   centrifugation	   (Grieger	   &	   Samulski	   2012).	   This	   purification	  method	   was	   chosen	   after	   it	   was	   noticed	   that	   iodixanol	   density	   gradient	  purification	   delivered	   greater	   yields	   and	   better	   purity	   for	   AAV8	   preparations	  compared	  to	  AVB	  sepharose	  chromatography	  purification.	  Titration	  and	  purity	  assessment	  of	  AAV	  vectors	  was	  done	  by	  total	  particle	  and	  genome	   containing	   particle	   titration.	   The	   genome	   titre	   was	   determined	   by	  alkaline	  agarose	  gel	  electrophoresis.	  While	  real	  time	  PCR	  can	  be	  a	  more	  precise	  method	  for	  AAV	  genome	  titration,	  alkaline	  gel	  electrophoresis	  allows	  for	  a	  visual	  quality	   control	   of	   the	   vector’s	   genome	   purity	   and	   integrity.	   Total	   particle	   and	  alkaline	  agarose	  gel	  genome	  titration	  showed	  titres	  of	  5.2x1013	  particles/ml	  and	  1.69x1013	   gcp/ml,	   respectively	   (Table	   9),	   indicating	   that	   the	   viral	   genome	  was	  efficiently	  packaged	  upon	  production	  (i.e.	  capsid:genome	  ratio	  ≤	  10)	  (Figure	  18).	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Titration	   AAV2/8-­‐LP1-­‐GCH1-­‐LP1-­‐tTH-­‐WPRE	  
Particle	  titre	  (particles/ml)	   5.2x1013	  
Genome	  titre	  (gcp/ml)	   1.69x1013	  
Ratio	  particle:genome	  titre	   3	  
	  
Table	  9:	  Particle	  and	  genome	  titres	  of	  AAV2/8-­‐LP1-­‐GCH1-­‐LP1-­‐tTH-­‐WPRE.	  
Titres	  were	  determined	  by	  SDS-­‐PAGE	  and	  agarose	  alkaline	  gel.	  A	  particle:genome	  ratio	  of	  
<10	  is	  indicative	  of	  efficient	  genome	  packaging.	  
	  
	  
Figure	   18:	   SDS-­‐PAGE	   and	   alkaline	   agarose	   gel	   for	   AAV2/8-­‐LP1-­‐GCH1-­‐LP1-­‐tTH-­‐WPRE	  
titration	  
(A)	  SDS-­‐PAGE	  for	  AAV	  capsid	  titration	  showing	  AAV	  capsid	  proteins	  VP1,	  VP2	  and	  VP3	  (top	  
to	   bottom).	   (B)	   Alkaline	   gel	   electrophoresis	   showing	   the	   genome	   of	   AAV2/8-­‐LP1-­‐GCH1-­‐
LP1-­‐tTH	  (4.4kb	  band)	  and	  a	  second	  band	  of	  2.8kb	  formed	  upon	  vector	  production	  with	  the	  
AAV	  production	  plasmid	  pAA019.	  Vector	  lanes	  represent	  dilutions	  of	  the	  same	  prep.	  Titres	  
calculated	  from	  A	  and	  B	  are	  shown	  in	  Table	  9.	  	  When	  the	  vector	  AAV2/8-­‐LP1-­‐GCH1-­‐LP1-­‐tTH-­‐WPRE	  was	  analysed	  by	  alkaline	  gel	   electrophoresis,	   the	   presence	   of	   a	   second	   band	   of	   approximately	   2.8kb	   in	  length	  was	  consistently	  observed	  (Figure	  18B	  –	  lower	  band).	  A	  similar	  band	  was	  also	   observed	   when	   different	   vectors	   with	   the	   same	   dual-­‐promoter	   genome	  configuration	  were	  analysed	  by	  alkaline	  agarose	  gel	  electrophoresis.	  Therefore,	  I	  hypothesised	   that	   this	   secondary	   band	   was	   a	   by-­‐product	   of	   homologous	  recombination	   (HR)	   triggered	   by	   the	   presence	   of	   two	   identical	   promoter	  sequences.	  If	  true,	  the	  predicted	  outcome	  of	  this	  process	  would	  be	  the	  excision	  of	  the	   LP1-­‐GCH1	   cassette	   followed	   by	   its	   degradation	   and	   packaging	   of	   the	   ITR-­‐flanked	   LP1-­‐tTH-­‐WPRE	   cassette	   to	   form	   a	   functional	   virus.	   A	   schematic	  representation	  of	  the	  HR	  outcome	  is	  shown	  in	  Figure	  19.	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Figure	  19:	  Schematic	  representation	  of	  by-­‐product	  formation	  upon	  HR	  of	  the	  AAV	  vector.	  
HR	  is	  triggered	  by	  the	  dual	  LP1	  promoter,	  which	  leads	  to	  the	  excision	  and	  degradation	  of	  
the	  GCH1	  cassette.	  The	  remaining	  tTH	  cassette	  is	  packaged	  into	  an	  AAV	  capsid	  due	  to	  the	  
presence	   of	   the	   flanking	   viral	   ITR	   sequences.	   Small	   arrows	   below	   the	   HR	   by-­‐product	  
vector	   indicate	   the	   annealing	   sites	   of	   the	   primers	   used	   in	   the	   sequencing	   reaction	   that	  
confirmed	  the	  presence	  of	  both	  ITRs	  flanking	  the	  expression	  cassette.	  	  To	   test	   the	   HR	   hypothesis,	   the	   2.8kb	   DNA	   band	   was	   extracted	   from	   the	  alkaline	  gel	  and	  sequenced	  (primers	  used	  for	  sequencing	  are	  indicated	  by	  arrows	  in	  Figure	  19).	  A	  reverse	  primer	  was	  designed	  that	  annealed	  at	  the	  5’	  end	  of	  the	  
TH	   gene	   and	   read	   through	   the	   LP1	   promoter	   and	   part	   of	   the	   L-­‐ITR.	   A	   second	  primer	   was	   designed	   to	   bind	   at	   the	   3’	   end	   of	   the	  WPRE	   and	   to	   read	   into	   the	  beginning	  of	  the	  R-­‐ITR.	  The	  sequencing	  results	  showed	  that	  the	  LP1-­‐tTH	  cassette	  was	   indeed	   flanked	   by	   two	   AAV	   ITRs,	   thus	   confirming	   the	   occurrence	   of	  intramolecular	   HR	   during	   the	   production	   of	   the	   bicistronic	   liver	   vector.	   These	  findings	   show	   that	   the	   generation	  of	   the	  bicistronic	   liver	   vector	  will	   inevitably	  lead	   to	   the	   formation	   of	   a	   second	   vector	   harbouring	   the	   TH	   cassette	   only	  (AAV2/8-­‐LP1-­‐tTH-­‐WPRE).	  	  
3.2.4 In	  vitro	  Validation	  of	  the	  Bicistronic	  Liver	  Vector	  The	  in	  vitro	  validation	  of	  the	  bicistronic	  liver	  vector	  was	  performed	  in	  order	  to	  confirm	   the	   functionality	   of	   both	   transgene	   expression	   cassettes,	   more	  specifically	  promoter	  function	  and	  protein	  stability	  prior	  to	   in	  vivo	   testing.	  This	  was	  done	  by	  transducing	  the	  hepatocellular	  carcinoma	  cell	  line	  Huh7.5	  with	  the	  recombinant	   bicistronic	   vector	   and	   verifying	   GCH1	   and	   TH	   expression	   by	  western	   blot.	   Because	   this	   cell	   line	   is	   refractory	   to	   standard	   transfection	  techniques,	  validation	  of	  protein	  expression	  	  was	  performed	  by	  infection	  instead	  of	   transfection	   with	   the	   producer	   plasmid	   pAA019.	   Although	   AAV8	   has	   the	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ability	  to	  efficiently	  transduce	  liver	  tissue	  in	  vivo,	  efficient	  in	  vitro	  transduction	  is	  difficult	   to	   achieve	   in	   immortalised	   liver	   cell	   lines.	   Therefore,	   to	   ensure	   high	  transduction	   levels,	   cells	  were	   infected	  at	  a	  high	  MOI	  of	  106	  gcp/cell	  and	  viral-­‐mediated	   protein	   expression	  was	   detected	   by	  western	   blot	   48h	   post-­‐infection.	  Figure	   20	   shows	   that	   the	   AAV2/8-­‐LP1-­‐GHC1-­‐LP1-­‐tTH-­‐WPRE	   and	   its	  recombination	   by-­‐product	   were	   able	   to	   express	   TH	   and	   GCH1.	   Uninfected	  Huh7.5	   cells	   showed	   basal	   GCH1	   expression	   as	   a	   result	   of	   the	   endogenous	  expression	  of	  this	  enzyme	  in	  the	  liver	  (Tatham	  et	  al.	  2009).	  	  	  
	  
Figure	  20:	  In	  vitro	  validation	  of	  AAV2/8-­‐LP1-­‐GCH1-­‐LP1-­‐tTH-­‐WPRE.	  
Western	   blot	   was	   performed	   on	   cell	   extracts	   of	   the	   Huh7.5	   cell	   line	   infected	   with	   the	  
vector.	   1x105	   cells	   were	   infected	   at	   a	   MOI	   106	   gcp/cell.	   Protein	   expression	   from	   both	  
transgenes	  was	  assessed	  48h	  post-­‐infection.	  
	  
3.2.5 In	  vivo	  Efficacy	  of	  the	  Bicistronic	  Liver	  Vector	  After	  it	  was	  confirmed	  that	  both	  transgene	  cassettes	  were	  able	  to	  express	  TH	  and	   GCH1	   in	   vitro,	   a	   small-­‐scale	   study	   was	   performed	   in	   female	   mice.	   This	  experiment	  aimed	  to	  assess:	  1)	  whether	  a	  single	  systemic	  injection	  of	  the	  vector	  leads	   to	   broad	   hepatic	   transduction;	   2)	   whether	   hepatic	   transduction	   was	  associated	  with	  tissue	  damage	  and	  leukocyte	  infiltration;	  and	  3)	  whether	  hepatic	  transduction	  by	  the	  vector	  was	  associated	  with	  increased	  levels	  of	  circulating	  L-­‐DOPA.	  Hepatic	  transduction	  was	  assessed	  by	  IHC.	  Screening	  for	  histological	  signs	  of	  tissue	   damage	   and	   leucocyte	   infiltration	  was	   done	   by	   haematoxylin	   and	   eosin	  (H&E)	  staining.	  Finally,	  hepatic	  L-­‐DOPA	  synthesis	  was	  assessed	  by	  HPLC	  analysis	  of	   plasma	   collected	  28	  days	   post-­‐injection	   after	   animals	  were	   treated	  with	   the	  AADC	  and	  COMT	  inhibitors	  benserazide	  and	  entacapone.	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The	  doses	  tested	  in	  this	  study	  (3.6x1012	  and	  1.3x1012	  gcp/mouse)	  represent	  a	  50	   and	   19-­‐fold	   increase	   relative	   to	   the	   study	   with	   the	   monocistronic	   vectors	  (Table	  10).	  	  
Treatment	  Group	   Dose	  (gcp/mouse)	   n	  
Vehicle	   -­‐	   3	  
AAV2/8-­‐LP1-­‐GCH1-­‐LP1-­‐tTH-­‐WPRE	   3.6x1012	   3	  
AAV2/8-­‐LP1-­‐GCH1-­‐LP1-­‐tTH-­‐WPRE	   1.3x1012	   3	  
	  
Table	  10:	  Treatment	  groups	  and	  doses	  of	  bicistronic	  AAV	  liver	  vector	  injected	  into	  mice.	  	  The	  timeline	  of	   this	  study	  was	  slightly	  different	   from	  the	  one	  that	  tested	  the	  efficacy	   of	   the	   monocistronic	   vectors.	   Here,	   vehicle-­‐	   and	   vector-­‐treated	   mice	  were	  all	  sacrificed	  on	  the	  same	  day.	  In	  addition,	  a	  different	  treatment	  regimen	  of	  benserazide	  and	  COMT	  inhibitor	  (this	  time	  entacapone	  instead	  of	  tolcapone)	  was	  administered	   prior	   to	   sacrifice	   in	   one	   dose	   instead	   of	   three	   sub-­‐doses	   (Figure	  21).	  Entacapone	  and	  tolcapone	  are	  both	  inhibitors	  of	  COMT.	  The	  main	  difference	  between	   these	   inhibitors	   is	   the	   ability	   of	   tolcapone	   to	   cross	   the	   blood	   brain	  barrier.	   Since	   our	   interest	   is	   in	   peripheral	   L-­‐DOPA	   synthesis,	   the	   choice	   of	   the	  COMT	  inhibitor	  used	  in	  this	  study	  is	  not	  of	  major	  importance.	  	  
	  
	  
Figure	  21:	  Timeline	  of	  the	  second	  mouse	  study.	  
On	  day	  0	  animals	  were	  injected	  in	  the	  tail-­‐vein	  with	  AAV	  vectors	  at	  two	  different	  doses.	  On	  
day	   28,	   mice	   received	   a	   single	   intraperitoneal	   injection	   of	   benserazide	   and	   an	   oral	  
treatment	  with	  entacapone	  at	  a	  dose	  of	  12	  and	  30	  mg/kg,	  respectively.	  One	  hour	  after	  the	  
benserazide	  and	  entacapone	  treatment,	  blood	  was	  collected,	  animals	  were	  sacrificed	  and	  
their	  livers	  were	  harvested	  for	  fixation.	  	  
	   
Injection	  with	  AAV	  or	  vehicle Administration	  of	  a	  single	  dose-­‐regimen	  of	  benserazide	  and	  entacapone	  to	  all	  mice,	  bleeding,	  sacrifice	  and	  harvesting	  of	  the	  liver 
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Hepatic	  transduction	  of	  the	  bicistronic	  liver	  vector	  for	  both	  doses	  tested	  was	  assessed	  by	  IHC	  in	  paraffin	  embedded	  liver	  sections.	  Both	  doses	  mediated	  broad	  hepatic	   expression	   of	   TH	   and	   GCH1.	   Variation	   in	   transduction	   efficiency	   was	  observed	  between	  animals	  (Figure	  22	  -­‐	  TH	  staining	  in	  all	  three	  mice).	  However,	  on	  average,	   levels	  were	  similar	  to	  the	  65.8	  ±	  9%	  transduction	  levels	  previously	  described	  for	  a	  dose	  of	  1.8x1012	  gcp/mouse	  of	  AAV8	  (Nakai	  et	  al.	  2005).	  It	  must	  be	  noticed	  that	  this	  extrapolation	  must	  be	  done	  with	  caution	  since	  the	  reference	  value	   from	  Nakai	  et	  al.	  was	  taken	  from	  mice	   injected	  via	   the	  portal	  vein,	  which	  was	   shown	   to	   lead	   to	   a	   higher	   transduction	   of	   the	   mouse	   liver	   than	   tail-­‐vein	  injection.	  Furthermore,	  the	  stronger	  staining	  observed	  in	  the	  higher	  dose	  group	  suggests	  a	  stronger	  transgene	  expression	  per	  hepatocyte	  than	  in	  the	  lower	  dose	  group,	  most	  likely	  due	  to	  the	  presence	  of	  more	  viral	  genome	  copies	  per	  cell.	  The	  quantification	   of	   the	   vector	   genome	   copies	   per	   cell	   could	   not	   be	   performed	  because	  the	  whole	  liver	  was	  fixed	  after	  the	  animals	  were	  sacrificed.	  Of	  note,	  the	  broader	  liver	  transduction	  observed	  in	  this	  experiment	  supports	  the	  notion	  that	  animals	  in	  the	  first	  study	  were	  underdosed	  with	  the	  monocistronic	  vectors.	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Figure	  22:	  Transduction	  efficiency	  of	  the	  liver	  vector	  measured	  by	  IHC.	  
Stainings	  were	  performed	  against	  TH	  (three	  upper	  lanes)	  and	  GCH1	  (bottom	  lane).	  Stained	  
cells	   (brown)	   indicate	   vector-­‐mediated	   expression	   of	   TH	   and	   GCH1.	   TH	   staining	   for	   all	  
three	  mice	  is	  shown	  in	  order	  to	  highlight	  the	  variability	  in	  transduction	  between	  animals.	  
Liver	   sections	   stained	   without	   primary	   antibody	   incubation	   were	   used	   to	   control	   for	  
unspecific	   staining.	   The	   images	   for	   unspecific	   staining	   control	   are	   the	   same	   for	   TH	   and	  
GCH1	  but	  each	  one	  was	  subject	  to	  the	  same	  adjustments	  as	  the	  other	  images	  in	  the	  same	  
lane.	  Scale	  bar	  100	  µm.	  	  In	   addition	   to	   transduction	   efficiency,	   the	   integrity	   of	   the	   hepatic	   tissue	   28	  days	   post-­‐injection	  was	   assessed	   by	   H&E	   staining	   (Figure	   23).	   Hepatocytes	   of	  treated	   animals	   showed	   normal	   morphology	   similar	   to	   that	   of	   vehicle-­‐treated	  animals.	   Furthermore,	   no	   hepatocyte	   necrosis	   or	   inflammatory	   cell	   infiltration	  was	   observed	   in	   any	   of	   the	   groups	   and	   no	   abnormal	   chromatin	   condensation	  (heterochromatin)	   was	   seen,	   indicating	   that	   the	   hepatocytes	   were	  transcriptionally	  active	  and	  functional	  (Wang	  et	  al.	  2015;	  Maeda	  et	  al.	  2016).	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Figure	   23:	   H&E	   staining	   on	   liver	   sections	   of	   animals	   treated	   with	   the	   bicistronic	   liver	  
vector.	  
Staining	  were	  performed	  28	  days	  post-­‐injection	  and	  no	  sign	  of	  tissue	  damage	  was	  detected	  
in	  any	  of	  the	  groups.	  Scale	  bar	  100	  µm.	  
	   	  Following	  the	  IHC	  analysis	  of	  TH	  and	  GCH1	  expression	  in	  the	  liver,	  plasma	  L-­‐DOPA	   levels	   were	  measured	   by	   HPLC	   coupled	   with	   electrochemical	   detection.	  For	  this	  study,	  a	  protocol	  was	  established	  in	  collaboration	  with	  Dr.	  Sarah	  Salvage	  at	  King’s	  College	  London.	  As	   shown	   in	   Table	   11,	   L-­‐DOPA	   concentration	   in	   the	   plasma	   was	  0.27±0.01nmol/ml	  in	  the	  vehicle-­‐treated	  group,	  whereas	  vector-­‐treated	  animals	  showed	   0.47±0.16	   and	   0.47±0.12nmol/ml	   after	   treatment	  with	   the	   higher	   and	  lower	   doses,	   respectively.	   The	   rise	   in	   systemic	   L-­‐DOPA	   corresponds	   to	   an	  average	  1.8-­‐fold	  increase	  relative	  to	  vehicle-­‐treated	  animals	  (Figure	  24).	  Plasma	  L-­‐DOPA	   levels	   in	   vector-­‐treated	   animals	   showed	   substantial	   intra-­‐group	  variability.	  	  	  
Group	   L-­‐DOPA	  plasma	  (nmol/ml)	  
Vehicle	   0.27±0.01	  
Vector	  3.6x1012	  gcp/ml	   0.47±0.16	  
Vector	  1.3x1012	  gcp/ml	   0.47±0.12	  
	  
Table	  11:	  L-­‐DOPA	  plasma	  levels	  of	  animals	  injected	  with	  different	  doses	  of	  the	  bicistronic	  
liver	  vectors.	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Figure	   24:	   Scatter	   plot	   of	   L-­‐DOPA	   plasma	   levels	   of	   animals	   injected	  with	   the	   bicistronic	  
liver	  vector.	  	  
L-­‐DOPA	   from	   individual	   animals	   was	   measured	   by	   HPLC	   coupled	   with	   electrochemical	  
detection.	  An	  average	  1.8-­‐fold	   increase	   in	  systemic	  L-­‐DOPA	  levels	  was	  observed	   for	  both	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medication	  in	  PD	  patients	  and	  to	  serve	  as	  a	  reference	  for	  comparison.	  Following	  plasma	  collection	  and	  sacrifice	  of	   the	  animals	  28	  days	  post-­‐injection,	   the	   livers	  were	  divided	  for	  fixation	  and	  snap	  freezing	  in	  order	  to	  allow	  for	  a	  broader	  range	  of	  analysis.	  	  
3.2.6 Efficacy	   of	   the	   Bicistronic	   Liver	   Vector	   is	   not	   altered	   by	   Different	  
AADC	  /COMT	  Inhibition	  Regimen	  and	  Sex	  The	  data	  described	   in	   the	  previous	  section	  of	   this	  chapter	  show	  that	  despite	  broad	  and	  efficient	  hepatic	  transduction	  with	  the	  bicistronic	  liver	  vector,	  L-­‐DOPA	  plasma	   levels	   increased	   only	   marginally	   28	   days	   post-­‐injection.	   Studies	   have	  been	  published	  highlighting	  a	  gender-­‐related	  effect	  in	  the	  mouse	  liver	  using	  AAV	  vectors	   (Pañeda	   et	   al.	   2009).	   Therefore,	   to	   assess	  whether	   animal	   gender	   also	  affected	   hepatic	   transduction	   of	   the	   bicistronic	   vector,	   the	   in	   vivo	   experiment	  was	   repeated	   with	   male	   mice.	   Similarly	   to	   the	   one	   described	   in	   the	   previous	  section,	  this	  experiment	  aimed	  to	  assess:	  1)	  whether	  a	  single	  systemic	  injection	  of	   the	   vector	   led	   to	   broad	   hepatic	   transduction	   in	   male	   mice	   and	   2)	   whether	  hepatic	   transduction	   by	   the	   vector	   was	   associated	   with	   increased	   levels	   of	  circulating	  L-­‐DOPA.	  Here,	  hepatic	  transduction	  was	  assessed	  by	  IHC	  and	  western	  blot	  in	  individual	  mice.	  In	  addition,	  viral	  genome	  copy	  numbers	  per	  hepatocyte	  were	  quantified	  by	  qPCR.	   Hepatic	   L-­‐DOPA	   synthesis	   was	   assessed	   by	   HPLC	   analysis	   of	   plasma	  collected	  28	  days	  post-­‐injection	  after	  animals	  were	   treated	  with	   the	  AADC	  and	  COMT	  inhibitors	  benserazide	  and	  tolcapone.	  In	   this	   study,	   animal	   groups	   and	   treatment	   doses	   were	   carried	   out	   as	  described	   in	   Table	   12	   and	   Figure	   25.	   A	   group	   of	  male	  mice	   (n=3)	  was	   treated	  with	  vehicle,	  a	  second	  group	  (n=5)	  was	  treated	  with	  1.3x1012	  gcp/mouse	  and	  a	  third	  group	  (n=3)	  was	  given	  10mg/kg	  L-­‐DOPA	  orally.	  On	  the	  day	  of	  sacrifice,	  all	  animals	   were	   treated	   three	   times	   with	   4mg/kg	   benserazide	   and	   10mg/kg	  tolcapone	  and	  sacrificed	  1h	  after	  the	  last	  dose.	  An	  exception	  was	  made	  with	  the	  oral	   L-­‐DOPA	   group,	   which	   was	   given	   L-­‐DOPA	   1h	   after	   the	   last	  benserazide/tolcapone	   treatment	   and	   sacrificed	  1h	   thereafter.	  The	  vector	  dose	  selected	   for	   this	   experiment	   was	   based	   on	   the	   observation	   from	   the	   previous	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study	  in	  which	  a	  dose	  three	  times	  higher	  led	  to	  a	  similar	  raise	  in	  L-­‐DOPA	  plasma	  levels.	  Furthermore,	  it	  was	  known	  from	  experience	  that	  the	  generation	  of	  a	  more	  concentrated	   AAV	   preparation	   would	   be	   cumbersome	   and	   impractical	   i.e.	  beyond	  the	  production	  limits	  of	  our	  laboratory.	  Scalability	  is	  of	  special	  relevance	  if	  vector	  production	  needs	  to	  be	  upscaled	   in	  the	   future	   for	  use	   in	   larger	  animal	  models.	  	  
Treatment	  Group	   Dose	  (gcp/mouse)	   n	  
Vehicle	   -­‐	   3	  
AAV2/8-­‐LP1-­‐GCH1-­‐LP1-­‐tTH-­‐WPRE	   1.3x1012	   5	  
Oral	  L-­‐DOPA	   10	  mg/kg	   3	  
	  
Table	  12:	  Groups	  and	  doses	  of	  mice	  treated	  with	  bicistronic	  AAV	  liver	  vector	  and	  oral	  L-­‐
DOPA.	  	  	  
	  
Figure	  25:	  Timeline	  of	  the	  third	  mouse	  study.	  
On	  day	  0	  animals	  were	  dosed	  with	  vehicle	  or	  AAV	  vector.	  On	  day	  28,	  all	  animals	  received	  
three	   intraperitoneal	   injections	   of	   benserazide	   and	   oral	   doses	   of	   tolcapone	   at	  
approximately	  4	  hours	  intervals	  in	  a	  total	  dose	  of	  12	  and	  30	  mg/kg,	  respectively.	  Animals	  
were	  sacrificed	  one	  hour	  thereafter,	  with	  the	  exception	  of	  the	  oral	  L-­‐DOPA	  treated	  group,	  
which	  received	  an	  oral	  gavage	  of	  10	  mg/kg	  L-­‐DOPA	  and	  sacrificed	  one	  hour	  later.	  
	  	  Unfortunately,	  two	  vector-­‐treated	  animals	  were	  lost	  during	  the	  course	  of	  the	  experiment:	   one	  mouse	   (#4)	   had	   to	   be	   sacrificed	   at	   day	   7	   due	   to	   fight-­‐related	  injuries	   and	   mouse	   #5	   died	   on	   the	   final	   day	   immediately	   after	   the	   terminal	  isoflurane	  anaesthesia	  for	  reasons	  not	  clear	  to	  us.	  As	  soon	  as	  it	  was	  noticed	  that	  the	  mice	  were	   fighting,	   they	  were	   separated	   and	  kept	   in	   individual	   cages	   until	  
	   
Injection	  with	  AAV	  or	  vehicle Administration	  of	  3x	  dose-­‐regimen	  of	  benserazide	  and	  tolcapone	  to	  all	  animals	  followed	  by	  oral	  gavage	  in	  L-­‐DOPA	  treated	  group.	  Bleeding,	  sacrifice	  and	  harvesting	  of	  liver 
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the	   termination	   of	   the	   experiment.	   The	   livers	   of	   both	   dead	   animals	   were	  harvested	  and	  frozen	  but	  blood	  could	  not	  be	  collected	  for	  future	  analysis.	  Hepatic	   transduction	   of	   the	   bicistronic	   liver	   vector	  was	   assessed	   by	   IHC	   on	  paraffin	   embedded	   liver	   sections	   and	   quantitative	   assessment	   of	   transduction	  was	   performed	   for	   all	   mice	   except	   #4.	   This	   mouse	   was	   excluded	   from	   the	  analysis	  because	   its	   sacrifice	   at	   an	  early	   time-­‐point	   (day	  7)	  did	  not	   allow	   for	   a	  direct	  comparison	  with	  the	  other	  mice.	  As	   in	   the	   previous	   animal	   study,	   IHC	   demonstrated	   variation	   in	   the	  transduction	   levels	   between	   animals:	   53%	   and	   52%	   in	   mice	   #2	   and	   #3,	  respectively,	  and	  22%	  and	  15%	  for	  #1	  and	  #5,	  respectively.	  Mice	  #2	  and	  #3	  had	  transduction	  levels	  comparable	  to	  those	  described	  by	  Nakai	  et	  al.	  However,	  this	  comparison	  must	  be	  done	  with	  caution	  due	  to	  the	  slightly	  different	  doses	  tested	  (1.3x1012	  vs.	  1.8x1012	  gcp/mouse)	  and	   the	  different	  administration	   routes	   (tail	  vein	   vs.	   portal	   vein).	  A	   similar	   transduction	  pattern	  was	  observed	   for	  GCH1	   in	  vector-­‐treated	   animals.	   Vehicle	   and	   oral	   L-­‐DOPA	   treated	   animals	   showed	   no	  positive	  staining	  for	  either	  enzyme	  (Figure	  26).	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Figure	  26:	  Transduction	  efficiency	  of	  the	  bicistronic	  liver	  vector	  measured	  by	  IHC	  against	  TH	  (upper	  lane)	  and	  GCH1	  (bottom	  lane).	  	  
Images	  of	  all	  vector-­‐treated	  mice	  are	  shown	  except	  mouse	  #4,	  which	  was	  sacrificed	  7	  days	  post-­‐injection	  due	  to	  fight-­‐related	  injuries.	  Brown	  staining	  
indicates	  vector-­‐mediated	  expression	  of	  TH	  and	  GCH1.	  TH	  positive	  cells	  were	  manually	  counted	  and	  compared	  to	  the	  total	  number	  of	  cells	  per	  field	  (244	  
in	  average).	  Liver	  sections	  stained	  without	  primary	  antibody	  incubation	  were	  used	  to	  control	  for	  unspecific	  staining.	  The	  images	  for	  unspecific	  staining	  
control	  are	  the	  same	  for	  TH	  and	  GCH1	  but	  each	  one	  was	  subject	  to	  the	  same	  adjustments	  as	  the	  other	  images	  in	  the	  same	  lane.	  Scale	  bar	  100	  µm.	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In	  parallel	  to	  the	  IHC	  staining,	  transgene	  expression	  was	  assessed	  by	  western	  blot.	   Consistent	   with	   the	   IHC	   results,	   western	   blot	   on	   liver	   extracts	   showed	  varying	  levels	  of	  transgene	  expression	  among	  the	  vector-­‐treated	  group.	  Mice	  #2	  and	  #3	  had	  the	  highest	  expression	  of	  TH	  and	  GCH1,	  followed	  by	  mice	  #1	  and	  #5.	  Mouse	  #4,	  included	  in	  the	  western	  blot	  analysis,	  shows	  negligible	  TH	  expression	  and	  a	  more	  prominent	  GCH1	  band	  (Figure	  27).	  	  
	  
Figure	  27:	  Western	  blot	  detection	  of	  TH	  and	  GCH1	  expression	  in	  extracts	  from	  mouse	  liver.	  
The	   organs	  were	   harvested	   28	   days	   post	   AAV	   injection	   and	   total	   protein	  was	   extracted	  
from	  30µg	  of	  liver	  tissue	  for	  the	  detection	  of	  vector-­‐expressed	  proteins.	  All	  animals	  used	  
in	  the	  study	  are	  shown.	  	  In	   addition	   to	   the	   transgene	   expression	   levels,	   the	   number	   of	   viral	   genome	  copies	   per	   hepatocyte	  was	   quantified	   by	   real-­‐time	   quantitative	   PCR.	   Figure	   28	  shows	  that	  mice	  #2	  and	  #3	  had	  the	  highest	  viral	  copy	  numbers	  with	  794	  vs.	  409	  
TH	  copies	  and	  480	  vs.	  202	  GCH1	  copies	  per	  hepatocyte,	  respectively.	  Mice	  #1	  and	  #5	  presented	  338	  vs.	  108	  TH	  copies	  and	  235	  vs.	  59	  GCH1	  copies	  per	  hepatocyte,	  respectively.	   The	   amount	   of	   genome	   copies	   per	   hepatocyte	   followed	   the	   same	  pattern	  seen	  for	  the	  IHC	  and	  the	  western	  blot	  analysis:	  #2>#3>#1>#5.	  Although	  mouse	  #4	  presented	  high	  viral	  copy	  numbers,	  at	  the	  time	  of	  its	  sacrifice	  protein	  expression	   from	   the	   vector	   had	   not	   reached	   maximal	   levels	   yet.	   As	   expected,	  vehicle	  and	  L-­‐DOPA	  treated	  mice	  had	  basal	  levels	  (<0.5)	  of	  TH	  and	  GCH1.	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Figure	  28:	  Quantification	  of	  viral	  genome	  copy	  numbers	  per	  hepatocyte.	  
The	  quantification	  was	  performed	  using	  independent	  primer	  pairs	  for	  each	  transgene.	  Cell	  
numbers	  were	  estimated	  by	  quantifying	  the	  copy	  numbers	  of	  the	  mouse	  cyclophilin	  gene.	  
Results	  are	  presented	  as	  viral	  genome	  copies	  per	  hepatocyte.	  	  Taken	   together,	   these	   results	   indicate	   a	   difference	   in	   the	   amount	   of	   vector	  present	   in	   the	   liver	   of	   each	   mouse,	   which	   reflects	   the	   observed	   variation	   in	  transduction	   efficiency.	   Of	   note,	   the	   copy	   number/hepatocyte	   of	   TH	   was	   on	  average	   1.7x	   times	   higher	   than	   that	   of	   GCH1.	   This	   can	   be	   explained	   by	   the	  homologous	  recombination	  of	   the	  vector,	  which	   leads	   to	   the	   formation	  of	  a	  by-­‐product	  consisting	  of	  the	  TH	  cassette	  only.	  Thus,	  more	  TH	  than	  GCH1	  copies	  were	  present	  in	  the	  vector	  preparation	  injected	  in	  the	  mice.	  Following	   the	  detection	  of	  viral	   genomes	  and	  expression	   in	   the	  mouse	   liver,	  the	   plasma	   L-­‐DOPA	   concentration	   was	   measured	   by	   HPLC	   coupled	   with	  electrochemical	   detection.	   Plasma	   L-­‐DOPA	   quantification	   revealed	   a	   1.8-­‐fold	  increase	   in	   vector-­‐treated	   animals	   relative	   to	   the	   vehicle	   group.	   This	   increase	  was	   the	   same	   as	   observed	   in	   the	   previous	   experiment,	   which	   suggests	   that	   a	  saturation	  of	  the	  system	  and	  not	  inefficient	  COMT	  inhibition	  might	  be	  the	  reason	  why	  no	   further	   increase	   in	  plasma	  L-­‐DOPA	  was	  observed	  despite	  efficient	   liver	  transduction.	   Mice	   treated	   orally	   showed	   a	   9-­‐fold	   increase	   in	   plasma	   L-­‐DOPA	  levels,	   indicating	   that	   the	   potency	   of	   this	   gene	   therapy	   approach	   is	   still	   below	  what	  would	   be	   required	   to	   demonstrate	   a	   potential	   therapeutic	   benefit	   (Table	  13).	  Of	  note,	  absolute	  numbers	  of	  plasma	  L-­‐DOPA	  concentrations	  differ	  between	  this	  and	  the	  previous	  animal	  study	  likely	  due	  to	  the	  difference	  in	  the	  benserazide	  and	  COMT	  inhibitor	  treatment	  regimen	  adopted	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Group	   L-­‐DOPA	  plasma	  (nmol/ml)	  
Vehicle	   0.91±0.15	  
Vector	  1.3x1012	  gcp/ml	   1.67±0.58	  
Oral	  L-­‐DOPA	   8.13±4.18	  
	  
Table	  13:	  L-­‐DOPA	  plasma	  levels	  of	  animals	  injected	  with	  the	  bicistronic	  liver	  vector	  in	  the	  
second	  mouse	  study.	  	  Levels	   of	   plasma	   L-­‐DOPA	  mirrored	   the	   viral	   genome	   copy	   numbers	   per	   cell	  and	  TH	  expression	  data,	  with	  mouse	  #2>#3>#1.	  Again,	  significant	  variability	  was	  seen	  between	  vector	  treated	  mice.	  Interestingly,	  L-­‐DOPA	  plasma	  levels	  showed	  a	  big	  variability	  in	  the	  orally	  treated	  group	  as	  well	  (Figure	  29).	  	  	  
	  
Figure	  29:	  Scatter	  plot	  of	  L-­‐DOPA	  plasma	  levels	  of	  mice	  injected	  with	  the	  bicistronic	  liver	  
vector	  in	  study	  2.	  
L-­‐DOPA	   levels	   from	   individual	   animals	   were	   measured	   by	   HPLC	   with	   electrochemical	  
detection.	  A	  1.8-­‐fold	  and	  9-­‐fold	  increase	  were	  seen	  in	  vector	  and	  oral	  L-­‐DOPA	  treated	  mice,	  
respectively,	  relative	  to	  the	  vehicle	  group.	  Bars	  represent	  median	  values	  ±	  range.	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Figure	  30:	  L-­‐DOPA	  biosynthetic	  pathway	  in	  the	  liver	  and	  putative	  steps	  at	  which	  L-­‐DOPA	  
synthesis	  is	  being	  deterred.	  
	  (1)	  Insufficient	  TH	  to	  efficiently	  convert	  tyrosine	  into	  L-­‐DOPA;	  (2)	  inefficient	  release	  of	  L-­‐
DOPA	  from	  hepatocytes	   into	  the	  bloodstream;	  (3)	  degradation	  of	  synthesised	  L-­‐DOPA	  by	  
liver	  COMT.	  	  To	  test	  each	  of	  the	  hypotheses,	  the	  pathway	  of	  hepatic	  L-­‐DOPA	  synthesis	  was	  dissected	  by	  measuring	  TH	  activity	  in	  the	  liver	  as	  well	  as	  hepatic	  L-­‐DOPA	  and	  3-­‐OMD	  concentrations.	  If	   enough	  TH	   is	   present	   in	   the	   liver	   of	   the	   vector-­‐treated	   animals	   to	   sustain	  high	  levels	  of	  L-­‐DOPA	  synthesis,	  a	  significant	  difference	  in	  the	  TH	  activity	  in	  liver	  extracts	   of	   vector-­‐treated	   mice	   relative	   to	   untreated	   animals	   is	   expected.	   TH	  enzymatic	  activity	  was	  quantified	  by	  measuring	   the	  rate	  at	  which	   tyrosine	  was	  converted	  into	  L-­‐DOPA	  after	  being	  incubated	  with	  homogenates	  equivalent	  to	  3	  mg	   of	   hepatic	   tissue.	   The	   conversion	   rate	   in	   vector-­‐treated	   mice	   was	   1.7-­‐fold	  higher	   than	   that	   in	   vehicle	   and	   oral	   L-­‐DOPA	   treated	   animals.	   However,	   when	  compared	   to	   the	   activity	   levels	   in	   naïve	   striatal	   tissue,	   vector-­‐treated	   animals	  demonstrated	  a	  15-­‐fold	  lower	  TH	  activity	  (Figure	  31).	  	  
	  
Figure	  31:	  Scatter	  plot	  of	  hepatic	  TH	  activity	  of	  mice	  from	  study	  2.	  
TH	   activity	   was	   measured	   from	   liver	   extracts	   by	   HPLC	   with	   electrochemical	   detection.	  
Bars	  represent	  median	  values	  ±	  range.	  	  Given	   that	   an	   increase	   in	   L-­‐DOPA	   plasma	   levels	   was	   consistently	   observed	  after	  vector	   treatment,	   it	   is	  unlikely	   that	   the	  TH	  expressed	  by	   the	  vector	   is	  not	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functional.	   Rather,	   the	   amount	   of	   TH	   expressed	   by	   the	   vector	   is	   insufficient	   to	  further	   raise	   L-­‐DOPA	   plasma	   levels.	   To	   test	   this	   hypothesis	   the	   amount	   of	   TH	  present	  in	  the	  liver	  of	  the	  two	  mice	  expressing	  the	  highest	  levels	  was	  compared	  with	  the	  striatum	  of	  a	  naïve	  mouse.	  Figure	  32	  shows	  that	  mice	  #2	  and	  #3	  express	  respectively	   2.5	   and	   17-­‐fold	   less	   TH	   than	   normally	   present	   in	   striatal	   tissue.	  While	  the	  difference	  in	  TH	  expression	  levels	  and	  TH	  activity	  between	  the	  liver	  of	  mouse	  #3	  and	  naïve	  striatal	  tissue	  was	  similar	  (~15-­‐fold),	  mouse	  #2	  presented	  low	  hepatic	  TH	  activity	  despite	  expressing	  half	  the	  amount	  of	  TH	  found	  in	  striatal	  tissue	  (Figure	  32).	  	  
	  
Figure	   32:	   Relative	   amount	   of	   TH	   present	   in	   transduced	   liver	   normalised	   to	   naïve	  
striatum.	  
Total	  protein	  was	  extracted	  from	  30µg	  of	   liver	  of	  mice	  #2	  and	  #3	  and	  striatal	   tissue	  of	  a	  
naïve	  mouse.	  TH	   levels	  were	  assessed	  by	  western	  blot,	  quantified	  and	  normalised	  to	   the	  
amount	  of	  HSP90.	  	  These	   results	   allow	   two	   possible	   interpretations:	   (1)	   the	   truncated	   TH	  expressed	  by	  the	  vector	  is	  less	  active	  than	  the	  wild-­‐type	  striatal	  TH	  or	  (2)	  TH	  is	  not	  being	   expressed	   in	   sufficient	   amounts	   to	   raise	  L-­‐DOPA	  plasma	   levels	  more	  than	  1.8-­‐fold.	  If	  hypothesis	  (1)	  is	  correct,	  the	  truncated	  form	  must	  be	  replaced	  by	  the	   full-­‐length	   TH	   and	   re-­‐tested	   in	   vivo.	   However,	   if	   hypothesis	   (2)	   is	   true,	   TH	  delivery	  must	  be	  significantly	  improved	  by	  enhancing	  expression	  from	  the	  vector	  or	   by	   broadening	   the	   range	   of	   tissues	   that	   can	   be	   targeted	   by	   the	   vector.	  Alternatively,	  increasing	  the	  AAV	  dose	  would	  lead	  to	  more	  vector	  genome	  copies	  per	  hepatocyte.	  However,	  further	  upscaling	  vector	  production	  is	  impractical.	  Next,	   L-­‐DOPA	   release	   from	   the	   liver	   was	   assessed	   by	   measuring	   its	  accumulation	   in	   the	   hepatocytes.	   Accumulation	   of	   hepatic	   L-­‐DOPA	   to	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concentrations	  higher	  than	  those	  observed	  in	  the	  plasma	  would	  be	  indicative	  of	  inefficient	  release	  into	  the	  bloodstream.	  There	  was	  a	  2.3-­‐fold	  accumulation	  of	  L-­‐DOPA	  in	  the	  liver	  of	  vector	  treated	  animals	  relative	  to	  the	  vehicle	  treated	  group	  (Figure	  33).	   This	  mirrors	   the	  difference	   in	  plasma	   levels	   seen	  between	  vector-­‐	  and	  vehicle-­‐treated	  animals	  (Table	  13)	  suggesting	  that	   the	  L-­‐DOPA	  synthesised	  in	  the	  liver	  is	  readily	  released	  into	  the	  bloodstream.	  The	  concentration	  of	  hepatic	  L-­‐DOPA	   matched	   the	   pattern	   observed	   for	   transgene	   expression	   and	   L-­‐DOPA	  plasma	   levels,	   with	   mouse	   #2	   having	   the	   highest	   concentration,	   followed	   by	  mouse	  #3	  and	  finally	  mouse	  #1.	  Mouse	  #5	  had	  similar	  hepatic	  L-­‐DOPA	  levels	  as	  vehicle-­‐treated	   animals.	   This	   animal	   also	   had	   the	   lowest	   vector	   genome	   copy	  numbers	   per	   cell	   (Figure	   28)	   and	   showed	   the	   weakest	   expression	   of	   TH	   and	  GCH1	  by	  IHC	  and	  western	  blot	  (Figure	  26	  and	  Figure	  27).	  Mouse	  #2	  was	  the	  only	  animal	   that	  could	  suggest	  hepatic	  accumulation	  of	  L-­‐DOPA	  as	   it	  had	  a	  5-­‐fold	  L-­‐DOPA	   enrichment	   relative	   to	   control	   animals.	   Mice	   treated	   with	   oral	   L-­‐DOPA	  showed	   no	   difference	   in	   intrahepatic	   L-­‐DOPA	   compared	   to	   vehicle-­‐treated	  animals	  (3.35±0.25	  vs.	  2.99±0.21	  ng/mg	  liver).	  Mouse	  #4	  was	  not	  considered	  in	  this	  assay	  due	  to	  its	  early	  death.	  	  
	  
Figure	  33:	  Scatter	  plot	  of	  hepatic	  L-­‐DOPA	  levels	  from	  mice	  from	  study	  2.	  
Hepatic	   L-­‐DOPA	   was	   measured	   from	   individual	   animals	   by	   HPLC	   with	   electrochemical	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degraded,	  it	  is	  a	  good	  predictor	  of	  the	  stability	  of	  L-­‐DOPA	  synthesised	  in	  the	  liver	  and	  the	  efficacy	  of	  the	  COMT	  inhibition	  regimen	  adopted	  in	  the	  study.	  Therefore,	  detection	   of	   high	   levels	   of	   3-­‐OMD	   in	   the	   liver	   would	   be	   indicative	   of	   L-­‐DOPA	  degradation	  and	  insufficient	  COMT	  inhibition.	  As	   Figure	   34	   shows,	   there	   was	   no	   hepatic	   enrichment	   of	   3-­‐OMD	   in	   vector-­‐treated	  animals.	  Mice	  #2	  and	  #3,	  which	  showed	  the	  highest	  plasma	  and	  hepatic	  L-­‐DOPA	   levels,	   had	   0.21	   and	   0.56	   ng	   of	   3-­‐OMD	   per	   mg	   of	   liver	   tissue,	  respectively.	   3-­‐OMD	   levels	   in	   vector-­‐treated	   mice	   #1	   and	   #5	   as	   well	   as	   in	   all	  vehicle-­‐treated	  animals	  were	  below	  the	  assay’s	  detection	  limit.	  Big	  variation	  was	  observed	   in	   mice	   treated	   with	   oral	   L-­‐DOPA,	   with	   one	   mouse	   showing	   a	   low	  concentration	  (0.36ng/mg	  liver)	  and	  the	  other	  two	  showing	  much	  higher	  levels	  (1.23	  and	  3.05ng/mg	  liver).	  	  	  
	  
Figure	  34:	  Scatter	  plot	  of	  hepatic	  3-­‐OMD	  concentrations.	  
Hepatic	   levels	  of	  3-­‐OMD	   in	   individual	  animals	  28	  days	  post-­‐injection	  measured	  by	  HPLC	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peripheral	   L-­‐DOPA	   synthesis	   in	   other	   organs	   in	   addition	   to	   the	   liver	   and	   (2)	  comparing	  the	  activity	  of	  the	  tTH	  vs.	  full-­‐length	  TH	  in	  vitro.	  
3.2.8 Peripheral	  L-­‐DOPA	  Synthesis	  in	  Additional	  Tissues	  The	  aim	  of	  the	  proposed	  gene	  therapy	  for	  L-­‐DOPA	  synthesis	  in	  the	  periphery	  is	   to	   deliver	   L-­‐DOPA	   in	   a	   continuous	   manner.	   By	   targeting	   the	   liver	   with	   the	  bicistronic	   vector,	   a	   rise	   in	   plasma	   levels	   from	   0.91	   to	   1.67nmol/ml	   was	  observed,	  which	  corresponds	  to	  a	  1.8-­‐fold	  increase.	  In	  humans,	  the	  threshold	  for	  minimal	   clinical	   effect	   is	   estimated	   to	   be	   around	   7nmol/ml,	   about	   the	   same	  plasma	   L-­‐DOPA	   concentration	   reached	   in	   mice	   treated	   with	   the	   oral	   L-­‐DOPA	  regimen	   (Dethy	   et	   al.	   1997;	  Nutt	  &	  Woodward	  1986).	  Therefore,	   although	   this	  gene	  therapy	  strategy	  does	  not	  aim	  to	  match	  the	  L-­‐DOPA	  plasma	  levels	  reached	  by	  the	  oral	  L-­‐DOPA	  therapy,	  but	  rather	  to	  provide	  a	  continuous	  basal	  supply,	  an	  AAV-­‐mediated	   increase	   in	   L-­‐DOPA	   levels	   to	   at	   least	   half	   of	   that	   achieved	  with	  oral	  L-­‐DOPA	  medication	  is	  desired.	  Such	  a	  rise	  would	  be	  sufficient	  to	  allow	  for	  a	  significant	   decrease	   in	   oral	   L-­‐DOPA	   intake	   and	   potentially	   improve	   LID	   by	  diminishing	  plasma	  peaks	   and	   troughs.	  The	   results	  presented	   so	   far	   show	   that	  further	  optimisation	  is	  necessary	  in	  order	  to	  reach	  a	  basal	  L-­‐DOPA	  supply	  with	  a	  therapeutic	   potential	   when	   combined	   with	   the	   standard	   oral	   L-­‐DOPA	  pharmacotherapy.	   The	   first	   step	   towards	   achieving	   this	   goal	   is	   testing	   if	   the	  truncated	   TH	   presents	   diminished	   catalytic	   activity	   relative	   to	   the	   full-­‐length	  form.	   Allowing	   L-­‐DOPA	   synthesis	   to	   occur	   at	   additional	   peripheral	   sites	   like	  skeletal	   muscle	   could	   potentially	   further	   increase	   plasma	   L-­‐DOPA	   levels.	  Therefore,	   the	   vector	   was	   redesigned	   to	   allow	   for	   transgene	   expression	   in	  skeletal	  muscle	   in	   addition	   to	   the	   liver.	   It	   is	   known	   from	   several	   gene	   therapy	  trials	   that	   different	   tissues,	   including	   muscle,	   can	   be	   used	   as	   a	   system	   for	  synthesis	   and	   delivery	   of	   biologically	   active	   molecules	   (Ding	   et	   al.	   2008;	  Nathwani	   et	   al.	   2011;	   Balazs	   et	   al.	   2012).	   Thus,	   allowing	   additional	   tissues	   to	  participate	  in	  the	  peripheral	  synthesis	  of	  L-­‐DOPA	  has	  the	  potential	  to	  bridge	  the	  gap	  needed	  to	  achieve	  increased	  levels	  of	  systemic	  L-­‐DOPA.	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3.2.9 Design	  of	  an	  AAV	  Vector	  for	  L-­‐DOPA	  Synthesis	  in	  Additional	  Tissues	  Using	  AAV8	  as	  a	  vector	   for	  gene	  therapy	   leads	  mainly	  to	  the	  transduction	  of	  liver,	  skeletal	  and	  cardiac	  muscle.	  However,	  gene	  addition	  of	  GCH1	  and	  TH	  will	  not	   lead	   to	   L-­‐DOPA	   synthesis	   in	   the	  muscle	   due	   to	   the	   lack	   of	   the	  TH	   cofactor	  BH4	   in	   this	   tissue.	   In	   this	  scenario,	   the	  second	  enzyme	   in	   the	  BH4	  biosynthetic	  pathway	   -­‐	   6-­‐pyruvoyl	   tetrahydropterin	   synthase	   (PTPS)	   -­‐	   must	   be	   present	   in	  order	  for	  BH4	  synthesis	  to	  occur	  and	  consequently	  for	  TH	  to	  function	  normally	  (Ding	  et	  al.	  2008).	  Therefore,	  two	  AAV	  vectors	  were	  constructed	  that	  harbour	  the	  
TH,	  PTPS	  and	  GCH1	  genes	  in	  one	  single	  genome.	  Both	  vectors	  are	  almost	  identical	  with	  the	  only	  difference	  being	  in	  the	  TH	  gene.	  One	  vector	  contains	  a	  truncated	  TH	  gene,	  while	  the	  other	  has	  the	  465bp	  that	  comprise	  the	  regulatory	  domain	  at	  the	  N-­‐terminus	  portion	  of	  TH,	   allowing	  us	   to	   assess	  whether	   the	   tTH	   is	   less	   active	  then	  the	  full-­‐length	  TH	  (Figure	  25).	  	  
	  
	  
Figure	  35:	  Schematic	  of	  systemic	  tricistronic	  vectors.	  
Vectors	   express	   the	   truncated	   TH	   (tTH)	   (A)	   or	   the	   full-­‐length	   TH	   (B).	   Three	   genes	  
necessary	  for	  L-­‐DOPA	  synthesis	  in	  the	  periphery	  are	  expressed	  from	  a	  single	  constitutive	  
human	  promoter.	  The	  TH	  gene	  is	  separated	  by	  an	  IRES	  from	  the	  PTPS,	  which	  is	  followed	  by	  
the	   FMDV	   2A	   sequence	   and	   then	   the	   GCH1	   gene.	   The	   miRNA208	   target	   sequence	   will	  
prevent	  expression	  of	  this	  vector	  in	  cardiac	  cells.	  	  To	  achieve	  expression	  of	  the	  three	  proteins	  from	  a	  single	  mRNA,	  the	  design	  of	  the	   vector	  was	  modified	   relative	   to	   the	   bicistronic	   construct.	   The	   truncated	   or	  full-­‐length	  forms	  of	  the	  TH	  coding	  sequence	  are	  immediately	  downstream	  of	  the	  EF1α	  promoter,	  a	  constitutive	  promoter	  of	  human	  origin.	  This	  is	  in	  turn	  followed	  by	  the	  encephalomyocarditis	  virus	  (EMCV)	  IRES	  that	  will	  allow	  translation	  of	  the	  
PTPS	   and	   GCH1	   genes,	   which	   are	   linked	   by	   the	   foot-­‐and-­‐mouth	   disease	   virus	  (FMDV)	  2A	  sequence.	  Because	   the	  PTPS	  stop	  codon	   is	  absent	   in	   this	   construct,	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once	  the	  ribosome	  reaches	  the	  2A	  sequence,	  it	  will	  read	  through	  and	  skip	  to	  the	  
GCH1	   coding	   sequence,	   leading	   to	   the	   expression	  of	   two	   independent	  proteins.	  The	   resulting	   independent	   proteins	   will	   be	   slightly	   different	   to	   the	   wild-­‐type	  forms	  due	  to	  the	  presence	  of	  the	  2A	  sequence:	  the	  PTPS	  enzyme	  will	  have	  a	  27	  amino	   acid	   overhang	   at	   the	   C-­‐terminus	   and	   the	   GCH1	   will	   have	   a	   proline	  upstream	  of	   the	  start	  methionine.	  Between	  the	  GCH1	  and	  the	  polyA,	   the	  WPRE	  sequence	   was	   added	   to	   enhance	   expression	   from	   this	   mRNA.	   Finally,	  immediately	   downstream	  of	   the	   polyA	   sequence,	   two	   copies	   of	   the	  microRNA-­‐208a	  target	  sequence	  (miR208aT)	  were	  added	  in	  tandem.	  Cardicac	  muscle	  cells	  express	   the	   22nt	   long	   non-­‐protein-­‐coding	   microRNA208a	   which,	   upon	  interaction	  with	  the	  3’	  untranslated	  region	  of	  its	  target	  sequence	  miR208aT,	  will	  inhibit	  its	  translation,	  leading	  to	  the	  silencing	  of	  the	  vector	  (Roudaut	  et	  al.	  2013;	  Wang	  et	  al.	  2014).	  Thus,	  microRNA-­‐mediated	  gene	  silencing	  of	  the	  vector	  in	  the	  heart	   will	   avoid	   off-­‐target	   effects	   such	   as	   L-­‐DOPA-­‐induced	   cardiac	   arrhythmia	  (Landsberg	   1972).	   The	   tricistronic	   vector	   was	   constructed	   by	   replacing	  individual	  elements	  in	  pAA019	  to	  make	  pAA062	  -­‐	  expressing	  truncated	  TH	  –	  or	  pAA063	   –	   expressing	   full-­‐length	   TH.	   Once	   the	   cloning	   was	   finalised,	   plasmids	  were	  verified	  by	  sequencing	  and	  the	  integrity	  of	  the	  ITRs	  was	  confirmed	  by	  SmaI	  restriction	  endonuclease	  analysis.	  	  
3.2.10 In	  vitro	  validation	  of	  the	  systemic	  vectors	  The	   in	   vitro	   validation	   of	   the	   systemic	   vectors	   was	   done	   by	   verifying	   the	  expression	  of	   the	   three	  enzymes	   in	  HEK293T	  cells.	  Cells	  were	   transfected	  with	  increasing	  amounts	  of	  DNA	  and	  protein	  expression	  was	  assessed	  by	  western	  blot	  48	   post-­‐transfection.	   Figure	   36	   shows	   that	   the	   construct	   harbouring	   the	  truncated	  TH	  successfully	  expresses	  the	  three	  transgenes	  from	  a	  single	  mRNA	  in	  
vitro.	   A	   dose-­‐response	   effect	   is	   observed	   relative	   to	   the	   amount	   of	   transfected	  DNA.	   Moreover,	   the	   FMDV	   2A	   sequence	   leads	   to	   the	   efficient	   translation	   of	  independent	  PTPS	  and	  GCH1	  proteins.	  Because	  the	  construct	  expressing	  the	  full-­‐length	  TH	  was	  generated	  at	  a	   later	  point,	   its	  expression	  could	  not	  be	  validated	  before	   this	   thesis	   was	   written.	   Although	   the	   data	   are	   missing	   at	   this	   point,	   a	  similar	  expression	  pattern	  as	  seen	  in	  Figure	  36	  is	  expected.	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Figure	  36:	  In	  vitro	  validation	  of	  the	  tricistronic	  vector	  construct.	  
Western	  blot	  was	  performed	  on	  cell	  extracts	  of	  the	  HEK293T	  cell	  line	  transfected	  with	  the	  
tricistronic	   AAV	   producer	   plasmid	   harbouring	   the	   truncated	   TH	   gene.	   4x105	   cells	   were	  
infected	  in	  a	  12	  well	  plate	  with	  different	  amounts	  of	  plasmid.	  Protein	  expression	  from	  the	  
three	  transgenes	  was	  assessed	  48h	  post-­‐transfection.	  NTC:	  non-­‐transfected	  cells.	  	  The	  strategy	  adopted	  to	  allow	  the	  expression	  of	  the	  three	  genes	  from	  a	  single	  mRNA	  was	   possible	   due	   to	   the	   inclusion	   of	   the	   FMDV	   2A	   sequence.	   However,	  after	  the	  “cleavage”	  that	  will	  separate	  the	  PTPS	  from	  the	  GCH1	  peptide,	  PTPS	  will	  contain	   27	   additional	   C-­‐terminal	   amino	   acids.	   Given	   that	   this	   enzyme	   forms	   a	  homohexamer	   for	   its	   catalytic	   activity,	   the	  effect	  of	   these	  extra	  amino	  acids	  on	  the	   formation	   of	   higher-­‐order	   structures	   is	   unknown.	   Thus,	   to	   validate	   the	  catalytic	  activity	  of	   the	  PTPS	  expressed	  by	   the	  new	  construct,	  COS-­‐7	  cells	  were	  transfected	  and	  the	  catalytic	  activity	  of	  PTPS	  is	  currently	  being	  measured	  using	  a	  protocol	  adapted	  from	  Heintz	  et	  al.	  (Heintz	  et	  al.	  2012).	  	  
3.3 Discussion	  In	   this	   chapter	   I	   tested	   the	   feasibility	   of	   AAV-­‐mediated	   continuous	   L-­‐DOPA	  synthesis	   in	   the	   periphery	   as	   a	   potential	   therapy	   to	   reduce	   the	   side	   effects	  currently	  associated	  with	  chronic	  oral	  L-­‐DOPA	  uptake.	  To	  this	  end,	  I	  used	  rAAV8	  vectors	  to	  achieve	  extrachromosomal	  gene	  addition	  of	  TH	  and	  GCH1	  in	  the	  liver	  of	  healthy	  mice	  in	  order	  to	  induce	  L-­‐DOPA	  synthesis	  in	  this	  organ.	  I	  was	  able	  to	  show	  that	  the	  bicistronic	  vector	  is	  able	  to	  efficiently	  transduce	  the	  liver	  in	  both	  female	  and	  male	  mice	  and	   is	  well	   tolerated.	  A	  single	  systemic	   injection	   led	  to	  a	  1.8-­‐fold	   increase	   in	   the	   levels	   of	   circulating	   L-­‐DOPA,	   however,	   this	   rise	   is	   not	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likely	   to	   translate	   into	   therapeutic	   benefit	   and	   the	   gene	   therapy	   strategy	  must	  still	  be	  further	  optimised.	  I	   explored	   two	   approaches	   to	   achieve	  peripheral	   L-­‐DOPA	  production.	   In	   the	  first	   one,	   the	   TH	   and	   GCH1	   genes	   were	   delivered	   by	   separate	   vectors.	   The	  rationale	  was	  that	  this	  strategy	  would	  allow	  the	  investigation	  of	  whether	  vector-­‐induced	  BH4	  synthesis	  is	  necessary	  to	  support	  TH	  activity.	  BH4	  occurs	  naturally	  in	  the	  liver	  and	  it	  functions	  as	  a	  cofactor	  for	  the	  enzyme	  PAH.	  In	  this	  experiment,	  dsAAV	   vectors	   were	   used	   to	   take	   advantage	   of	   their	   rapid	   onset	   of	   transgene	  expression;	  the	  target	  vector	  dose	  was	  in	  the	  range	  of	  1x1011	  gcp/mouse	  (Wang	  et	  al.	  2003).	  Sufficient	  vector	  could	  be	  generated	  to	  treat	  mice	  with	  a	  total	  dose	  of	  7x1010	  gcp/mouse,	  which	  is	  close	  to	  the	  dose	  of	  1x1011	  gcp/mouse	  shown	  to	  lead	  to	  broad	  liver	  transduction	  with	  a	  dsAAV8	  vector	  expressing	  its	  transgene	  from	  the	   same	   liver-­‐specific	   LP1	   promoter	   (Nathwani	   et	   al.	   2006).	   Surprisingly,	  hepatic	   transduction	   achieved	   with	   this	   dose	   was	   below	   1%,	   which	   was	   not	  sufficient	   to	   increase	  L-­‐DOPA	  plasma	   levels	  28	  days	  post-­‐AAV	   injection	  (Figure	  16	  and	  Table	  3).	  The	  reasons	  for	  the	  low	  transduction	  efficiency	  observed	  with	  these	   vectors	   are	   not	   yet	   entirely	   clear.	   DNA	   sequencing	   and	   endonuclease	  quality	  control	  digestion	  demonstrated	  correct	  DNA	  sequences	  and	  ITR	  integrity	  in	  both	  vector	  producer	  plasmids.	  Likewise,	  SDS-­‐PAGE	  analysis	  of	  both	  vectors	  showed	  preparations	  of	  high	  purity	  (Figure	  14).	  In	  addition,	  given	  that	  both	  AAV	  producer	   plasmids	   were	   generated	   by	   a	   single	   cloning	   step	   to	   replace	   the	  transgene	  from	  the	  already	  validated	  dsAAV2/8-­‐LP1-­‐hFIXco,	  which	  harboured	  a	  codon	  optimised	  version	  of	  the	  human	  factor	  IX	  cDNA,	  protein	  expression	  from	  both	   vectors	   was	   not	   verified	   in	   vitro	   prior	   to	   injection.	   However,	   the	   low	  transduction	   efficiency	   observed	  with	   the	  monocistronic	   vectors	   urges	   for	   the	  verification	   of	   TH	   and	  GCH1	   expression	   from	  both	   vectors	   in	   order	   to	   confirm	  transgene	  cassette	  integrity.	  The	   findings	   of	   this	   experiment	   indicated	   that	   most	   likely	   transduction	  efficiency	  had	  to	  be	  significantly	  improved	  by	  increasing	  the	  injection	  dose.	  The	  optimal	   dose	   could	   be	   determined	   by	   preforming	   a	   dose	   escalation	   study,	  however,	   	   packaging	   efficiency	   of	   the	   dsAAV8-­‐LP1-­‐tTH	   vector	   was	   very	   low	   -­‐	  total	   particle:gcp	   titre	   ratio	   >	   10	   (Table	   6)	   –	   and	   significantly	   upscaling	   the	  production	   of	   this	   vector	  would	   not	   yield	   sufficient	   vector	   for	   the	   injection	   of	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higher	   doses.	   Therefore,	   the	   dual	   vector	   approach	   was	   abandoned	   and	   a	   new	  vector	  was	  generated	   that	   combines	   the	  TH	   and	  GCH1	   genes	   into	   a	   single	  AAV	  genome.	  A	  similar	  vector	  had	  previously	  been	  shown	  to	  express	  both	  enzymes	  in	  the	  optimal	  5:1	  ratio	  and	  to	  lead	  to	  continuous	  L-­‐DOPA	  synthesis	  in	  the	  striatum	  of	  a	  rat	  model	  of	  PD	  (Cederfjäll	  et	  al.	  2012).	  With	  the	  experiments	  using	  the	  bicistronic	  vector,	  I	  was	  able	  to	  demonstrate	  that	   it	   expressed	   both	   proteins	   in	   vitro	   and	   that	   in	   vivo	   doses	   of	   1x1012	   and	  3.6x1012	  gcp/mouse	  are	  well	  tolerated	  and	  lead	  to	  a	  broad	  vector	  spread	  in	  the	  liver	  (Figure	  22	  and	  Figure	  13).	  The	  IHC	  results	  showed	  a	  strong	  TH	  and	  GCH1	  staining,	   however,	   the	   broad	   viral	   transduction	   did	   not	   reflect	   in	   a	   significant	  increase	  of	  plasma	  L-­‐DOPA,	  where	  only	  a	  modest	  1.8-­‐fold	  increase	  was	  observed	  (Figure	  24).	   Interestingly,	   the	  magnitude	  of	   the	  effect	  on	  plasma	  L-­‐DOPA	   levels	  was	  similar	  for	  both	  doses	  tested,	  suggesting	  a	  possible	  saturation	  of	  the	  system.	  Alternatively,	   it	   is	  possible	   that	   the	  difference	  between	  both	  doses	  was	  not	  big	  enough	  to	  evoke	  distinct	  effects	  detectable	  at	  the	  plasma	  level.	  The	  IHC	  staining	  was	   on	   average	   more	   intense	   in	   animals	   that	   received	   the	   higher	   dose,	  suggesting	   the	   presence	   of	  more	   vector	   copies/cell.	   This	   is	   the	  most	   plausible	  interpretation	   for	   this	   result	   given	   that	   there	   is	   a	   positive	   correlation	  between	  vector	   copy	   numbers	   and	   transgene	   expression	   (McIntosh	   et	   al.	   2013).	  Unfortunately,	   quantification	   of	   vector	   genome	   copy	   numbers	   per	   hepatocyte	  was	  not	  possible	  in	  these	  mice	  because	  their	  livers	  were	  fixed	  with	  PFA	  after	  the	  termination	  of	  the	  experiment.	  The	  efficiency	  of	  the	  AADC	  and	  COMT	  inhibition	  given	  to	  the	  animals	  prior	  to	  blood	  collection	  and	  sacrifice	  was	  also	  questioned.	  Firstly,	  the	  dosing	  regimen	  used	  differed	  from	  that	  in	  our	  previous	  experiment	  –	  here	  mice	  were	   treated	  with	   one	   single	   dose	   instead	   of	   three	   sub-­‐doses	   –	   and	  secondly	   because	   the	   COMT	   inhibitor	   may	   not	   have	   been	   sufficiently	   fresh	   to	  guarantee	   optimal	   activity.	   Because	   of	   the	   surprisingly	   low	   transduction	   seen	  with	  the	  monocistronic	  dsAAV	  vectors,	  the	   in	  vivo	  assessment	  of	  the	  bicistronic	  vector	   was	   at	   first	   conceptualised	   as	   a	   preliminary	   study	   with	   the	   aim	   to	  determine	  hepatic	   transduction	  efficiency	  by	   IHC	  on	  paraffin	   embedded	   tissue.	  However,	  on	  the	  day	  of	  sacrifice	  plasma	  collection	  from	  the	  animals	  for	  L-­‐DOPA	  measurement	   was	   added	   to	   the	   study	   protocol.	   This	   change	   in	   protocol	   was	  responsible	  for	  the	  modified	  AADC	  and	  COMT	  inhibitor	  regimen	  as	  well	  as	  for	  the	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use	  of	   an	  old	   reagent	   for	   the	  COMT	   inhibition.	  The	   fact	   that	   good	   transduction	  was	   seen	   after	   increasing	   the	   dose	   19-­‐fold	   suggests	   that	   animals	   injected	  with	  the	  dsAAV	  vectors	  in	  the	  previous	  experiment	  had	  been	  underdosed.	  The	  hepatic	  transduction	   observed	   for	   both	   doses	   of	   the	   bicistronic	   vector	   agrees	  with	   the	  65%	   hepatic	   transduction	   published	   for	   single-­‐stranded	   AAV8	   (Nakai	   et	   al.	  2005).	   In	   addition,	   the	   lack	   of	   evidence	   of	   tissue	   injury	   or	   inflammation	   is	   in	  agreement	  with	  the	  low	  toxicity	  and	  high	  tolerability	  of	  humans	  and	  animals	  to	  AAV	  vectors	  (Kaplitt	  et	  al.	  2007;	  Muramatsu	  et	  al.	  2010).	  Finally,	  the	  vector	  was	  able	  to	  increase	  the	  levels	  of	  circulating	  L-­‐DOPA	  in	  female	  mice.	  Because	   good	   transduction	  was	   observed	  with	   the	   bicistronic	   vector,	  which	  led	  to	  a	  1.8-­‐fold	  increase	  in	  plasma	  L-­‐DOPA	  at	  both	  doses	  tested	  (3.6-­‐	  and	  1x1012	  gcp/mouse),	   the	   lower	  dose	  was	  selected	   for	   the	  experiment	   in	  male	  mice.	  For	  this	   experiment,	   the	   number	   of	   animals	   in	   the	   vector-­‐treated	   group	   was	  increased	   from	   3	   to	   5.	   Furthermore,	   the	   original	   AADC	   and	   COMT	   inhibitor	  regimen	  from	  the	  first	  study	  was	  adopted	  and	  a	  group	  of	  mice	  receiving	  oral	  L-­‐DOPA	  treatment	  was	  included	  to	  mimic	  the	  typical	  route	  and	  dose	  taken	  by	  PD	  patients	  to	  treat	  their	  motor	  symptoms	  (Table	  12	  and	  Figure	  25).	  As	  seen	  in	  the	  female	  mice,	  male	  mice	   showed	   a	   1.8-­‐fold	   increase	   in	   plasma	  L-­‐DOPA	  28	   days	  post-­‐injection,	  a	  contrasting	  result	  to	  studies	  that	  show	  a	  gender	  effect	  in	  murine	  hepatic	   transduction	   with	   AAV	   vectors	   (Davidoff	   et	   al.	   2003).	   Variability	   in	  vector	   transduction	  was	   observed	   between	  mice,	  which	  was	   confirmed	   by	   the	  vector	  genome	  copy	  numbers	  per	  cell,	  IHC	  and	  western	  blot	  data.	  Although	  IHC	  assessment	   of	   transduction	   indicated	   similar	   AAV	   expression	   levels	   between	  mice	   #2	   and	   #3	   and	  mice	   #1	   and	   #5,	   the	   western	   blot	   data	   showed	   that	   the	  variation	   in	   the	   amount	   of	   TH	   expressed	   in	   the	   liver	   of	   the	   animals	  was	  more	  pronounced.	   The	   western	   blot	   data	   is	   supported	   by	   the	   quantification	   of	   the	  vector	  genome	  copy	  numbers	  per	  hepatocyte.	  The	  close	  correlation	  between	  the	  vector	  genome	  copies	  quantification	  and	  the	  western	  blot	  data	  can	  be	  explained	  by	  the	  higher	  sensitivity	  of	  both	  methods	  compared	  to	  IHC.	  Possible	   reasons	   for	   the	  observed	  variability	  were:	   the	  use	  of	  CD-­‐1	  mice,	   an	  outbred	  strain,	  can	  have	  contributed	  to	  the	  variability	  in	  transduction	  levels.	  For	  example,	   the	   use	   of	   CD-­‐1	   mice	   has	   been	   shown	   to	   mask	   effects	   in	   toxicity	  screenings	   otherwise	   detected	   when	   inbred	   mouse	   strains	   are	   used	   (Festing	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2010).	   Genetic	   variation	   could	   also	   explain	   the	   variability	   in	   plasma	   L-­‐DOPA	  levels	   in	   the	   group	   treated	  with	   oral	   L-­‐DOPA.	   However,	   inaccuracy	   during	   the	  injection	  of	  the	  vector	  cannot	  be	  excluded	  as	  the	  source	  of	  variability.	  On	  the	  day	  of	   injection	   it	  was	  observed	   that	   the	  mice	  had	  been	   fighting	   and	  most	   of	   them	  had	   body	   injuries	   including	   the	   tail.	   This	  made	   the	   localisation	   of	   the	   tail-­‐vein	  and	   the	   injection	  procedure	  more	  difficult	  and	  possibly	  more	  variable	  between	  mice.	   The	   variability	   in	   the	   L-­‐DOPA	   levels	   seen	   in	   the	   orally	   treated	   animals	  could	  be	  explained	  by	  factors	  that	  also	  affect	  L-­‐DOPA	  peak	  doses	  in	  humans	  after	  oral	   medication:	   erratic	   gastric	   emptying	   and	   competition	   with	   other	   amino	  acids	  for	  absorption	  in	  the	  intestine	  (Kurlan	  et	  al.	  1988;	  Camargo	  et	  al.	  2014).	  Despite	   the	  variation	   in	  vector	   transduction,	  mice	   showed	  on	  average	  a	  1.8-­‐fold	  increase	  in	  plasma	  L-­‐DOPA	  levels.	  The	  highest	  levels	  were	  seen	  in	  mouse	  #2,	  which	  was	  the	  most	  aggressive	  one	  and	  did	  not	  show	  clear	  signs	  of	  fight-­‐related	  injuries	   on	   its	   tail	   on	   the	   day	   of	   injection.	   Even	   if	   analysed	   alone,	   the	   fold-­‐increase	   in	   plasma	   L-­‐DOPA	   in	   mouse	   #2	   relative	   to	   untreated	   mice	   was	   2.5.	  When	   compared	   to	   the	   levels	   after	   L-­‐DOPA	  oral	   treatment,	   vector-­‐mediated	   L-­‐DOPA	  production	  is	  modest	  and	  not	  likely	  to	  provide	  a	  basal	  L-­‐DOPA	  supply	  with	  a	  potential	  therapeutic	  benefit.	  In	  an	  attempt	  to	  further	  understand	  the	  reasons	  for	  the	  modest	  L-­‐DOPA	  rise,	  three	  possible	  roadblocks	  for	  AAV-­‐mediated	  hepatic	  L-­‐DOPA	  synthesis	  were	  investigated:	  (1)	  insufficient	  amount	  of	  TH	  expressed	  by	  the	   vector;	   (2)	   inefficient	   L-­‐DOPA	   secretion	   form	   the	   hepatocyte;	   and	   (3)	  inadequate	  hepatic	  COMT	  inhibition.	  These	   findings	  suggest	   that	   the	  amount	  of	  TH	  expressed	   in	   the	  mouse	   livers	  was	  lower	  than	  that	  found	  in	  the	  naïve	  striatum.	  Although	  only	  the	  livers	  of	  two	  mice	  were	  compared	  with	  the	  striatum,	  mouse	  #2	  expressed	  half	  the	  amount	  of	  TH	  present	  in	  the	  naïve	  striatum,	  while	  mouse	  #3	  expressed	  16-­‐fold	  less	  (Figure	  32).	  Although	  the	  livers	  of	  mice	  #1	  and	  #5	  were	  not	  quantified	  by	  western	  blot,	  they	  had	  even	  less	  TH	  than	  mouse	  #3	  as	  seen	  from	  the	  IHC	  and	  western	  blot	  data	  (Figure	   16	   and	   Figure	   27).	   In	   general,	   the	   hepatic	   TH	   activity	   data	   does	   not	  correlate	   directly	   with	   the	   levels	   of	   transgene	   expression	   seen	   by	   IHC	   and	  western	  blot	  or	  with	  the	  genome	  copy	  numbers	  per	  cell.	  Taken	  together,	  the	  TH	  activity	  data	  suggest	  that	  the	  truncated	  form	  of	  the	  TH	  expressed	  by	  the	  vector	  is	  less	  active	   than	   the	   full-­‐length	  wild-­‐type	   form	  present	   in	   the	  striatum.	  There	   is	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no	  evidence	  in	  the	  literature	  to	  support	  a	  decreased	  catalytic	  activity	  of	  TH	  after	  the	   removal	   of	   its	   regulatory	   domain.	   In	   fact,	   the	   opposite	   seems	   to	   be	   true:	  truncations	   of	   the	   first	   40-­‐165	   amino	   acids	   (the	   truncated	   form	   used	   in	   the	  vector	   described	   here	   lacks	   the	   first	   155	   amino	   acids),	   which	   comprise	   the	  enzyme’s	  regulatory	  domain,	  have	  been	  reported	  to	  increase	  enzymatic	  activity	  by	  up	  to	  200%	  (Walker	  et	  al.	  1994).	  Nevertheless,	  the	  data	  presented	  here	  might	  suggest	  the	  contrary	  and	  the	  means	  by	  which	  this	  question	  will	  be	  addressed	  is	  discussed	  later	  in	  this	  section.	  After	   comparing	   the	   levels	   of	   TH	   expressed	   in	   the	   liver	   and	   the	   striatum,	  analysis	   of	   intrahepatic	   accumulation	   and	   the	   degradation	   of	   newly	   formed	   L-­‐DOPA	  was	  performed.	  The	  data	  showed	  2.3-­‐fold	  increased	  hepatic	  L-­‐DOPA	  levels	  in	  vector-­‐treated	  animals	   relative	   to	  vehicle-­‐treated	  ones.	  This	   is	   similar	   to	   the	  fold-­‐increase	  observed	   in	  plasma	  L-­‐DOPA	  and	   indicates	   that	  newly	  synthesised	  L-­‐DOPA	   is	   readily	   released	   from	   the	   liver.	   However,	   it	   must	   be	   noticed	   that	  mouse	  #2	  had	  a	  5-­‐fold	  hepatic	  L-­‐DOPA	  accumulation.	  Measurement	   of	   hepatic	   3-­‐OMD,	   the	   metabolite	   formed	   upon	   L-­‐DOPA	  degradation	  by	  COMT,	  indicate	  that	  the	  inhibitor	  regimen	  adopted	  in	  this	  study	  was	   adequate	   and	   efficiently	   blocked	   the	   COMT-­‐mediated	   degradation	   of	   L-­‐DOPA.	   Due	   to	   its	   half-­‐life	   of	   ~15h,	   degradation	   of	   L-­‐DOPA	   would	   lead	   to	   the	  accumulation	  of	  this	  metabolite	  in	  the	  liver,	  however	  this	  was	  not	  observed.	  A	  fourth	  alternative	  that	  could	  explain	  why	  plasma	  L-­‐DOPA	  levels	  do	  not	  seem	  to	   increase	   any	   further	   than	   1.8-­‐fold	   is	   that	   the	   amount	   of	   tyrosine	   and	   BH4	  present	   in	   the	   liver	   are	   not	   sufficient	   to	   sustain	   TH	   activity	   and	   L-­‐DOPA	  synthesis.	  Although	  hepatic	   levels	  of	  both	  molecules	  were	  not	  measured	  before	  the	  completion	  of	  this	  thesis,	  it	  seems	  unlikely	  that	  BH4	  could	  be	  a	  limiting	  factor	  given	  its	  natural	  occurrence	  in	  the	   liver	  and	  the	  additional	  synthesis	  supported	  by	   vector-­‐mediated	   GCH1	   expression.	   The	   measurement	   of	   hepatic	   tyrosine	  levels	  is	  planned	  for	  the	  future.	  Taken	   together,	   the	   data	   presented	   in	   this	   chapter	   indicate	   that	   L-­‐DOPA	  synthesis	   is	  hampered	  at	   some	   level	   following	  AAV-­‐mediated	  expression	  of	  TH	  and	  GCH1	  in	  the	  liver.	  As	   discussed	   above,	   despite	   successful	   hepatic	   transduction	   and	   TH	  expression	   in	   two	   independent	   experiments,	   L-­‐DOPA	   plasma	   levels	   do	   not	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increase	  more	  than	  1.8-­‐fold.	  Possible	  reasons	  could	  be:	  (1)	  lack	  of	  tyrosine	  in	  the	  liver,	   (2)	   insufficient	   amount	   of	   TH	   in	   the	   liver	   or	   (3)	   sub-­‐optimal	   catalytic	  activity	  of	   the	   truncated	  TH	  expressed	  by	   the	  vector.	  Possible	  ways	   to	   address	  hypotheses	  (1)	  and	  (2)	  would	  be	  to	  generate	  a	  vector	  that	  can	  transduce	  not	  only	  the	   liver	   but	   additional	   tissues,	   thereby	   allowing	   more	   cells	   to	   synthesise	   L-­‐DOPA.	   Because	   not	   all	   AAV8	   particles	   end	   up	   in	   the	   liver	   after	   systemic	  administration,	  cells	  from	  other	  tissues	  efficiently	  targeted	  by	  this	  serotype,	  e.g.	  skeletal	   muscle,	   could	   bridge	   the	   gap	   needed	   to	   achieve	   systemic	   levels	   of	   L-­‐DOPA	   that	   have	   therapeutic	   potential.	   In	   line	   with	   this	   hypothesis,	   I	   have	  generated	  and	  validated	  the	  expression	  of	  a	  vector	  that	  has	  the	  potential	  to	  lead	  to	   L-­‐DOPA	   synthesis	   in	   both	   liver	   and	   skeletal	   muscle	   (Figure	   35).	   Although	  expression	  of	  the	  three	  enzymes	  has	  been	  confirmed	  by	  western	  blot,	  the	  in	  vitro	  validation	  of	   their	  enzymatic	  activity	  has	  not	  been	  performed	  yet.	  Validation	  of	  enzymatic	  activity	  is	  particularly	  important	  for	  the	  PTPS	  enzyme,	  which	  is	  linked	  at	   the	   DNA	   level	   to	   the	   GCH1	   gene	   by	   the	   FMDV	   2A	   cleavage	   sequence.	   Once	  “cleaved”,	  the	  2A	  sequence	  will	   leave	  27	  extra	  amino	  acids	  at	  the	  C-­‐terminus	  of	  PTPS,	  which	  can	  potentially	  affect	  its	  ability	  to	  form	  the	  higher-­‐order	  oligomeric	  forms	   required	   for	   its	   catalytic	   activity.	   For	   this	   purpose,	   a	   collaboration	   was	  established	  with	  Prof.	  Beat	  Thöny	  at	  the	  University	  of	  Zürich	  who	  is	  testing	  the	  enzymatic	   activity	   of	   the	   PTPS	   expressed	   from	   this	   new	   vector.	   In	   parallel,	   a	  similar	  vector	  was	  generated,	  which	  harbours	  the	  full-­‐length	  TH	  gene.	  These	  two	  almost	   identical	   constructs	   allow	   for	   the	   in	   vitro	   comparison	   of	   the	   catalytic	  activity	   in	   both	   truncated	   and	   full-­‐length,	   thereby	   addressing	   alternative	   (3)	  mentioned	  above.	  Once	  validated,	   this	   vector	  will	   be	   tested	  at	  doses	  of	  1x1012,	  5x1011	  and	  1x1011	  gcp/mouse	  in	  groups	  of	  six	  mice.	  As	  in	  the	  previous	  study,	  a	  group	  of	  mice	  treated	  orally	  with	  L-­‐DOPA	  will	  serve	  as	  a	  positive	  control.	  If	  the	  therapeutic	   potential	   of	   the	   new	  vector	   is	   confirmed	  by	   significantly	   increased	  plasma	  L-­‐DOPA	  levels,	  a	  biodistribution	  analysis	  of	  the	  vector	  in	  different	  organs	  such	   as	   spleen,	   lungs,	   brain,	   heart,	   liver	   and	   skeletal	   muscle	   is	   proposed.	  However,	  if	  this	  new	  strategy	  still	  does	  not	  lead	  to	  significantly	  increased	  plasma	  levels	  of	  L-­‐DOPA,	  the	  project	  will	  be	  abandoned.	  Prior	   to	   the	   injection	   of	   the	   new	   vector	   in	   animals,	   it	   might	   be	   well	   worth	  replacing	   the	   genes	   in	   the	   construct	   by	   codon-­‐optimised	   sequences.	   Codon	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optimisation	   is	   based	   on	   the	   codon	   usage	   bias	   of	   different	   organisms;	   because	  the	   genetic	   code	   is	   degenerated,	   the	   overabundance	   in	   the	   number	   of	   codons	  allows	  many	  amino	  acids	   to	  be	   encoded	  by	  more	   than	  one	   codon.	  The	   relative	  frequency	  of	  codon	  usage	  varies	  widely	  between	  organisms	  and	  algorithms	  have	  been	  developed,	  which	  convert	  the	  sequence	  of	  a	  given	  gene	  to	  one	  that	  matches	  the	   codon	   usage	   bias	   of	   the	   target	   organism	   without	   altering	   the	   amino	   acid	  sequence	   of	   the	   protein.	   Codon	   optimisation	   has	   been	   used	   in	   gene	   therapy	  strategies	   with	   AAV	   vectors	   and	   it	   has	   been	   shown	   to	   increase	   protein	  expression	  more	   than	  10-­‐fold	  without	   the	  necessity	   to	   increase	   the	  number	   of	  viral	  genome	  copies	  provided	  (McIntosh	  et	  al.	  2013).	  In	   conclusion,	  hepatic	  L-­‐DOPA	  synthesis	   can	  be	  achieved	  using	  AAV	  vectors,	  however	  the	  plasma	  levels	  reached	  are	  unlikely	  to	  provide	  therapeutic	  benefit	  in	  a	  disease	  context.	  The	  reasons	  for	  the	  modest	  rise	  in	  circulating	  L-­‐DOPA	  despite	  efficient	   hepatic	   transduction	   are	   currently	   under	   investigation.	  Nonetheless,	   a	  modification	  in	  the	  vector	  design	  that	  allows	  additional	  tissues	  to	  take	  part	  in	  the	  synthesis	   of	   L-­‐DOPA	   might	   be	   enough	   to	   further	   increase	   the	   therapeutic	  potential	  of	  this	  gene	  therapy	  and	  the	  testing	  of	  this	  hypothesis	  will	  initiate	  once	  the	  newly	  designed	  vector	  has	  been	  completely	  validated.	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Chapter	  4 AAV-­‐mediated	   Continuous	   L-­‐DOPA	   Synthesis	   in	   the	  
Central	  Nervous	  System	  	  
4.1 Introduction	  The	   ultimate	   goal	   in	   translational	   research	   is	   to	   practically	   apply	   the	  knowledge	  gained	  from	  years	  of	  lab	  work	  in	  a	  way	  that	  matters	  to	  patients	  and	  the	   community.	   From	   bench-­‐to-­‐bedside	   projects	   require	   joint	   efforts	   from	  scientists,	   clinicians	   and	   investors	   to	   successfully	   translate	   basic	   science	  discoveries	  into	  medicine.	  The	   early	   stages	   of	   this	   project	   date	   back	   to	   1998	   when	   Mandel	   et	   al.	  demonstrated	   that	   the	   gold-­‐standard	   treatment	   for	   PD	   (i.e.	   systemic	   L-­‐DOPA)	  was	  amenable	  to	  gene	  therapy.	  At	  the	  time,	  the	  notion	  that	  gene	  transfer	  of	  the	  
TH	   and	   GCH1	   genes	   was	   necessary	   and	   sufficient	   for	   L-­‐DOPA	   synthesis	   in	  cultured	   cells	  was	   already	  well	   established.	  The	  pioneer	   study	  of	  Mandel	   et	   al.	  demonstrated	  key	  aspects	  that	  strongly	  increased	  the	  potential	  of	  gene	  therapy	  for	  the	  treatment	  of	  PD.	  Recapitulating	  the	  results	  obtained	  in	  cultured	  cells,	  they	  demonstrated	  that	  AAV-­‐mediated	  TH	  and	  GCH1	  expression	  in	  the	  striatum	  led	  to	  
in	  vivo	  synthesis	  of	  L-­‐DOPA	  in	  a	  rat	  model	  of	  PD.	  Secondly,	  transgene	  expression	  was	   shown	   to	   be	   long	   lasting	   (over	   one	   year	   post-­‐gene	   therapy)	   and,	   equally	  important,	   it	   was	   well	   tolerated.	   Finally,	   this	   study	   defined	   the	   striatal	   cell	  population	   transduced	  by	  rAAV2	  as	  being	  overwhelmingly	  neuronal	   (Uchida	  et	  al.	   1992;	   Bencsics	   et	   al.	   1996;	   Mandel	   et	   al.	   1998).	   In	   the	   following	   14	   years,	  additional	  studies	  provided	  further	  insight	  into	  the	  AAV-­‐mediated	  TH	  and	  GCH1	  gene	  transfer	  approach,	  which	  allowed	  for	  its	  refinement,	  bringing	  it	  ever	  closer	  to	  translation.	  In	   2002,	   a	   study	   from	   Kirk	   et	   al.	   showed	   that,	   beyond	   long-­‐term	   L-­‐DOPA	  synthesis,	   AAV-­‐mediated	   TH	   and	   GCH1	   expression	   in	   the	   striatum	   of	   6-­‐OHDA	  lesioned	   rats	   was	   able	   to	   achieve	   L-­‐DOPA	   synthesis	   at	   levels	   required	   for	   the	  reversal	  of	  motor	  impairments	  (Kirik	  et	  al.	  2002).	  Soon	  after,	  an	  important	  study	  demonstrated	   that	   in	   vivo	   gene	   therapy	   using	   AAV-­‐TH	   and	   AAV-­‐GCH1	   vectors	  promoted	   a	   significant	   reduction	   of	   abnormal	   involuntary	  movements	   induced	  by	   L-­‐DOPA	   therapy	   and	   near	   complete	   reversal	   of	   motor	   deficits	   in	   6-­‐OHDA	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lesioned	  rats	  (Carlsson	  et	  al.	  2005).	  Another	  study	  complemented	  these	  previous	  findings	  by	  establishing	  a	  direct	   correlation	  between	  motor	   improvement	  after	  AAV-­‐mediated	  TH	  and	  GCH1	  expression	  in	  the	  striatum	  and	  the	  restoration	  of	  a	  functional	  dopamine	  pool	  that	  reached	  the	  post-­‐synaptic	  dopaminergic	  receptors	  in	   the	   striatum	   at	   physiological	   levels	   (Leriche	   et	   al.	   2009).	   Furthermore,	   in	  another	  important	  study	  Björklund	  et	  al.	  used	  two	  separate	  AAV5	  vectors	  coding	  for	   either	   TH	   or	   GCH1	   to	   investigate	   the	   stoichiometric	   ratio	   of	   both	   enzymes	  that	   led	   to	   optimal	   TH	   activity.	   By	   maintaining	   a	   fixed	   dose	   of	   the	   AAV5-­‐TH	  vector	  and	  co-­‐injecting	  increasing	  amounts	  of	  AAV5-­‐GCH1	  into	  the	  striatum	  of	  6-­‐OHDA	  lesioned	  rats,	  they	  determined	  a	  5:1	  TH:GCH1	  ratio	  as	  optimal	  for	  robust	  TH	   activity	   and	   efficient	   L-­‐DOPA	   synthesis	   (Björklund	   et	   al.	   2009).	   This	   study	  also	   promoted	   a	   better	   understanding	   of	   the	   enzymatic	   processes	   and	  compartments	   involved	   in	   the	   continuous	   L-­‐DOPA	   delivery	   by	   revealing	   that	  endogenous	   AADC	   present	   in	   serotonergic	   neurons	   participates	   in	   the	  conversion	   of	   ectopically	   delivered	   L-­‐DOPA	   into	   dopamine.	   This	   was	   an	  important	  finding,	  since	  this	  strategy	  relies	  on	  endogenous	  AADC	  for	  dopamine	  synthesis	   and	   serotonergic	   neurons	   are	   affected	   to	   a	   lesser	   extent	   than	  dopaminergic	   neurons	   in	   PD.	   Furthermore,	   this	   was	   the	   first	   study	   that	   used	  AAV5	   vectors	   for	   L-­‐DOPA	   delivery	   and	   it	   demonstrated	   that	   transduction	  efficiency	  with	  this	  serotype	  was	  superior	  to	  the	  previously	  used	  AAV2.	  Finally,	  an	   AAV	   vector,	   which	   expresses	   TH	   and	   GCH1	   from	   a	   single	   genome	   in	   the	  optimal	   5:1	   TH:GCH1	   ratio	   was	   proposed.	   Intrastriatal	   delivery	   of	   this	   single	  vector	   to	   the	  6-­‐OHDA	  lesioned	  rat	  model	  of	  PD	   led	  to	  L-­‐DOPA	  synthesis,	  which	  was	  superior	   to	  what	  had	  previously	  been	  achieved	  with	   two	  separate	  vectors.	  Consequent	  restoration	  of	  extracellular	  dopamine	  levels	  and	  complete	  recovery	  of	  motor	  function	  was	  demonstrated	  in	  a	  series	  of	  behavioural	  tests	  (Cederfjäll	  et	  al.	  2012).	  These	  features	  made	  this	  bicistronic	  vector	  the	  first	  clinical	  candidate	  vector	   for	   the	   continuous	   L-­‐DOPA	   synthesis	   approach.	   To	   translate	   these	  findings	   into	   the	   clinics,	  Prof.	  Anders	  Björklund,	   a	  world	   leader	   in	  PD	  research	  founded,	   together	   with	   other	   scientists	   and	   investors,	   the	   biotech	   company	  Genepod	  Therapeutics®,	  which	  funded	  the	  preclinical	  studies	  in	  the	  NHP	  model	  of	  PD	  discussed	  here.	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The	  data	  presented	  in	  this	  chapter	  describe	  the	  preclinical	   testing	  of	  a	  novel	  gene	   therapy	   for	   continuous	  L-­‐DOPA	  synthesis	   in	   the	  CNS.	  Behavioural	   studies	  on	  a	  MPTP-­‐lesioned	  NHP	  model	  of	  PD	  are	  described	  as	  well	  as	  the	  progress	  and	  challenges	  encountered	  towards	  the	  translation	  of	  this	  therapeutic	  strategy	  into	  a	  Phase	  I	  clinical	  trial.	  The	  specific	  aim	  of	  this	  chapter	  was	  to	  test	  the	  preclinical	  efficacy	  of	  a	  candidate	  AAV	  vector	   for	  clinical	   trials	  as	  well	  as	  develop	  and	  test	  improved	  versions	  thereof.	  	  This	   project	   involved	   collaborative	   efforts	   from	   four	   different	   teams.	   Our	  laboratory	   at	   King’s	   College	   London	   contributed	   to	   the	   design,	   cloning,	  generation	   and	   the	   in	   vitro	   testing	   of	   the	   different	   viral	   vectors	   used	   in	   the	  animal	   studies.	   Rodent	   studies	   were	   performed	   in	   Dr.	   Tomas	   Björklund’s	  laboratory	   in	   Lund	   where	   I	   participated	   in	   the	   behavioural	   evaluation	   of	   the	  animals	  and	  performed	  some	  of	  the	  post-­‐mortem	  molecular	  analyses	  such	  as	  IHC	  assessment	   of	   vector	   transduction	   in	   the	   rat	   brain.	   The	   Gene	   Therapy	  Consortium	  at	  University	  College	  London	  manufactured	  the	  vectors	  used	   in	  the	  NHP	  studies;	  these	  were	  outsourced	  to	  Motac	  Neuroscience,	  a	  contract	  research	  organisation	   based	   in	   Manchester,	   UK	   and	   Bordeaux,	   France.	   Motac	  Neuroscience	   performed	   the	  NHP	   in	  vivo	   studies	   in	   Beijing,	   China	   through	   the	  Institute	  of	  Laboratory	  Animal	  Sciences	  (ILAS)	  at	  the	  China	  Academy	  of	  Medical	  Sciences	  and	  reported	  the	  behavioural	  data	   to	   the	  scientists	   in	  Manchester	  and	  Bordeaux	  on	  a	  regular	  basis.	  My	  involvement	  in	  the	  NHP	  studies	  included	  a	  short	  stay	   in	   Bordeaux	   where	   I	   got	   familiarised	   with	   the	   study	   protocols	   and	   the	  different	   behavioural	   tests	   through	   demonstrations	   of	   video	   scorings	   for	   the	  clinical	   rating	  of	  NHP	  as	  well	  as	  discussions	  on	   the	   techniques	  used	   for	   the	  ex-­‐
vivo	  analyses	  of	  the	  NHP	  brain.	  The	  molecular	  and	  behavioural	  data	  generated	  by	  Motac	  were	  provided	  to	  all	  people	  directly	  involved	  in	  the	  study.	  The	  generation	  of	  the	  graphics,	   the	  statistical	  analysis	  of	  the	  data,	  and	  the	  interpretation	  of	  the	  results	  presented	  in	  this	  thesis	  were	  done	  by	  me.	  Likewise,	  the	  assessment	  of	  the	  gene	  therapy	  in	  the	  rodent	  model	  of	  PD	  was	  done	  by	  me	  and,	  where	  necessary	  to	  ensure	  that	  the	  implications	  of	  my	  findings	  are	  clear	  to	  the	  reader,	  contributions	  from	  Dr.	  Björklunds’s	  lab	  are	  included	  and	  clearly	  indicated	  in	  the	  figure	  legends.	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4.2 Results	  
4.2.1 Development	  and	  Efficacy	  of	  a	  Bicistronic	  Brain	  Vector	  Tested	  in	  the	  
MPTP-­‐lesioned	  NHP	  Model	  The	  AAV	  vector	   used	   in	   this	   study	  was	   first	   described	  by	  Cederfjäll	   et	   al.	   in	  2012.	  Its	  genome	  codes	  for	  TH	  and	  GCH1,	  the	  two	  rate-­‐limiting	  enzymes	  shown	  to	  be	  sufficient	  and	  necessary	  for	  L-­‐DOPA	  synthesis	  in	  vivo.	  In	  addition,	  each	  gene	  is	   expressed	   from	   an	   independent	   cassette	   under	   the	   control	   of	   the	   human	  neuron-­‐specific	  synapsin	  (SYN)	  promoter.	  The	  TH	  gene	  is	  followed	  by	  the	  WPRE	  sequence	   in	   order	   to	   enhance	   its	   expression	   and	   ensure	   the	   optimal	   TH:GCH1	  ratio	   for	   in	   vivo	   L-­‐DOPA	  synthesis.	  The	   serotype	   selected	   for	   this	   gene	   therapy	  approach	   was	   AAV5	   based	   on	   its	   superiority	   in	   transducing	   the	   putamen	   and	  caudate	  nucleus	  (which	   together	   form	  the	  striatum)	  of	  NHP	  compared	  to	  other	  serotypes	  as	  well	  as	  on	  its	  ability	  to	  efficiently	  deliver	  L-­‐DOPA	  in	  the	  rat	  brain	  in	  a	   continuous	   manner	   (Dodiya	   et	   al.	   2010;	   Cederfjäll	   et	   al.	   2013).	   Following	  successful	   preclinical	   studies	   by	   Cederfjäll	   et	   al.	   in	   the	   6-­‐OHDA-­‐lesioned	   rat	  model,	   vector	  production	  was	   scaled	  up	   for	   toxicology	  and	  efficacy	   tests	   in	   the	  MPTP-­‐lesioned	  NHP.	  MPTP	   (1-­‐methyl-­‐4-­‐phenyl-­‐1,2,3,6-­‐tetrahydropyridine)	   is	   a	  neurotoxin	   that	   is	   selectively	   taken	   up	   by	   dopaminergic	   neurons,	   where	   it	   is	  metabolised	   into	   the	   toxic	   cation	  1-­‐methyl-­‐4-­‐phenylpyridinium	  (MPP+)	   leading	  to	   neuronal	   cell	   death	   through	   oxidative	   stress.	   MPTP-­‐treated	   NHP	   have	   been	  shown	   to	   recapitulate	  most	  of	   the	  pathophysiological	   changes	   that	  occur	   in	  PD	  and	  are	  therefore	  used	  as	  PD	  model	  in	  research	  (Bezard	  et	  al.	  1997).	  For	  the	  upscaling	  of	  vector	  production,	  both	  GCH1	  and	  TH	  transgene	  cassettes	  were	   synthesised	   as	   one	   single	   DNA	   molecule	   flanked	   by	   BglII	   endonuclease	  restrictions	  sites	  and	  subsequently	  cloned	  into	  an	  AAV-­‐ITR	  containing	  backbone.	  The	   plasmid	   was	   named	   pGPT002	   and	   used	   to	   generate	   a	   recombinant	   AAV	  vector	  of	  the	  AAV5	  serotype	  (Figure	  37).	  This	  vector	  will	  hereafter	  be	  referred	  to	  as	  GPT002.	  	  
	  
Figure	  37:	  Schematic	  representation	  of	  the	  GPT002	  genome.	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4.2.1.1 MPTP	  Lesion,	  Induction	  of	  LID	  and	  Validation	  of	  NHP	  Model	  Prior	  to	  the	  brain	  surgery	  for	  AAV	  vector	  injection,	  NHP	  were	  treated	  with	  the	  neurotoxin	  MPTP	  in	  order	  to	  develop	  parkinsonism	  and,	  after	  recovery,	  primed	  with	  L-­‐DOPA	  in	  order	  to	  develop	  LID.	  The	  following	  data	  describe	  the	  validation	  of	   the	   lesioning	   (i.e.	   development	   of	   PD	   motor	   symptoms)	   as	   well	   as	   the	  development	   of	   LID.	   In	   total,	   forty	   naïve	   macaques	   (Macaca	   mulatta)	   were	  lesioned	  with	  daily	  MPTP	  injections	  (0.2mg/kg,	  i.v.)	  to	  induce	  parkinsonism	  and	  treatment	  was	  halted	  once	  the	  animals	  reached	  a	  parkinsonian	  disability	  score	  of	  6	   on	   the	   Benazzouz	   clinical	   scale	   (Benazzouz	   et	   al.	   1993).	   This	   clinical	   rating	  scale	   measures	   motor	   behaviour	   in	   both	   normal	   and	   parkinsonian	   monkeys	  according	  to	  the	  symptoms	  presented	  in	  Table	  14.	  Scores	  range	  from	  0-­‐25	  and	  a	  score	  ≥	  15	  corresponds	  to	  full	  parkinsonism,	  similarly	  to	  stage	  IV	  of	  the	  scale	  of	  Hoehn	  and	  Yahr	  used	  for	  humans	  (Hoehn	  &	  Yahr	  2001).	  The	   score	   of	   6	   corresponds	   to	   a	   mild	   degree	   of	   parkinsonism	   and	   it	   was	  chosen	  in	  order	  to	  allow	  for	  the	  forthcoming	  surgical	  procedures	  to	  occur	  with	  a	  minimal	  risk	  and	  not	  to	  compromise	  animal	  recovery	  and	  post-­‐surgical	  health.	  	  	  
Benazzouz	  rating	  scale	  for	  parkinsonian	  
disability	  
Score	  range	  
Tremor	   0-­‐3	  
Bradykinesia	   0-­‐3	  
Change	  in	  posture	   0-­‐3	  
Vocalization	   0-­‐2	  
Freezing	   0-­‐2	  
Rigidity	  (per	  arm)	   (0-­‐3)	  x	  2	  
Frequency	  of	  arm	  movements	  (per	  arm)	   (0-­‐3)	  x	  2	  
Total	   0-­‐25	  
	  
Table	  14:	  Benazzouz	  parkinsonian	  macaque	  clinical	  rating	  scale.	  	  The	  MPTP	  treatment	  lasted	  on	  average	  25	  days,	  ranging	  from	  17	  to	  47	  days.	  The	   slightly	   longer	   treatment	   time	   required	   for	   some	   individuals	   might	   have	  been	  due	   to	   the	   fact	   that	  estimates	   for	   treatment	   time	  are	  based	  on	   the	   lighter	  primate	  Macaca	   fascicularis	   (3kg	   vs.	   7.7kg	   average	  weight	   of	   an	   adult	  male	  M.	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mulatta).	   After	   the	   lesioning	   period,	   the	   NHP	   were	   left	   untreated	   until	   their	  disabilities	   stabilised	   and	   remained	   constant	   for	   a	   period	   of	   2	  weeks.	   Animals	  that	  appeared	  to	  be	  unlesioned	  or	  excessively	  lesioned	  based	  on	  the	  Benazzouz	  behavioural	  scoring,	  were	  excluded	  from	  the	  subsequent	  phases	  of	  the	  study.	  In	  total,	  29	  NHP	  were	  selected	  for	  the	  next	  phase	  of	  the	  study.	  Following	   recovery	   from	   the	   MPTP	   lesion,	   a	   two-­‐week	   treatment	   with	  Madopar®	  (L-­‐DOPA/benserazide,	  ratio	  4:1,	  p.o.,	  hereafter	  referred	  to	  as	  L-­‐DOPA)	  was	  conducted	  in	  order	  to	  induce	  dyskinesia	  in	  the	  NHP.	  This	  model	  mimics	  the	  clinical	  condition	  of	  a	  patient	  who	  has	  received	   long-­‐term	  L-­‐DOPA	  therapy	  and	  has	  developed	  LID.	  L-­‐DOPA	  was	  given	  to	  29	  NHP	  twice	  daily	  at	  a	  dose	  adjusted	  for	   each	   individual.	   The	   dose	  was	   selected	   to	  maximally	   reverse	   parkinsonian	  motor	   symptoms	   and	   cause	   hyperactivity	   in	   the	   animals,	   which	   has	   been	  associated	  with	  the	  development	  of	  dyskinesia.	  This	  L-­‐DOPA	  treatment	  regimen	  was	  administered	  until	  dyskinesia	   stabilised.	  After	   the	  L-­‐DOPA	  priming	  period,	  the	  lowest	  dose	  able	  to	  produce	  a	  complete	  reversal	  of	  parkinsonian	  symptoms	  was	  defined	  as	  “100%	  L-­‐DOPA	  treatment”	  or	  “treatment	  dose”	  (Table	  15).	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Priming	  dose	  (mg/kg)	   Treatment	  dose	  (mg/kg)	  S1	   4.1	   37	   27	  S2	   4.5	   24	   18	  S3	   4.1	   32	   24	  S4	   5.4	   46	   35	  S5	   4.8	   33	   25	  S7	   5.7	   39	   29	  S9	   4.9	   27	   20	  S10	   5.1	   35	   26	  S11	   4.2	   21	   16	  S13	   4.5	   33	   25	  S14	   3.9	   26	   19	  S15	   4	   33	   24	  S16	   5	   20	   15	  S17	   5.3	   32	   24	  S18	   5.5	   27	   20	  S20	   4.8	   46	   34	  S21	   4.3	   30	   23	  S23	   4.6	   52	   39	  S26	   4.9	   41	   31	  S27	   6	   42	   31	  S28	   4.1	   37	   27	  S30	   3.8	   58	   43	  S31	   4	   25	   19	  S32	   6.3	   25	   19	  S33	   4.4	   32	   24	  S35	   4.6	   39	   29	  S36	   4.5	   29	   22	  S38	   4.7	   28	   21	  S40	   4.1	   32	   24	  
	  
Table	  15:	  L-­‐DOPA	  priming	  and	  treatment	  doses	  for	  the	  29	  NHP	  defined	  post-­‐MPTP	  lesion	  
and	  prior	  to	  group	  selection	  for	  gene	  therapy.	  
	  Following	  the	  L-­‐DOPA	  priming	  period,	  the	  29	  NHP	  were	  video-­‐recorded	  for	  1h	  in	   the	  OFF	   state	   (i.e.	   off	   L-­‐DOPA	  medication)	   and	   for	   4h	  over	  10-­‐min	   intervals	  following	   L-­‐DOPA	   treatment	   with	   the	   “priming”	   and	   “treatment”	   doses.	  Parkinsonian	  disability	  scoring	  was	  performed	  post	  hoc	  on	  video	  recordings	  of	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animals	   freely	  moving	   in	   their	   home	   cages	   following	   a	   slightly	   different	   rating	  scale	  adapted	  from	  the	  Benazzouz	  scale	  (Table	  16).	  	  
Parkinsonian	  disability	   Score	  range	  
Range	  of	  movement	   0-­‐4	  
Bradykinesia	   0-­‐3	  
Posture	   0-­‐2	  
Tremor	   0-­‐1	  
Total	   0-­‐10	  
	  
Table	   16:	   Parkinsonian	   disability	   rating	   scale	   used	   for	   NHP	   selection	   and	   subsequent	  
monthly	  assessments	  post-­‐gene	  therapy.	  	  In	   this	   rating	   scale,	   “vocalisation”	   is	   not	   accounted	   for.	   “Freezing”	   and	  “rigidity”	   fall	   under	   bradykinesia,	   while	   “frequency	   of	   arm	   movements”	   falls	  under	  range	  of	  movement.	  The	  parkinsonian	  disability	  was	  scored	  by	  assessing	  the	  four	  subcategories	  mentioned	  in	  Table	  11	  and	  calculated	  by	  the	  formula:	  (4	  –	  range	  of	  movement)	  +	  bradykinesia	  +	  posture	  +	  tremor.	  Behaviour	  was	  assessed	  for	   4h	   post	   L-­‐DOPA	   administration	   and	   scored	   over	   10	   min	   intervals	   by	   an	  observer	  blinded	  to	  treatment.	  The	  final	  scores	  from	  each	  10-­‐minute	  observation	  period	  were	  cumulative	  throughout	  the	  4h	  observation	  period.	  After	  the	  NHP	  were	  rated	  for	  parkinsonian	  disability,	  they	  were	  scored	  for	  the	  two	   most	   common	   features	   in	   LID:	   chorea	   and	   dystonia.	   The	   score	   for	   each	  feature	   ranges	   from	   0-­‐4	   (best	   to	  worst)	   and	   the	   combination	   of	   both	   features	  constitutes	  the	  global	  dyskinesia	  score.	  For	  any	  given	  time	  point,	  the	  dyskinesia	  score	  assigned	  to	  the	  NHP	  was	  the	  highest	  one	  from	  either	  chorea	  or	  dystonia.	  Figure	   38	   shows	   that	   both	   priming	   and	   treatment	   doses	   elicited	   dyskinesia	  with	  an	  expected	  time-­‐course,	  which	  mirrored	  the	  anti-­‐parkinsonian	  action	  of	  L-­‐DOPA.	   The	   L-­‐DOPA	   response	   profiles	   (anti-­‐parkinsonian	   and	   pro-­‐dyskinetic)	  were	   in	   agreement	   with	   previous	   studies	   using	   the	   MPTP-­‐lesioned	   macaque	  model	   of	   PD	   (Bézard	   et	   al.	   2003;	   Hill	   et	   al.	   2004;	   Berton	   et	   al.	   2009),	   which	  further	  supported	   the	   inclusion	  of	   the	  animals	   in	   the	  subsequent	  phases	  of	   the	  study.	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Figure	  38:	  Mean	  parkinsonian	  disability	  and	  dyskinesia	  scores	  of	  primed	  NHP.	  
Acute	  response	  to	  L-­‐DOPA	  was	  scored	  in	  MPTP-­‐lesioned	  NHP.	  Parkinsonian	  disability	  (A)	  
and	  dyskinesia	  (B)	  scores	  of	  the	  NHP	  selected	  for	  the	  study	  are	  shown.	  	  After	   cessation	   of	   MPTP	   treatment	   and	   L-­‐DOPA	   priming,	   animals	   were	  assessed	   for	  disability	   in	   the	  OFF	   state	   and	   for	   their	   acute	   response	   to	   an	  oral	  dose	  of	  L-­‐DOPA.	  Eighteen	  animals	  with	  similar	  behaviour	  scores	  were	  selected,	  randomised	  and	  assigned	   into	  one	  of	   the	   three	   treatment	  groups:	  vehicle,	   low-­‐dose	  or	  high-­‐dose	  gene	  therapy.	  No	  statistical	  difference	  in	  parkinsonian	  motor	  symptoms	  was	  found	  between	  groups	  prior	  to	  gene	  therapy	  surgery.	  In	  addition	  to	  the	  18	  animals	  selected	  for	  the	  study,	  six	  MPTP-­‐lesioned	  animals	  were	  kept	  as	  ‘reserve’	  in	  case	  of	  any	  losses	  during	  surgery,	  which	  did	  not	  occur.	  Further	  validation	  of	  the	  MPTP	  lesion	  was	  done	  post-­‐mortem	  on	  the	  brains	  of	  the	  NHP.	  Stereological	  counting	  of	  TH+	  cells	  in	  the	  SNc	  demonstrated	  that	  MPTP	  treatment	  caused	  pronounced	  cell	  loss	  (Mann-­‐Whitney	  test,	  p<0.001;	  Figure	  39).	  There	  was	   no	   significant	   difference	   in	   the	   number	   of	   TH+	   neurons	   in	   the	   SNc	  among	   lesioned	   animals	   at	   the	   end	   of	   the	   study,	   indicating	   that	   AAV-­‐mediated	  gene	   transfer	   to	   the	   putamen	   and	   caudate	   nucleus	   does	   not	   affect	   MPTP-­‐mediated	  cell	  death	  in	  the	  SNc.	  
	   	   154	  
	  
Figure	  39:	  Stereological	  counting	  of	  TH+	  neurons	  in	  the	  SNc	  of	  NHP	  after	  MPTP	  lesioning.	  	  
NHP	  were	  given	  daily	  i.v.	  injections	  of	  0.2mg/kg	  MPTP	  for	  ~25	  days.	  Unlesioned	  NHP	  were	  
used	  as	  controls.	  Mann-­‐Whitney	  test	  of	  unlesioned	  vs.	  MPTP-­‐treated	  (p<0.01).	  Mean	  ± 	  SEM	  
values	  are	  shown.	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Figure	  40:	  Timeline	  of	  NHP	  behavioural	  study	  to	  test	  the	  efficacy	  of	  GPT002.	  
Following	  MPTP-­‐lesioning	  and	  priming	  with	  L-­‐DOPA	   to	   induce	  LID,	  animals	  were	  scored	  
for	  baseline	  locomotor	  activity,	  parkinsonian	  disability	  and	  dyskinesia.	  Animals	  were	  then	  
treated	   with	   vehicle	   or	   AAV	   vector	   and	   scored	   once	   monthly	   for	   up	   to	   5	   months	   (low-­‐
dose),	  6	  months	  (vehicle)	  and	  7	  months	  (high-­‐dose).	  	  A	  first	  group	  (n=6)	  received	  bilateral	  injections	  of	  GPT002	  at	  a	  titre	  of	  1x1011	  gcp/ml	   into	   the	   putamen	   (striatum)	   along	   3	   tracks	   per	   hemisphere	   with	   2	  deposits	  per	   track	  (6	  stereotactic	   injections	  of	  7.5	  µl;	   that	   is	  45	  µl	  per	  striatum	  and	   a	   total	   of	   90	   µl	   per	   animal).	   This	   group	   was	   called	   “low-­‐dose”.	   A	   second	  group	  (n=6)	  received	  bilateral	  injections	  of	  the	  same	  volumes	  of	  a	  1x1012	  gcp/ml	  GPT002	  preparation	  (“high-­‐dose”	  group).	  A	  third	  group	  (n=6)	  received	  bilateral	  injections	   of	   the	   vehicle	   solution	   in	   the	   same	   deposit	   coordinates	   as	   the	  treatment	  groups.	  	  4.2.2.1.1 Locomotor	   activity	   and	   Parkinsonian	   Disability	   After	   Gene	   Therapy	  With	  GPT002	  In	   the	   months	   following	   gene	   therapy	   surgery,	   NHP	   were	   assessed	   OFF	   L-­‐DOPA	  and	  after	  50%	  L-­‐DOPA	  treatment	  in	  order	  to	  closely	  mimic	  a	  future	  clinical	  scenario	   in	   which	   gene	   therapy	   will	   be	   given	   combined	   with	   oral	   L-­‐DOPA	  pharmacotherapy	  to	  improve	  the	  treatment	  of	  PD.	  Animals	  were	  recorded	  once	  per	  month	  for	  4h	  and	  video	  recordings	  for	  each	  individual	  were	  scored	  over	  10-­‐minute	  intervals	  post	  hoc	  by	  a	  rater	  blind	  to	  the	  treatment	  groups.	  Following	  gene	   therapy,	  NHP	   treated	  with	  GPT002	  demonstrated	   significant	  improvement	  in	  locomotor	  activity	  compared	  to	  the	  vehicle-­‐treated	  group	  in	  the	  OFF	  state	  as	  well	  as	  following	  50%	  L-­‐DOPA	  treatment.	  In	  the	  absence	  of	  L-­‐DOPA	  treatment	   (OFF	   L-­‐DOPA),	   low-­‐dose	   and	  high-­‐dose	   treated	   animals	   significantly	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improved	   their	   locomotor	   activity	   compared	   to	   vehicle-­‐treated	   animals	   in	   the	  time	  course	  of	  5	  and	  6	  months,	  respectively	  (Wilcoxon	  signed	  rank	  test,	  p<0.05).	  A	  significant	   increase	  in	   locomotor	  counts	  was	  also	  seen	  between	  high-­‐dose	  vs.	  vehicle	  treated	  animals	  after	  50%	  L-­‐DOPA	  treatment	  (Wilcoxon	  signed	  rank	  test,	  p<0.05).	   Furthermore,	   when	   compared	   against	   baseline	   scores,	   high-­‐dose-­‐treated	  animals	  showed	  a	  significantly	  higher	  locomotor	  activity	  at	  months	  3	  and	  7	  post-­‐gene	   therapy	  OFF	  L-­‐DOPA	  and	  at	  month	  7	  after	  50%	  L-­‐DOPA	  treatment	  (Friedman	  test	  followed	  by	  Dunn’s	  multiple	  comparison,	  p<0.05)	  (Figure	  41).	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Figure	  41:	  Locomotor	  activity	  of	  lesioned	  NHP	  treated	  with	  GPT002.	  
Comparison	  between	  treatments	  was	  done	  with	  the	  non-­‐parametric	  Wilcoxon	  signed	  rank	  
test,	   while	   intragroup	   comparison	   against	   baseline	   scores	  was	   done	  with	   the	   Friedman	  
test	  (the	  non-­‐parametric	  equivalent	  of	  the	  repeated	  measures	  ANOVA)	  followed	  by	  Dunn’s	  
multiple	   comparisons.	   Values	   are	   shown	   as	  mean	  ± 	   SEM	   and	   only	   upper	   error	   bars	   are	  
shown	   for	   clarity.	   All	   values	   are	   normalised	   to	   the	   baseline	   scores.	   In	   the	   absence	   of	   L-­‐
DOPA	   treatment	   both,	   low-­‐	   and	   high-­‐dose	   treated	   NHP	   showed	   an	   improvement	   in	  
locomotor	  activity	  relative	  to	  the	  vehicle-­‐treated	  group	  throughout	  the	  5	  and	  6	  months	  of	  
the	   experiment,	   respectively	   (p<0.05).	   When	   compared	   to	   baseline	   scores,	   high-­‐dose-­‐
treated	   NHP	   showed	   a	   significant	   improvement	   at	  months	   3	   and	   7	   (p<0.05).	   Significant	  
improvement	  in	  locomotor	  activity	  relative	  to	  vehicle	  was	  also	  seen	  in	  both	  vector-­‐treated	  
groups	   after	   50%	   L-­‐DOPA	   treatment	   (p<0.05).	   When	   compared	   to	   the	   baseline	   scores,	  
high-­‐dose	  treated	  NHP	  showed	  a	  significant	   improvement	  at	  month	  7	  post-­‐AAV	  injection	  
(p<0.05).	   Asterisks	   behind	   treatment	   group	   legends	   indicate	   there	   was	   a	   statistical	  
difference	  relative	  to	  the	  vehicle-­‐treated	  group.	  A	  Friedman	  test	  performed	  on	  all	  groups	  
up	   to	   month	   5	   showed	   a	   significant	   difference	   (p<0.05)	   between	   vehicle	   and	   vector-­‐
treated	  animals	  for	  the	  low-­‐dose	  group	  OFF	  L-­‐DOPA	  and	  for	  both	  treated	  groups	  after	  50%	  
L-­‐DOPA	  treatment	  (results	  for	  this	  test	  are	  not	  indicated	  by	  asterisks	  in	  the	  figure).	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  However,	  it	  must	  be	  noticed	  that	  a	  spontaneous	  improvement	  occurred	  in	  all	  treatment	   groups	   at	   month	   3	   OFF	   and	   ON	   L-­‐DOPA.	   Furthermore,	   at	   month	   7,	  vehicle-­‐treated	   NHP	   were	   not	   scored	   alongside	   the	   high-­‐dose	   NHP,	   therefore	  locomotor	   scores	   for	   high-­‐dose-­‐treated	   animals	   at	   this	   time	   point	   can	   only	   be	  compared	  to	  the	  group’s	  baseline	  scores.	  Surprisingly,	  MPTP-­‐lesion	  did	  not	  cause	  a	   marked	   decrease	   in	   the	   locomotor	   counts	   relative	   to	   normal	   NHP	   (Kruskal-­‐Wallis	   test,	   p>0.05).	  As	   seen	   in	   Figure	  42,	   baseline	   levels	   of	   locomotor	   activity	  pre-­‐gene	  therapy	  intervention	  show	  that	  vehicle,	  low-­‐dose	  and	  high-­‐dose	  groups	  had	  a	  decreased	  locomotor	  activity	  of	  42%,	  19%	  and	  30%	  relative	  to	  unlesioned	  NHP,	   respectively.	   This	   might	   indicate	   that	   stopping	   MPTP	   lesion	   once	   NHP	  reach	   a	   score	   of	   6	   in	   the	   Benazzouz	   disability	   rating	   scale	   is	   not	   sufficient	   to	  cause	   a	   parkinsonian	   phenotype	   that	   can	   be	   detected	   by	   automatic	   counts	   of	  infra-­‐read	  beam	  breaks.	   	  
	  
Figure	  42:	  Baseline	  locomotor	  counts	  on	  MPTP-­‐lesioned	  and	  unlesioned	  NHP.	  
Comparison	  between	  groups	  was	  done	  with	   the	  Kruskal-­‐Wallis	   test	   (the	  non-­‐parametric	  
equivalent	  of	  the	  non-­‐repeated	  measures	  ANOVA).	  Values	  are	  shown	  as	  mean	  ± 	  SEM.	  	  Clinical	  rating	  showed	  an	  improvement	  in	  the	  parkinsonian	  disability	  score	  of	  the	  high-­‐dose	  treated	  group	  throughout	  months	  1	  to	  7	  OFF	  L-­‐DOPA.	  At	  month	  7	  NHP	  had	  100%	  decreased	  parkinsonian	  disability	  relative	  to	  baseline	  (Friedman	  test,	  p<0.05).	  No	  significant	  effect	  was	  observed	  when	  the	  NHP	  were	  challenged	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with	   50%	   L-­‐DOPA	   treatment,	   however	   disability	   decreased	   in	   both	   vector-­‐treated	  groups	  (Figure	  43).	  	  
	  
Figure	   43:	   Disability	   scores	   of	   NHP	   treated	  with	   GPT002	  OFF	   L-­‐DOPA	   and	   after	   50%	   L-­‐
DOPA	  treatment.	  
Comparison	  between	  treatments	  was	  done	  with	  the	  non-­‐parametric	  Wilcoxon	  signed	  rank	  
test,	   while	   intragroup	   comparison	   against	   baseline	   scores	  was	   done	  with	   the	   Friedman	  
test	   followed	   by	   Dunn’s	  multiple	   comparisons.	  Median	   ± 	   interquartile	   range	   values	   are	  
shown	  and	  only	  upper	  error	  bars	  are	  shown	  for	  clarity.	  All	  values	  are	  normalised	  to	   the	  
baseline	  scores.	  Vector	  treatment	  caused	  symptomatic	  improvement	  in	  the	  OFF	  state	  and	  
after	  50%	  L-­‐DOPA	  treatment.	  A	  statistically	  significant	  decrease	  in	  parkinsonian	  disability	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4.2.2.1.2 Dyskinesia	  and	  Good	  On-­‐time	  Because	  standard	  oral	  treatment	  with	  L-­‐DOPA	  provides	  powerful	  relief	   from	  PD	   motor	   symptoms	   but	   also	   induces	   uncontrolled,	   disabling	   drug-­‐induced	  dyskinesias,	   their	   incidence	   post	   AAV	   gene	   therapy	   was	   investigated.	  Administration	   of	   GPT002	   alone	   did	   not	   induce	   dyskinesia	   in	   the	   lesioned	  animals	  without	  co-­‐medication	  with	  oral	  L-­‐DOPA	   for	   the	  entire	  duration	  of	   the	  study	  –	  i.e.	  dyskinesia	  was	  absent	  at	  all	  time	  points.	  This	  indicates	  that	  the	  gene	  therapy	  provides	  symptomatic	  relief	  without	  triggering	  LID.	  To	   closely	   mimic	   a	   potential	   future	   clinical	   trial	   situation	   in	   dyskinetic	  patients,	  NHP	  were	  challenged	  with	  50%	  L-­‐DOPA	  treatment	  and	  the	  occurrence	  of	  chorea	  and	  dystonia	  was	  recorded	  for	  a	  period	  of	  4h.	  Chorea	  and	  dystonia	  are	  the	  most	  common	  features	  in	  LID	  and	  their	  scores	  in	  the	  rating	  scale	  adopted	  in	  this	  study	  range	  from	  0	  to	  4.	  At	  each	  time	  point	  animals	  were	  given	  the	  score	  that	  corresponded	  to	  the	  highest	  value	  from	  either	  feature	  and	  the	  global	  score	  given	  was	   representative	   of	   each	   10-­‐minute	   observation.	   Good	   on-­‐time	   (i.e.	   the	  timespan	  after	  L-­‐DOPA	  oral	  medication	  in	  which	  animals	  show	  no	  bradykinesia	  and	  little	  to	  no	  dyskinesia)	  was	  also	  measured	  to	  evaluate	  the	  ability	  of	  the	  gene	  therapy	   to	   ameliorate	  LID	   (Figure	  44	  –	  bottom).	  Groups	   tested	  with	  both	  gene	  therapy	   doses	   showed	   decreasing	   dyskinesia	   relative	   to	   baseline	   scores	   up	   to	  month	   5,	   however,	   this	   trend	  was	   also	   followed	   by	   the	   vehicle	   treated	   group,	  which	   showed	   an	   up	   to	   60%	   spontaneous	   reduction	   in	   dyskinesia	   during	   the	  experiment.	   This	   observation	   undermines	   the	   interpretation	   of	   a	   causal	  relationship	  between	  gene	  therapy	  and	  a	  decrease	  in	  dyskinesia.	  Unlike	   other	   gene	   therapy	   preclinical	   trials,	   in	   which	   L-­‐DOPA	   doses	   are	  constantly	   adjusted	   relative	   to	   the	   primates’	   locomotor	   scores	   (Jarraya	   et	   al.	  2009),	   throughout	   this	   study	   the	  NHP	  received	   the	   same	  dose,	  defined	  as	  50%	  treatment	   prior	   to	   gene	   therapy.	   Therefore,	   any	   change	   in	   weight	   that	   might	  have	   occurred	   during	   the	   experimental	   months	   can	   have	   affected	   the	   L-­‐DOPA	  mg/kg	   ratio	   and	   consequently	   the	   ability	   of	   oral	   L-­‐DOPA	   treatment	   to	   trigger	  LID.	   Nevertheless,	   the	   fact	   that	   AAV	   treatment	   did	   not	   increase	   previously	  established	  LID	  is	  of	  clinical	  importance.	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Figure	  44:	  Dyskinesia	  scores	  and	  good	  on-­‐time	  in	  NHP	  treated	  with	  GPT002.	  
Scores	   for	   dyskinesia	   (top)	   and	   good	   on-­‐time	   (bottom)	   are	   presented	   as	   median	   ± 	  
interquartile	  range	  (dyskinesia)	  and	  mean	  ± 	  SEM	  (good	  on-­‐time),	  respectively.	  All	  values	  
are	  normalised	  to	  the	  baseline	  scores.	  Only	  upper	  error	  bars	  are	  shown	  for	  clarity.	  
	  
4.2.3 Efficacy	  of	  an	  Increased	  Dose	  of	  GPT002	  and	  of	  its	  Truncated	  Variant	  	  Taken	  together,	  treatment	  with	  GPT002	  provides	  symptomatic	  improvement	  without	   increasing	   pre-­‐established	   dyskinesia.	   However,	   this	   efficacy	   was	  considered	  partial	  and	  insufficient	  to	  justify	  clinical	  investigation.	  We	   hypothesised	   that	   the	   gene	   therapy	   doses	   tested	   in	   the	   first	   NHP	   study	  possibly	  led	  to	  a	  modest	  increase	  in	  intrastriatal	  L-­‐DOPA	  levels	  that	  were	  slightly	  above	  the	  threshold	  needed	  to	  evoke	  a	  robust	  behavioural	  response	  (Kirik	  et	  al.	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2002).	   We	   also	   pondered	   whether	   enhancing	   TH	   activity	   would	   lead	   to	   an	  increased	  behavioural	  response	  i.e.	  less	  parkinsonian	  disability	  and	  LID.	  To	  test	  this	  possibility,	  we	  decided	  to	  enhance	   the	  catalytic	  activity	  of	  TH	  by	  removing	  its	   regulatory	   domain,	   thereby	   rendering	   it	   constitutively	   active.	   A	   similar	  strategy	   was	   adopted	   in	   another	   intrastriatal	   gene	   therapy	   approach	   for	  dopamine	   replacement	   (Jarraya	  et	   al.	   2009).	  The	   removal	  of	   the	  TH	  regulatory	  domain	   also	   abolishes	   the	   end-­‐product	   feedback	   inhibition	   mechanism,	   which	  TH	   is	   subject	   to	   (Daubner	   et	   al.	   2011).	   Thus,	   a	   variant	   form	   of	   GPT002	   was	  generated	   which	   lacked	   the	   first	   155	   amino	   acids	   of	   TH	   (Figure	   45).	   The	  truncated	  variant	  of	  GPT002	  was	  generated	  by	  deleting	  the	  first	  465nt	  of	  the	  TH	  gene	   by	   overlapping	   PCR	   followed	   by	   isothermal	   assembly.	   The	   truncated	   TH	  used	  here	  is	  identical	  to	  the	  one	  used	  in	  the	  liver	  vector	  (Chapter	  1).	  	  
	  
Figure	  45:	  Schematic	  representation	  of	  the	  truncated	  GPT002	  genome.	  
Dashed	  square	  in	  the	  TH	  cassette	  symbolises	  the	  deletion	  of	  the	  155	  amino	  acids	  at	  the	  N-­‐
terminus	  portion	  of	  the	  enzyme.	  	  Efficacy	   assessment	   of	   this	   truncated	   variant	   of	   GPT002	   was	   performed	   in	  NHP	  following	  an	  identical	  protocol	  as	  used	  in	  the	  previous	  study	  but	  with	  a	  10-­‐fold	   higher	   dose.	   In	   addition,	   transduction	   efficiency	   of	   the	   truncated	   GPT002	  was	  compared	  to	  the	  full-­‐length	  form	  in	  the	  striatum	  of	  6-­‐OHDA	  lesioned	  rats.	  	  
4.2.3.1 Striatal	   Spread	  of	   the	  Truncated	  GPT002	   in	   the	  6-­‐OHDA	  Lesioned	  
Rat	  With	   the	   aim	   to	   compare	   striatal	   spread	   of	   the	   newly	   generated	   truncated	  vector	  with	  GPT002,	  a	  qualitative	  assessment	  was	  performed	  in	  the	  6-­‐OHDA	  rat	  model	  of	  PD	  prior	  to	  injection	  in	  NHP.	  A	  total	  dose	  of	  2x109	  gcp	  of	  GPT002	  and	  of	  its	  truncated	  variant	  was	  injected	  in	  the	  striatum	  of	  unilaterally	  6-­‐OHDA	  lesioned	  rats	  followed	  by	  IHC	  analysis	  of	  TH	  expression	  six	  weeks	  post-­‐injection	  (n=	  3	  per	  vector).	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Injection	   of	   6-­‐OHDA	   into	   the	   medial	   forebrain	   bundle	   (MFB)	   in	   one	  hemisphere	  resulted	  in	  a	  complete	  loss	  of	  the	  neurons	  located	  in	  the	  ipsilateral	  SNc,	  while	  the	  contralateral	  side	  remained	  visually	  unaffected.	  A	  stronger	  striatal	  transduction	  was	  observed	  with	  GPT002	  vector	  relative	  to	  its	  truncated	  variant,	  as	  seen	  by	  the	  area	  positively	  stained	  for	  TH	  (Figure	  46).	  	  	  
	  
	  
Figure	  46:	  Transduction	  of	  AAV	  vectors	   in	  unilaterally	  6-­‐OHDA	  lesioned	  rats	  detected	  by	  
IHC	  of	  TH	  in	  the	  striatum.	  
Six	   weeks	   post-­‐AAV	   injection,	   animals	   treated	   with	   GPT002	   (n=3)	   and	   its	   truncated	  
variant	   (n=3)	  were	   deeply	   anesthetised	  with	   pentobarbital,	   transcardially	   perfused;	   the	  
brains	  readily	  dissected,	  and	  then	  incubated	  in	  paraformaldehyde	  (PFA)	  for	  2	  hours.	  After	  
overnight	  incubation	  in	  sucrose	  the	  brains	  were	  cut	  in	  35µm	  coronal	  sections.	  Full-­‐length	  
GPT002	  showed	  stronger	  transduction	  and	  broader	  spread	  in	  the	  striatum.	  Sections	  of	  the	  
midbrain	  in	  the	  left	  column	  show	  the	  complete	  absence	  of	  TH+	  cells	  in	  the	  SNc	  on	  the	  side	  
ispilateral	   to	   the	   6-­‐OHDA	   injection,	  whereas	   on	   the	   contralateral	   side	   the	   dopaminergic	  
cells	  were	  virtually	  unaffected.	  This	  validates	  the	  unilateral	  6-­‐OHDA	  lesion	  and	  indicates	  
that	   any	   TH	   staining	   in	   the	   lesioned	   side	   of	   the	   striatum	   must	   be	   attributed	   to	   AAV-­‐
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mediated	  TH	  expression.	  Each	  row	  corresponds	   to	  a	  different	  animal.	  Str:	  Striatum;	  SNc:	  
Substantia	   nigra	   pars	   compacta.	   Scale	   bar:	   2mm	   midbrain	   and	   0.2mm	   lesioned	   brain	  
hemisphere.	  These	   stainings	  were	  performed	  by	   the	   staff	   in	  Dr.	  Björklund’s	   lab	   and	  are	  
reproduced	  here	  with	  his	  permission.	  	  
4.2.3.2 Behavioural	   Assessment	   of	   GPT002	   and	   its	   Truncated	   Variant	   in	  
MPTP-­‐lesioned	  NHP	  Because	  only	  a	  partial	  behavioural	  improvement	  was	  observed	  with	  high	  dose	  GPT002,	   	   a	   second	   study	   was	   performed	   with	   an	   increased	   vector	   dose.	   In	  parallel,	  the	  vector	  expressing	  the	  truncated	  TH-­‐variant	  was	  included	  in	  order	  to	  assess	  whether	  enhanced	  TH	  catalytic	  activity	  could	  lead	  to	  an	  increased	  vector	  potency	  in	  vivo.	  In	  this	  study,	  the	  original	  vehicle	  group	  from	  study	  1	  was	  reused	  and	  the	  6	  reserve	  lesioned	  animals	  were	  injected	  with	  a	  ten-­‐fold	  higher	  dose	  of	  GPT002	  (hereafter	  referred	  to	  as	   the	  “full-­‐length”	  group).	  Animals	   treated	  with	  the	   low	  dose	   in	  study	  1	  were	  re-­‐injected	  with	   the	   truncated	  TH	  GPT002	  at	   the	  same	  dose	  as	  the	  “full-­‐length”	  group.	  The	  parkinsonian	  disability	  and	  dyskinesia	  scores	  observed	  for	  the	  low-­‐dose-­‐treated	  group	  in	  study	  1	  did	  not	  differ	  from	  the	  vehicle	   group	   over	   the	   duration	   of	   the	   study	   (Figure	   43	   and	   Figure	   44).	  Therefore,	   the	   locomotor,	   disability	   and	   dyskinesia	   scores	   recorded	   for	   this	  group	  immediately	  prior	  to	  the	  injection	  with	  the	  truncated	  GPT002	  were	  used	  as	  the	  new	  baseline	  against	  which	  the	  efficacy	  of	  this	  intervention	  was	  assessed.	  As	   in	   study	   1,	   animals	   were	   assessed	   for	   their	   locomotor	   activity	   (automatic	  counts	   of	   infra-­‐red	  beam	  breaks),	   parkinsonian	  disability	   (range	   of	  movement,	  bradykinesia,	  posture	  and	  tremor)	  and	  dyskinesia	  (chorea	  and	  dystonia)	   in	   the	  OFF	  state	  as	  well	  as	  following	  treatment	  with	  50%	  L-­‐DOPA	  for	  four	  months	  post	  gene	  therapy.	  	  4.2.3.2.1 Locomotor	   activity	   and	   Parkinsonian	   disability	   after	   gene	   therapy	  with	  GPT002	  and	  its	  truncated	  variant	  Gene	  therapy	  with	  the	  full-­‐length	  and	  truncated	  GPT002	  at	  an	  increased	  dose	  led	   to	   an	   improvement	   in	   locomotor	   activity	   in	   treated	   animals	   relative	   to	  vehicle-­‐treated	  during	   the	   time	  course	  of	  4	  months	  when	  animals	  were	  OFF	  L-­‐DOPA	   (Friedman	   test	   followed	   by	   Dunn’s	   multiple	   comparisons,	   p<0.05).	  Furthermore,	  at	   individual	   time	  points,	   locomotor	  activity	   showed	  a	   significant	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increase	   relative	   to	   baseline	   scores	   at	   months	   4	   and	   2	   in	   the	   full-­‐length	   and	  truncated	  vector-­‐treated	  NHP	  OFF	  L-­‐DOPA,	  respectively,	  and	  at	  months	  2	  and	  3	  in	   both	   full-­‐length	   and	   truncated	   vector-­‐treated	   animals	   on	   50%	   L-­‐DOPA	  (Friedman	  test	   followed	  by	  Dunn’s	  multiple	  comparisons,	  p<0.05).	  However,	  as	  seen	  in	  study	  1,	  spontaneous	  improvement	  in	  locomotor	  activity	  at	  month	  3	  was	  also	   observed	   in	   vehicle-­‐treated	   NHP	   after	   50%	   L-­‐DOPA	   treatment,	   thus	  weakening	  any	  interpretation	  of	  a	  causal	  relationship	  between	  gene	  therapy	  and	  increased	  locomotor	  activity	  at	  this	  time	  point	  (Figure	  47).	  	  
	  
Figure	  47:	  Locomotor	  activity	  of	  MPTP-­‐lesioned	  NHP	  treated	  with	  the	  full-­‐length	  and	  the	  
truncated	  variant	  of	  GPT002	  OFF	  L-­‐DOPA	  and	  after	  50%	  L-­‐DOPA	  treatment.	  
Comparison	   between	   vehicle	   and	   vector-­‐treated	   groups	   as	   well	   as	   at	   individual	   time-­‐
points	  relative	  to	  the	  baseline	  was	  done	  with	  the	  non-­‐parametric	  Friedman	  test	  followed	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by	  Dunn’s	  multiple	  comparisons.	  Values	  are	  shown	  as	  mean	  ± 	  SEM	  and	  are	  normalised	  to	  
the	   baseline	   scores.	   In	   the	   absence	   of	   L-­‐DOPA	   treatment,	   both	   vector-­‐treated	   groups	  
showed	  improved	  locomotor	  activity	  relative	  to	  vehicle	  treated	  animals	  (p<0.05).	  GPT002	  
showed	  a	  significant	  difference	  relative	  to	  the	  baseline	  at	  month	  4	  (p<0.05,	  blue	  asterisk),	  
while	  the	  truncated	  vector-­‐treated	  animals	  showed	  a	  difference	  to	  the	  baseline	  at	  month	  2	  
(p<0.05	  green	  asterisk).	  Difference	  at	   individual	   time	  points	  was	  also	  seen	  upon	  50%	  L-­‐
DOPA	   treatment	   at	   months	   2	   and	   3	   for	   both	   vector-­‐treated	   groups	   (p<0.05,	   black	  
asterisks),	  however	  no	  difference	  was	  seen	  relative	   to	  vehicle	   treated	  animals.	  Asterisks	  
behind	  treatment	  group	  legends	  indicate	  there	  was	  a	  statistical	  difference	  relative	  to	  the	  
vehicle-­‐treated	  group.	  	  It	  is	  noteworthy	  that	  the	  baseline	  locomotor	  counts	  of	  the	  MPTP-­‐lesioned	  NHP	  in	  this	  study	  did	  not	  differ	  significantly	  from	  the	  non-­‐lesioned	  NHP	  used	  in	  study	  1.	  It	  is	  acceptable	  to	  compare	  study	  2	  lesioned	  animals	  vs.	  study	  1	  non-­‐lesioned	  animals	  given	  that	  the	  vehicle	  and	  truncated	  groups	  are	  the	  same	  animals	  used	  in	  study	  1.	  Furthermore,	  the	  reserve	  animals	  used	  for	  treatment	  with	  the	  higher	  dose	  full-­‐length	  GPT002	  were	  lesioned	  together	  with	  the	  other	  NHP	  (Figure	  48).	  As	   in	   the	   previous	   study,	   the	   extent	   of	   the	   MPTP	   lesion	   was	   probably	   not	  sufficient	  to	  cause	  a	  parkinsonian	  phenotype	  that	  can	  be	  detected	  by	  automatic	  counts	  of	  infra-­‐read	  beam	  breaks.	  	  	  	  
	  
Figure	   48:	   Locomotor	   activity	   in	   non-­‐lesioned	   NHP	   from	   study	   1	   and	   MPTP-­‐lesioned	  
animals	  in	  study	  2.	  
The	   severity	   of	   the	   MPTP	   lesion	   did	   not	   result	   in	   a	   significant	   difference	   in	   locomotor	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Clinical	   rating	   4	   months	   post-­‐gene	   therapy	   showed	   an	   effect	   in	   vector-­‐	   vs.	  vehicle-­‐treated	   NHP	   (Friedman	   test,	   p<0.05).	   A	   decrease	   of	   up	   to	   40%	   in	  parkinsonian	  disability	  was	  seen	  in	  NHP	  treated	  with	  the	  truncated	  and	  the	  full-­‐length	   vector-­‐treated	   NHP	   OFF	   L-­‐DOPA	   at	   months	   4	   and	   2,	   respectively.	  Disability	  scores	  remained	  stable	  throughout	  half	  the	  duration	  of	  the	  study,	  with	  vector	  treatment	   leading	  to	  a	  clear	  symptomatic	   improvement.	  Upon	  treatment	  with	   50%	  L-­‐DOPA	   a	   numerical	   decrease	   in	   disability	  was	   seen	   in	  NHP	   treated	  with	  truncated	  GPT002	  (Figure	  49).	  
	   	  
Figure	  49:	  Disability	  scores	  in	  NHP	  treated	  with	  GPT002	  and	  its	  truncated	  variant	  OFF	  L-­‐
DOPA	  and	  after	  50%	  L-­‐DOPA	  treatment.	  
Disability	   scores	   decreased	   after	   treatment	  with	   both	   vectors	   in	   the	   OFF	   state	   but	   only	  
with	  the	  truncated	  variant	  after	  50%	  L-­‐DOPA	  treatment.	  Comparison	  between	  treatments	  
and	  at	   individual	   time-­‐points	   relative	   to	   the	  baseline	  was	  done	  with	   the	  non-­‐parametric	  
Friedman	   test	   followed	   by	   Dunn’s	   multiple	   comparisons.	   Median	   ± 	   interquartile	   range	  
values	  are	  shown.	  Only	  upper	  error	  bars	  are	  shown	  for	  clarity.	  All	  values	  are	  normalised	  
OFF#L%DOPA




























	   	   168	  
to	   the	   baseline	   scores.	   NHP	   OFF	   L-­‐DOPA	   showed	   decreased	   disability	   at	   month	   2	   (full-­‐
length	   vector,	   p<0.05,	   blue	   asterisk)	   and	   at	   month	   4	   (truncated-­‐vector,	   p<0.05,	   green	  
asterisk).	  	  4.2.3.2.2 Dyskinesia	  and	  Good	  On-­‐time	  The	   ability	   of	   the	   increased	   dose	   of	   GPT002	   and	   its	   truncated	   variant	   to	  prevent	   LID	   was	   assessed	   by	   rating	   chorea	   and	   dystonia	   for	   4h	   after	   the	  administration	  of	  50%	  L-­‐DOPA.	   Improvements	  at	   individual	   time	  points	  vs.	   the	  baseline	  scores	  show	  that	  dyskinesia	  decreased	  by	  82%	  at	  month	  2	  and	  by	  44%	  at	  month	  3	   in	  truncated	  vector-­‐treated	  NHP.	  This	  decrease	  was	  mirrored	  by	  an	  increase	   of	   50min	   in	   the	   good	   on-­‐time	   relative	   to	   the	   baseline.	   However,	   a	  spontaneous	   decrease	   in	   dyskinesia	   was	   observed	   in	   vehicle-­‐treated	   animals	  during	  the	  first	  two	  months,	  which	  reached	  47%	  at	  month	  2	  and	  was	  followed	  by	  an	   increase	   at	  months	   3	   and	   4.	   These	   changes	   in	   the	   dyskinesia	   scores	   of	   the	  vehicle	  group	  did	  not	  reflect	  in	  significant	  alteration	  of	  good	  on-­‐time	  (Figure	  50).	  Nonetheless,	  the	  spontaneous	  improvement	  in	  dyskinesia	  seen	  in	  vehicle-­‐treated	  animals	  urges	  for	  caution	  in	  the	  interpretation	  of	  the	  results	  from	  vector-­‐treated	  NHP.	  When	  assessed	  OFF	  L-­‐DOPA,	   dyskinesia	   scores	   remained	   zero	   at	   all	   time	  points	  for	  all	  NHP,	  indicating	  that	  an	  increased	  dose	  of	  GPT002	  does	  not	  trigger	  LID	  by	  itself.	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Figure	   50:	   Dyskinesia	   scores	   and	   good	   on-­‐time	   in	   NHP	   treated	   with	   GPT002	   and	   its	  
truncated	  variant.	  
Scores	   for	   dyskinesia	   (top)	   and	   good	   on-­‐time	   (bottom)	   are	   presented	   as	   median	   ± 	  
interquartile	  range	  (dyskinesia)	  and	  mean	  ± 	  SEM	  (good	  on-­‐time),	  respectively.	  All	  values	  
are	  normalised	  to	  the	  baseline	  scores.	  Only	  upper	  error	  bars	  are	  shown	  for	  clarity.	  	  
4.2.3.3 Post-­‐mortem	  Detection	  of	  TH+	  and	  GCH1+	  Cells	   in	  the	  Putamen	  of	  
NHP	  To	   determine	   the	   transduction	   efficiency	   of	   the	   AAV	   vectors,	   post-­‐mortem	  quantitative	   histological	   analysis	   of	   transgene	   expression	   was	   performed	   by	  immunofluorescence	  staining	  against	  TH	  and	  GCH1	  in	  the	  putamen	  followed	  by	  optical	   density	   quantification.	   As	   seen	   in	   Figure	   51,	   MPTP	   depletion	   of	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dopaminergic	   cells	   in	   the	   SNc	   led	   to	   a	   reduced	  number	   of	   TH+	  neurons	   in	   the	  putamen.	  Surprisingly,	  little	  to	  no	  difference	  in	  the	  number	  of	  TH+	  neurons	  was	  observed	  between	  vehicle-­‐	  and	  AAV-­‐treated	  NHP	  several	  months	  post-­‐injection.	  Gene	  therapy	  with	  GPT002	  led	  to	  an	  increase	  in	  GCH1+	  neurons	  in	  the	  putamen	  of	   NHP	   but	   the	   difference	  was	   only	   significant	   in	   NHP	   treated	  with	   full-­‐length	  GPT002	  (Mann-­‐Whitney,	  p<0.05)	  (Figure	  51).	  GPT002	  has	  previously	  been	  shown	  to	  efficiently	  transduce	  the	  striatum	  and	  lead	   to	   improvement	   in	   behavioural	   tests	   in	   the	   6-­‐OHDA	   lesioned	   rat	   model,	  attesting	   the	   ability	   of	   this	   vector	   to	   express	   TH	   (Cederfjäll	   et	   al.	   2012).	   In	  addition,	  an	  increase	  in	  AAV-­‐mediated	  GCH1	  expression	  is	  observed	  in	  the	  brains	  of	  one	  group	  of	  vector-­‐treated	  NHP.	  Furthermore,	  AAV-­‐mediated	  TH	  expression	  in	  the	  putamen	  of	  MPTP	  lesioned	  NHP	  has	  been	  detected	  after	  treatment	  with	  a	  similar	  AAV	  dose	  65	  days	  post-­‐injection	  (Muramatsu	  et	  al.	  2002).	  This	  suggests	  possible	   technical	   issues	   with	   the	   TH	   staining.	   Further	   insight	   into	   possible	  reasons	   for	   the	   lack	   of	   TH	   detection	   could	   be	   gained	   through	   gene	   expression	  analysis.	  An	   accumulation	  of	  TH	  and	  GCH1	  mRNA	  would	   indicate	  whether	   any	  repression	   is	   happening	   at	   the	   transcriptional	   or	   translational	   level.	   Finally,	  more	  sensitive	  analysis	  of	  tissue	  extracts	  such	  as	  western	  blot	  could	  complement	  the	   immunofluorescence	   quantification	   of	   transgene	   expression.	   However,	  handling	  of	  the	  NHP	  brain	  tissue	  is	  not	  allowed	  in	  our	  facilities	  due	  to	  the	  risk	  of	  the	   presence	   of	   herpes	   B	   virus	   in	   the	   specimens,	   therefore	   these	   experiments	  were	  not	  performed.	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Figure	   51:	   Optical	   density	   measurement	   of	   putamen	   sections	   stained	   with	   antibodies	  
against	  TH	  and	  GCH1.	  
Values	  presented	  as	  mean	  ± 	  SEM	  of	  14	  sections	  covering	  different	  regions	  of	  the	  putamen	  
(Mann-­‐Whitney	  test,	  p<0.05).	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showed	  less	  parkinsonian	  disability	  and	  increased	  locomotor	  activity	  relative	  to	  vehicle-­‐treated	  NHP.	  The	  results	  of	   locomotor	  activity,	  however,	  must	  be	   taken	  with	   caution	   given	   that	   the	   degree	   of	   parkinsonism	   in	   these	   animals	   was	   not	  sufficiently	   severe	   to	   significantly	   affect	   locomotor	   counting	   baseline	   scores.	  Dyskinesia	   scores	  must	   also	   be	   interpreted	  with	   caution.	   Although	   a	   decrease	  was	  seen	  post-­‐AAV	  gene	   therapy,	  vehicle-­‐treated	  animals	   showed	  some	  degree	  of	   spontaneous	   amelioration.	   When	   comparing	   the	   efficacy	   of	   full-­‐length	   vs.	  truncated	   TH,	   both	   vectors	   led	   to	   increased	   locomotor	   activity	   and	   decreased	  parkinsonism.	  Therefore,	   similar	   efficacy	  was	  demonstrated	  with	  both	  GPT002	  forms	  and	  the	  results	  did	  not	  justify	  the	  replacement	  of	  the	  full-­‐length	  TH	  by	  the	  truncated	  variant	  for	  future	  studies.	  
	  
4.2.4 In	  vivo	  Assessment	  of	  the	  GPT002	  By-­‐product	  Efficacy	   of	   AAV	   gene	   therapy	   in	   studies	   1	   and	   2	   was	   observed	   for	   some	  endpoints	  and,	  most	  importantly,	  it	  did	  not	  lead	  to	  LID	  in	  vector-­‐treated	  NHP.	  By	  the	  time	  these	  studies	  were	  completed,	  molecular	  analysis	  of	  the	  bicistronic	  liver	  vector	   (Chapter	   1)	   had	   shown	   intramolecular	   HR,	   which	   is	   triggered	   by	   the	  presence	   of	   two	   identical	   promoters	   in	   the	   vectors	   (Figures	   18B	   and	   19).	  Similarly	   to	  what	   occurred	  with	   the	   bicistronic	   liver	   vector,	   the	   presence	   of	   2	  copies	  of	  the	  SYN	  promoter	  in	  GPT002	  induced	  the	  formation	  of	  a	  second	  smaller	  vector	  also	  occurred	  with	  GPT002	  (Figure	  52).	  	  	  
	  
Figure	   52:	   Alkaline	   gel	   electrophoresis	   showing	   the	   genomes	   of	   GPT002	   and	   its	   by-­‐
product	  comprised	  by	  the	  TH	  expression	  cassette	  only.	  
The	   4.6	   kb	   band	   corresponds	   to	   the	   bicistronic	   GPT002	   genome,	  while	   the	   3.3	   kb	   band	  
corresponds	  to	  the	  by-­‐product	  vector.	  	  While	   HR	   was	   not	   a	   major	   concern	   for	   the	   proof-­‐of-­‐principle	   study	   for	  peripheral	   L-­‐DOPA	   synthesis,	   the	   unexpected	   formation	   of	   a	   secondary	   virus	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poses	   a	   potential	   hurdle	   for	   the	   translation	   of	   this	   therapeutic	   approach.	  Regardless	   of	   the	   efficacy	   of	   the	   brain	   bicistronic	   vector	   in	   alleviating	  parkinsonism	  without	   inducing	  LID	   in	   the	  NHP	  model	  of	  PD,	   from	  a	  regulatory	  perspective	  it	  is	  important	  to	  know	  whether	  the	  by-­‐product	  vector	  formed	  upon	  HR	   is	   a	   functional	   virus	   able	   to	   express	   TH.	   The	   uncontrolled	   formation	   of	   an	  inactive	   by-­‐product	   can	   potentially	   be	   seen	   as	   a	   contaminant	   in	   the	   AAV	  preparation	   and	   therefore	   considered	   not	   suitable	   for	   use	   in	   humans.	  Furthermore,	  whether	  the	  ratios	  at	  which	  each	  species	  is	  formed	  under	  standard	  GMP	  vector	  manufacturing	  procedures	   is	   constant	  or	  variable	   is	   critical	   for	   the	  reliable	  prediction	  of	   treatment	  outcome	   in	   a	   future	  PD	  patient.	  Therefore,	   the	  functionality	  of	  the	  GPT002	  by-­‐product	  virus	  was	  tested	  in	  a	  small-­‐scale	   in	  vivo	  study	  by	  comparing	  the	  TH	  expression	  of	  different	  viral	  vectors	  and	  preparations	  in	   two	   MPTP-­‐lesioned	   NHP.	   For	   this	   purpose,	   a	   vector	   mimicking	   the	   HR	   by-­‐product	   of	   GPT002	   -­‐	   containing	   only	   the	   SYN-­‐TH	   expression	   cassette	   -­‐	   was	  constructed	  by	  removing	  the	  SYN-­‐GCH1	  cassette	  from	  GPT002.	  This	  vector	  was	  named	  “lower	  band	  virus”	  in	  reference	  to	  its	  lower	  molecular	  size	  on	  the	  alkaline	  gel	  (Figure	  52	  –	  lower	  band).	  Additionally,	  the	  HR	  by-­‐product	  virus	  was	  removed	  by	  CsCl	  density	  gradient	   centrifugation	   from	  a	  GPT002	  preparation	   in	  order	   to	  generate	  a	  prep	  containing	  only	  the	  bicistronic	  species	  (seen	  on	  the	  alkaline	  gel	  as	   the	   higher	   band	   –	   Figure	   52).	   These	   two	   preparations	   were	   assessed	   for	  intrastriatal	   TH	   expression	   in	   two	   MPTP-­‐lesioned	   NHP	   alongside	   two	   other	  preparations.	   One	   was	   a	   “complete”	   GPT002	   prep,	   in	   which	   the	   “higher”	   and	  “lower	   band”	   virus	   species	  were	   present.	   The	   other	  was	   a	  monocistronic	   AAV	  vector	   expressing	   the	   TH	   gene	   from	   a	   CMV	   promoter	   previously	   described	   by	  Muramatsu	  et	  al.	  (Muramatsu	  et	  al.	  2002).	  In	  this	  experiment,	  both	  NHP	  received	  an	   intracranial	   injection	   of	   each	   preparation	   in	   four	   different	   areas	   of	   the	  putamen	   -­‐	   two	   different	   preparations	   injected	   into	   each	   brain	   hemisphere.	   All	  preparations	  were	  injected	  at	  the	  same	  dose	  (7.5x109	  gcp/injection),	  except	  for	  the	  “lower	  band”	  virus	  (HR	  by-­‐product),	  which	  was	  given	  at	  a	  3-­‐fold	  lower	  dose	  to	   mimic	   the	   estimated	   by-­‐product	   formation	   ratio	   of	   higher:lower	   band	  observed	   in	   the	   lab.	   Animals	   were	   sacrificed	   6	   weeks	   post	   injection	   and	   IHC	  staining	  of	  brain	  sections	  was	  performed	  to	  assess	  vector	  spread	  in	  the	  putamen.	  Quantification	  of	   transduction	  efficiency	   for	  each	  vector	  was	  done	  by	  assessing	  
	   	   174	  
vector	   spread	   in	   the	   three	   histological	   sections	   closest	   to	   each	   needle	   track	  (Figure	   53)	   and	   quantified	   by	   automatic	   threshold	   quantification	   of	   positively	  stained	  regions	  using	  the	  ImageJ	  software	  (Table	  17).	  	  	  
	  
Figure	   53:	   TH	   staining	   of	   the	   striatum	   of	   NHP	   used	   in	   the	   small-­‐scale	   study	   to	   test	  
expression	  of	  the	  by-­‐product	  of	  GPT002.	  
TH	  staining	  of	  brain	  sections	  around	  the	  needle	  track	  for	  the	  different	  vectors	  tested.	  Each	  
row	  represents	  one	  animal	  and	  columns	  represent	  the	  different	  preps	  injected	  in	  different	  
areas	  of	  the	  putamen.	  	  	  	  
Preparation	   %	  Putamen	  transduction	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  NHP1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  NHP2	  
AAV2/5	  GPT002	   0.6	   19.65	  
AAV2/5	  Upper	  band	   0.61	   16.94	  
AAV2/5	  Lower	  band	   1.17	   7.32	  
AAV2/5	  CMV-­‐TH	   13.89	   30.88	  
	  
Table	  17:	  Percentage	  of	  transduced	  striatum	  per	  prep	  per	  animal	  assessed	  by	  TH	  staining.	  	  	  While	   the	   transduction	  efficiency	  was	  variable	   for	   the	  different	  preparations	  between	   both	   NHP,	   the	   results	   clearly	   demonstrate	   that	   the	   lower	   band	   virus	  (GPT002	  by-­‐product)	   is	  a	   functional	  virus	  able	   to	  express	  TH.	   It	   is	  evident	   that	  the	   vector	   containing	   the	   CMV-­‐TH	   cassette	   had	   a	   stronger	   transduction	   than	  GPT002	  and	  its	  isolated	  components.	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Although	   the	   recombination	   by-­‐product	   was	   shown	   to	   be	   functional,	   the	  observation	   that	   the	   CMV-­‐TH	   vector	   had	   a	   stronger	   transduction	   led	   to	   the	  decision	   to	   redesign	   of	   the	   bicistronic	   brain	   vector.	   The	   redesign	   involved	   the	  replacement	  of	  the	  TH	  cassette	  in	  GPT002	  by	  the	  CMV-­‐TH	  cassette	  tested	  in	  the	  small-­‐scale	  NHP	  study	  described	  above.	  	  
4.2.5 Redesign	  of	  the	  Bicistronic	  Brain	  Vector	  and	  Assessment	  of	  its	  in	  vivo	  
Efficacy	  	  Based	  on	  the	  bigger	  striatal	  spread	  and	  stronger	  TH	  expression	  from	  the	  CMV-­‐TH	   vector	   in	   the	   small-­‐scale	   NHP	   study,	   the	   bicistronic	   brain	   vector	   was	  redesigned.	  The	  new	  vector,	  called	  GPT004,	  still	  expresses	  GCH1	  and	  TH	  from	  a	  single	  AAV	  genome	  and	  the	  difference	  between	  GPT002	  and	  GPT004	  is	  confined	  to	  the	  TH	  expression	  cassette.	  In	  the	  new	  vector,	  TH	   is	  under	  the	  control	  of	  the	  CMV	   promoter,	   followed	   by	   a	   human	   growth	   hormone	   intron.	   A	   further	  difference	   between	   both	   TH	   cassettes	   is	   that	   while	   GPT002	   contains	   the	   TH	  coding	   sequence	   followed	   by	   the	   WPRE,	   the	   TH	   gene	   in	   the	   new	   vector	   is	  followed	  by	   its	  3’	  UTR.	  The	  CMV-­‐TH	  cassette	   in	  GPT004	   is	   identical	   to	   the	  one	  from	   the	   CMV-­‐TH	   virus	   used	   in	   the	   small-­‐scale	   NHP	   study	   (Figure	   53).	   A	  schematic	  representation	  of	  GPT004	  is	  shown	  in	  Figure	  54.	  	  
	  
	  
Figure	  54:	  Schematic	  representation	  of	  the	  GPT004	  genome.	  
The	  vector	  was	  constructed	  by	  modifying	  the	  TH	  expression	  cassette	  in	  GPT002.	  The	  SYN	  
promoter	  was	  replaced	  by	  the	  CMV	  promoter	  and	  the	  WPRE	  was	  replaced	  by	  the	  3’	  UTR	  of	  
TH.	  	  
4.2.6 Molecular	   and	   Behavioural	   Assessment	   of	   GPT004	   in	   the	   6-­‐OHDA	  
Lesioned	  Rat	  Model	  To	  compare	  the	  new	  vector	  GPT004	  to	  GPT002,	  transduction	  and	  therapeutic	  efficacy	  was	  assessed	  in	  6-­‐OHDA-­‐lesioned	  rats	  (n=	  6	  per	  treatment	  group).	  The	  motor	   deficits	   induced	   by	   the	   6-­‐OHDA	   lesion	   were	   assessed	   at	   5	   weeks	   post-­‐lesion	   in	   the	   amphetamine-­‐induced	   rotation	   test	   and	   only	   animals	   exhibiting	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more	   than	   six	   full-­‐body	   turns	  per	  minute	   towards	   the	  dopamine-­‐depleted	   side	  were	   included	   in	   the	   study.	   Next,	   motor	   baseline	   scores	   were	   taken	   for	   the	  cylinder,	  corridor	  and	  stepping	  tests	  confirming	  that	  the	  near	  complete	  lesion	  of	  the	   ascending	   dopamine	   innervation	   by	   injection	   of	   6-­‐OHDA	   in	   the	   medial	  forebrain	  bundle	  (MFB)	  in	  the	  left	  brain	  hemisphere	  causes	  a	  severe	  impairment	  in	  right	  limb	  use.	  At	  6	  weeks	  post-­‐6-­‐OHDA	  lesion,	  animals	  received	  an	  injection	  of	  either	  GPT002	  or	  GPT004	  in	  the	  lesioned	  side;	  changes	  in	  motor	  performance	  in	  the	  three	  tests	  were	  monitored	  over	  12	  weeks.	  The	   cylinder	   test	   was	   carried	   out	   to	   assess	   exploratory	   forelimb	   use	  asymmetry	   by	   placing	   the	   animal	   in	   a	   cylinder	   and	   counting	   the	   frequency	   of	  right	   and	   left	   forelimb	   touches	   on	   the	   glass	  wall.	   Compared	   to	   the	   baseline,	   8	  weeks	   post-­‐AAV	   treatment	   GPT004	   animals	   still	   showed	   a	   strong	   tendency	  towards	   using	   only	   the	   left	   forepaw:	   right	   forelimb	   use	   was	   25.6	   ±	   1.86%	   at	  baseline	   and	   27.2	   ±	   4.4%	   of	   total	   at	   week	   8.	   At	   this	   time	   point,	   asymmetrical	  forepaw-­‐use	  was	  restored	  in	  GPT002-­‐treated	  rats:	  right	  forelimb	  use	  was	  23.3	  ±	  3.4%	  at	  baseline	  vs.	  47.8	  ±	  5%	  at	  week	  8	  (Figure	  56A).	  The	  corridor	  test	  was	  used	  to	  study	  the	  sensorimotor	  aspect	  of	  the	  lesion.	  In	  this	   test,	   the	   read-­‐out	  variable	   is	   the	  animals’	   lateralised	   response	   selection	  by	  nose-­‐pokes	  in	  small,	  equally	  spaced,	  containers	  filled	  with	  sugar	  pellets	  along	  a	  corridor	  (Figure	  55).	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Figure	  55:	  Schematic	  representation	  of	  the	  corridor	  test.	  
Upon	   unilateral	   depletion	   of	   dopaminergic	   neurons	   by	   6-­‐OHDA	   lesion,	   rats	   develop	  
contralateral	   special	   neglect	   and	   retrieve	   sugar	   pellets	   from	   one	   side	   only	   (left	   image,	  
untreated).	   Upon	   treatment	   with	   gene	   therapy,	   lesioned	   rats	   recover	   their	   ability	   to	  
retrieve	   sugar	   pellets	   from	   both	   sides	   of	   the	   corridor	   (right	   image,	   vector-­‐treated,	  
GPT002).	  (From	  Cederfjäll	  E.	  et	  al.	  Molecular	  Therapy	  2012	  Jul;20(7):1315-­‐26).	  	  In	  the	  corridor	  test,	  8	  weeks	  post-­‐injection	  animals	  treated	  with	  GPT004	  still	  showed	  a	  bias	   towards	   retrieving	  pellets	   from	   the	   side	   ipsilateral	   to	   the	   lesion	  (right	   side	   retrievals	   12.5	   ±	   4.1%	  of	   total)	  wile	   the	  GPT002	   group	   displayed	   a	  behavioural	  improvement	  towards	  a	  symmetrical	  response	  (right	  retrievals	  37.3	  ±	  6.1%	  of	  total).	  This	  behaviour	  remained	  virtually	  unchanged	  in	  both	  groups	  for	  up	  to	  12	  weeks	  post-­‐AAV	  treatment	  (right	  retrievals	  14.2	  ±	  4%	  and	  38.3	  ±	  5.7%	  of	  total	  for	  GPT004	  and	  GPT002,	  respectively)	  (Figure	  56	  B).	  The	   stepping	   test	   was	   used	   to	   assess	   forelimb	   akinesia	   by	   quantifying	   the	  ability	  to	  do	  adjusting	  side	  steps.	  Eight	  weeks	  post-­‐AAV	  treatment,	  animals	  in	  the	  GPT002	  group	  showed	  a	  significant	  improvement	  in	  left	  forepaw	  use	  relative	  to	  baseline	   (82.2	  ±	  3.7%	  vs.	  14.43	  ±	  4.1%	   forepaw	  steps	   relative	   to	   intact	   side	  at	  week	  8	  and	  baseline,	  respectively).	  In	  the	  GPT004	  group	  the	  animals	  showed	  an	  increased	  performance	  with	   the	   right	   forepaw	   (contralateral	   to	   the	   lesion)	  but	  the	   improvement	  was	  not	  as	   remarkable	  as	   in	  GPT002-­‐treated	  animals	   (45.9	  ±	  9.8%	  vs.	  17	  ±	  4.2%	  forepaw	  steps	  relative	  to	  intact	  side	  at	  week	  8	  and	  baseline,	  respectively).	  This	  recovery	  was	  maintained	  up	  to	  week	  12	  post-­‐AAV	  treatment	  (80.3	  ±	  2.5%	  and	  47.7	  ±	  8.4%	  forepaw	  steps	  relative	  to	  intact	  side	  GPT002	  and	  GPT004,	  respectively)	  (Figure	  56	  C).	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Figure	  56:	  Behavioural	  tests	  run	  over	  a	  period	  of	  12	  weeks	  post-­‐AAV	  treatment.	  
(A)	   Cylinder	   test;	   (B)	   corridor	   test;	   (C)	   stepping	   test	   (Friedman	   test	   followed	   by	  Dunn’s	  
multiple	   comparison,	   p	   <0.05).	   In	   the	   cylinder	   tests	   treatment	   with	   GPT002	   led	   to	   a	  
significant	  increase	  in	  the	  use	  of	  the	  right	  forepaw.	  Improvement	  after	  GPT002	  treatment	  
was	  also	  seen	   in	   the	  corridor	  test	  8	  weeks	  post-­‐injection.	  Retrieval	  of	  sugar	  pellets	   from	  
the	  right	  side	  remained	  stable	  up	   to	  12	  weeks	  post-­‐injection.	  The	  ability	   to	  do	  adjusting	  
sidesteps	  with	   the	   right	   forepaw	   increased	   after	   treatment	  with	   both	   vectors.	  However,	  
while	   GPT002	   already	   sowed	   an	   effect	   after	   8	   weeks,	   GPT004	   only	   led	   to	   improved	  
behaviour	  12	  weeks	  post-­‐AAV	  injection.	  	  In	   a	   separate	   group	   of	   rats	   (n=5	   per	   group),	   IHC	   was	   used	   to	   qualitatively	  assess	   transgene	   expression	   6	   weeks	   post-­‐AAV	   injection.	   The	   injection	   of	   6-­‐OHDA	   into	   the	   MFB	   in	   one	   hemisphere	   resulted	   in	   a	   complete	   loss	   of	   the	  dopaminergic	  neurons	   that	   innervate	   the	   striatum,	  while	   the	   contralateral	   side	  remained	  visually	  unaffected.	  Both,	  GPT002	  and	  GPT004	  vectors	  induced	  ectopic	  TH	  and	  GCH1	  expression	  in	  the	  rat	  striatum	  at	  similar	  levels	  (Figure	  57).	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Figure	  57:	  Transgene	  expression	  of	  GPT002	  and	  GPT004	  detected	  by	  IHC.	  
The	  first	  column	  shows	  both	  brain	  hemispheres	  of	  unilaterally	  6-­‐OHDA-­‐lesioned	  rats:	  non-­‐
lesioned	  hemisphere	  on	  the	  left;	  lesioned	  hemisphere	  on	  the	  right.	  The	  other	  four	  columns	  
show	  only	  the	  lesioned	  hemisphere	  six	  weeks	  post-­‐AAV	  injection.	  Animals	  from	  both	  the	  
GPT002	   (n	   =	   5)	   and	   GPT004	   (n	   =	   5)	   were	   deeply	   anesthetised	   with	   pentobarbital,	  
transcardially	   perfused;	   brains	   were	   readily	   dissected,	   and	   then	   fixed	   in	  
paraformaldehyde	   (PFA)	   for	   2	   hours.	   After	   overnight	   incubation	   in	   sucrose	   the	   brains	  
were	  then	  cut	  in	  35µm	  coronal	  sections.	  	  
4.2.7 Behavioural	   Assessment	   of	   GPT004	   in	   the	   MPTP-­‐lesioned	   NHP	  
Model	  To	  further	  investigate	  the	  ability	  of	  GPT004	  to	  correct	  parkinsonism	  without	  inducing	   dyskinesia,	   18	   NHP	   were	   lesioned	   with	   daily	   MPTP	   injections	   and	  randomly	  assigned	  to	  one	  of	  three	  groups	  after	  the	  cessation	  of	  MTPT	  treatment	  (n=6	   per	   group).	   The	   first	   group	   received	   a	   total	   volume	   of	   90	   µl	   of	   a	   5x1011	  gcp/ml	   GPT004	   preparation	   (low-­‐dose)	   and	   a	   second	   one	   received	   the	   same	  volume	  of	  a	  5x1012	  gcp/ml	  preparation	  of	  GPT004	  (high-­‐dose).	  A	  third	  group	  of	  MPTP-­‐lesioned	   NHP	   did	   not	   receive	   any	   treatment.	   Injections	   were	   given	  bilaterally	   in	   the	   same	   areas	   of	   the	   putamen	   as	   in	   the	   previous	   two	   studies.	  Behavioural	   assessment	   of	   locomotor	   activity,	   parkinsonian	   disability	   and	  dyskinesia	   was	   carried	   out	   over	   6	   months	   once	   monthly	   in	   the	   absence	   of	   L-­‐DOPA	  treatment	  and	  after	  a	  sub-­‐threshold	  dose	  of	  L-­‐DOPA,	  called	  50%	  L-­‐DOPA	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treatment	  –	  half	  of	   the	  dose	  needed	   to	   completely	   reverse	  parkinsonian	  motor	  symptoms.	  	  
4.2.7.1 Locomotor	  Activity	  and	  Parkinsonian	  Disability	  in	  GPT004-­‐treated	  
NHP	  During	   the	   study,	   no	   significant	   improvement	   in	   locomotor	   activity	   was	  observed	   in	   the	   absence	   of	   L-­‐DOPA	   treatment	   (OFF	   L-­‐DOPA)	   or	   after	   a	   sub-­‐threshold	   dose	   (50%	   L-­‐DOPA).	   Intriguingly,	   locomotor	   activity	   in	   all	   three	  groups	  decreased	  over	   the	   time	  course	  of	   the	  experiment	  upon	   treatment	  with	  50%	  L-­‐DOPA	  (Figure	  58).	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Figure	  58:	  Locomotor	  activity	  of	  lesioned	  NHP-­‐treated	  with	  GPT004.	  
Comparison	  between	  treatments	  and	  intragroup	  comparison	  against	  baseline	  scores	  was	  
done	  with	  the	  Friedman	  test	  followed	  by	  Dunn’s	  multiple	  comparisons.	  Values	  are	  shown	  
as	  mean	  ± 	  SEM	  and	  only	  upper	  error	  bars	  are	  shown	  for	  clarity.	  All	  values	  are	  normalised	  
to	  the	  baseline	  scores.	  	   Because	   non-­‐lesioned	   animals	  were	   not	   included	   in	   this	   study,	   the	   baseline	  measurements	   of	   the	  MPTP-­‐treated	  NHP	  were	   compared	  with	   the	   scores	   from	  the	   non-­‐lesioned	   NHP	   from	   study	   1.	   MPTP-­‐lesioned	   NHP	   had	   decreased	  locomotor	  counts	  of	  75%,	  82%	  and	  91%	  in	  the	  vehicle,	  low-­‐dose	  and	  high-­‐dose	  treated	  groups,	  respectively	  (Figure	  59).	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Figure	   59:	   Locomotor	   activity	   in	   normal	   NHP	   from	   study	   1	   and	   MPTP-­‐lesioned	   NHP	   in	  
study	  3.	  
The	  difference	  between	  groups	  was	  tested	  by	  Friedman	  test	  (*p>0.05).	  Mean	  values	  ± 	  SEM	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Figure	  60:	  Disability	  scores	  of	  NHP	  treated	  with	  GPT004.	  
Comparison	  between	  treatments	  was	  performed	  with	  the	  non-­‐parametric	  Friedman	  test,	  
while	   intragroup	   comparison	   against	   the	   baseline	   was	   done	   with	   the	   Friedman	   test	  
followed	  by	  Dunn’s	  multiple	  comparisons.	  Median	  values	  ± 	  interquartile	  range	  are	  shown.	  
Only	   upper	   error	   bars	   are	   shown	   for	   clarity.	   All	   values	   are	   normalised	   to	   the	   baseline	  
scores.	  
	  
4.2.7.2 Dyskinesia	  and	  Good	  On-­‐time	  Priming	   L-­‐DOPA	   treatment	   was	   given	   to	   NHP	   following	   MPTP-­‐lesioning	   in	  order	   to	   induce	  sustained	  and	  severe	  dyskinesia	   in	   these	  animals.	  We	  assessed	  whether	   treatment	   with	   GPT004	   was	   able	   to	   decrease	   the	   occurrence	   and	  severity	   of	   chorea	   and	   dystonia,	   the	   two	   hallmarks	   of	   LID.	   Treatment	   with	  GPT004	   showed	   a	   statistically	   significant	   reduced	   dyskinesia	   in	   NHP	   that	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received	   a	   low-­‐dose	   of	   the	   vector	   (Friedman	   test,	   p<0.05).	   This	   result	   was	  mirrored	  by	  an	   increase	   in	   the	  good	  on-­‐time	  –	   time	  after	  L-­‐DOPA	   treatment	   in	  which	  NHP	   show	  no	  bradykinesia	   and	  minimal	  dyskinesia.	  However,	   given	   the	  lack	   of	   symptomatic	   improvement	   in	   the	   locomotor	   counts	   and	   parkinsonian	  disability	  scores,	   this	  observation	  does	  not	  have	  clinical	  significance.	  No	  effects	  were	  seen	  in	  NHP	  treated	  with	  high-­‐dose	  of	  GPT004	  (Figure	  61).	  
	  
	  
Figure	  61:	  Dyskinesia	  scores	  and	  good	  on-­‐time	  in	  the	  NHP	  treated	  with	  GPT004.	  
Scores	   for	   dyskinesia	   (top)	   and	   good	   on-­‐time	   (bottom)	   are	   presented	   as	   median	   ± 	  
interquartile	   range	   (dyskinesia)	   and	   mean	   ± 	   SEM	   (good	   on-­‐time).	   All	   values	   are	  
normalised	   to	   the	   baseline	   scores.	   Only	   upper	   error	   bars	   are	   shown	   for	   clarity.	   NHP	  
treated	  with	  the	  low-­‐dose	  of	  GPT004	  showed	  a	  significant	  decrease	  in	  dyskinesia	  (p<0.05)	  
with	  a	  concomitant	   increase	   in	   the	  on-­‐time	  (p<0.05)	  relative	   to	   the	  vehicle	   treated	  NHP.	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4.2.8 In	  vitro	  Assessment	  of	  GPT004	  The	  surprisingly	  low	  efficacy	  of	  GPT004	  seen	  in	  both,	  the	  rat	  and	  NHP	  model	  of	  PD	  called	   for	   further	  analyses	   to	  elucidate	   the	   reasons	   for	   its	  poor	  outcome.	  Valuable	   insight	   will	   be	   gained	   through	   post-­‐mortem	   analyses	   of	   the	   animals,	  such	  as	  confirmation	  and	  comparison	  of	  transgene	  and	  protein	  expression	  levels	  in	   the	   striatum,	  measurement	  of	  TH	  activity	  and	   intrastriatal	   levels	  of	  L-­‐DOPA.	  However,	  at	   the	  time	  the	  rodent	  study	  was	  terminated,	   the	  NHP	  study	  was	  still	  ongoing	  and	  it	  was	  decided	  that	  the	  rodents’	  brains	  were	  to	  remain	  frozen	  until	  later	  efficacy	  time	  points	  were	  available	  from	  the	  NHP	  study.	  These	  analyses	  are	  now	  ongoing	  but	  at	  the	  time	  this	  thesis	  was	  being	  written	  no	  data	  was	  available.	  Because	  a	   post-­‐mortem	   analysis	   of	   the	   animals’	   brains	  was	   not	   possible,	   an	  investigation	   of	   transgene	   and	   protein	   expression	   from	   the	   brain	   vectors	   was	  performed	   in	   vitro.	   For	   this	   purpose,	   GPT002,	   GPT004	   and	   the	   AAV-­‐CMV-­‐TH	  vector	   were	   pseudotyped	   in	   an	   AAV2	   vector	   and	   used	   to	   infect	   the	  neuroblastoma	   cell	   line	   SH-­‐SY5Y.	   The	   decision	   to	   use	   AAV2	   in	   the	   in	   vitro	  experiments	  was	  made	  because	  an	  infection	  curve	  for	  this	  serotype	  in	  SH-­‐SY5Y	  cells	  had	  been	  previously	  been	  performed	  in	  our	  lab	  and	  we	  knew	  that	  an	  MOI	  of	  104	  gcp	  would	   lead	   to	  40%	  transduction.	  A	   transduction	  curve	   for	  AAV5	   in	   the	  same	  cell	  line	  had	  not	  been	  done	  in	  our	  lab.	  The	  AAV-­‐CMV-­‐TH	  vector	  was	  used	  as	  a	  positive	  control	  since	  it	  had	  shown	  strong	  in	  vivo	  transduction	  in	  2	  NHP	  (Figure	  53)	  and	  because	  the	  identical	  TH	  expression	  cassette	  was	  present	  in	  GPT004.	  Transduction	   of	   SH-­‐SY5Y	   cells	   led	   to	   increased	  TH	   gene	   expression	   from	  all	  three	  vectors	  and	  increased	  GCH1	  gene	  expression	  from	  GPT004	  only	  (Figure	  62	  A).	  TH	  gene	  expression	  from	  GPT004	  and	  AAV-­‐CMV-­‐TH	  was	  100-­‐fold	  higher	  than	  from	   GPT002.	  While	   a	   6-­‐fold	   increase	   in	  GCH1	   gene	   expression	  was	   observed	  upon	  infection	  with	  GPT004,	  its	  expression	  after	  GPT002	  and	  CMV-­‐TH	  infection	  was	  similar	  to	  that	  from	  uninfected	  cells.	  No	  DNA	  amplification	  was	  detected	  in	  the	  real	  time	  quantitative	  PCR	  in	  any	  of	  the	  -­‐RT	  samples	  -­‐	  reverse	  transcriptions	  performed	  in	  the	  absence	  of	  the	  reverse	  transcriptase	  enzyme	  -­‐,	  confirming	  that	  the	  DNA	  detected	   in	   the	   test	   samples	  was	  cDNA	   that	  had	  been	  converted	   from	  mRNA	  and	  not	  contaminant	  genomic	  or	  viral	  DNA.	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Western	  blot	   analysis	  of	  TH	  expression	   revealed	   the	   same	  pattern	  observed	  for	  the	  mRNA	  expression:	  GPT004	  and	  CMV-­‐TH	  vectors	  showed	  a	  much	  stronger	  expression	  than	  GPT002	  (Figure	  62	  B).	  	  
	  
Figure	  62:	  In	  vitro	  comparison	  of	  gene	  and	  protein	  expression	  of	  GPT002	  and	  GPT004.	  
Gene	  expression	  (A)	  and	  protein	  expression	  (B)	  of	  GPT002	  was	  compared	  with	  GPT004.	  As	  
a	  positive	  control,	  the	  AAV-­‐CMV-­‐TH	  vector	  was	  used.	  SH-­‐SY5Y	  cells	  were	  transduced	  with	  
GPT002,	   GPT004	   and	   AAV-­‐CMV-­‐TH	   at	   an	   MOI	   of	   104	   gcp;	   mRNA	   and	   proteins	   were	  
extracted	  48h	  post-­‐infection	  for	  gene	  and	  protein	  expression	  analyses.	  GPT004	  and	  AAV-­‐
CMV-­‐TH	   show	   higher	   expression	   than	   GPT002	   at	   the	   gene	   and	   protein	   levels.	   Results	  
presented	  are	  the	  mean	  of	  two	  independent	  experiments.	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4.3 Discussion	  In	  this	  chapter	  I	  investigated	  the	  efficacy	  of	  a	  clinical	  candidate	  AAV	  vector	  in	  the	  MPTP-­‐lesioned	  NHP	  model	  of	  PD.	  The	  efficacy	  and	  safety	  studies	  described	  here	   represent	   a	   crucial	   step	   towards	   the	   translation	   of	   a	   novel	   gene	   therapy	  strategy	  following	  preclinical	  data	  generated	   in	  the	  6-­‐OHDA-­‐lesioned	  rat	  model	  of	  PD	  (Cederfjäll	  et	  al.	  2012).	  In	  total,	   four	  NHP	  studies	  were	  carried	  out,	  which	  evaluated	  different	  vector	  designs,	   putaminal	   spread	   and	   doses	   for	   their	   ability	   to	   improve	   locomotor	  activity,	  parkinsonian	  disability	  and	  dyskinesia	  in	  the	  MPTP-­‐lesioned	  NHP	  model	  of	  PD.	  In	  the	  first	  NHP	  efficacy	  study,	  18	  MPTP-­‐lesioned	  primates	  were	  assigned	  to	  one	   of	   three	   treatment	   groups	   (vehicle,	   low-­‐dose	   and	  high-­‐dose	   gene	   therapy)	  and	   submitted	   to	   behavioural	   tests	   (locomotor	   counts,	   parkinsonian	   disability	  and	  dyskinesia)	  OFF	  L-­‐DOPA	  and	  after	  challenge	  with	  a	  sub-­‐threshold	  dose	  of	  L-­‐DOPA	  for	  up	  to	  7	  months.	  Here,	  a	  significant	  difference	  in	  locomotor	  counts	  was	  observed	  relative	   to	  vehicle-­‐treated	  NHP	   in	   low-­‐	  and	  high-­‐dose-­‐treated	  groups,	  both	  OFF	  L-­‐DOPA	  and	  after	  challenge	  with	  50%	  L-­‐DOPA.	  Moreover,	  a	  significant	  improvement	   relative	   to	   the	   baseline	   was	   observed	   for	   the	   high-­‐dose	   treated	  group	   at	   months	   3	   and	   7	   OFF	   L-­‐DOPA	   and	   at	   month	   3	   after	   50%	   L-­‐DOPA	  treatment	  (Figure	  41).	  Because	  the	  behavioural	  assessments	  stopped	  at	  different	  months	   for	   the	   three	   groups,	   the	   Wilcoxon	   matched	   pairs	   test	   –	   the	   non-­‐parametric	  equivalent	  of	  the	  t-­‐test	  –	  was	  performed	  individually	  on	  both	  treated	  groups	  vs.	  vehicle	  for	  up	  to	  months	  5	  and	  6	  with	  the	  low-­‐	  and	  high-­‐dose	  groups,	  respectively.	   The	   Friedman	   test	   –	   the	   non-­‐parametric	   equivalent	   of	   repeated	  measurements	   ANOVA	   –	   was	   also	   performed	   on	   all	   groups	   up	   to	   month	   5	   in	  order	  to	  remain	  consistent	  in	  the	  tests	  run	  in	  all	  three	  NHP	  studies.	  This	  showed	  a	  significant	  difference	  between	  vehicle-­‐	  and	  vector-­‐treated	  animals	  for	  the	  low-­‐dose	   group	   OFF	   L-­‐DOPA	   and	   for	   both	   treated	   groups	   after	   50%	   L-­‐DOPA	  treatment.	  A	  slight	  improvement,	  although	  not	  significant,	  was	  also	  observed	  in	  the	  vehicle	  treated	  animals	  at	  month	  3	  both	  in	  OFF	  L-­‐DOPA	  state	  and	  after	  50%	  L-­‐DOPA	  medication.	  High-­‐dose-­‐treated	  NHP	  also	  showed	  significantly	  increased	  locomotor	   activity	   at	   month	   7	   relative	   to	   the	   baseline.	   However,	   there	   are	   no	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data	   for	   the	   vehicle	   control	   group	   at	   this	   time	   point	   to	   allow	   for	   a	   direct	  comparison	  between	  groups.	  In	   addition	   to	   these	   analyses,	   baseline	   locomotor	   counts	   of	   MPTP-­‐lesioned	  NHP	   were	   compared	   with	   normal	   NHP.	   Four	   non-­‐lesioned	   NHP	   had	   been	  included	  in	  the	  study	  and	  it	  was	  surprising	  to	  observe	  that	  the	  difference	  in	  the	  baseline	   scores	   between	   normal	   and	   lesioned	  NHP	  was	   not	   significant	   (Figure	  42).	   Although	   effective	  MPTP	   lesioning	  was	   demonstrated	   in	   the	  NHP	   through	  parkinsonian	  disability	  and	  dyskinesia	  scoring	  prior	  to	  the	  initiation	  of	  the	  study	  (Figure	   38)	   and	   was	   validated	   by	   post-­‐mortem	   stereological	   counting	   of	   TH+	  neurons	   in	   the	   SNc	   (Figure	   39),	   a	   difference	   in	   locomotor	   counts	   was	   also	  expected	  between	  normal	  and	  lesioned	  NHP.	  In	  this	  study,	  daily	  MPTP	  treatment	  to	   induce	  parkinsonism	  was	  halted	  when	  primates	   reached	   a	   score	   of	   6	   in	   the	  Benazzouz	  rating	  scale	  (Table	  14),	  which	  ranges	  from	  0	  (normal)	  to	  25	  (severe	  parkinsonism).	  Although	  this	  score	  was	  used	  as	  a	  threshold	  for	  the	  cessation	  of	  MPTP	   treatment	   in	   order	   to	   ensure	   survival	   of	   the	   NHP	   in	   the	   forthcoming	  surgical	  procedures,	  previous	  studies	  using	  the	  Benazzouz	  scale	  to	  measure	  the	  extent	   of	   the	   MPTP	   lesion	   only	   halted	   the	   treatment	   once	   the	   NHP	   reached	   a	  score	  of	  8	  (Bezard	  et	  al.	  1997).	  In	  addition,	  the	  degree	  of	  parkinsonian	  disability	  at	  which	  the	  MPTP	  treatment	  was	  stopped	  in	  this	  study	  corresponds	  to	  24%	  of	  the	  maximum	  score	  (6	  out	  of	  25),	  whereas	  in	  a	  similar	  study	  from	  Jarraya	  et	  al.,	  which	  also	  evaluated	  the	  efficacy	  of	  gene	  therapy	  for	  the	  treatment	  of	  PD,	  MPTP	  treatment	  was	  halted	  when	  71%	  of	  the	  maximum	  disability	  score	  was	  achieved:	  
≥10	  out	  of	  14	  in	  a	  rating	  scale	  adapted	  from	  Papa	  and	  Chase	  (Imbert	  et	  al.	  2000;	  Jarraya	   et	   al.	   2009).	   Finally,	   in	   the	   study	   from	   Jarraya	   et	   al.,	   decrease	   in	  locomotor	   activity	   was	   used	   to	   decide	   when	   to	   stop	   MPTP	   treatment.	   It	   is	  therefore	   possible	   that	   the	   severity	   of	   the	   MPTP	   lesioning	   used	   in	   the	  experiments	  described	  in	  thesis	  was	  sufficient	  to	  cause	  parkinsonism	  and	  allow	  for	  the	  development	  of	  LID	  but	  not	  to	  significantly	  affect	  locomotor	  counts.	  It	   was	   also	   noted	   that	   in	   the	   first	   NHP	   study	   dyskinesia	   scores	   decreased	  gradually	  in	  all	  groups,	  including	  the	  vehicle-­‐treated	  (Figure	  44	  top).	  The	  reasons	  for	   this	   spontaneous	   improvement	   are	  not	   entirely	   clear	  but	   it	   is	   possible	   that	  changes	  in	  the	  NHP	  weight	  could	  be	  responsible	  for	  this	  phenomenon.	  The	  NHP	  were	   treated	   every	   month	   with	   the	   same	   sub-­‐threshold	   amount	   of	   L-­‐DOPA	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established	  at	  the	  beginning	  of	  the	  experiment.	  Therefore,	  an	  increase	  in	  weight	  could	   have	   had	   an	   influence	   on	   the	   effective	   dose	   (mg/kg)	   given.	   In	   the	   study	  from	   Jarraya	   et	   al.,	   the	   L-­‐DOPA	   dose	   given	   to	   animals	   was	   adjusted	   to	   their	  weight.	  Despite	  the	  spontaneous	  improvement	  in	  the	  dyskinesia	  scores	  upon	  L-­‐DOPA	   challenge	   seen	   in	   this	   study,	   dyskinesia	   was	   absent	   in	   GPT002-­‐treated	  NHP	  in	  the	  OFF	  state	  at	  all	  time	  points	  measured	  and	  did	  not	  worsen	  when	  they	  were	  challenged	  with	  50%	  L-­‐DOPA.	  	  In	  summary,	  symptomatic	  improvement	  in	  the	  first	  NHP	  study	  was	  observed	  for	   the	  endpoints	   locomotor	  activity	   in	   the	  high-­‐dose-­‐treated	  group	   in	   the	  OFF	  state	  and	  after	  50%	  L-­‐DOPA	  treatment	  as	  well	  as	  in	  parkinsonian	  disability	  in	  the	  OFF	   state.	   Overall,	   these	   effects	   were	   considered	   only	   partial	   and	   thus	  insufficient	  to	  justify	  clinical	  investigation.	  Following	   the	   termination	   of	   study	   1,	   a	   second	   study	   was	   conducted	   for	   4	  months	   to	   test	   the	   efficacy	  of	   a	   10-­‐fold	  higher	  dose	  of	  GPT002.	   In	   addition,	   an	  almost	   identical	   vector	   expressing	   a	   truncated	   form	   of	   TH	   was	   injected	   in	   a	  group	  of	  NHP.	  This	  vector	  was	   included	   in	  order	   to	   test	  whether	   increased	  TH	  catalytic	  activity	  was	  able	  to	  enhance	  the	  in	  vivo	  potency	  of	  the	  vector	  (Walker	  et	  al.	   1994).	   Support	   for	   the	   use	   of	   a	   truncated	   TH	   also	   came	   from	   a	   successful	  preclinical	  study	  and	  Phase	  I	  gene	  therapy	  trial	  for	  the	  treatment	  of	  PD,	  in	  which	  a	   vector	   containing	   a	   truncated	   TH	   was	   used	   (Jarraya	   et	   al.	   2009;	   Palfi	   et	   al.	  2014).	  The	  6	  NHP	  injected	  with	  the	  truncated	  vector	  were	  the	  same	  “low-­‐dose”	  NHP	   from	   study	   1.	   The	   decision	   to	   reuse	   these	   animals	   was	   based	   on	   the	  observation	  that	  a	   low-­‐dose	  treatment	  with	  GPT002	  did	  not	  have	  any	  effect	  on	  the	  endpoints	  parkinsonian	  disability	   and	  dyskinesia	   for	   the	  entire	  duration	  of	  study	   1	   (Figure	   43	   and	   Figure	   44).	   A	   group	   of	   reserve	   NHP	   lesioned	   together	  with	   those	   from	  study	  1	  was	   injected	  with	   the	  new	  dose	  of	  GPT002,	  while	   the	  same	  vehicle-­‐treated	  group	  from	  study	  1	  was	  reused	  in	  study	  2.	  After	  4	  months,	  efficacy	  was	   observed	   for	   both	   vectors,	   full-­‐length	   and	   truncated,	   OFF	   L-­‐DOPA	  for	  the	  endpoints	  locomotor	  counts	  and	  parkinsonian	  disability.	  Since	   some	  of	   the	  NHP	   in	   this	   study	  were	   the	   same	  ones	  used	   in	   study	  1	  or	  lesioned	   at	   the	   same	   time,	   the	   lack	   of	   difference	   in	   locomotor	   counts	   between	  lesioned	  and	  normal	  NHP	  in	  study	  2	  remains	  a	  caveat	  in	  the	  measurement	  of	  this	  endpoint	   (Figure	   48).	   Interestingly,	   no	   difference	   in	   efficacy	   was	   observed	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between	   the	   full-­‐length	   and	   the	   truncated	   vector,	   despite	   predicted	   increased	  activity	   of	   the	   truncated	   form	   of	   TH	   (Walker	   et	   al.	   1994).	   Analysis	   of	   vector	  transduction	   in	   the	   rat	  model	   showed	   increased	   transduction	  of	   the	   full-­‐length	  vector	   relative	   to	   the	   truncated	   variant	   (Figure	   46).	   If	   this	   differential	  transduction	   is	  also	   true	   for	   the	  NHP,	   the	  similar	  efficacy	  of	   the	   two	  vectors	   in	  NHP	  might	  be	  attributed	  to	  the	  enhanced	  catalytic	  activity	  of	   the	  truncated	  TH.	  However,	  post-­‐mortem	   analysis	   of	   the	  NHP	  brains	   showed	  no	  difference	   in	   the	  levels	   of	   ectopic	   TH	   between	   the	   full-­‐length-­‐	   and	   the	   truncated	   vector-­‐treated	  NHP	  (Figure	  51).	  The	  behavioural	  effect	  observed	  upon	  vector	  treatment	  in	  both	  NHP	   studies	   suggests	   vector-­‐mediated	  L-­‐DOPA	   synthesis.	  As	   the	  post-­‐lesioning	  staining	   of	   the	   SNc	   showed,	   TH	   depletion	   was	   equivalent	   in	   all	   MPTP-­‐treated	  NHP	   (Figure	   39),	   therefore	   behavioural	   improvement	   seen	   in	   vehicle-­‐treated	  NHP	   relative	   to	   vector-­‐treated	  NHP	   is	   unlikely	   to	   have	   been	   caused	   by	   spared	  dopaminergic	  neurons	  alone.	  Furthermore,	  the	  lack	  of	  differential	  TH	  expression	  in	   the	   putamen	   between	   vector-­‐treated	   and	   untreated	  NHP	   is	   unlikely	   to	   be	   a	  true	   reflection	   of	   a	   lack	   of	   transgene	   expression	   from	   the	   vector	   as	   the	   post-­‐
mortem	   histological	   data	   suggest.	   Firstly,	   the	   same	   GPT002	   vector	   has	   been	  shown	   to	   efficiently	   express	   both	   its	   transgenes	   in	   the	   striatum	   of	   rodents	  (Cederfjäll	  et	  al.	  2012	  and	  Figure	  36).	  Furthermore,	  an	   increase	   in	  GCH1+	  cells	  was	   seen	   in	   NHP	   treated	   with	   the	   full-­‐length	   vector.	   Finally,	   a	   similar	   gene	  therapy	  study	  in	  NHP	  was	  able	  to	  demonstrate	  high	  levels	  of	  TH	  expression	  from	  an	   AAV	   vector	   injected	   into	   the	   putamen	   at	   similar	   doses	   (Muramatsu	   et	   al.	  2002).	   It	  can	  be	  argued	  that	  the	  vector	  used	  by	  Muramatsu	  et	  al.	  expressed	  TH	  from	  the	  CMV	  promoter,	  which	  could	  have	  led	  to	  a	  much	  stronger	  TH	  expression	  than	   a	   SYN-­‐driven	   TH.	   On	   the	   other	   hand,	   the	  Muramatsu	   study	   used	   an	   AAV	  vector	   of	   serotype	   2,	   which	  was	   shown	   to	   possess	   an	   8-­‐	   to	   10-­‐fold	   decreased	  ability	  to	  transduce	  the	  striatum	  relative	  to	  AAV5	  (Burger	  et	  al.	  2004).	  Based	  on	  these	  three	  facts,	  it	  is	  possible	  that	  technical	  issues	  in	  the	  detection	  of	  TH	  are	  the	  reason	  why	  no	  difference	  was	  seen	  in	  the	  number	  of	  TH+	  cells	  between	  vector-­‐	  and	  vehicle-­‐treated	  NHP.	  During	  the	  4	  months	  of	  study	  2,	  dyskinesia	  scores	  showed	  a	  trend	  towards	  a	  decrease	  in	  both	  vector-­‐treated	  groups	  and	  an	  increase	  in	  the	  good	  on-­‐time	  (time	  in	   which	   parkinsonian	   disability	   is	   low	   and	   no	   severe	   dyskinesia	   is	   present).	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However,	  these	  observations	  were	  not	  statistically	  significant	  relative	  to	  vehicle	  treated	  NHP.	  Nevertheless,	  the	  fact	  that	  gene	  therapy	  treatment	  was	  not	  able	  to	  trigger	  dyskinesia	  after	  oral	  L-­‐DOPA	  treatment	  is	  of	  clinical	  relevance.	  In	  a	  Phase	  I	   lentiviral-­‐based	   gene	   therapy	   for	   the	   treatment	   of	   PD,	   increased	   LID	   after	   L-­‐DOPA	  oral	  medication	  was	  associated	  with	  vector	   treatment.	  However,	   it	  must	  be	  highlighted	  that	  these	  dyskinetic	  events	  had	  not	  been	  identified	  in	  the	  efficacy	  studies	   in	   MPTP-­‐lesioned	   NHP	   and	   they	   could	   be	   resolved	   by	   decreasing	   the	  patient’s	  L-­‐DOPA	  oral	  medication	  (Jarraya	  et	  al.	  2009;	  Palfi	  et	  al.	  2014).	  In	  summary,	  efficacy	  in	  study	  2	  was	  seen	  for	  the	  endpoints	  locomotor	  activity	  and	   parkinsonian	   disability	   for	   both	   vectors	   in	   the	   OFF	   state.	   Although	  dyskinesia	  did	  not	  decrease	   significantly,	   the	   fact	   that	   it	   did	  not	   increase	  post-­‐gene	  therapy	  treatment	  is	  relevant.	  Despite	   increased	   efficacy	   observed	   with	   the	   truncated	   and	   full-­‐length	  GPT002	   vectors	   relative	   to	   study	   1,	   the	   identification	   of	   HR	   in	   these	   vectors	  posed	  a	  potential	  deterrent	  for	  the	  approval	  of	  this	  compound	  as	  a	  medicine.	  In	  order	   to	   be	   regarded	   as	   safe	   for	   human	   use,	   the	   ratio	   of	   both	   vector	   species	  (Figure	  52)	  must	  be	  constant	  across	  preparations.	  However,	  this	  was	  not	  tested.	  In	  addition,	  if	  the	  by-­‐product	  vector	  formed	  upon	  HR	  does	  not	  have	  the	  ability	  to	  express	  TH,	  it	  can	  be	  regarded	  as	  a	  contaminant.	  Therefore,	  to	  address	  the	  latter	  concern,	   the	   different	   fractions	   of	   a	   GPT002	   preparation	   -­‐	   i.e.	   complete	   prep,	  “higher	   band”	   only	   and	   “lower	   band”	   only	   -­‐	  were	   injected	   in	   the	   striatum	  of	   2	  NHP.	  As	  positive	  control,	  the	  CMV-­‐TH	  vector	  from	  Muramatsu	  et	  al.	  was	  included	  in	   the	   study	   (Muramatsu	   et	   al.	   2002).	   Analysis	   of	   vector	   transduction	   in	   the	  putamen	  indicated	  that	  the	  by-­‐product	  SYN-­‐TH	  vector	  formed	  upon	  HR	  was	  able	  to	  express	  TH.	  However,	  expression	  from	  the	  CMV-­‐TH	  vector	  was	  the	  strongest	  (Figure	  53).	  This	  observation,	  added	  to	  the	  potential	  regulatory	  issue	  caused	  by	  the	  HR	  of	  the	  vector,	  prompted	  us	  to	  design	  a	  new	  and	  improved	  vector.	  The	  new	  vector,	  named	  GPT004,	  contained	  the	  same	  CMV-­‐TH	  expression	  cassette	  present	  in	  Muramatsu’s	  vector.	  By	  eliminating	  the	  first	  SYN	  promoter	  the	  intramolecular	  HR	  was	  abolished.	  The	   poor	   efficacy	   of	   GPT004	   in	   the	   rodent	   and	   NHP	   models	   of	   PD	   was	  unexpected	  given	  that	  the	  small-­‐scale	  NHP	  study	  showed	  that	  the	  CMV	  promoter	  led	   to	   strong	   TH	   expression	   (Figure	   53).	   Interestingly,	   the	   poor	   outcome	   of	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GPT004	  in	  the	  rodents	  was	  predictive	  for	  the	  NHP	  study,	  where	  efficacy	  was	  not	  met	   for	   any	   of	   the	   study’s	   endpoints.	   The	   only	   effect	   seen	   in	   the	   NHP	   was	   a	  decrease	  in	  dyskinesia	  in	  the	  group	  treated	  with	  the	  low-­‐dose	  of	  GPT004	  but	  due	  to	  the	  lack	  of	  symptomatic	  improvement	  in	  locomotor	  counts	  and	  parkinsonian	  disability,	  this	  observation	  was	  not	  considered	  clinically	  significant	  (Figure	  61).	  	  The	   reasons	   for	   the	  unexpectedly	   low	   in	  vivo	  efficacy	  of	  GPT004	  are	  not	  yet	  entirely	  clear.	  Strong	  expression	  from	  the	  CMV-­‐TH	  cassette	  was	  achieved	  from	  a	  monocistronic	   vector	   in	   the	   small	   study	   using	   the	   2	   NHP	   and	   the	   study	   from	  Muramatsu	  et	  al.	  (Figure	  43	  and	  Muramatsu	  et	  al.	  2002).	  Therefore,	  it	  is	  possible	  that	   the	   different	   vector	   designs	   (i.e.	   monocistronic	   vs.	   bicistronic)	   has	   an	  influence	   on	   transgene	   expression. Substantial	   promoter	   interference	   between	  internal	   heterologous	   promoters	   has	   been	   described	   to	   occur	   in	   a	   retroviral	  vector	   expressing	   its	   transgenes	   from	   the	   CMV	   and	   EF1α	   promoters,	   which	  affected	  the	  expression	  of	  both	  transgenes	  (Curtin	  et	  al.	  2008).	  The	  mechanisms	  by	  which	   promoter	   interference	   occurs	   have	   been	   described	   as	   being	   through	  the	   formation	   of	   a	   read-­‐through	   transcript	   from	   the	   upstream	   gene	   into	   the	  regulatory	  region	  of	  the	  second	  one,	  which	  disrupts	  the	  binding	  of	  transcription	  factors	   and	  other	  DNA-­‐binding	  proteins	   (Greger	   et	   al.	   1998).	   Alternatively,	   the	  formation	   of	   a	   read-­‐through	   transcript	   with	   an	   abnormal	   3’UTR	   could	   lead	   to	  mRNA	   targeted	   degradation	   by	   the	   nonsense-­‐mediated	   mRNA	   decay	   pathway	  (Bicknell	   et	   al.	   2012).	   Another	   proposed	   mechanism	   to	   explain	   bidirectional	  promoter	   interference	   is	   competition	   between	   promoters	   for	  transcription	  factors,	   enhancers	   or	   their	   binding	   proteins.	   Promoter	   interference-­‐like	   effects	  could	  also	  occur	  through	  post-­‐transcriptional	  mechanisms,	  such	  as	  competition	  between	   the	   different	   vector-­‐encoded	   transcripts	   for	   ribosomal	   association.	  Intriguingly,	   these	   proposed	   interpretations	   for	   the	   in	   vivo	   data	   could	   not	   be	  confirmed	  by	  in	  vitro	  experiments.	  As	  seen	  in	  Figure	  62,	  transcript	  stability	  and	  translation	  of	  TH	  are	  not	  affected	  in	  either	  GPT002	  or	  GPT004.	  In	  fact,	  the	  strong	  TH	   expression	   observed	   in	   vitro	   does	   not	   correspond	   to	   the	   poor	   in	   vivo	  performance	  of	  the	  rats	  and	  NHP	  injected	  with	  GPT004.	  Promoter	  interference,	  however,	  can	  be	  suggested	  for	  the	  transcription	  of	  the	  GCH1	  cassette	  in	  GPT002,	  which	  showed	  similar	  transcript	  levels	  as	  uninfected	  cells.	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The	   analysis	   of	   the	   brains	   of	   the	   animals	   used	   in	   these	   experiments	   will	  provide	   important	   indications	   on	   possible	   reasons	   for	   the	   poor	   in	   vivo	  performance	  of	  GPT004.	  Some	  insight	  was	  gained	  through	  the	  IHC	  analysis	  of	  a	  small	  group	  of	  rats,	  which	  demonstrated	  similar	  striatal	  transduction	  levels	  with	  both	   vectors.	   This	   is	   in	   contrast	   to	   the	   differential	   TH	   expression	   seen	   in	   vitro	  (Figure	  57	  and	  Figure	  62).	  However,	  the	  animals	  used	  for	  the	  IHC	  analysis	  were	  not	  the	  same	  ones	  as	  those	  used	  for	  the	  behavioural	  tests.	  The	  GPT004	  efficacy	  study	  in	  the	  NHP	  was	  terminated	  only	  recently	  and	  the	  brains	   of	   the	   rodents	   and	   of	   the	   NHP	   are	   currently	   being	   analysed.	   The	   post-­‐
mortem	  analyses	  will	  allow	  for	  the	  comparison	  of	  transgene	  mRNA	  and	  protein	  expression	  levels	  in	  the	  striatum.	  This	  analysis	  will	  confirm	  whether	  expression	  levels	  correlate	  with	  the	  behavioural	  efficacy.	  Furthermore,	  ex	  vivo	  measurement	  of	   intrastriatal	   TH	   activity	   and	   L-­‐DOPA	   levels	   will	   provide	   a	   readout	   of	   the	  activity	  levels	  of	  each	  vector.	  Given	   the	   low	   numbers	   of	   gene	   therapy	   trials	   that	   have	   been	   able	   to	   show	  efficacy	   in	   double	   blind,	   placebo	   controlled	   trials,	   it	   is	   sensible	   to	   aim	   for	  stronger	  preclinical	  efficacy	  from	  an	  improved	  vector	  before	  tests	  in	  humans	  are	  conducted	   (Bartus	   et	   al.	   2014).	   In	   order	   to	   accomplish	   this,	   understanding	   the	  reasons	  behind	  the	  poor	  efficacy	  of	  GPT004	  is	  crucial.	  If	  promoter	  interference	  is	  suggested	  by	  the	  post-­‐mortem	  analyses	  of	  the	  animals,	  the	  use	  of	  an	  IRES	  to	  allow	  the	  expression	  of	  two	  different	  transgenes	  without	  using	  separate	  promoters	  can	  be	   explored	   by	   redesigning	   the	   vector	   similarly	   to	   the	   tricistronic	   vector	  proposed	  in	  Chapter	  3	  or	  the	  vector	  that	  was	  used	  in	  the	  lentiviral	  gene	  therapy	  trial	   for	   intrastriatal	   dopamine	   synthesis	   (Figure	   26	   and	   Jarraya	   et	   al.	   2009).	  Alternatively,	   transgene	   expression	   from	   different	   monocistronic	   AAV	   vectors	  can	  be	  considered.	  Although	  this	  strategy	  does	  not	  ensure	  that	  all	  neurons	  will	  be	  equally	   transduced	   with	   both	   vectors,	   there	   is	   evidence	   of	   preclinical	   efficacy	  using	  this	  approach	  (Muramatsu	  et	  al.	  2002).	  	  	  	  	  	  	  
	   	   194	  
	  
Chapter	  5 Addendum	  	  
5.1 Attempt	   to	   Abolish	   the	   Intramolecular	   Recombination	   in	   the	  
Bicistronic	  Liver	  Vector	  The	  original	  vectors	  proposed	  for	  intrahepatic	  and	  intrastriatal	  AAV-­‐mediated	  continuous	   synthesis	   of	   L-­‐DOPA	   expressed	   both	   rate-­‐limiting	   enzymes	   in	   the	  synthesis	   of	   L-­‐DOPA	   from	   a	   single	   AAV	   genome.	   Each	   gene	   was	   driven	   by	   an	  identical	  promoter	  sequence,	  which	  allowed	  their	  expression	  from	  independent	  cassettes	   (Figure	  17	  and	  Figure	  37).	  Prior	   to	   the	  conceptualisation	  of	   the	  AAV-­‐mediated	   hepatic	   L-­‐DOPA	   approach,	   preclinical	   efficacy	   with	   GPT002	   had	  already	   been	   shown	   in	   the	   6-­‐OHDA	   rat	   model	   of	   PD	   (Cederfjäll	   et	   al.	   2012).	  Therefore,	  the	  same	  vector	  design	  was	  adopted	  for	  the	  bicistronic	  liver	  vector.	  Intramolecular	  HR	  recombination	  was	  at	  first	  identified	  in	  the	  liver	  bicistronic	  vector	  during	  its	  genome	  titration	  by	  alkaline	  agarose	  gel	  (Figure	  18B	  and	  Figure	  19)	  and	  subsequently	  in	  GPT002	  (Figure	  52).	  While	  this	  was	  not	  a	  major	  concern	  for	   the	  proof-­‐of-­‐principle	   liver	  approach,	   it	  was	  potentially	  problematic	   for	   the	  already	  ongoing	  efficacy	  studies	  in	  NHP.	  Therefore,	  finding	  a	  way	  to	  abolish	  the	  HR	  without	  dramatically	  altering	  the	  vector	  design	  was	  of	  relevance	  to	  this	  gene	  therapy	  strategy.	  AAV	   has	   been	   shown	   to	   achieve	   relatively	   efficient,	   high-­‐fidelity,	   non-­‐mutagenic	   gene	   repair	   in	   host	   cells	   through	   HR	   following	   transduction	  with	   a	  rAAV,	   in	   which	   the	   viral	   genes	   are	   replaced	   by	   sequences	   homologous	   to	   the	  target	   chromosomal	   locus.	   Usually	   the	   modification	   is	   introduced	   between	  stretches	  of	  homology	  called	  5’	  and	  3’	  homology	  arms,	  which,	  upon	  transduction,	  lead	   to	   recombination	   with	   the	   chromosomal	   target.	   The	   higher	   targeting	  efficiencies	  achieved	  with	  AAV	  relative	  to	  other	  methods	  such	  as	  electroporation	  or	   other	   viral	   vectors	   is	   thought	   to	   be	   achieved	   through	   the	   recruitment	   of	  components	  of	  the	  HR	  pathway	  by	  the	  T-­‐shaped	  ITRs.	  	  	  The	   length	   of	   the	   homology	   arms	   is	   known	   to	   be	   crucial	   for	   AAV-­‐mediated	  gene	  targeting.	  Furthermore,	  a	  single	  mismatch	  in	  these	  homologous	  sequences	  can	   dramatically	   decrease	   targeting	   success	   (Khan	   et	   al.	   2011).	   I	   therefore	  hypothesised	   that	   insertion	  of	  point	  mutations	   along	   the	   first	   LP1	  promoter	   in	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the	  liver	  bicistronic	  vector	  would	  have	  the	  potential	  to	  dramatically	  decrease	  the	  chances	   of	   intramolecular	   HR	   during	   vector	   production.	   To	   test	   this,	   different	  nucleotides	  (nt)	  along	  the	  first	  LP1	  promoter	  were	  mutated	  in	  pAAV-­‐LP1-­‐GCH1-­‐LP1-­‐tTH	  (pAA019)	  and	  vectors	  were	  subsequently	  produced	  to	  assess	  the	  effect	  of	  the	  mutations	  in	  HR	  (Figure	  63).	  
	  
Figure	   63:	   Schematic	   representation	   of	   the	   LP1	   promoter	   and	   the	   12	   point	   mutations	  
introduced	  in	  its	  sequence.	  
Numbers	  represent	  the	  nucleotide	  position	  relative	  to	  the	  first	  nucleotide	  in	  the	  enhancer	  
sequence.	  The	  whole	  LP1	  promoter	  comprises	  545	  nt.	  The	  orange	  region	  comprises	  nt	  1-­‐
192	  and	  corresponds	  to	  the	  human	  apolipoprotein	  E/C-­‐I	  gene	  locus	  control	  region;	  the	  red	  
region	  comprises	  nt	  194-­‐255	  and	  corresponds	  to	  the	  human	  α1-­‐antitrypsin	  promoter;	  the	  
purple	   region	   comprises	   nucleotides	   453-­‐545	   and	   corresponds	   to	   the	   modified	   SV40	  
intron.	  	  The	   effect	   of	   the	   different	   mutations	   on	   HR	   was	   assessed	   by	   running	   viral	  preps	  containing	  different	  numbers	  of	  mutations	  on	  an	  alkaline	  agarose	  gel	  and	  quantifying	   the	  HR	   by-­‐product	   (2.8kb	   band)	   relative	   to	   the	   full-­‐length	   genome	  (4.4kb	   band).	   Surprisingly,	   the	   ratio	   between	   both	   bands	   remained	   unaffected	  even	   after	   12	   mutations	   were	   inserted	   in	   the	   first	   LP1	   promoter	   sequence	  (Figure	   64).	   These	   results	   indicate	   that	   point	   mutations	   do	   not	   hinder	   the	  occurrence	  of	  intramolecular	  HR	  during	  rAAV	  production	  of	  the	  liver	  bicistronic	  vector.	  Previous	  reports	  have	  shown	  the	  ability	  of	  AAV	  to	  repair	  deletions	  in	  one	  ITR	  during	  viral	  replication	  (Samulski	  et	  al.	  1983).	  To	  investigate	  whether	  a	  similar	  phenomenon	   was	   happening	   with	   the	   mutated	   vectors,	   the	   2.8	   kb	   band	   was	  isolated	   from	   the	   alkaline	   gel,	   purified	   and	   sent	   for	   sequencing.	   Sequencing	  results	   revealed	   that	   the	   LP1	   sequence	   of	   the	   by-­‐product	   virus	   was	   partially	  reverted	  back	  to	  the	  original	  sequence	  from	  nucleotide	  258	  onwards,	  indicating	  that	  the	  intact	  LP1	  sequence	  served	  as	  a	  template	  for	  the	  sequence	  correction.	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Figure	  64:	  Effect	  of	  point	  mutations	  in	  the	  LP1	  sequence.	  
HR-­‐mediated	  formation	  of	  by-­‐product	  vector	  (2.8kb)	  in	  the	  bicistronic	  liver	  vector	  is	  not	  
affected	  by	  the	  insertion	  of	  point	  mutations	  in	  the	  first	  LP1	  promoter	  sequence:	  the	  ratios	  
between	  upper	  and	  lower	  bands	  are	  equal	  in	  all	  vector	  preparations.	  	  It	   remains	   to	  be	  analysed	  whether	   the	  second	  LP1	  sequence,	  which	  was	  not	  altered	   by	   mutagenesis,	   is	   also	   targeted	   by	   the	   mutated	   LP1	   during	   vector	  production	   resulting	   in	   a	   promoter	   with	   a	   mutated	   sequence.	   However,	   these	  questions	  were	  put	  on	  hold	  once	  the	  decision	  was	  made	  to	  redesign	  the	  vectors	  in	   order	   to	   achieve	   higher	   transduction	   levels	   in	   both	   the	   liver	   and	   brain	  approach	  for	  continuous	  L-­‐DOPA	  synthesis.	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Chapter	  6 General	  Discussion	  	  Almost	   60	   years	   after	   its	   discovery	   as	   a	   powerful	   drug	   to	   treat	   the	   motor	  symptoms	   of	   PD,	   L-­‐DOPA	   still	   remains	   the	   most	   effective	   antiparkinsonian	  medication.	  Virtually	  all	  patients	  respond	  to	  it	  and	  no	  other	  therapy	  has	  yet	  been	  shown	   to	   provide	   greater	   symptomatic	   relief.	   However,	   chronic	   oral	   L-­‐DOPA	  therapy	  is	  associated	  with	  the	  development	  of	  disabling	  motor	  complications	  in	  most	   patients.	   Among	   them	   is	   LID,	   which	   has	   proven	   extremely	   difficult	   to	  manage	   thanks	   to	   the	   inconveniently	   short	   half-­‐life	   of	   L-­‐DOPA	   and	   its	   poorly	  understood	  interactions	  with	  the	  disease	  progression.	  The	   studies	   presented	   in	   this	   thesis	   describe	   and	   evaluate	   two	   novel	   gene	  therapy	  strategies	  using	  AAV	  vectors	  to	  improve	  the	  treatment	  of	  PD	  through	  a	  constant	  L-­‐DOPA	  supply	  to	  the	  brain.	  The	  first	  one	  describes	  the	  assessment	  of	  a	  gene	  therapy	  for	  continuous	  L-­‐DOPA	  synthesis	  in	  the	  periphery,	  a	  strategy	  with	  compelling	   scientific	   rationale	   but	   for	   which	   feasibility	   had	   not	   been	   tested	  before.	  The	  second	  study	  pertains	  to	  AAV-­‐mediated	  gene	  therapy	  for	  continuous	  L-­‐DOPA	   synthesis	   in	   the	   CNS,	   a	   project	   that	   is	   built	   on	   solid	   and	   promising	  preclinical	  studies	  in	  a	  rodent	  model	  of	  PD	  (Cederfjäll	  et	  al.	  2013).	  In	   the	   proof-­‐of-­‐concept	   study	   for	   continuous	   L-­‐DOPA	  delivery	   in	   the	   liver,	   I	  was	  able	  to	  show	  that	  plasma	  L-­‐DOPA	  levels	  could	  be	  increased	  in	  healthy	  mice	  through	   AAV-­‐mediated	   delivery	   of	   the	   essential	   genes	   involved	   in	   L-­‐DOPA	  synthesis.	  However,	  the	  magnitude	  of	  the	  effect	  achieved	  with	  the	  initial	  vector	  is	  not	  likely	  to	  be	  of	  clinical	  significance,	  which	  led	  to	  the	  proposition	  and	  redesign	  of	   an	   optimised	   vector	   that	   is	   currently	   being	   validated.	   The	   testing	   and	  optimisation	   of	   different	   vectors	   is	   a	   process	   common	   to	   the	   early	   stages	   of	   a	  gene	  therapy	  project	  and,	  like	  all	  phases	  in	  the	  development	  of	  a	  therapy,	  it	  has	  to	   overcome	   several	   challenges.	   Examples	   of	   such	   challenges	   can	   be	   gathered	  from	   the	   development	   of	   AAV	   vectors	   for	   the	   treatment	   of	   haemophilia.	   The	  expression	  levels	  of	  the	  therapeutic	  protein	  required	  for	  a	  phenotype	  correction	  led	   to	   the	   development	   of	   the	   artificial	   LP1	   liver-­‐specific	   promoter.	   This	  promoter	  had	  to	  be	  tissue-­‐specific,	  strong	  and	  at	  the	  same	  time	  short	  in	  length	  in	  order	   to	   accommodate	   its	   transgene	   in	   a	   self-­‐complementary	   AAV	   vector.	  Further	  optimisation	  of	  the	  promoter	  -­‐	  i.e.	  shortening	  without	  loss	  of	  strength	  -­‐	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was	  required	  to	  allow	  for	  the	  accommodation	  of	  even	  bigger	  transgene	  cassettes.	  In	   addition	   to	  modifications	   to	   the	   promoter,	   different	   bioengineered	   forms	   of	  the	  therapeutic	  protein	  –	  i.e.	  human	  clotting	  factor	  –	  were	  tested	  until	  an	  optimal	  candidate	   was	   selected	   for	   the	   preclinical	   studies	   (Nathwani	   et	   al.	   2006;	  McIntosh	  et	  al.	  2013).	  The	  novel	  concept	  of	  AAV-­‐mediated	  L-­‐DOPA	  synthesis	   in	  the	   periphery	   is	   based	   on	   the	   gold-­‐standard	   L-­‐DOPA	   pharmacotherapy	   given	  orally	  to	  patients.	  Once	  ingested,	  L-­‐DOPA	  becomes	  systemically	  available,	  crosses	  the	  blood-­‐brain-­‐barrier	   and	   reaches	   the	  basal	   ganglia,	  where	   it	   is	   converted	   to	  dopamine.	   A	   novel	   and	   improved	   form	   of	   L-­‐DOPA	   delivery	   to	   patients	   that	  further	  supports	   the	  rationale	   for	   the	  proposed	  gene	   therapy	   is	   the	  continuous	  intrajejunal	   infusion	   of	   L-­‐DOPA	   (Olanow	   et	   al.	   2014).	   This	   technology,	   now	  approved	  for	  commercialisation,	  provides	  patients	  with	  a	  formulation	  of	  L-­‐DOPA	  and	   AADC	   inhibitor	   and	   has	   been	   shown	   to	   increase	   ON-­‐time	   without	  troublesome	  dyskinesia.	   In	  contrast	   to	  the	  duodenal	   infusion	  strategy,	   the	  gene	  therapy	  approach	  does	  not	  provide	  continuous	  AADC	   inhibition	  and	  peripheral	  degradation	  of	  L-­‐DOPA	  must	  be	  supplied	  alongside	  oral	  L-­‐DOPA	  therapy.	  Although	   the	   levels	   of	   plasma	   L-­‐DOPA	   after	   hepatic	   targeting	   with	   the	  bicistronic	   AAV-­‐vector	   increased	   relative	   to	   vehicle-­‐treated	   animals,	   they	  may	  not	  be	  sufficiently	  high	  to	  guarantee	  therapeutic	  effect.	  Despite	  these	  seemingly	  modest	  results,	  it	  is	  important	  to	  note	  that	  the	  L-­‐DOPA	  dose	  of	  10mg/kg	  given	  to	  the	   orally-­‐treated	   group	   was	   higher	   than	   the	   usual	   6mg/kg	   given	   to	   induce	  behavioural	   improvement	   (Carlsson	   et	   al.	   2005).	   Therefore,	   the	   benchmark	  against	  which	  the	  gene	  therapy	  was	  compared	  to	  was	  potentially	  too	  stringent.	  In	  summary,	  the	  data	  show	  that	  peripheral	  L-­‐DOPA	  synthesis	  can	  be	  achieved	  and	  further	  optimisations/modifications	  of	   the	  vector	  may	  be	  needed	  to	  bridge	  the	   gap	  necessary	   to	   achieve	   therapeutic	   levels	   of	   circulating	  L-­‐DOPA.	  Because	  the	  proposed	  gene	  therapy	  aims	  to	  provide	  a	  basal	  and	  constant	  L-­‐DOPA	  supply	  in	   the	   periphery,	   once	   this	   is	   achieved,	   a	   reduction	   in	   the	   oral	   dosage	  will	   be	  possible,	  thereby	  decreasing	  the	  side	  effects	  caused	  by	  the	  peaks	  and	  troughs	  in	  circulating	  L-­‐DOPA.	  The	  second	  gene	  therapy	  proposed	  in	  this	  thesis	  is	  in	  a	  more	  advanced	  stage.	  The	   studies	   presented	   here	   evaluated	   the	   efficacy	   of	   a	   vector	   that	   had	   already	  shown	  therapeutic	  potential	  in	  a	  small	  animal	  model	  of	  PD	  and	  here,	  the	  efficacy	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and	   safety	   of	   the	   vector	  was	   assessed	   in	   the	  MPTP-­‐lesioned	  NHP	  model.	   I	  was	  able	   to	   show	   that	   the	  vector	  was	   safe	  and	   led	   to	   symptomatic	   improvement	  of	  NHP	   without	   worsening	   pre-­‐established	   dyskinesia.	   The	   clinical	   relevance	   of	  these	   findings	  and	  their	  potential	  benefit	   to	  patients	  are	  positive.	  However,	   the	  observed	   HR	   of	   GPT002	   and	   the	   partial	   motor	   improvement	   observed	   in	   the	  study’s	  endpoints	  do	  not	  support	  the	  advancement	  of	  this	  therapy	  to	  early	  phase	  trials.	  Gene	   therapy	   strategies	   showing	   preclinical	   safety,	   symptomatic	  improvement	   and	   strong	   clinical	   potential	   have	   contributed	   immensely	   to	   the	  progress	   of	   the	   field.	   These	   studies	   have	   led,	   in	   the	   past	   decade	   alone,	   to	   nine	  gene	  therapy	  trials	  being	  conducted	  to	  treat	  PD,	  most	  of	  them	  using	  AAV	  vectors.	  All	  nine	  trials	  have	  supported	  the	  safety	  of	  targeting	  the	  CNS	  with	  viral	  vectors.	  However,	   so	   far	  no	   study	  was	  able	   to	  demonstrate	   robust	  efficacy	   to	   justify	   its	  broad	  application	   in	  humans	  (Bartus	  et	  al.	  2014).	   In	  most	  cases,	   the	  preclinical	  findings	   in	   NHP	   were	   not	   predictive	   of	   the	   outcome	   in	   the	   early	   phase	   trials,	  which	   highlights	   the	   necessity	   of	   better	   and	   more	   predictive	   animal	   models	  (Bankiewicz	   et	   al.	   2000;	   Emborg	   et	   al.	   2007;	   Kaplitt	   et	   al.	   2007;	   Jarraya	   et	   al.	  2009;	  Mittermeyer	  et	  al.	  2012;	  Palfi	  et	  al.	  2014).	  The	  best	  PD	  models	  currently	  available	  do	  not	  present	  a	  similar	  aetiology	  nor	  do	  they	  recapitulate	  the	  stages	  of	  disease	   progression	   observed	   in	   humans.	   While	   genetic	   models	   show	   an	  accumulation	  of	  α-­‐synuclein	  but	  fail	  in	  presenting	  the	  motor	  impairment	  seen	  in	  patients,	   toxin-­‐based	   models,	   generated	   by	   the	   selective	   destruction	   of	   the	  nigrostriatal	   dopaminergic	   neurons,	   present	   most	   of	   the	   motor	   complications	  associated	   with	   PD	   but	   fail	   to	   show	   Lewy	   body	   inclusions,	   the	   pathological	  hallmark	  of	  PD.	  Therefore,	  progress	   in	   the	  understanding	  of	   the	  pathology	  and	  disease	  development	  must	  advance	  hand	   in	  hand	  with	   the	   improvement	  of	   the	  current	   animal	  models	   in	   order	   for	   preclinical	   results	   to	   be	  more	   reliable	   and	  predictive	  (Lane	  &	  Dunnett	  2008;	  Bartus	  et	  al.	  2014).	  Working	  with	  models	  that	  only	  artificially	  mimic	  the	  features	  observed	  in	  a	  disease	  can	  not	  only	  lead	  to	  the	  testing	  in	  humans	  of	  therapies	  bound	  to	  fail	  when	  exposed	  to	  the	  real	  context	  of	  the	  disease	  but	  may	  also	  prevent	  potentially	  promising	  therapies	  from	  entering	  clinical	  trials.	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The	  rodent	  and	  NHP	  models	  used	  in	  these	  studies	  are	  the	  best	  ones	  available	  to	   date	   and	   approval	   for	   clinical	   trials	   still	   relies	   on	   efficacy	   data	   generated	   in	  these	   animals.	   Despite	   the	   fact	   that	   experience	   has	   shown	   poor	   clinical	  translation	  of	  treatment	  in	  these	  models,	  a	  more	  careful	  selection	  of	  human	  trial	  candidates	  could	  improve	  the	  chances	  of	  success	  of	  a	  novel	  therapy.	  For	  example,	  the	   success	  of	  neuroprotective	  gene	   therapy	   strategies	   for	  PD	  may	  come	  much	  sooner	   if	   trials	   select	   patient	   cohorts	   at	   earlier	   stages	   of	   the	   disease,	  who	   can	  potentially	  benefit	  more	  from	  neuroprotective	  strategies	  than	  later	  stage	  patents	  (Bartus	  et	  al.	  2014).	  The	   most	   effective	   therapy	   for	   LID	   currently	   available	   is	   deep	   brain	  stimulation	   (DBS)	  of	   the	  STN	  and	   the	  GPi.	  Until	  now,	  no	  gene	   therapy	   strategy	  has	  proven	  more	  efficacious	  than	  DBS	  for	  the	  treatment	  of	  LID.	  Similarly	  to	  the	  proposed	  gene	  therapy,	  DBS	  is	  able	  to	  improve	  LID	  by	  allowing	  a	  reduction	  in	  the	  L-­‐DOPA	  dosage.	  Notwithstanding,	  DBS	  is	  a	  procedure	  prone	  to	  failure	  for	  reasons	  such	   as	   misplacement	   of	   the	   stimulating	   electrodes,	   poor	   programming	   and	  inadequate	  balancing	  between	  stimulation	  and	  pharmacological	  treatment,	  thus,	  this	  technology	  is	  only	  applied	  in	  patients	  that	  no	  longer	  respond	  satisfactorily	  to	  pharmacological	   treatment	   (Kühn	   &	   Volkmann	   2016).	   Gene	   therapy	   for	  continuous	  L-­‐DOPA	  delivery,	  on	  the	  other	  hand,	  once	  well	  established,	  will	  have	  the	   potential	   to	   treat	   the	   non-­‐responsiveness	   to	   pharmacotherapy	   or	   at	   least	  significantly	   delay	   the	   onset	   of	   L-­‐DOPA	   induced	   complications	   with	   a	   single	  intervention.	  	  Transplant	  of	  foetal	  tissue	  –	  i.e.	  neuroblasts	  -­‐	  has	  also	  been	  successfully	  used	  to	   treat	   the	   motor	   symptoms	   of	   PD.	   Clinical	   trials	   have	   demonstrated	   post-­‐transplantation	  graft	  survival,	  synaptic	  integration	  of	  dopaminergic	  neurons	  and	  significant	   reduction	   in	   motor	   deficit	   in	   patients	   (Barker	   et	   al.	   2013).	  Unfortunately,	  due	  to	  the	  limited	  availability	  of	  tissue	  for	  transplantation,	  foetal	  tissue	   has	   not	   become	   a	   routine	   treatment	   for	   PD.	   The	   problem	   of	   the	   limited	  amount	   of	   tissue	   for	   transplantation	   can	   be	   solved	   with	   stem	   cells.	   The	   rapid	  development	   of	   clinically-­‐compliant	   strategies	   for	   stem	   cell	   maintenance	   and	  directed	   differentiation	   have	   brought	   their	   application	   closer	   to	   the	   clinic.	   The	  current	   major	   roadblock	   for	   their	   wide	   application	   to	   treat	   PD	   symptoms	   is	  safety,	  most	  notably	  graft-­‐induced	  dyskinesia	   (GID)	  (Rylander	  Ottosson	  &	  Lane	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2016)	   and	   a	   better	   understanding	   and	   control	   of	   this	   phenomenon	   is	   an	  imperative	  for	  the	  future	  application	  of	  transplantation	  for	  the	  treatment	  of	  PD.	  A	   recent	   study	  has	   shed	   some	   light	   in	  our	  understanding	  of	   some	  mechanisms	  underlying	   GID	   by	   unveiling	   the	   link	   between	   serotonin	   5-­‐HT6	   receptor	  stimulation,	  dysplastic	  dopamine	  release	  and	  GID	  (Aldrin-­‐Kirk	  et	  al.	  2016).	  PD	  has	  emerged	  as	  a	  prototype	  platform	  for	  the	  development	  of	  gene	  therapy	  strategies	   targeting	   the	   CNS	   due	   to	   the	   well-­‐defined	   and	   targetable	   neuronal	  systems	  involved	  in	  the	  motor	  symptoms,	  the	  need	  for	  relatively	  small	  titres	  and	  volumes	   of	   vector	   needed	   to	   target	   those	   sites	   and	   the	   increasing	   demand	   for	  improved	   therapeutics	  with	  an	  aging	  population.	  However,	   it	  has	  become	  clear	  that	  PD	  is	  far	  more	  complex	  than	  once	  appreciated.	  The	  understanding	  of	  many	  aspects	  of	  the	  disease	  aetiology,	  pathogenesis	  and	  symptoms	  still	  remain	  obscure	  to	  us.	  These	   factors	  contribute	   to	   the	  uncertainty	  and	  difficulty	   in	  developing	  a	  successful	   therapeutic	   strategy.	   Nonetheless,	   gene	   therapy	   for	   PD	   has	   made	  remarkable	   progress	   in	   the	   past	   decade.	   Gene	   therapy	   strategies	   for	   other	  diseases	   such	   as	   haemophilia	   B	   did	   not	   lead	   to	   the	   cure	   of	   a	   patient	   before	  encountering	   obstacles	   not	   foreseen	   in	   preclinical	   studies	   and	   addressing	   a	  variety	  of	  other	  issues:	  design	  of	  more	  optimised	  expression	  cassettes,	  improved	  AAV	   serotypes,	   identification	   of	   an	   optimal	   route	   of	   vector	   delivery,	   dose	   and	  genome	   conformation	   as	   well	   as	   the	   inclusion	   of	   a	   short	   course	   of	   corticoid	  administration	   to	   temporarily	   supress	   a	   T	   cell-­‐mediated	   immune	   response	  against	  the	  AAV	  capsid	  (George	  &	  Fogarty	  2015).	  The	  treatment	  of	  haemophilia	  with	   gene	   therapy,	   although	   quite	   established	   and	   very	   effective,	   continues	   to	  undergo	  improvements	  with	  respect	  to	  vector	  design	  and	  treatment	  regimen.	  As	  an	  even	  more	  complex	  disease,	  gene	  therapy	  for	  PD	  faces	  more	  challenges	  on	  its	  journey	  towards	  the	  translation	  from	  animals	  to	  patients.	  Taken	   together,	   the	   seemingly	   disappointing	   results	   achieved	   so	   far	   in	   the	  field	  of	  gene	  therapy	  to	  treat	  PD	  should	  not	  be	  considered	  discouraging.	   In	  fact	  they	  represent	  crucial	  steps	  that	  must	  be	  taken	  in	  the	  advancement	  towards	  its	  translation.	  Given	  the	  safety	  record	  of	  the	  use	  of	  viral	  vectors	  for	  the	  treatment	  of	  diseases	  that	  affect	  the	  CNS,	  the	  continuous	  advancement	   in	  our	  understanding	  of	   PD	   and	   the	   increasing	   awareness	   for	   the	   importance	   of	   more	   reliable	   and	  predictive	   animal	   models,	   it	   is	   safe	   to	   assume	   that	   gene	   therapy	   will	   be	   an	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Appendix	  A. List	  of	  Primers	  
Primer	  Name	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sequence	  5'-­‐>3'	  AA01	   CCAAGCTGAGCCCCTAAAATGGGCAAACATTG	  	  AA02	   CCAACCTGCAGGTCAGTTCCAAAGGTTGGAATC	  AA03	   CACCAACCTGCAGGATGGAGAAGGGCCCTGTG	  AA004	   CACCAAGACAAGGTCGGTCGACTAAAAAACCTC	  C	  AA006	   CCAAGACAAGGTCCCCTAAAATGGGCAAACATTG	  	  AA07	   CCCAATTCGAATCAGTTCCAAAGGTTGGAATC	  AA09	   TTCAAGTCCCACCACTCGCG	  AA10	   AGCTGGTCGGGTGGCTCGT	  AA16	   CCAAGCTAGCATGGAGAAGGGCCCTGTG	  AA17	   CCAAGCTAGCGGTCGACTAAAAAACCTCC	  AA33	   CCAAGCTAGCATGAGCCCCGCGGGGCCCAAG	  AA34	   CCAAGCTAGCGGGGGATCTTCGATGCTAGAC	  	  AA37	   CCAATCTAGAGCTGAGCCCCTAAAATGGGCAAACATTG	  AA38	   CCAATCTAGAGCATGCCCAATTCGAAGACAAGGTCGGTCGACTAAAAAACCTCCCACAC	  AA39	   AAGACTACAAGTTCAGGAGCG	  AA40	   ACACCTCGCATTACCATACAC	  AA41	   TCCCAAGAAAAGTGTCAGAGC	  AA42	   AAGGCGATCTCAGCAATCAG	  AA60	   GTACCAGTCAGTCTACTTCGT	  	  AA65	   GATTCCAACCTTTGGAACTGATTCGAAATTCAAGCTGCTAGCAAGGATC	  AA73	   CACCAA	  CCTGCAGGATTCAAGCTGCTAGCAAGG	  AA84	   CAATGTTTGCCCATTTTAGGGGACCTTGTCAGATCTGGTCGACTAAAAAACCTCC	  AA85	   GGAGGTTTTTTAGTCGACCAGATCTGACAAGGTCCCCTAAAATGGGCAAACATTG	  AA133	   CCAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTT	  TAGTCGACCGAATTGGCCGCTACGCGTACTAGTTATTAATAGTAATCAATTACGG	  AA134	   CCAAAGATCTGGGGGATCTTCGATGCTAGACGATCCAGACATGATAAGATACATTG	  ATGAGTTTG	  AA150	   CCAAGCTGAGCTATCGATTGGCTCCGGTGC	  AA151	   CCAACCTGCAGGCCGCGTCACGACACCTGTG	  AA152	   CCAACCTGCAGGATTCAAGCTCGTAGCAAGGATCC	  AA153	   CCAAAGATCTTTAGCCAATGGCACTCAGCG	  AA154	   TCGAGGTTTAAACGCGG	  AA155	   CCAATTCGAATGTGGCCATATTATCATCGTG	  AA156	   CCAATTCGAAATGAGCACGGAAGGTGG	  AA157	   CCAAACTAGTTAGCTCCTAATGAGAGTCAGG	  AA158	   CCAAGTCGACATAAGACGAGCAAAAGCTTGTATAAG	  LA43	   CCAAAGATCTGGGCTGCAGGAATTGGCCGCT	  LA44	   CTTGGGCCCCGCGGGGCTCATGGTGACCGGTGGATCCTT	  LA45	   AAGGATCCACCGGTCACCATGAGCCCCGCGGGGCCCAAG	  LA46	   CCAAAGATCTGGGGGATCTTCGATGCTAGAC	  LA47	   CCAAATGCATCCCCATCGATGATCC	  LA48	   CCAACCTCAGACAGGCAGTGCAGG	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Genotype	  pAA001	   pTRUF11::LP1	  pAA002	   pTRUF11::LP1-­‐GCH1	  pAA003	   pSUB201::LP1-­‐GCH1	  pAA004	   pUC18::LP1-­‐GCH1	  pAA005	   pUC18::LP1-­‐GCH1-­‐LP1	  pAA006	   pBluescript::LP1-­‐GCH1-­‐LP1	  pAA009	   sc-­‐backbone::LP1-­‐GCH1	  pAA010	   sc-­‐backbone::LP1-­‐Δ155TH	  pAA016	   sc-­‐backbone::HLP-­‐Δ155TH	  pAA017	   pBluescript::LP1-­‐GCH1-­‐LP1-­‐tTH	  pAA018	   pBluescript::LP1-­‐GCH1-­‐LP1-­‐tTH	  pAA019	   pSUB201::LP1-­‐GCH1-­‐LP1-­‐tTH	  pAA020	   pBluescript::LP1-­‐PTS-­‐2A-­‐GCH1-­‐LP1-­‐tTH	  pAA056	   sc-­‐backbone::EF1a-­‐Δ155TH-­‐miR208aT	  pAA057	   pBluescript::EF1a-­‐GCH1-­‐LP1-­‐tTH-­‐WPRE	  pAA058	   pBluescript::EF1a-­‐tTH-­‐LP1-­‐tTH-­‐WPRE	  pAA059	   pBluescript::EF1a-­‐tTH-­‐IRES-­‐tTH-­‐WPRE	  pAA060	   pSUB201::EF1a-­‐tTH-­‐IRES-­‐tTH-­‐WPRE	  pAA061	   pSUB201::EF1a-­‐tTH-­‐IRES-­‐PTPS-­‐GCH1-­‐WPRE	  pAA062	   pSUB201::EF1a-­‐tTH-­‐IRES-­‐PTPS-­‐GCH1-­‐WPRE-­‐miR208aT	  pAA063	   pSUB201::EF1a-­‐TH-­‐IRES-­‐PTPS-­‐GCH1-­‐WPRE-­‐miR208aT	  pGPT002	   pTRUF11::SYN-­‐GCH1-­‐SYN-­‐TH-­‐WPRE	  pLA109	   pTRUF11::SYN-­‐GCH1-­‐SYN-­‐tTH-­‐WPRE	  pGPT004	   pTRUF11::SYN-­‐GCH1-­‐CMV-­‐TH	  	  	  
